|
|
·|û¡GCliff10135274 µoªí®É¶¡:2017/5/7 ¤U¤È 11:02:30
|
¡u¤ß®®¥ÍÂå¥H¯f±wªº»Ýn¬°Àu¥ý¦Ò量¡A±Mª`©ó¤¤¼Ï¯«¸g¯e¯f»â°ì¡AÂåÀø»Ý¨D©|¥¼³Qº¡¨¬ªº³¡¥÷¶i¦æ·sÃĬãµo¡C¡v ´Á³\ª©¤W½Ñ½å¡A¥H¤ß®®²£«~ªº°ò¥»±¡B¥«³õÄvª§¹ï¤â°ÊºAµ¥°T®§´£¨Ñ±´°Q¡A»P¥t¤@Ó¡u¤ß®®¥ÍÂåÄw½X°lÂÜ©«¡vª©°µ¥X°Ï¹j¡A¤]Åwªï¥t¶}¡u§Þ³N¤ÀªRª©¡v»P¡u²á¤Ñª©¡v¡AÅý¦Uª©Äݩʧó©ú½T¡A¥H«Kª©¤ÍŪ¨ú¡C Ų©ó¥i¯à¹ï¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¹B§@·P¨ì¯¥Í¡A«Øij¥ý¨ã³Æ¬ÛÃö°ò¥»»{ÃÑ«á¸û¯àº¥¤J¨Î¹Ò¡C ¥Bê©ó¥»ª©µLªkÅã¥Ü¹Ï«¬¸Ñ»¡¡A«Øij¥ý°Ñ¦Ò¥H¤U¸ê®Æ¡C ¡uliaw6575¡v¡G¡uhttp://liawbf.pixnet.net/blog¡v¡C·PÁ»·¦b«n¥xÆWµoÁnªº¹ù¤j¤j¨¯¶Ôªº¯Ñ¯Ð¡C ¡uSNOOPYÁ¿¥j¡v¡G¡]ì§}¤wÃö³¬¡F¦ýºô§}«O¯d¦b¦¹¤£§R°£¡A¬O¬°¤F·PÁ¦ѥv¤j¤j´¿¸gµL¨pªº¥I¥X¡C¡^¡umychannel.pchome.com.tw/channels/s/n/snoopychiang/content.htm?page=1&ord=v&vol=100¡v |
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/23 ¤W¤È 08:20:08²Ä 1149 ½g¦^À³
|
êɤj¤F ! §ó¥¿¤@¤U ! ±¹ï Cliff¤j®¦¼w¦p¥v¸Ö¯ëªº¸àÄÀ , ¤pªº³º§â¦¨»y¼g¿ù , ÁÙ¿ù±oÂ÷ÃÐ ¦³½Ð¤j®aì½Ì¤pªº³sªxªx³£¤£¦p [ ©Ü¯ð±Ù´Æ ] ¤~¬O¥¿½Tªº ÁÂÁ¤j®a ! ¥t¥~ , ¶K«h·s»D ¥¢´¼¯g»P©¬ª÷´Ë¤ó¯g±Ï¬P ¬üµo²{²M°£¸£³¡¦³¬r³J¥Õªº¤èªk 03:01 2021/01/23 ¤¤®É·s»Dºô ¦¿¬R㸠www.chinatimes.com/realtimenews/20210123000706-260408?ctrack=pc_main_headl_p16&chdtv ²`«×ºÎ¯v |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/23 ¤W¤È 07:03:46²Ä 1148 ½g¦^À³
|
ÁÂÁÂCliff¤j®¦¼wµ¹¤pªºªº±Ò¥Ü©M±Ð»£ ¤pªº¤§«e¹ïªk»¡·|ªº·P¨ü¬O§t»W¦Ó«O¦u ©ó¤µ¡AÅ¥¤FCliff¤j®¦¼w²`¤Jªº¸àÄÀ ²`ı½²±Ð±Âµ½¥Î¦Û¨¬ì¾Çªº©³Ä ¡A·n¨¤@Åܦ¨爲爲¤ß®®±Ù¯ð¼A´Æ¶}³Ð©Z³~ªº½²¸³ ¡u§t»Wªº¥~ªí¼çÂðí¼Ýªº¥ø¹Ï¤ß ¡v¬O¤pªº³Ì·sªº·P¨ü ±q¥«³õªºªí²{ ¡A´Nª¾¹D¦p¤pªº¤@¼Ëªº¼s¤j¸s²³¬Ýªkªº¦Æ¦Æ ¡A¬OµLªk¸ó¶V©M²z¸Ñ¥ýª¾ªÌ§»Æ[«äºûªº²`¼h·N¹Ò ¤£¹L ¡A¨SÃö«Y ¡I·íÀÆ¥ú¨ÓÁ{®É ¡A¤j®a´N·|ª¾¹D¥ýª¾¥ýıªÌ©Ò¨M§Ó¦æ¤§ªº»·¤j ¦A¦¸·PÁÂCliff¤j®¦¼w ¨S¦³±zªº³o®u¸Ü ¡A¤pªº¥i¬OÁÙ¦b¥HÂç¿s¤Ñ©O¡I ÁÂÁ¤j®a¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2021/1/23 ¤W¤È 01:01:07²Ä 1147 ½g¦^À³
|
2021/1/19ªk»¡·| §¤§x·T«° ¤@¦~«e¶}©l¦b¦U°ê½¯©µªº·s«aªÍª¢³y¦¨¦U°ê¶¡ªº¤H¬y¡Bª«¬y¡Bª÷¬yªº¤¤Â_¡A¹ï쥻¥u»Ý¦A¥[¦¬¬ù30¦W¥ª¥kªºSND-13Á{§É¸ÕÅç±a¨ÓµL¥iÁקKªº¥¨¤j½ÄÀ»¡A¥´¶Ã¤F쥻ªº¦¬®×¸`«µ¡C©Î³\ÁÙ¤£Pºc¦¨¥Í¦sªº«Â¯Ù¡A¦ýµ´¹ï±a¨ÓÀç¹B¤Wªº¬D¾Ô¡C½²¸³W«ä¸Ñ¤è¡C Ų©¹ª¾¨Ó ¤d¦~¤j¬Ì¤Ñªá¡]small pox¡^ ¦b¦è¤è¡G±q³QÃhºÃ¦]¨ü¬V¤Ñªá¦Óª\©ó¦è¤¸«e1157¦~ªº®J¤Î«Ò°êªk¦Ñ©Ô¬ü¦è´µ¤¥@¡]Ramesses V¡^¡]Slide No.12¡^¡]µù1¡^¡A¨ì³y¦¨Ã¹°¨«Ò°ê¥Ñ²±Âà°I¡]Slide No.13¡^¡A¦A¨ì1980¦~³Q¤½§i·Àµ´¡A¤Ñªá¾î¥å¤HÃþ¾ú¥v¶W¹L3000¦~¡C ¦bªF¤è¡GªFº~¥½¦~ÀZ®zªº®Ù¡BÆF¡BÄm«Ò¦~¶¡¡A³e¬ïÃQ®Ê«n¥_´Âªº¤j¬Ì¡Aì¨Ó¤]¬O¤Ñªá¡]Slide No.13¡^¡F«Ø¦w¤Q¤T¦~¨ª¾À¤§¾Ô¡A±äxÁÙ¦]¤Ñªá¬Ì±¡¦ÓºMx¡]Slide No.13¡^¡C¾Ú¥vÄy°O¸ü¡A±qªFº~¦w«Ò¨ìªF®Ê®É´ÁÃzµoªº¨º¤@³õ«ùÄò200¦h¦~ªº¤j½E¬Ì¡A¶Ê¥Í¤F¹D±Ðªº¥X²{¡]µù2¡^¡C ¦Ê¦~¤j¬Ì«aª¬¯f¬r¡]centennial corona pandemia¡^ 130¦~«eªº«Xù´µ¬y·P¡]Russian flu¡F1889-1895¡^¡A2005¦~ªº°ò¦]©w§Ç¤ñ¹ï¬ã¨sµo²{¤¸¥û³ºµM¤£¬O¬y·P¯f¬r¡A¦Ó¬O«aª¬¯f¬rªºOC43®è¡A´¦¶}¤F«aª¬¯f¬r«Iŧ¤HÃþªº§Ç¹õ¡A³y¦¨100¸U¤H¦º¤`¡C¡]·í®É¥þ¥@¬É¤H¤f¬ù¦³15»õ¡^¡A¦P®Éµo²{±wªÌ¦³¤¤¼Ï¯«¸g¨t²Îªº¯gª¬¡]Slide No.15¡^¡C ³o130¦h¦~¨Ó¡A¤£¦P®èªº«aª¬¯f¬r³y¦¨¤HÃþªÀ·|ªº¬Ì±¡¬y¦æ¡A³£¥ý³y¦¨¬y¦æ¦A³vº¥°·Å´î®`¦Ü·P«_ªºµ{«×¡FB814 (1961¦~)¡B229E (1962¦~)¡BHCoV-OC43 (1967¦~)¡BSARS-CoV (2002-2004¦~)¡BHCoV NL63 (2003¦~)¡BHCoV HKU1 (2004¦~)¡BMERS-CoV (2012¦~, 2015¦~&2018¦~)¤Î SARS-CoV-2 (2019¦~)¡]Slide No. 16¡^¡C ¨ä¤¤MERS-CoVªºP¦º²v«Ü°ª©Ò¥H³Q·P¬VªÌ¤£©ö¦A¦³¾÷·|¶Ç¼½¦h¤H¡A¦Ó¤µ¤ÑªºSARS-CoV-2«h¬O¨ã¦³°ª«×¶Ç¬V©Ê¡A©Ò¥H§ÚÌn°§C¨ü¬V¤H¼Æ¡C¦ý¤£¥Îºò±i¡A³oÓ¯f¤@©w·|¹L¥hªº¡A½²¸³¦ôp¤£¥²¦A¸g¹L¤@¦Ê¦~¤~·|°·Å¡A¦ý¬O¤Q¦~¬O¶]¤£±¼ªº¡C ³o¤Q¦~´N¬O¤ß®®ªº¤@Ó¾÷·|¡C ¶¶®ÉÀ³¶Õ ©Ò¥H§Ü¬Ì¤jp°£¤Fn°µ¦nÃä¹ÒºÞ¨î¡B¹jÂ÷¡BÀ¹¤f¸n¤§¥~¡AÁÙ»Ýn¬Ì]¡A«ì´_´Á¦å¼ß¤Î³æ®è§ÜÅé°t¦X¡A¦A¥[¤W§Ü¯f¬rÃĪ«(°µªì¯Å»P¦¸¯Å¨¾Å@)»P§Üµoª¢ÃĪ«ªº»²§U¨Ó¦@¦P¹ï§Ü¡]Slide No.18 ¡^¡CµM¦Ó¬Ì]¤£¥i¯à¹F¨ì¦Ê¤À¦Êªº¨¾Å@®ÄªG¡A¦]¦¹§ó¥YÅãªvÀøÃĪ«ªº«n©Ê¡]Slide No. 20-26¡^¡C °µ¬°³Q¦Ê¦~¤j¬Ì¸vh¤Uªº¥ÍÂ夽¥q¡A¤@¤è±»Ýn§ä´M¥Í¦s¤§¹D¡A¥t¤@¤è±¤]Ä@ºÉ´ÖÁ¡§Ü¬Ì¡F³o´£¨Ñ¤F¤ß®®¤¶¤JªºªÅ¶¡¡A¦]¬°¦b¬J¦³²£«~¤¤¨ã¦³¦P®É¥i¦b§Ü¯f¬rÃĪ«»â°ì¤W§@¥X°^Ämªº¾÷·|¡C ¥[¤WÁÙµo²{¤F·s«aªÍª¢¯f¬r¨ü¬VªÌ©ö¦³ºë¯«¯e¯f¡BµJ¼{©Î¼~Æ{±¡§Î¡]Slide No.40-42¡^¡F¦P®Éºë¯«¯e¯f±wªÌ¤]¬O·s«a¯f¬rªº°ª¦MÀI¸s¡F¦p¦¹¤@¨Ó³o¤@¾Ô²z¤§©Ò·íªï¡A±¡¤§©ÒÃø§K¡F§ð¥´·s«a¯f¬rªº«Å¾ÔÀʤ奿¦¡¥XÄl¡I®v¥X¦³¦W¡A¶¶®ÉÀ³¶Õ¡C ¬h·tªá©ú §¤§x·T«°¤§»Ú¡Aµo²{²{¦³²£«~½u¤¤¡A¦³¤@§â¥¿ÀqÀq³zµÛ°{«Gª÷ÄÝ¥ú¿AªºªZ¾¹¡A¨º¤£¬O§Gº¡Äô³ªº¨I¨F§é´u¡A¦Ó¬O¤@§â¶VÀ¿¶V«Gªº½Ä¾Wºj¡A¥i¥H±a»â¤½¥q±þ¥X«³ò²M¥X¤@±ø¤j¹D¨Ó¡GSNB01¡I ¤fªA¡B¤Æ¾Ç¤À¤lÃÄ¡B§í¨î«nÂù酶¡B¹ïªx«aª¬¯f¬r¯f®è³£¦³®Ä¡]µù3¡^¡F¥B¤w¦³¬Û·í¼Æ¾Ú¤£¥²±qÀY°µ°_¡]µù4¡^¡F¥i°w¹ï¼s¤j»´¯g±wªÌ°µªvÀø¡A²Å¦X¥«³õ»Ý¨D¡A¤]²Å¦X¤½¥q¶¥¬q©Ê»Ýn¡F¬O¦M¾÷¡A¤]¬OÂà¾÷¡C µ´¦a¤Ï§ð ½²¸³±q¬Ý¨ìModernaªºmRNA¬Ì]§Þ³Nªº¦¨¥\¡A¹w¨¥¥¼¨Ó¬ü°ê·|°fÂà³Ó¡A¥L¬Û«H¦b¦~©³«e·|¥´§¹¬Ì]¡FÓ¤H»{¬°¥L©Ò«üªº¤£¶È¤î©ó¬Ì±¡±±¨îªº¹w´ú¡AÁÙ¥]¬A¹w¨¥¥¼¨ÓÂåÀø§Þ³Nªº¦A¤É¯Å¡C¥¼¨Ó¥i±NÀù¯g¡B¨u¨£¯e¯fµ¥¯e¯fªº°ò¦]¥HmRNAªº·§©Àªí²{¨Ó¬ãµo·sªºªvÀø¤èªk©Î»s¾¯¡C³o¼Ëªº§Þ³N¼h¦¸¥¥¨|¤F¥¼¨Ó¬ü°ê¦A¦¸°¶¤jªº«´¾÷¡C Ó¤H«h±q½²¸³¤@¸ô¾Ä¤O¦V¤Wªº¼Ý¤O»P¨M¤ß¡A¬Ý¨ìSNB01¹ï³o¦¸¤HÃþ¬Ì±¡°^Äm¼ç¤O»P¤½¥q¥¼¨Ó«e³~ªº«n©Ê¡C¦A¥[¤W·s¸uªº°]°Èªø¡A´Á¬ß±q¦¹¶}©l±Æ°£»Ùêµ´¦a¤Ï§ð¡C Á{§É¸ÕÅçpµeSNB011±Ä½Õ¾ã¦¡(adaptive)¤G/¤T´ÁÁ{§É³]p¡AÂùª¼¡BÀH¾÷¤À°t¡B¦w¼¢¾¯¹ï·Óªº¦h¤¤¤ß¬ã¨s¡A¥Dn¦¬®×±ø¥ó¬°PCR½T¶E¥¼º¡48¤p®É¥B²Å¦X»´«×·s«a¯e¯f¯gª¬ªÌ¡C¥Dnµû¦ô«ü¼Ð¬°±Ä¼Ë¤§¯f¬r§t¶q¡CÁ{§É¸ÕÅç±N¤À¨â¶¥¬q¡A²Ä¤@¶¥¬q(§Y¤G´ÁÁ{§É) ³W¹º¦¬®×90¤H¡A¦ôp¬ù¤TÓ¤ë«á¥i±æ¶i¦æ´Á¤¤¤ÀªR¡A¦A®Ú¾Ú´Á¤¤¤ÀªRµ²ªG´£¨Ñ²Ä¤G¶¥¬q(§Y¤T´ÁÁ{§É)ªº°õ¦æ«Øij¡A¬ù¦¬®×300¤H¡F¦pªG´Á¤¤¤ÀªRµ²ªG°T¸¹¤£°÷ÅãµÛªº¸Ü¡A¥i¥[¦¬Ó®×¦Ü600¦ì¡C ¨±°j«e¶i ¦¨¥\¤§¸ô±q¨Ó´N¤£¬O³Ìµuªº¨º±øª½½u±¶®|¡C¬°¤F¹ê²{³Ì²×ªº²z·Q¡A¶¹L²´«eªºªýꨱ°j«e¶i¤]¤£ºâ¨¯W¡C ¾ÉºtÃQ¼w¸tªº¤jÄ@»Ýn¤W»õªº¸êª÷¡A¥L¿ï¾Ü¥ý¶}©ç¤@³¡²LÅã¦Ó®e©öÅýÆ[²³²£¥Í¦@»ïªº¤p«¬§@«~¡u®ü¨¤¤C¸¹¡v¡A·N¥~¦a±È°_¤F¤@°}Ãöª`¤Î¤ä«ù°ê¤ùªº¼ö¼é¡F¥L±q¤¤°£¤F²Ö¿n§ó¦h©ç¤ùªº¸gÅ礧¥~¡AÓ¤Hª¾¦W«×¤]¥´¶}¤F¡A¬°«á¨ÓªºÁɼw§J¡D¤ÚµÜ¡A¬Æ¦Ü²{¦bÄw¹º¤¤ªº§ó¤j«¬ªº©ç¤ùpµe¡G45»õ¥x¹ôªº¡u¥xÆW¤T³¡¦±¡v³þ©w¤F«D±`«nªº°ò¦¡C SNB01¤§©ó½²¸³¼ç¤ß¤T¤Q¦h¦~¨Óªººë¯«¯e¯fªvÀø·s¹Ò¬Éªº§»Ä@¡A¾á¥ô¤F»âÀY¦Ïªº¨¤¦â¡A¹³·¥¤FÃQ¾Éºtªº®ü¨¤¤C¸¹¡F¦pªGSNB01¯à«ö³¡´N¯Z¦a¹ï¥þ¥@¬É¤HÃþ³£·P¦P¨¨üªº·s«a¯f¬r¦Ê¦~¤j¬ÌªºªvÀø§@¥X°^Ämªº¸Ü¡A§Ú·Q¤ß®®«áÄòªº²£«~¤]±N·|¤@¤@ªº³Q¼ö¯P¦aÃöª`»P¤ä«ù¡AÓ¤H¹ï©óSNB01´Á¬ß¬Æ®ï¡A§Æ±æ¥¦¯à³y´N¹³®ü¨¤¤C¸¹ªº¦¨¥\¡A¤]¹³§J¬y·P¡]Tamiflu¡^¤@¼Ëªº¦n¥Î¡C µù¡G 1.°Ñ¬Ý©xºô2021/1/19ªk»¡·|²³ø½s¸¹¡G¡uwww.syneurx.com/20210119.pdf ¡v 2.¡ukknews.cc/n/e5e489q.html¡v 3.³y¦¨1889-1895¦~«Xù´µ¤j¬y·Pªº²Ä¤@®è«aª¬¯f¬rHCoV-OC43¡A¨äMpro»PSARS-CoV-2®t§O¬Æ¤j¡A«Å|ªº¥u¦³¦Ê¤À¤§¥|¤Q´X¡A¦ý¦b¹êÅç«Ç¤¤SNB01¨ÌµM¹ï¨äªí²{¨}¦n§í¨î§@¥Î¡C 4.SND5»PSNB01ªº¥D¦¨¤À¡]API¡^¬Û¦P¡A¤@¥Û¤G³¾¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/22 ¤W¤È 08:41:02²Ä 1146 ½g¦^À³
|
°Ñ¦Ò¤@¤U ³æ¹ç»Ä¤À¤l¤Ø¤o¡]³Ì¤j1.2¡Ñ2.4 nm¡^ SARS-CoV-2 is an enveloped virus ≈0.1 £gm ( 100 nm ) in diameter The average size of a human cell is about 100 £gm ( 100,000 nm ) in diameter. The smallest of which is the red blood cell, and it also has not nucleus. RBC ¡V Red Blood Cells : Size varies from 6 ¡V 8 µm ( 6,000 nm ~ 8,000 nm ) in diameter. ì¨Ó TAªº¤Ø¤o ¸ò¯f¬r©M²ÓM¤ñ°_¨Ó ÁÙ¬O«Ü°g§A ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/22 ¤W¤È 06:53:07²Ä 1145 ½g¦^À³
|
SARS-CoV-2 Needs Cholesterol to Invade Cells and Form Mega Cells SARS-CoV-2»ÝnÁx©T¾J¤J«I²ÓM¨Ã§Î¦¨¥¨«¬²ÓM www.hhmi.org/news/sars-cov-2-needs-cholesterol-to-invade-cells-and-form-mega-cells ¬ã¨s¤p²Õ¦b2020¦~12¤ë14¤éµo§G¨ìbioRxiv.orgªº¹w¦L¥»¤¤¼g¹D¡A¨S¦³Áx©T¾J¡A¸Ó¯f¬r´NµLªk¶V¹L²ÓMªº«OÅ@«Ì»Ù¨Ã¤Þ°_·P¬V¡C Áx©T¾J¬O²ÓM©M¬Y¨Ç¯f¬r¡]¥]¬ASARS-CoV-2¡^©P³ò½¤ªº²Õ¦¨³¡¤À¡C´¶ªL´µ¹y¤j¾Çªº¥Íª«ª«²z¤uµ{®vBrangwynne»¡¡G¡§³o¹ï·P¬V¦ÜÃö«n¡C¡¨ www.iasj.net/iasj/download/70f399df97b4800a The result showed that treatment with GA significantly reduced the elevated levels of plasma and tissue cholesterol (CHL), triglycerides (TG), Low Density Lipid (LDL), Very Low Density Lipid (VLDL) and also significantly increased the level of High Density Lipid (HDL). ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/21 ¤U¤È 06:44:58²Ä 1144 ½g¦^À³
|
South African SARS-CoV-2 variant escapes antibody neutralization www.news-medical.net/news/20210120/South-African-SARS-CoV-2-variant-escapes-antibody-neutralization.aspx ¬ã¨s¤p²Õ»¡¡A¬ã¨sµ²ªGªí©ú¡A¾¨ºÞ¥þ²y³\¦h¤H¤w¸g¦b¥þ²y·P¬V¤FSARS-CoV-2¡A¨Ã³Q»{¬°¤w¸g¿n²Ö¤F¤@©wµ{«×ªº§K¬Ì¤O¡A¦ý·sªºÅÜÅé¡A¨Ò¦p501Y.V2¡A«oºc¦¨¤F¦A¦¸·P¬Vªº¥¨¤j·ÀI¡C ¬ã¨s¤p²ÕÁ`µ²»¡¡G¡§ 501Y.V2¤¶¾Éªº§K¬Ì°k¶hªº³t«×©M½d³ò¥i¥H±q¤w¦³ªº¤¤©M§ÜÅ餤²æ¿o¦Ó¥X¡A¬ðÅã¤F¹ï§Ö³t¾AÀ³©Ê¬Ì]³]p¥¥xªº¢¤Á»Ý¨D¡A¨Ã¥B»ÝnŲ©w¥X¸û¤Ö¥iÅܩʪº¯f¬r¹v¼Ð¥H¾ã¦X¨ì¥¼¨Óªº§K¬Ì줤¡C¡¨ |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/21 ¤U¤È 06:25:53²Ä 1143 ½g¦^À³
|
¥Ñ³Ìªñ¨â¤Ñªº¸ê°T¬Ý¨Ó Åܺطs«a¯f¬r¹ï¬Ì]¥i¯à¦³¼ç¦b«OÅ@¤£¶gªº°ÝÃD ? ¤S¥Ñ^°êªº¬ã¨s , ¦³§ÜÅ骺±wªÌ¤´¥i¯à·|¶Ç¼½¯f¬r ? ¥H³o¼Ëªºµo®i¨Ó¬Ý , ¦ü¥G¬°ªvÀøÃĪ««O¯d¤F¤@®u¤§¦a ¦ý¬OÅܺدf¬r·|¤£·|¤]¹ïªvÀøÃĪ«¦³§Ü©Ê ? °²¦p¬ðÅܳ£µo¥Í¦b¯f¬rS³J¥Õªºµ²ºc°ì , ©Î³\¹ï¤£¬O§@¥Î¦bS³J¥Õµ²ºc°ìªºÃĪ« , À³¤£·|¦³¼vÅT ? ¦ýY¬O§@¥Î¦b¸Óµ¥µ²ºc°ìªºÃĪ« , ´N¥i¯à·|¦³§Ü©Ê ? ¹ï©óSNB01¨Ó»¡ , ¥H¤½¥qµoªíªº¾÷¨î , ¤@Ó¬O°w¹ï±J¥D²ÓMTMPRSS2ªº§í¨î , ¤@Ó¬O¹ï¯f¬rMproªº½Æ»s§í¨î ½²±Ð±Â¤]»¡©ú HCoV-OC43 ©M SARS-CoV-2 ªº¬Û¦ü«×¥u¦³40´X% , ¨ÌµM§í¨îªº«Ü¦n ³o¤]Åý½²±Ð±Â¹ïSNB01§í¨îªx«aª¬¯f¬r¥[²`¤F«H¤ß , Ä~Äò¬ãµo SNB02 ¤Î SNB03 ³o¦¸ªºªk»¡·| , Ó¤H»{¬°È±oª`·Nªº¨Æ±¡¦³¤T 1. ªx«aª¬¯f¬rªº·§©À , ¤£¥u¬°²{¦b§G§½ , ¤]¬°¥¼¨Óº÷Á[ 2. SNB01 ªÅ¸¡¦Y , ¦å²G¿@«×´N·|¤W¨Ó TA ªº bioavailability ¦V¨Ó¬°¤H¸á¯f ³o¦¸¤½¥qªº SNB01 ²½¥XªÅ¸¡ªA¥Î , ÁקK©M³J¥Õ½èªÈÄñ ¤S¤½¥q¥H¤Æ¾Ç»s¾¯ªº¤è¦¡ , ·|¤£·|¦³§ó¦nªº§Q¥Î«× , ½²±Ð±Â¥¼ªí©ú ½²±Ð±Â¥H¤£¹w´Á°µ§¹ 90 ¤H´N·|¦]Àø®Äµ´¨Î¦Ó´£«eµ²§ôÁ{§É , ¦ü¥G¤£Ä@¤j®a°µ¶W¥G¹w´Áªº·Q¹³ ³o¬O¤£¬O¦b»¡ , YªGÀø®Ä¶W¥G¹w´Áªº¦n , ´N¹³¤pªº§ä¤F¦hºØ TA ¥NÁª«©M¥¦ÌÁp¦Xªº§í¨î¾÷¨î¤@¼Ë , 90¤H´N¥i NDA ¤F¶Ü ? 3. SND-13 ©Î³\¤wÀòFDA¦P·N¦b¥xÆW¦¬®× ( ? ) , ´XÓ¤ë«á´N·|±Ò°Ê , ¨Ã©ó¦~©³¶i¦æ²Ä¤G¦¸´Á¤¤¤ÀªR §Æ±æ¦b¥xÆW¦¬®×·|§Ö¨Ç ¨CÓ¤H¹ï¤½¥qªk»¡·|ªº·P¨ü¤£¦P ; §t»W¦Ó«O¦u , ¬O¤pªº·P·Q , ³o¬O©M4132°µªk©Ò°µªº¹ï¤ñ ¤j®a³£¨¯W¤F ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/21 ¤U¤È 04:23:50²Ä 1142 ½g¦^À³
|
¥xÆW¤]¥X²{L452RÅܲ§¡@¬ü°êÅܺدf¬r§ó¨ã¶Ç¬V©Ê¡H www.cw.com.tw/article/5107129 The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity www.cell.com/cell/pdf/S0092-8674%2820%2930877-1.pdf D614G¥H¤Î¦P®É¥]§tD614G©M¥t¤@Ó®ò°ò»ÄÅܤƪº´XÓÅÜÅé¡A§ó¨ã·P¬V©Ê¡C¤j¦h¼Æ¦b¨üÅéµ²¦Xµ²ºc°ì¨ã¦³®ò°ò»ÄÅܤƪºÅÜÅé·P¬V¤O¸û¤p¡A¦ý¥]¬AA475V¡AL452R¡AV483A©MF490LªºÅÜÅé¹ï¬Y¨Ç¤¤©M§ÜÅé²£¥Í§Ü©Ê¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/21 ¤U¤È 02:04:53²Ä 1141 ½g¦^À³
|
SARS-CoV-2ªº·sÅÜÅé¥i¥H°k²æ¬Ì]¶Ü¡H www.sciencesetavenir.fr/sante/les-nouveaux-variants-peuvent-ils-echapper-au-vaccin_150978 2021¦~1¤ë20¤é ±M®a¹ï¹w¦L¥»ªº¤ÏÀ³¡G«n«DSARS-CoV-2ÅÜÅé501Y.V2°k²æ¤FCOVID-19¨ÑÅé¦å¼ßªº¤¤©M§@¥Î www.sciencemediacentre.org/expert-reaction-to-preprint-reporting-that-the-south-african-sars-cov-2-variant-501y-v2-escapes-neutralisation-by-covid-19-donor-plasma/ |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/21 ¤W¤È 08:54:55²Ä 1140 ½g¦^À³
|
www.genetinfo.com/international-news/item/45069.html ^°ê¬ã¨s ¦³§ÜÅéªÌ¤´¥i¯à·|¶Ç¼½¯f¬r °²¦p³o¼Ë ¤S§ó¤£§®¤F !? www.genetinfo.com/international-news/item/34547.html ×´_¸z¹DÂH½¤«Ì»Ù §ïµ½µoª¢ª¬ªp ¦³±æªvÀø¦hºØ¯e¯f TA ¤]¥i¥H§ïµ½¥J½Þªº¸z¹D«Ì»Ù ¤£ª¾¦b¤HÃþ¬O§_¥i¥H¾A¥Î ? ³æ¹ç»Ä³q¹L§ïµ½Â_¥¤¥J½Þªº¸z¹D«Ì»Ùªº§¹¾ã©Ê©M¥\¯à ¨Ó¨¾¤îÂ_¥¤«á¸¡Âm link.springer.com/article/10.1186/s40104-020-00496-5 ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/20 ¤U¤È 07:38:18²Ä 1139 ½g¦^À³
|
«e¤å§Ñ¤F¸`¿ý¨âÓ«n¤º®e However, activity against SARS-CoV-2 variants encoding E484K or N501Y or the K417N:E484K:N501Y combination was reduced by a small but significant margin. ⋯ However, neutralization by 14 of the 17 most potent mAbs tested was reduced or abolished by either K417N, or E484K, or N501Y mutations. Small but significant here means it was a big enough reduction to be a potential problem. ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ¡I |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/20 ¤U¤È 05:50:07²Ä 1138 ½g¦^À³
|
°²¦p·s«a¯f¬r¬ðÅÜÀW²v«Ü°ª , ´N¤£¤Ó§®¤F? ¤µ¤Ñ³Ì·s¦ýÁÙ¥¼¸g¦P¦æ¼f¬dªº¬ã¨s mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants www.biorxiv.org/content/10.1101/2021.01.15.426911v1 Taken together the results suggest that the monoclonal antibodies in clinical use should be tested against newly arising variants, and that mRNA vaccines may need to be updated periodically to avoid potential loss of clinical efficacy. ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2021/1/19 ¤U¤È 09:54:39²Ä 1137 ½g¦^À³
|
¦³ÃöIC50»PEC50´£¨ÑÓ¤HÆ[ÂI¥H¨Ñ°Ñ¦Ò¡G IC50ªºI¡A«¦bInhibition¡]§í¨î¡^¡A¥Î¨Ó¤F¸Ñ¬YÓ§í¨î¾¯©Î酶(»Ã¯À)¹ï¨ü酶½è¡]substrate¡^ªº§@¥Î¯à¤O¡F§@¥Î¯à¤O¶V¦nªÌ¡A¹F¨ì§í¨î50%ªº®ÄªG®É©Ò»Ýªº§í¨î¾¯©Î酶ªº¿@«×·|¶V§C¡C©Ò¥H±`¨£©óÁ{§É«eªº¥ÍÅé¥~¡]in vitro¡^¬ã¨s®É¨Ï¥Î¡C Á|¨Ò¡C¡uwww.ajcr.us/files/ajcr0123480.pdf¡v Fig.1C¤ÎFig.4C Åã¥ÜTannic acid ³oÓ§í¨î¾¯¹ï¨âºØ酶ªº§í¨îªí²{¡A¬O¥HIC50¼Æȧe²{¡C¦]¬°¬O±´°QTannic acid¹ïMpro¤ÎTMPRSS2ªº§@¥Îªí²{¡A¦bÃĪ«ªºªì´Á¬ãµo¶¥¬q·íµM¥u¦b¹êÅç«Ç¥H²ÓM¥~¹êÅç°µ¨ì³o¼Ëªº¤ÀªR¡C ¦ýÃļt³Ì²×¥Øªº¬On»s³y¥X¦³®ÄªºÃĨӪvÀø¤HÃþ¯e¯f¡A©Ò¥H³oÓ·sÃĶi¤J¥ÍÅé(in vivo)«á¡A³Ì²×ªº¡uÀø®Ä¡v¦³¦h¤Ö¡A´N¤£¥u¬Ý¥¦¯à§í¨î¥Dn酶ªº®ÄªG¦Ó¤w¡A·|¬Ý¾ãÅé²ÓM³Q§í¨î«áªº®ÄªG¡A´N±o¬ÝEC50¡C EC50ªºE¡A«¦bEffect¡]®ÄªG¡^¡A¬Ýªº¬O¾ãÅé¥Íª«ªí²{¡C©Ò¥H¬Ý2020/9/6©xºôSNB01²³øslide No.7/10§e²{ªº¬OEC50<0.77£gM¡C©Ò¨Ã¦C¤ñ¸ûªº¥|ºØ³£¬O¡uÃĪ«¡v¡A¤£¬O¬YºØ酶ªº§í¨î¾¯¦Ó¤w¡C À³¸Ó¥i¥H³o¼Ë»¡¡A¦pªGSNB01§í¨î¨â酶ªºIC50¤£¨Î¡A¨ºEC50¤]¦n¤£¨ìþ¸Ì¡F ¦pªG·QnEC50«Ü¦n¡A¨º¥¦ªºIC50¤@©wn«Ü¦n¤~¦æ¡C ¥t¥~¡A¡uwww.ajcr.us/files/ajcr0123480.pdf¡v Fig.1C¤ÎFig.4C ©ÒÅã¥ÜTannic acid ³oÓ§í¨î¾¯¹ï¨âºØ酶ªº§í¨îªí²{±o¨ì¡G TA¹ïMpro ªº§í¨î ( IC50 = 13.4£gM )¡A¼Æ¾Ú¨Ã¤£¥O¤HÅåÆA¡F ¹ïTMPRSS2ªº§í¨î ( IC50 = 2.31£gM )¡C ¦ý®Ú¾Ú¥H«e±q¤½¥q±M§Qªº¤F¸Ñ¡A±q¤j¦ÛµM¤¤¤£¦P«~ºØªº¤¿¤l¾ð©Ò±Äªº¨S¹¤l(gallnut)¨ä§í¨îDAAOªº®ÄªG®t¶Z»á¤j¡A¥HRhus chinensis«~ºØ¬°¨Î¡A¦ý¦P¼Ë³o«~ºØªº¨S¹¤lªº¤Ø¤o¤]¼vÅTÀø®Ä¡Fª½®|3-4¤½¤ÀªºIC50¡×0.393-0.424£gMÀu©óª½®|6-7¤½¤ÀªºIC50¡×0.441-0.553£gM¡C¤½¥q¤w´x´¤µÑ¨ú³o¦¨¥÷ªºknow how¡A©Ò¥H³o³¡¤Àªº¼Æ¾Ú¥H¤½¥q©x¤èªº¼Æ¾Ú¬°·Ç¡A§O®a¬ã¨s¼Æ¾Ú¬Ý¬Ý´N¦n¡C |
|
|
·|û¡G¨Dª¾Y´÷10148579 µoªí®É¶¡:2021/1/19 ¤W¤È 12:14:35²Ä 1136 ½g¦^À³
|
¤p§Ì³Ìªñ³£¦bÃhºÃ¡A§Ú¬ÝªºSNB1²³ø»Pª©¤W¥ý¶i©Ò¬Ýªº¤£¦P¡A ¤p§Ì¬ÝªºÂ²³ø-¦bSNB01±j¤O§í¨î3CLpro¶±¡AEC50 < 0.77 £g£O¡A¦Ó¥BÁÙ¬O¼Ð¬õ¦â¦r¡A ÁöIC50»PEC50pºâ/Åã¥Ü¤è¦¡¤£¦P¡A¦ýȪº®t¶Z³o»ò¤j¡A ¬Ý¨Ó¤p§Ì©Ò¬Ý¹Lªº¡A¯uªºÀ³¸Ó¬O¥t¤@¥÷¤£¦PªºÂ²³ø¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/18 ¤W¤È 08:54:06²Ä 1135 ½g¦^À³
|
www.genetinfo.com/international-news/item/44965.html www.genetinfo.com/international-news/item/36352.html ¥L¤s¤§¥Û A Tannic Acid-based Medical Food, Cesinex®, Exhibits Broad-spectrum Antidiarrheal Properties: a Mechanistic and Clinical Study °ò©ó³æ¹ç»ÄªºÂåÃĹ«~¡ACesinex ®¡A®i²{¼sÃФîÂmÄÝ©Ê¡G¤@Ó¾÷²z©MÁ{§É¬ã¨s www.ncbi.nlm.nih.gov/pmc/articles/PMC3244547/ µ²½× Cesinex ®ºt¥Ü¤FªvÀø¸¡Âmªº¦³®Ä©M¦w¥þ©Ê¡CCesinex®ªº¼sÃФîÂm§@¥Î¥i¥HÂk¦]©ó¦hºØ¦]¯Àªº²Õ¦X¡G¨ä§ïµ½¤W¥Ö«Ì»Ù©Ê¯à¡A§í¨î¸z²G¤Àªc¡A©M°ª§Ü®ñ¤Æ©Ê¯àªº¯à¤O¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2021/1/17 ¤U¤È 05:24:01²Ä 1134 ½g¦^À³
|
²q·Q¤j1115½g¶K¤å¸`¿ý: TA ¹ï¡@Mpro ªº§í¨î ( IC50 = 13.4 £gM ) ; ¹ï TMPRSS2 ªº§í¨î ( IC50 = 2.31 £gM ) µ¥©ó¬O SNB01 ¥´¤F¤@¤äº¡³e¯¥ ( ¥|ºØ¦L«×¾ÇªÌ©Ò´¦¥Üªº§í¨î¾÷¨î ¥þ¥] ) ---------------------------------------------------------------- ¥xÆW½ÃªA³¡µ¹¤T®a¬Ì]¼t¨C¤@®a³£¶W¹L¥|»õ¤¸¡A ¦Ó¬Ì]¤G´Á´N»Ýn¦³¤T¤d§ÓÄ@ªÌ¬I¥´¡C SNB01ªº¤G´ÁÁ{§É¥u»Ý40¦ì±wªÌ(§Úªº¦L¶H¡A¤£ª¾¬O§_¦³»~ ¡H) ¿Å¶q²{¦b¥xÆW¬Ì±¡¡A¯àµu´Á¦¬®×§¹¦¨ªº¥i¯à©Ê¤j¼W¡C ¦pªG»P¥xÆWFDA¡BNIH²`¤Á·¾³q¡A¥´ÃÄ«~°ê®a¶¤¡A¤ß®®ªºSNB01¦³¥i¯à¬O¥t¤@¥xÆW¤§¥ú ¡H ©Ò¥H½Ð½²±Ð±Â¥´¶}¤ß¯Ý¡A¸Õ¸Õ¬Ý¥xÆW¬F©²¬O§_¯àÀ°¤W¦£¡C |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2021/1/17 ¤U¤È 04:41:33²Ä 1133 ½g¦^À³
|
·M¨£·Q±j½Õªº¬O : ½Ð³]ªkÁp¦X¤jÀ°¤â¨Ó¥[§Ö³t«×¡A¤£½×¬O¥xÆWFDA¡BNIH¡A©Î¬ü°êFDA¡BNIH¡A©Î¬O¨ä¥L¯àÀ°¦£ªÌ¡A³£½Ð¹Á¸Õ¬Ý¬Ý¡C ¥H¥Ø«e¬Ì±¡µo®i¬Ý¡A¦³ÃĪ«ªvÀø©Î³\¤ñ¬Ì]§ó«n¡B§ó«æ¢¡C ½²±Ð±Âªº¤ß®®¹Î¶¤¡AÁٽЦh¥[ªo¡C ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/17 ¤U¤È 12:54:34²Ä 1132 ½g¦^À³
|
ÁÂÁ¤j®aªº°T®§ ¤j®a¹ïSNB01ªº¼ö«×¶V¨Ó¶V°ª , ¤pªº¤]¿U°_¼ö±¡ ¤µ¤Ñ¤S¥[¯Z§V¤O§ä½×¤å , ¾¬±æ¯à¹ï SNB01 ªº¥\¯àÀA¤W²Kªá ¨º´N¬O butyrate ¥H¤Uªº²Ä¤@½g¤å³¹¦®¦b»¡©ú TA ªº bioavailability A Naturally Occurring £]-Secretase Modulator, Tannic Acid, Improves Behavioral Impairment and Mitigates Alzheimer-Like Pathology www.sciencedirect.com/topics/medicine-and-dentistry/tannin It is important to consider the issue of TA bioavailability. TA is a high molecular weight molecule (1,701.2 g/mol) that does not easily penetrate the cell or freely cross the blood¡Vbrain barrier. However, TA is readily metabolized into much lower molecular weight, absorbable tannins that are biologically active in various organs including the brain . In this regard, hydrolyzable tannins were shown to degrade to gallic acid, pyrogallol, phloroglucinol, and finally to acetate and butyrate ( ¤B»ÄÆQ ) via sequential enzymatic action . §@¬° TA ³Ì²×¥NÁª«ªº butyrate , ¨ì©³·|©M·s«a¯f¬r²£¥Í¬Æ»ò¼Ëªº¤õªá ´NÅý§Ų́ӬݬݤT½g¤å³¹ *** 1. Butyrate Regulates COVID-19¡VRelevant Genes in Gut Epithelial Organoids From Normotensive Rats www.x-mol.com/paper/1349909274849734656 Finally, changes in gut microbiome associated with short-chain fatty acids, particularly butyrate, is found in both hypertension and COVID-19. ¡K Therefore, treatment with this short-chain fatty acid would regulate ACE2 and its partners influencing antiviral genes. This could be critical in the control of gut viral infection and rebalancing of the gut-lung axis. We performed high-throughput RNA sequencing to determine the effects of butyrate on transcriptional program of colonic organoids. We observed 4526 upregulated genes (Pink dots) and 3167 downregulated genes (purple dots) in butyrate-treated organoids (Figure A). Many of these genes were related to SARS-CoV-2 infection: reads per kilobase per million ( RPKM ) of Ace2 and Tmprss2 that facilitate SARS-CoV-2 entry into host cells were both significantly decreased by butyrate and quantitative polymerase chain reaction confirmed this observation (Figure B/C). I ... These results indicate that butyrate may control SARS-CoV-2 replication through downregulation of Hmgb1 expression. *** 2. Altered gut microbial metabolites could mediate the effects of risk factors in Covid‐19 onlinelibrary.wiley.com/doi/10.1002/rmv.2211 6¹w¨¾©MªvÀøªº·N¸q ¤F¸Ñ¸z¹Dµß¸s¦bCovid-19µo¯f¾÷²zªº«n§@¥Î , ¥i¯à¹ï¯e¯fªº¹w¨¾©MªvÀø¨ã¦³«n·N¸q¡C°·±dªº¸z¹Dµß¸s¥i¥Hºû«ù§K¬Ì¨t²Î¥¿Å¡AÀH®É¥i¥H¤¤©MCovid-19¯f¬r§ðÀ»¡C¦]¦¹¡A¹w¥ý¦s¦b¥¿Åªº·L¥Íª«¥NÁ²£ª«¥i¥H¼ç¦b¦aÁקKCovid-19«áªº¹L«×ª¢¯g¡A±q¦Ó¹w¨¾ÄY«ªºCovid-19¡C §ïµ½¸z¹Dµß¸s¦³§U©ó´î¤Ö°ªÄÖCovid-19±wªÌ¤Þµo¹L«×ª¢¯gªº¥i¯à©Ê¡C¦p«e©Òz¡A²£¥Í§ó°ª¤ô¥ªº¤B»Ä©MÁx¥Ä»Äl¥Íª«¯à°÷¨ë¿ETreg²ÓM©MM2¥¨¾½²ÓMªº¸z¹Dµß¸s , ±N¬°¹w¨¾²ÓM¦]¤l·¼É´£¨Ñ¦³®Äªº§K¬Ì¨î°Ê¡C¸z¹Dµß¸s©M¤B»Äà¦b¹w¨¾©MªvÀøCovid‐19¹L«×ª¢¯g¤¤ªº§@¥Îȱo±Mªù¬ã¨s¡C ¦ý¬O¡A¤B»ÄÆQ¦b¤HÅ餺¨³³t¥NÁ¡A¾ÉP¥Íª«§Q¥Î«×§C¡C¦]¦¹¡A...¯S©wªº¾¯¶q¹ï©ó¹F¨ì§Üª¢§@¥Î¥i¯à«Ü«n¡C *** 3. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization www.gastrojournal.org/article/S0016-5085(20)34701-6/pdf In addition, antibiotics-driven gut microbiome perturbation can alter immunity to vaccines in humans. Improving efficacy of future immune interventions such as vaccines, through modulating the gut microbiome, in combating COVID-19 should be considered. One approach for promoting a healthy microbiome may include measures to enhance intestinal butyrate production ( ¼W±j¸z¹D¤B»Äªº²£¥Í ) through the promotion of microbial interactions by dietary changes, and reduction of proinflammatory states. «Ü·N¥~¦a , »´ä¾ÇªÌ´£¥X³oÓ¼W°ª§K¬Ì¤z¹w ( ¦p¬Ì] ) Àø®Äªº¤èªk ³ºµM¬O¼W¥[¸z¹Dªº¤B»Ä ( butyrate ) ³o¸òªA¥Î TA µM«á¥NÁ²£¥Í¤B»Ä , ©Î¦³²§¦±¦P¤u¤§§®? °²¦p SNB01 ·|¼W¥[¬Ì]ªº§K¬Ì¥\®Ä ¦b ª®±þ¯f¬r ? ( pyrogallol ) ¡B§í¨î¶i¤J±J¥D²ÓM ? ( TA ¡B GA ¡B butyrate ) §í¨î¯f¬r½Æ»s ? ( TA ¡B GA ¡B butyrate ) ¤§¥~ Y¤S¯à¼W±j¬Ì]ªº§K¬Ì¥\®Ä ? ( butyrate ) ¤£³×¤S¬° SNB01 ¶}ÅP¤@±ø¤j¹D ? ¨º»ò SNB01 ¹ï§Ü·s«a¯f¬rªº¥\¯à¤j¨o«v ? §Æ±æ SNB01Á{§ÉÀø®Ä¯à¦p½Ñ¦h¬ã¨s©Ò®i¥Üªºµ²ªG¤@¼Ë¥X¦â ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2021/1/17 ¤W¤È 11:23:17²Ä 1131 ½g¦^À³
|
³Ìªñ¥xÆW½T¶E¼Æ¼W¥[¡A ¥i§_¤]¸Õ¤@¸Õ¥xÆWNIH ¡H |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2021/1/17 ¤W¤È 07:33:53²Ä 1130 ½g¦^À³
|
·PÁÂ¥[¯Z¤jªº¦^ÂСC ¦pªG²{¦b¦Aµ¥FDAªº¦^À³¡A·M¨£¥H¬°ÁÙ¦³¤@¥ó¨Æ¥i¥H°µ¡C ´N¬O½Ð½²±Ð±Â·Ç³Æ¤@¥÷»¡©«¡A±NSNB01ªº©Ò¦³¤wª¾¡Aª½±µÂà§eNIH(¬ü°ê°ê®a½Ã¥Í°|National Institutes of Health¡^¡C ¬ü°ê¬Ì±¡ÄY«¡ANIH¬Û«H¤]¤Q¸U¤õ«æ§ä¸Ñ¤è¡AYSNB01ªº¾÷Âà¯uªº«Ü¦³¼ç¤O¡ANIH·|§K¶OÀ°¦£°µ¡C ¥ç§Y¶¹LFDA¡A ª½±µ§ðNIH¡C NIHY¿ï¤W¡A¸ê·½¯f¤H³£¨S°ÝÃD¡C ¦Ó½²±Ð±Â¦b»P©x¤è¾÷ºc¥æ¯A¤W¡A»á¨ã´¼¼z»P¸gÅç¡C 1/19 ¬O§_¥i¥H¦¹½Ð±Ð½²±Ð±Â ¡H |
|
|
·|û¡G¥[¯Z¤H¥Í10148422 µoªí®É¶¡:2021/1/16 ¤U¤È 03:06:05²Ä 1129 ½g¦^À³
|
À°¦£¦^ÂФ@¤U°T®§¡A ¤§«e¦³°Ý¹L¤½¥q¡A±o¨ìªº¦^ÂЦp¤U¡A ³Ì¿ð2¤ë¤W¦¯FDAnµ¹·N¨£ YµL·N¨£´N¦Û°Ê®Öã¡C ¤j¹«¸ÕÅ禤w§¹¦¨¡A¤]¦^ÂÐFDA¡C ¥Ø«e®É¶¡¨ä¹ê¬O¥d¦bFDA¤W¡C |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2021/1/15 ¤U¤È 09:37:25²Ä 1128 ½g¦^À³
|
¦U¦ìºô¤Wªº¥ý¶i¤j®a¦n¡A Cliff¤j©M²q·Q¤jÂI¿U¤F¤j®a¹ïSNB01ªº¼ö±¡¡C ¦ýªÅ¦³¼ö±¡«o¹ï«H¤ß¨SÀ°§U¡C §ÚÓ¤H¹ï©ó¥xÆWÃļt°µÁ{§É¡A¦]¦h¬O¾ÇªÌ¬ã¨sû¥X¨¡A¦Ñ¹ê»¡«Ü¨S¦³«H¤ß¡A¥]¬A½²±Ð±Â¦b¤º¡C ¦Ó¬Ý¨ìÃĵØÃÄ·~©e°U¼Ú¬wÃļtAOP°µªºÁ{§É¡A¹ê¦b¥O¤H¦L¶H²`¨è¡A¤@¨B¤@¸}¦L¡A§¹¦¨PhaseIII®³¤FÃÄÃÒ¡AÁÙÄ~Äò°lÂܼƾڡC ¸É°µ¤@Ó¤j¹«¹êÅ礣ª¾¹DÁÙnµ¥¦h¤[¡H ³o¬O³\¦hªÑªFªººÃ°Ý¡C FDA¤¹³\«á¡AÁ{§É·|¤£·|¤Sn©ì¦n´X¦~¡H ²{¦b¬Ì±¡¼Ú¬w¤]«Üºò«æ¡A¥þ¥@¬É³£¦b©M®É¶¡ÄvÁÉ¡A¦pªG¯à°Ñ¦ÒÃĵØÃļҦ¡»P¦³¸gÅ禳¸ê·½ªº¼Ú¬wÃļt¦X§@¡A·M¨£¬O¸û¦nªº¿ï¾Ü¡C ½²±Ð±Â«Ü·|½Í§P¡AÀ³¸Ó¥i¥H½Í¥X¤@Ó¦nªº deal¡C ¦Ó¤À¼í¤ñ²v¡A¥i¥H»P§¹¦¨Á{§É©Ò»Ý®É¶¡¸j¦A¤@°_¡C ¤ß®®¬J¨S¸ê·½¤]¨S¸gÅç¡A§Æ±æ¤£n¤@ª½¦bì¦a½ñ¨B¡A§â¾÷·|µ¹©ì±¼¤F¡C ¦pªG¦³¤H»{¦P¡A1/19½ÐÀ°¦£´£°Ý¦n¶Ü ¡H |
|
|
·|û¡GABC10134671 µoªí®É¶¡:2021/1/15 ¤W¤È 08:58:59²Ä 1127 ½g¦^À³
|
¿³ÂdªÑ¤ß®®¥ÍÂå«Å¥¬¡A¬ãµo¤¤·s«a¯e¯fÔ¿ï·sÃÄSNB01¡A¸g¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]FDA¡^¼fij¡A¶È»Ý¸É¥R¤@¶µ¤j¹«14¤Ñ¬r²z¹êÅç¡A§Y¥i¶i¦æ¤HÅéÁ{§É¸ÕÅç¡C ------------------------------------------------------------------------------------------- ¥Ø«e¶i«×¦p¦ó |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/15 ¤W¤È 08:40:35²Ä 1126 ½g¦^À³
|
www.genetinfo.com/international-news/item/44933.html Exploring the multifaceted neuroprotective actions of gallic acid: a review www.tandfonline.com/doi/full/10.1080/10942912.2020.1753769 ¤j¸£»Ýn25¢Hªº¤ß¿é¥X¶q¨Óº¡¨¬¨ä¥NÁ»ݨD¡C¦]¦¹¡A¸£¦å¬y¶qªº¥ô¦ó´î¤Ö³£¥i¯à¾ÉP§½³¡¯Ê¦å©M¯«¸g¨t²Î¯e¯f¡C¦b§½³¡¯Ê¦å´Á¶¡¡A¬y¦V¤j¸£ªº¦å²Gªº¼È®É©Î¥Ã¤[´î¤Ö·|¾ÉP´£¨Ñ²ÓMúA©Ò»Ýªº¸²µå¿}©M®ñ®ð´î¤Ö©Î¤£Âಾ¡C µM«á¡Aµo¥Í¦AÄéª`¶¥¬q¡A½u²ÉÅé¥\®Ä¨ü·l¡A¨¦®ò»ÄÄÀ©ñ©Mª¢©Ê¤¶½è¡A¬¡©Ê®ñºØÃþªº²£¥Í¥H¤Î¯×½èªº¹L®ñ¤Æ±Nµo¥Í¡C ªí3¡A¤À§OÅã¥Ü¨S¹¤l»Ä©M¥¦ªº¤@¨Çl¥Íª«ªº°§C¸£·l¶Ë¡A¸£¤ô¸~¡A¯«¸g¤¸·l¶Ëªº¤j¤p¡A¨Ã°§C§½³¡¯Ê¦å«á¨Öµo¯gªºµo¥Í²v¡C ©Î³\Äè¼Ä©ó¾÷¥ý , ´N¤£·|µo¥Í«áÄòªº¯gª¬ ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/14 ¤U¤È 04:56:31²Ä 1125 ½g¦^À³
|
Åwªï¤j®a´£¦±N¦UºØ°ÝÃD¶Çµ¹¤½¥q , ¤Î¦Åý¤½¥q/½²±Ð±Â·Ç³ÆÀ³µª , ÁÂÁ¤j®a ! ¤µ¤Ñ¤S¬Ý¨ì¤@½g¦³Ãö AD ªº¤å³¹ Restoration of the reduced CLSP activity alleviates memory impairment in Alzheimer disease www.nature.com/articles/s41398-020-01168-8 ¶t½Õ³J¥Õ¼Ë¥Ö½§³J¥Õ¡]CLSP¡^¬O¤@ºØ¤Àªc肽¡A¥i§í¨î°ò©ó²ÓMªºªü¯÷®üÀq¯g¡]AD¡^¼Ò«¬ªº¯«¸g¤¸¦º¤`¡ACLSP°ò¦]ªºÂà°ò¦]¹Lªí¹F¥i§í¨îAD¼Ò«¬¤p¹«APPswe / PS1dE9ªº¬ðIJ¥á¥¢©M°O¾Ð»ÙꪺÂùÂà°ò¦]¤p¹«¡]APP / PS1¤p¹«¡^¡C ¦b³o¶µ¬ã¨s¤¤¡A§Ú̺¥ýÅã¥Ü¯×Áp¯À ( adiponectin )¡]¤@ºØCLSP¼W±j¾¯/«OÅ@¾¯¡^¦b¤¤¼Ï¯«¸g¨t²Î¤¤¨ã¦³¨M©w©Êªº§@¥Î . ¹ê»Ú¤W¡A¦b¸û°ª¿@«×ªºCLSP§í¨î¾¯¦s¦b¤U¡A1 nM¯×Áp¯À´N¥i¨ÏCLSP¥R¤Àµo´§¬¡©Ê¡]¹Ï2¡^¡C¦]¦¹¡A¯×Áp¯À³Q»{¬°¬OCLSP¬¡©Êªº¨M©w¦]¯À¡C ¯×Áp¯À¥Dn³q¹L¨ä²yª¬µ²ºc°ì»P¨å«¬ªº¯×Áp¯À¨üÅéµ²¦X¡A±q¦Ó¦b¥~©P²Õ´¤¤µo´§¦UºØ¥NÁÂ¥\¯à¡A¥]¬A¸²µå¿}©M¯×½è¥NÁ¡C¥¦¥i¯à³q¹L²ÓM½¤¤Wªº¨âÓ¯×Áp¯À¨üÅé¼W¥[¯Ø®q¯À«H¸¹¶Ç¾É¡A§Üª¢¡A§Ü®ñ¤Æ©M§Ü°Ê¯ßµ°¼Ëµw¤Æ¥\¯à¡C ¦b¸û°ª¿@«×ªº¸ü¯×³J¥ÕE4 ( ApoE4 ) ªº¦s¦b¤U , ¯×Áp¯À¤´¥i¥HÅýCLSP¨ã¦³¬¡©Ê¡C *** Gallic Acid, the Active Ingredient of Terminalia bellirica, Enhances Adipocyte Differentiation and Adiponectin Secretion www.jstage.jst.go.jp/article/bpb/39/7/39_b16-00064/_article/-char/en Gallic acid (10¡V30 µM) enhanced the expression and secretion of adiponectin via adipocyte differentiation and ¡K µM¦Ó GA ¦b¤j¸£¤¤¬O§_¤]¥i¥H¹ï¯×Áp¯À ( adiponectin )ªºªí¹F©M¤Àªc¨ã¦³¼W±j§@¥Î ? ©Î³\¤j®a³£·Qª¾¹D ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/14 ¤U¤È 03:22:02²Ä 1124 ½g¦^À³
|
ÁÂÁ¹ù¥Sªº´£¿ô ¥»¤½¥q¨üÁÜ°Ñ¥[´I¨¹ÃÒ¨éÁ|¿ì¤§ªk¤H»¡©ú·|(§ó·sªk»¡·|¦aÂI) ¨Æ¹êµo¥Í¤é¡G110/01/19 1.¥l¶}ªk¤H»¡©ú·|¤§¤é´Á¡G110/01/19 2.¥l¶}ªk¤H»¡©ú·|¤§®É¶¡¡G15 ®É 00 ¤À 3.¥l¶}ªk¤H»¡©ú·|¤§¦aÂI¡G¥x¥_¥«ªQ¤s°Ï´°¤Æ«n¸ô1¬q108¸¹B2 (´I¨¹°ê»Ú·|ij¤¤¤ß) 4.ªk¤H»¡©ú·|¾Ün°T®§¡G¥»¤½¥q¨üÁÜ°Ñ¥[´I¨¹ÃÒ¨éÁ|¿ì¤§ªk¤H»¡©ú·|(§ó·sªk»¡·|¦aÂI) 1.¦]°Ñ»P¤H¼Æ¿ãÅD¬G§ó´«¥l¶}¦aÂI 2.¥»¦¸ªk»¡·|±N¦P¨B©óFacebookª½¼½¡Aª½¼½ºô§}¦p¤U¡Gwww.facebook.com/SyneuRx/live/ 5.ªk¤H»¡©ú·|²³ø¤º®e¡G¤º®eÀɮשó·í¤é·|«á¤½§i©ó¤½¶}¸ê°TÆ[´ú¯¸ 6.¤½¥qºô¯¸¬O§_¦³´£¨Ñªk¤H»¡©ú·|¤º®e¡G¦³¡Aºô§}¡G www.syneurx.com/ |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/14 ¤W¤È 08:29:14²Ä 1123 ½g¦^À³
|
¼F®`¤F ! Cliff¤j®¦¼w ¨D¯u¨Dµ½ ¡B°l®Ú¨s©³ªººë¯« , ¥O¤H´ÜÆg ! ÁÂÁ±zµ¹¤j®a¤@Ó¥¿½Tªº¸Ñµª , ¯u¨¯W±z¤F ! ³oÓ IC50 = 13.4 £gM for Mpro and IC50 = 2.31 £gM for TMPRSS2 ªºµ²ªG ¤~¬O¯u¥¿½×¤å©Òµ²½×ªº Thus, our results demonstrate that tannic acid has high potential of developing anti-COVID-19 therapeutics as a potent dual inhibitor of two independent enzymes essential for SARS-CoV-2 infection. ¥t¥~ , §Ų́ӸɥR¤@¤U¥»ª©²Ä 1115 ½gªº¾÷¨î SARS-CoV-2ÁJ³J¥Õªºµ²ºc©M¥\¯à¯S©Ê¡GCOVID-19ªº¼ç¦b§Ü¯f¬rÃĪ«¶}µo www.nature.com/articles/s41401-020-0485-4 ¡K Viral fusion : ¯f¬r¿Ä¦X¬O«ü¯f¬r½¤©M±J¥D²ÓM½¤¿Ä¦X¡A¾ÉP¯f¬r°ò¦]²ÕÄÀ©ñ¨ì±J¥D²ÓM¤¤¡C SARS-CoV-2 S¤W¯S©w¥±ªL³J¥Õ酶 ( furin ) ¤Á³Î¦ìÂIªº¦s¦b¥i¯à¬OSARS-CoV-2¨ã¦³¤ñSARS-CoV§ó¨ã¶Ç¬V©Êªºì¦]¤§¤@¡C ²Õ´³J¥Õ酶L ( cathepsin L ) : ¦¹¥~¡A·»酶Åé ( lysosomes ) ¤¤ªº²Õ´³J¥Õ酶 ( cathepsins ) ¹ï©ó³q¹L¤º§]§@¥Î¶i¤JSARS-CoV¦ÜÃö«n¡C²Õ´³J¥Õ酶L ( cathepsin L ) ªº§í¨î¾¯E-64d¥i¥Hªý¤îSARS-CoV©MSARS-CoV-2 PsVªº·P¬V. *** Furin ( PCSK3 ) link.springer.com/article/10.1007/s11010-020-03981-7/tables/4 Gallic acid Binding energy [kcal/mol] : −7.486 Interacting amino acid residues : Asp 258, Asp 301, Asp 306, Cys 303, Glu 257, Pro 256, Thr 262 *** Preventive role of gallic acid on alcohol dependent and cysteine protease-mediated pancreas injury pubmed.ncbi.nlm.nih.gov/23053933/ In conclusion, gallic acid treatments were decreased release of lysosomal cathepsin B and L enzymes into cytoplasmic fraction and prevented alcohol mediated pancreatic tissue injury. ¤£Y Cliff¤j®¦¼wªºªv¾ÇÄYÂÔ , ¤p§Ì«h¬O¬ïÆwªþ·| Y¦³±i«a§õÀ¹ªº±¡§Î , ½Ð¤j®a¤@¯º¸m¤§ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2021/1/13 ¤U¤È 11:59:18²Ä 1122 ½g¦^À³
|
°Ý¨ìµª®×¤F¡I 2021/1/11 ¥»ª©²Ä1113½g¦^À³©Ò´£¨ìªº¨º½g¬ã¨s¡A½×¤å¤¤¦h³B©Ò´£¨ìªºMpro»PTMPRSS2 ªºIC50¼ÆȪº¡u³æ¦ì¡v¨Ã¤£¤@P¡A¸g²q·Q¤j´¦ÅS©ó²Ä1114½g¦^À³¡A¤µ¤Ñ¥»¤HÀò±o¸Ó¤å²Ä¤@§@ªÌ¤¤°êÂåÃĤj¾Ç¤ý²ÐÝϱбªº¦^ÂСA½T»{¥¿½T³æ¦ì¬O¡u£gM¡v¡]micromolar¡^¡A¦Ó«DmM¡]millimolar¡^¡A¦b¦¹°µÓ°lÂÜ«áÄò¡AºK¿ý¤ý±Ð±Â¦^¨ç©ó«á¡A¨Ñ¤j®a°Ñ¦Ò¡C ¡uDear XXX¡A Thank you for your interest in our work. I confirm that all the concentration units should be in micromolar (uM). The reason of some of them appearing as mM may be dut the erroneous font setting conversion during publication process which somehow can not recognize the greek font. You can also see the response from the co-first author Dr. Yeh Chen¡¦s response below. Hope this can answer your question. Please feel free to contact us should we can be of help further. Good luck to your research! Best regards, Shao-Chun Shao-Chun Wang, PhD¤ý²ÐÝÏ Professor and Associate Dean, College of Medicine Director, Research Center for Cancer Biology China Medical University Investigator and Deputy Director, Center for Molecular Medicine China Medical University Hospital Taichung, Taiwan 404 ¡v «e¹Ð©¹¨Æ¡G ¥Zµn¦b°ê»Ú´Á¥Zªº½×¤å¦³®É·|¦³®Õ½Z©Î½s±Æªº¿ù»~¡A¨Ã«D³£¬Oª÷¬ì¥É«ß¡C Åý§Ú·Q°_2015¦~6¤ë¬ã¨s¤@Áçªk»s³yGlobo H¤ÎSSEAªº¨º½g½×¤å®É¡]Effective Sugar Nucleotide Regeneration for the Large-Scale Enzymatic Synthesis of Globo H and SSEA4¡^¡Aµo²{ÃöÁ䪺¹ÏªíTable 1ªº¤U¤è¥X²{¨âÓ allyl-Gb4¡]µù¡^¡F¦Ê«ä¥¼¯à±o¸Ñ¤§¤U¡A¨M©wª½±µ°Ý²Ä¤@§@ªÌ¡A¯Î«e°|ªøªº¤j§Ì¤l¤§¤@¡Gturtle½²¡Aµ²ªGµo²{¥L¤H¥¿¦b¥[¦{ªºThe Scripps Research Institute¡K¡K¡A³Ì«á¥u¦nµwµÛÀY¥Ö¥´¶V¬vSkype¸ò¥L½Ð±Ð«áµo²{¥kÃ䪺¨ºÓallyl-Gb4¬Oallyl-Gb5ªº»~´Ó¡C¦Ó¥Bªí®æ³Ì¤U¤èªº¤@±Æ¦Ê¤À¤ñªº¼Æ¦r¦³©úÅ㪺½s±Æ¤Wªº¨«¦ì¡C §º¡D±i¸ü¡G¡u¡K¡K©ó¤£ºÃ³B¦³ºÃ¡A¤è¬O¶i¨o¡C¡v µù: ¡uwww.google.com.tw/imgres?imgurl=https%3A%2F%2Fd3i71xaburhd42.cloudfront.net%2F0dd197f6a146bc1d4f62fe9fb2a69ffe7627e3d6%2F3-Table1-1.png&imgrefurl=https%3A%2F%2Fwww.semanticscholar.org%2Fpaper%2FEffective-sugar-nucleotide-regeneration-for-the-of-Tsai-Lee%2F0dd197f6a146bc1d4f62fe9fb2a69ffe7627e3d6%2Ffigure%2F1&tbnid=Jose_Hww6DyteM&vet=12ahUKEwi7p_ymnZnuAhUMUpQKHYNmBswQMygAegQIARB_..i&docid=Bv3BkY3WIotpMM&w=1400&h=926&itg=1&q=Table%201.%20Enzymatic%20Reactions%20Used%20to%20Prepare%20Allyl-Gb3%2C%20Allyl-Gb4%2C%20Allyl-Gb5%2C%20Allyl-Globo%20H%2C%20and%20Allyl-SSEA4&hl=zh-TW&ved=2ahUKEwi7p_ymnZnuAhUMUpQKHYNmBswQMygAegQIARB_¡v |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/13 ¤W¤È 07:07:57²Ä 1121 ½g¦^À³
|
ªü¤Ñ¤j ¦]爲¬ÛÃöªº¸ÕÅç²Ó¸`©|¥¼¤½§i ©Ò¥H¤pªº¥u¯à»¡¡A¥i¯à©Û¶Ò±wªÌªº±ø¥ó·|¦³®t²§¡A¨ä¾lÀ³¤£·|®t§O¤Ó¤j ¤S ÂÅÂå®v¹Î¶¤ªº³oÓ¸ÕÅç¡A§Ú·Q«ÂI©ÎÂ\¦bReHoªº¬ã¨s ¤£µMÀ³¤£·|¦bÀH¾÷¤À°t®ÉÅý¨â²Õ±wªÌªº»{ª¾µ{«×®t§O¦³·å²« ¤£¦¨¼ôªº¬Ýªk ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡Gªü¤Ñ10149120 µoªí®É¶¡:2021/1/12 ¤U¤È 09:45:40²Ä 1120 ½g¦^À³
|
·PÁ²q·Q¤jÄÀºÃ ©Ò¥H¤½¥qªºÁ{§É¤è¦V¬O¤£¤Ó¬Û¦Pªº¬O¶Ü¡H |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/12 ¤U¤È 06:34:49²Ä 1119 ½g¦^À³
|
ªü¤Ñ¤j ¥H¤U¬OÓ¤Hªº»{ª¾ , ¿ù»~°¾»á¦b©ÒÃø§K¤]! ¨â²ÕªvÀø«e«á¤§ADAS-cog§ïÅܤÀ¼Æ¥¼¹FÅãµÛ¡A¥Nªí¨â²Õ¨S¦³¦¨¥\°Ï¹j ³oÓ¸ÕÅ绡¨Óº¡¦³½ìªº Inclusion Criteria: 1. Clinical diagnosis of mild cognitive impairment 2. MMSE between 17-26 3. CDR 0.5 ¦b°ò½u®É , ¨â²Õ±wªÌªº ADAS-cog score SB²Õ : 15.1¡Ó3.9 ¹ï·Ó²Õ : 10.8¡Ó3.6 p=0.023 ( Mann-Whitney U test ) ¬O§_´N¬O»¡¨â²Õ±wªÌªº»{ª¾µ{«×¦³ÅãµÛªº°Ï§O ? ¹ï·Ó²Õ»{ª¾´c¤Æªº³t«×¥i¯à¸û½w ? ¦b³oºØ±wªÌ¨S¦³¦ì¦b¦P¤@°ò·Çªº±¡ªp¤U , ©Ò±o¨ìªºµ²ªG , ¬O§_·|¦³°¾»~? ¤£±o¦Óª¾ °O±o½²±Ð±Â´£¹L CDR 0.5ªº±wªÌ¬Û¸û©ó CDR 1.0 ªº»{ª¾ª¬ªp¨Ó±o»´ ¬O§_¦]¬°¨â²Õ±wªÌ³£«Ü»´·L , ¦ÓÅ㤣¥X¸ÕÅç²ÕªºÀø®Ä , ¥i¯à¤]¬O°ÝÃD¤§¤@ ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡Gªü¤Ñ10149120 µoªí®É¶¡:2021/1/12 ¤U¤È 05:14:49²Ä 1118 ½g¦^À³
|
¨â²ÕªvÀø«e«á¤§ADAS-cog§ïÅܤÀ¼Æ¥¼¹FÅãµÛ¡A¬O¥¢±Ñªº·N«ä¶Ü¡H |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/12 ¤U¤È 04:09:47²Ä 1117 ½g¦^À³
|
ÁÂÁ¹ù¥S¤À¨ÉÂÅÂå®v¹Î¶¤ªº³Ì·sSB¬ã¨s½×¤å liawbf.pixnet.net/blog/post/49574781 ì½×¤å³sµ² Brain activity of benzoate, a D-amino acid oxidase inhibitor, in patients with mild cognitive impairment in a randomized, double-blind, placebo controlled clinical trial watermark.silverchair.com/pyab001.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAArcwggKzBgkqhkiG9w0BBwagggKkMIICoAIBADCCApkGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMfh-i6L6yFy3M-SPdAgEQgIICakVLLFQmsQ4zMupKOI0g0BGLPxCnBMA45xhy0pqEOsHsynAqMaJTnyD3xxMZSlfOhP_LRIdlcdYrOA9_r7aNK39Bmiw7TSB7oHU0PA81xhLAGKx7C1C90Z7pv8R3i01QOEhE7fqGL94scukl6JxuipHPtbrvq7ULhYUYQJFn90SYYJhKT4oNp-J2-gkBHfVLb3tndAbXFA7oy8WJHa17ctMouItX6nWvI-BMexXqyVkQJ5ENZE6n0ueHOA9tObdRn8olfyc-SOVorFDQRQKcH_xUUnh1GFyTNbLzWWN78FK57dfIXCrQzcKcGN-_hde7dV0xBCheNRjirdmSYeky7xChaun9moOWUt7ttoJ6yyVpNpAzExml47KbFjGECBYWvufAR_rA4ws4CwyE-yKEIDhimwvbMcOR8dUew76rJDKj4G6rmdmRaNOAEleNBhGuO6OBqBgTXmOAWA9mtAINqVvMJSFyp7qvAEmZ-UG5lzG9lSYk8h9LeDa0DBUqcE6LuQ5txeU7OzlTO1Lc0MyJddh2NJc2ENlnP-mDOwYHSPrjr5gK-1x2SybnKyjYJH9uXIdyJ-wNTSijLQUdKqaZkcrVrv3OgXh4C_01Q0thvecr2W2bk0PiFqKBwy70lnbnGc3-FzkJnP5bWL9TWGAE6FA5y_f7gC4uJDV4QDoC-mB7BLPVnkQSrCB2MSWDwtJlgnLB3-m9nqpioStOGt_hI0_a4rCfn5f_TWkLpyaH4tuWs6VsvLocexTLs7Dhm34p-EH1Sd165sipH8KCkT631MvHAQmnPyzL0RrZkBXrZgM230lK4ZN8TIJM-g |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/12 ¤W¤È 11:16:17²Ä 1116 ½g¦^À³
|
Ó¤H·P·Q ¥»¨Ó¹ïSNB01¤w¦s¦b¥i¦³¥iµL¤£©ê´Á«Ýªºª¬ºA ¦ý¸g¬Q¤ÑCliff¤j®¦¼wªº½×¤åÁÙ¦³½Ñ¦h¦U°ê¾ÇªÌªº¬ã¨s©Ò±o Åý¤pªº¤£¸T¤S«¿U¼ö±¡ Ãh©ê§Æ±æ ¸Õ·Q n¯à°÷¤@Ó³æÃĦP®É¤Ñù¦aºôªº¾Ö¦³¥|¶µ¾÷¨î¨Ó¹ï§Ü·s«a¯f¬r ¦ó³B´M? ÁöµM©|¥¼¸g¤HÅéÅçÃÒ , µM¤w¨¬°÷Åý¤HÅå¹Ä §Æ±æ»°§ÖÁ{§É¨£ÃÒÀø®Ä , ¸ÕµÛ«OÅ@»´¯g±wªÌ§K©ó´c¤Æ , ¥H¨î¼Ä¾÷¥ý¨¾±w¥¼µM ¤µ¤é¤SŪ¤@½gÃö©ó AD ªº¤å³¹ Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer¡¦s disease www.nature.com/articles/s41398-020-01137-1 Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in blood samples, and has been associated with Alzheimer¡¦s disease (AD). Observations from the present study highlight the potential of plasma GFAP to contribute to a diagnostic blood biomarker panel (along with plasma A£]1¡V42/A£]1¡V40 ratios) for cognitively normal older adults at risk of AD. Findings from the current study show that plasma GFAP levels are increased in cognitively normal older adults with high brain A£] load, indicating that elevated plasma GFAP may serve as an early blood-based biomarker to identify individuals at risk of AD, prior to the manifestation of clinical symptoms. Åý¤H·Q°_ SND-51¬O§_¤]¥i¥H¦¨¬°³o¨Ç¦å¼ß¤¤GFAP ¤É°ªªºAD´Á«e¦Ñ¦~¤Hªº¹w¨¾ÃĪ« ? Gallic Acid Attenuated LPS-Induced Neuroinflammation: Protein Aggregation and Necroptosis pubmed.ncbi.nlm.nih.gov/31832973/ Compared with the vehicle-treated rats, systemic administration of GA (100 mg/kg) significantly attenuated LPS-induced increases in glial fibrillary acidic protein (a biomarker of activated astrocytes) and¡K ³o¬O¶§©ú¤j¾Ç©M¥_ºaªº¬ã¨s , ¦C¦³GAªº²³¦hªº¥\¯à , ½Ð°Ñ¨ä [ ºKn ] ¥t¥~¤@½g¬O¤é¥»¾ÇªÌªº¬ã¨s , ¤§«e§Ṳ́w¸g°Q½×¹L , ©Î¤´È±o¹ï SND-51ªvÀø AD ¦³¿³½ìªº¤j¤j¤@¦A¬ãŪ Gallic Acid is a Dual £\/£]-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice www.jbc.org/content/early/2020/09/10/jbc.RA119.012330.full.pdf ½Ð°ÑFig. 7 B «nªº¬O , ¨â½g¹«Åé¸ÕÅç¬Ò¬° ¤fªA GA ©ÒÅã²{¥X¨Óªº®ÄªG ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/11 ¤U¤È 07:10:32²Ä 1115 ½g¦^À³
|
¸É¥R ¬ü°ê»P¤Ú¦è¾ÇªÌ©Ò°µ¥X¨Óªº TA§í¨î Mpro ªº IC50¬O 2.1 £gM Biochemical screening for SARS-CoV-2 main protease inhibitors storage.googleapis.com/plos-corpus-prod/10.1371/journal.pone.0240079/1/pone.0240079.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa%40plos-prod.iam.gserviceaccount.com%2F20210111%2Fauto%2Fstorage%2Fgoog4_request&X-Goog-Date=20210111T102218Z&X-Goog-Expires=3600&X-Goog-SignedHeaders=host&X-Goog-Signature=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 We could additionally confirm tannic acid (4, Fig 3A), which has an IC50 of 3 £gM for SARS-CoV Mpro [10], as a SARS-CoV-2 Mpro inhibitor with an IC50 of 2.1 £gM. ¥t¥~ ¦L«×¾ÇªÌ°w¹ï¥i¯à±±¨îSARS-CoV-2¯f¬rµo¯f¾÷²zªº¥|ºØ³J¥Õ½è/酶 , ¶i¦æ¤À¤l¹ï±µ¤ÀªR In silico studies evidenced the role of structurally diverse plant secondary metabolites in reducing SARS-CoV-2 pathogenesis www.nature.com/articles/s41598-020-77602-0 ¥»¬ã¨s¦®¦b°w¹ï³o¨Ç´Óª«¦¸¥Í¥NÁ²£ª«¡]PSM¡^¡A°w¹ï¥i¯à±±¨îSARS-CoV-2¯f¬rµo¯f¾÷²zªº¥|ºØ³J¥Õ½è/酶ªº¯S©Ê¶i¦æµêÀÀ¿z¿ï¡C¥Î4,704Ó°tÅé°w¹ï¥|ºØ¹v³J¥Õ¶i¦æ¤À¤l¹ï±µªºµ²ªG . SARS-CoV-2 Spike protein ------------------ ( TA ¶i¤J«e10¦W ) . SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) . Human transmembrane serine protease (TMPRSS2) . SARS-CoV-2 Main protease (Mpro) ( www.nature.com/articles/s41598-020-77602-0/tables/1 ) ¤S¡@GA¹ïRdRp ªº§í¨î§@¥Î Inhibition of COVID-19 RNA-Dependent RNA Polymerase ( RdRp ) by Natural Bioactive Compounds: Molecular Docking Analysis www.researchsquare.com/article/rs-25850/v1 The present study aimed to assess polyphenolic compounds (gallic acid, quercetin, caffeine, resveratrol, naringenin, benzoic acid, oleuropein and ellagic acid) as COVID-19 RNA-dependent RNA polymerase (PDB ID 6M71) inhibitors, using a molecular docking. Remdesivir and ribavirin were used as standard antiviral drugs for comparison. Docking analysis results, ranked by binding energy value (£GG) of several tested ligands toward COVID-19 polymerase were; remdesivir > gallic acid > quercetin > caffeine > ribavirin > resveratrol > naringenin > benzoic acid > oleuropein > ellagic acid. The binding energies were -8.51, - 7.55, - 7.17, -6.10, - 6.01, - 5.79, - 5.69, - 5.54, - 4.94 and -4.59 kcal/mol, respectively. Therefore, gallic acid and quercetin may represent a potential treatment option for COVID-19. Y¤S¥[¤W ¤µ¤ÑCliff¤j®¦¼wªº½×¤å©ÒÅã¥Üªº TA ¹ï¡@Mpro ªº§í¨î ( IC50 = 13.4 £gM ) ; ¹ï TMPRSS2 ªº§í¨î ( IC50 = 2.31 £gM ) µ¥©ó¬O SNB01 ¥´¤F¤@¤äº¡³e¯¥ ( ¥|ºØ¦L«×¾ÇªÌ©Ò´¦¥Üªº§í¨î¾÷¨î ¥þ¥] ) ¦Ü©ó¦b¤HÅ骺ªí²{¦p¦ó? ©Î³\´XÓ¤ë«á´Nª¾¹D¤F ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/11 ¤U¤È 01:33:30²Ä 1114 ½g¦^À³
|
ÁÂÁÂCliff¤j®¦¼w®´¨Óªº°T®§ §zÔ¬§]´Ç¦aÂsÄý¤@¤U½×¤å ¦b [ ºKn ] ¸Ì IC50 of 13.4 mM for Mpro and 2.31 mM for TMPRSS2. ¦ý¦b¹Ï1 ©M¹Ï4 «o¼gµÛ IC50 = 13.4 £gM for Mpro and IC50 = 2.31 £gM for TMPRSS2 ±q¹Ï¨Ó¬Ý [ºKn]¸Ìªº³æ¦ìÀ³¸Ó¬O»~´Ó ¤j®a»{¬°©O ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2021/1/11 ¤W¤È 11:58:08²Ä 1113 ½g¦^À³
|
For SNB01 ¡uTannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease¡v¡]www.ajcr.us/files/ajcr0123480.pdf ¡^ ¥xÆWªº¤¤°êÂåÃĤj¾Çªº¬ã¨s¡A¥Zµn©óAm J Cancer Res : 2020/12/15¡C ³æ¹ç»Ä¦b°Êª«¬ã¨s¤¤¤£¥u¥i§í¨î3CLpro(Mpro)¡AÁÙ¯à§í¨î·s«a¯f¬r´Æ³J¥Õ(S protein)¶i¤J±wªÌ²ÓM½¤ªº«I¤J¾÷Âà(viral entry)ªº«n»Ã¯ÀTMPRSS2(transmembrane protease serine 2)¡C IC50 of 13.4 mM for Mpro and 2.31 mM for TMPRSS2. ¥i°Ñ·Ó¤ß®®©xºô¡u¤½¥q®ø®§¡v2020/9/6¡uSNB01¬ãµo¶i«×»¡©ú¡vªºSlide 4¡C¡]www.syneurx.com/press-releases/¡^¡F §í¨îTMPRSS2¬O¾÷Âà1¡F§í¨î3CLpro¬O¾÷Âà2¡C ©xºôªº¹Ï¥Ü»¡©ú¥Ø«e¥u´£¨ì§í¨î3CLpro¾÷Âà2¡C ¦³¿³½ìªÌ¥i¥ý¦Û¦æ¬ãŪ¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/10 ¤U¤È 04:58:33²Ä 1112 ½g¦^À³
|
Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis www.sciencedirect.com/science/article/pii/S0920996417306709?via%3Dihub ¦bºC©Êºë¯«¤Àµõ¯g±wªÌªº§Üºë¯«¯fÃĪ«ªvÀø´Á¶¡¡A¤wÆ[¹î¨ìÁ`Áx©T¾J©M¥Ìªo¤T»Äà¼W¥[»PÁ{§É§ïµ½¤§¶¡ªº¼ç¦bÁpô¡A³o¥i¯à¬O¥Ñ©óÃĪ«¹ï¯×½è¥Íª«¦X¦¨ªº¼vÅT¡C µ²ªG §Üºë¯«¯fÃĪ«ªvÀø´Á¶¡HDL¤É°ª»PPANSSt©Êµû¤À°§C¦³Ãö¡]B = − 0.48¡Ap = 0.03¡^¡C¦¹Ãö«Y¤£¨üBMIÅܤƪº¼vÅT¡]®Õ¥¿HDL¡GB = − 0.54¡Ap = 0.02¡^¡C¦b¦å¯×¡ABMI©MPANSS¥¿©Ê¤lµû¤À¤§¶¡¥¼µo²{©úÅãÃöÁp¡C µ²½× §Ú̵o²{§Üºë¯«¯fÃĪ«ªvÀø´Á¶¡HDL¤ô¥ªº¤É°ª»PFEPt©Ê¯gª¬ªº§ïµ½¦³Ãö¡C §Ú̪º¼Æ¾Ú¨Ã¥¼ÃÒ©úFEP±wªÌHDL¤É°ª»Pt©Ê¯gª¬°§C¤§¶¡¦s¦b¥ô¦ó¦]ªGÃö«Y¡C¤@Ó¦³½ì¦ý±À´ú©Êªº²z½×¬O±N¦å²M¤¤ªºHDLµø¬°¤j¸£¤¤Áx©T¾Jªº¶¡±µ´À¥Nª«¡A¦b¤j¸£¤¤Áx©T¾Jªº¨ÑÀ³¼W¥[¥i¯à¹ïÅèÀT§Î¦¨°_¿n·¥§@¥Î¡C¥ý«e¤w¸gªí©ú¡Aºë¯«¤Àµõ¯g±wªÌªº¤¤¼Ï¯«¸g¨t²ÎÅèÀT´î¤Ö *** THE EFFECT OF GALLIC ACID AS PROTECTIVE AGENT ON SOME BIOCHEMICAL PARAMETERS INDUCED HYPERCHOLESTEROLEMIA IN LABORATORY MALE RATS www.iasj.net/iasj/download/70f399df97b4800a The result showed that treatment with GA significantly reduced the elevated levels of plasma and tissue cholesterol (CHL), triglycerides (TG), Low Density Lipid (LDL), Very Low Density Lipid (VLDL) and also significantly increased the level of High Density Lipid (HDL). ªGY¦p¦¹ , GA·|¼W¶iSND13ªºt©Ê¯gª¬Àø®Ä¶Ü ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/9 ¤U¤È 07:17:09²Ä 1111 ½g¦^À³
|
§Q°öà¬ISM ¡BSEP-363856 ¡B KarXT ©M SND13ªº¤ñ¹ï «e¤TªÌªºÁ{§É¸ÕÅç¥H«æ©Ê¥[«ªººë¯«¤Àµõ¯g±wªÌ¬°¥Ø¼Ð , SND13«h¬°ºC©Êéw±wªÌ ©Û¶Òªº±wªÌÄݩʤ£¦P , Ó§Oªº¯gª¬ªí²{±E«±E»´¤]¤£¤@¼Ë PANSS total ¤À¼Æ©Î³\¬Ûªñ , ¦ý§t¬Aªº²Õ¦X©Î¦³¤£¦P ©Ò¥H¥u¯à¤ñ¹ï , ©Î¤£¯à¤ñ¸û ¦b¤ñ¹ï¤§«e , §ÚÌ¥ý¨Ó¬Ý¬Ý´X½g¤å³¹ ºë¯«¤Àµõ¯gªvÀøªº³Ì·sªvÀøµ¦²¤©M·s¿³ÃĪ«ªº§ó·s www.ajmc.com/view/an-update-on-current-treatment-strategies-and-emerging-agents-for-the-management-of-schizophrenia ºë¯«¤Àµõ¯g«æ©ÊªvÀøªºªvÀø¥Ø¼Ð¬O´î»´«æ©Ê¯gª¬¨Ã¨Ï±wªÌ«ì´_¨ä°ò½u¥\¯à¤ô¥¡C¤@¥¹¶}©lºû«ùªvÀø¡A¥Ø¼Ð¬O¨¾¤î¯gª¬´_µo¡AÀu¤Æ¥\¯à¨Ã§ïµ½¥Í¬¡½è¶q¡C ¥Ñ©ó¦b¦¹´Á¶¡¤j¸£¤¤µo¥Íªº¯f²z¥Í²zÅܤơA¹ïºë¯«¤Àµõ¯g±wªÌ¦b¨ä³Ìªìµo§@«áªºÀY5¦~¤º¤Î®É¦³®ÄªºÃĪ«ªvÀø¦ÜÃö«n¡Cºë¯«¤Àµõ¯gªº«æ©ÊªvÀø«ÂI¦b©ó´î»´ºë¯«¯f¯gª¬¡A¦P®É³Ì¤jµ{«×¦a°§C°Æ§@¥Î¡C±wªÌéw¤U¨Ó«á¡AÄ~Äò¶i¦æºû«ùªvÀø¦³§U©ó¹w¨¾´_µo¡A¼W¥[ªÀ¥æ©M§ïµ½¦Û§Ú«O°·©M±¡ºü¡C¥¼±µ¨üºû«ùªvÀøªº¤H»P±µ¨üºû«ùªvÀøªº¤H¬Û¤ñ¡Aºë¯«¤Àµõ¯gªº´_µo²vn°ª±o¦h¡]¤À§O¬°60¢H-80¢H©M18¢H-32¢H¡^¡C *** What does the PANSS mean? pubmed.ncbi.nlm.nih.gov/15982856/ Conclusions: The results provide a better framework for understanding the clinical meaning of the PANSS total score in drug trials of schizophrenia patients with acute exacerbations. Such studies may ideally use at least a 50% reduction from baseline cut-off to define response rather than lower thresholds. In treatment resistant populations, however, even a small improvement can be important, so that a 25% cut-off might be appropriate. ¦bªvÀøÃøªv±wªÌ¡A§Y¨Ï¬O¯gª¬¤pªº§ïµ½¡A¦pPANSS´î¤Ö20%©Î§ó¦nªº25% , ¦bÁ{§É¤W¥i¯à¬O«nªº¡CµM¦Ó¡A¦b«æ©Ê¯f±¡ , «DÃøªv±wªÌ50%ªº¼Ð·Ç¡]§YÁ{§É¤W¤jªº§ïµ½¡^¦ü¥G¬OÁ{§É¦³·N¸q§ïµ½ªº§ó«ê·í¤Ï¬M¡A¦]¬°¦¹Ãþ±wªÌ ( ¥H¥¿©Ê¯gª¬¬°¥D ) ³q±`¹ï§Üºë¯«¯fÃĪ«¤ÏÀ³¨}¦n¡C *** ¶q¤Æºë¯«¤Àµõ¯gªvÀøªºÁ{§É·N¸q www.ncbi.nlm.nih.gov/pmc/articles/PMC3298768/ BPRS / PANSS§ïµ½¦Ê¤À¤ñ»PCGI§ïµ½¤À¼Æªºµ¥¤ÀÃì±µÅã¥Ü¡A®Ú¾ÚCGI¡ABPRS / PANSS°ò½u¤À¼Æ´î¤Ö25¢H¤jP¬Û·í©ó³Ì¤p§ïµ½¡A¦Ó´î¤Ö50¢H«h¹ïÀ³¡§¤j¤j§ïµ½¡¨ ¡C¥Ñ©ó³\¦h±w¦³ºë¯«¤Àµõ¯gªº«æ©Ê¯f±wªÌ³q±`¹ïªvÀø¤ÏÀ³¨}¦n¡A¦]¦¹§Ú̱o¥Xµ²½×¡A¹ï©ó¦¹Ãþ±wªÌ¡A50¢HªºÁ{¬ÉȤñ°_¸û§CªºÁ{¬Éȧó¨ãÁ{§É·N¸q¡C¥t¤@¤è±¡A¦b«D±`ºC©Ê©ÎªvÀø@ÃĪº±wªÌ¤¤¡A§Y¨Ïµy¦³§ïµ½¤]¥i¯à¥NªíÁ{§É¤WÅãµÛªº®ÄªG¡A³oÃÒ©ú¦bªvÀøÃøªv©Ê±wªÌ¤¤¨Ï¥Î25¢HªºÁ{¬ÉȬO¦X²zªº¡C¦³½ìªº¬O¡A20¢HªºÁ{¬ÉȽT¹ê¬O³Ìªì¥Î©óÃøªv©Ê±wªÌªº¬ã¨s¡A¦ý«á¨Ó¼sªx¥Î©ó«DÃøªv©Ê¨ü¸ÕªÌªº¬ã¨s¡C *** PANSS¬O§_¥¿½T¨Ï¥Î¡H¨t²Îµû»ù bmcpsychiatry.biomedcentral.com/articles/10.1186/1471-244X-11-113 ¦p«e¤@½×¤å©Ò«ü¥Xªº¡APANSS¬O30¶µ°Ï¶¡¡A½d³ò¬O1-7¡A³o·N¨ýµÛ¤ñ²vªºpºâ¡]¨Ò¦p¦Ê¤À¤ñÅܤơA¦p±q°ò½u¨ì³Ì²×ºÝÂIªºXX¢HPANSS´î¤Ö¶qªºpºâ¡^¤£¬O¾A·í¡C©¿µø³o¤@¨Æ¹ê·|¾ÉPÄY«ªº¼Æ¾Ç°ÝÃD¡A±q¦Ó¾ÉP¹ï¹ê»ÚÅTÀ³²vªº§C¦ô¡A¬Æ¦Ü¥i¯à¾ÉP¿ù»~ªºµ²ªG¡C ¬°¤FÁקK¿ù»~ªºpºâ¡A³Ì¦nªº¸Ñ¨M¿ìªk¬O´î¥h²z½×¤Wªº³Ì¤pÈ¡]Á`¤À¬O30¡^¡A±o¥Xªº¤À¼Æ½d³ò±q¹s¶}©l¡C¥²¶·¨Ï¥Î¦¹PANSSªº§ó¥¿ª©¥»¨Ópºâ¦Ê¤À¤ñÅܤơ]PC¡^¡C ¥H¤U¬O 4 ÓÁ{§É¸ÕÅ窺¼Æ¾Ú , ´£¨Ñ¤j®a¤ñ¹ï°Ñ¦Ò *** Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation Published: 25 November 2020 www.nature.com/articles/s41537-020-00127-y Altogether, 438 patients were randomized (1:1:1) and 390 included in the modified ITT efficacy set. The PANSS total score (mean difference, 95% CI) improved significantly from baseline to day 85 with Risperidone ISM® 75 and 100 mg, with placebo-adjusted differences of −13.0 (95% CI, −17.3 to −8.8); (p < 0.0001), and −13.3 (−17.6 to −8.9); (p < 0.0001), respectively. Significantly improved mean changes were also obtained for CGI-S score from baseline to day 85 for both doses of Risperidone ISM® compared with placebo −0.7 (−1.0 to −0.5); p < 0.0001, for both doses. The statistically significant improvement for both efficacy outcomes were observed as early as 8 days after first injection. ³ø§i¤¤³Ì±`¥X²{ªºªvÀø¤£¨}¨Æ¥ó¬O¦å²G¶Ê¨Å¯À¤É°ª¡]7.8¢H¡^¡AÀYµh¡]7.3¢H¡^¡A°ª¶Ê¨Å¯À¦å¯g¡]5¢H¡^©MÅ髼W¥[¡]4.8¢H¡^¡C¨S¦³°O¿ý·sªº©Î·N¥~ªº¬ÛÃö¦w¥þ«H®§¡C ¹Ï 2 PANSSÁ`¤À¡A¨ä¤¤¥§¡PANSS¦b°ò½u¦w¼¢¾¯= 96.4¡]SD¡G7.21¡^±o¤À¡A§Q°öବ°ISM 75²@§J= 96.3¡]SD¡G8.47¡^©M§Q°öà¬ISM 100²@§J= 96.1¡]SD¡G8.42¡^¡C ¦w¼¢¾¯¦b°ò½u®Éªº¥§¡CGI-S¤À¼Æ= 4.9¡]SD¡G0.54¡^¡A§Q°öà¬ISM 75 mg = 4.9¡]SD¡G0.63¡^©M§Q°öà¬ISM 100 mg = 4.8¡]SD¡G0.53¡^¡C ¹Ï 3 PANSS¥¿¤À¶qªí¡A¨ä¤¤¥§¡PANSS¥¿¤À¶qªí±o¤À¦b°ò½u¦w¼¢¾¯= 25.3¡]SD¡G3.11¡^¡A§Q°öବ°ISM 75²@§J= 25.1¡]SD¡G3.15¡^©M§Q°öà¬ISM 100²@§J= 25.5¡]SD¡G3.40¡^¡C PANSSt¤À¶qªí¡A¦w¼¢¾¯°ò½u¥§¡PANSSµû¤À= 23.5¡]SD¡G3.34¡^¡A§Q°öà¬ISM 75 mg = 23.3¡]SD¡G4.19¡^¡A§Q°öà¬ISM 100 mg = 23.1¡]SD¡G3.73¡^¡C PANSS¤@¯ëºë¯«¯f²z¾Ç¦¸¯Å¶qªí¡A¨ä¤¤°ò½uªº¥§¡PANSS±o¤À¡G¦w¼¢¾¯= 47.7¡]SD¡G4.90¡^¡A§Q°öà¬ISM 75 mg = 47.8¡]SD¡G5.48¡^©M§Q°öà¬ISM 100 mg = 47.4¡]SD¡G5.06¡^¡C *** Karuna¤½¥qªº KarXT °w¹ï«æ©Ê¥[«ºë¯«¤Àµõ¯g investors.karunatx.com/static-files/c09991a8-81fa-4ab9-aa15-8f200d73f3d1 investors.karunatx.com/static-files/80bc57ae-97c0-4aea-aafb-362543383e53 investors.karunatx.com/static-files/d83d5614-9eb0-46ef-a4a5-e75f137c4410 PANSS total : 11.6 point improvement at week 5 with p < 0.0001 (-17.4 KarXT vs. -5.9 placebo) Cohen¡¦s d effect size of 0.75 PANSS positive : 3.2 point improvement at week 5 with p < 0.0001 (-5.6 KarXT vs. - 2.4 placebo) PANSS negative : 2.3 point improvement at week 5 with p < 0.001 (-3.2 KarXT vs. -0.9 placebo) CGI-S Score : 0.68-point improvement at week 5, with p<0.0001 investors.karunatx.com/static-files/2031194e-2ce9-4605-9681-199bcd7defaa Mean Baseline PANSS Total Score ¡Ó SD : KarXT : 97.3 ¡Ó 9.3 ; Placebo : 96.6 ¡Ó 8.4 Mean Baseline CGI-S Score : KarXT : 5.0 ¡Ó 0.5 ; Placebo : 4.9 ¡Ó 0.6 PANSS subscale°ò½uªº¤À¼Æ¸ê®Æ§ä¤£¨ì *** SEP-363856 A Non¡VD2-Receptor-Binding Drug for the Treatment of Schizophrenia www.nejm.org/doi/pdf/10.1056/NEJMoa1911772 We performed a randomized, controlled trial to evaluate the efficacy and safety of SEP-363856 in adults with an acute exacerbation of schizophrenia. The patients were randomly assigned in a 1:1 ratio to receive once-daily treatment with SEP-363856 (50 mg or 75 mg) or placebo for 4 weeks. The mean total score on the PANSS at baseline was 101.4 in the SEP-363856 group and 99.7 in the placebo group, and the mean change at week 4 was −17.2 points and −9.7 points, respectively (least-squares mean difference, −7.5 points; 95% confidence interval, −11.9 to −3.0; P=0.001). The reductions in the CGI-S and BNSS scores at week 4 were generally in the same direction as those for the primary outcome, but the results were not adjusted for multiple comparisons. The mean time since the onset of schizophrenia was 5 years. °ò½u : PANSS score¡± Total SEP-363856 : 101.4¡Ó8.4 ; placebo : 99.7¡Ó7.8 Positive subscale SEP-363856 : 25.8¡Ó3.3 ; placebo : 25.4¡Ó3.1 Negative subscale SEP-363856 : 24.7¡Ó3.9 ; placebo : 24.9¡Ó4.0 CGI-S scale score¶ SEP-363856 : 5.0¡Ó0.4 ; placebo : 4.9¡Ó0.5 µ²ªG : PANSS total score SEP-363856 : −17.2¡Ó1.7 ; placebo : −9.7¡Ó1.6 ; Difference (95% CI) : −7.5 (−11.9 to −3.0) The estimated effect size was 0.45 (P=0.001). PANSS positive subscale score SEP-363856 : −5.5¡Ó0.5 ; placebo : −3.9¡Ó0.5 ; Difference (95% CI) : −1.7 (−3.1 to −0.3) PANSS negative subscale score SEP-363856 : −3.1¡Ó0.4 ; placebo : −1.6¡Ó0.4 ; Difference (95% CI) : −1.5 (−2.6 to −0.4) PANSS general psychopathology subscale score SEP-363856 : −9.0¡Ó0.9 ; placebo : −4.7¡Ó0.8 ; Difference (95% CI) : −4.3 (−6.6 to −2.0) CGI-S score SEP-363856 : −1.0¡Ó0.1 ; placebo : −0.5¡Ó0.1 ; Difference (95% CI) : −0.5 (−0.7 to −0.2) *** Add-on Treatment of Benzoate for Schizophrenia A Randomized, Double-blind, Placebo-Controlled Trial of d-Amino Acid Oxidase Inhibitor jamanetwork.com/journals/jamapsychiatry/fullarticle/1746121 °ò½u : PANSS score Total SB : 90.3¡Ó16.3 ; placebo : 87.3¡Ó8.6 Positive subscale SB: 20.6¡Ó3.6 ; placebo : 20.4¡Ó4.4 Negative subscale SB : 26.1¡Ó6.9 ; placebo : 24.8¡Ó3.6 CGI-S scale score SB: 4.6¡Ó0.6 ; placebo : 4.5¡Ó0.8 µ²ªG : PANSS total score SB : −18.6 ; placebo : −5.9 ; Difference : -12.7 PANSS positive subscale score SB : −5.3 ; placebo : −1.6 ; Difference : -3.7 PANSS negative subscale score SB : −5.3 ; placebo : −1.7 ; Difference : −3.6 PANSS general psychopathology subscale score SB: −7.9 ; placebo : −2.6 ; Difference : −5.3 CGI-S score SB : −1.1 ; placebo : −0.2 ; Difference : −0.9 §Q°öà¬ISM ¡BSEP-363856 ©M KarXT ³£¬O¥H«æ©Ê¥[«±wªÌ¬°ªvÀø¥Ø¼Ð ©Ò¿×[¥[«]¤@¯ë¥HCGI-S score >= 4¬°¿z¿ï¼Ð·Ç ¦Ó SND13 ¤G´ÁÁ{§É «h¥HºC©Êéw±wªÌ¬°¼Ð·Ç ±q°ò½uªº¤À¼Æ §ÚÌ¥i¥H²Ê²¤¦a¬Ý¥X¨Ó ( ¤À¼Æ¶V°ª ¯gª¬¶VÄY« ) «e¤TªÌ ( KarXT¨S¦³ªþ°ò½u¤À¼Æ ) ªºPANSS positive subscale score ³£¬O¤j©óPANSS negative subscale score ¦Ó SND13 ´N«Ü©úÅã¦aPANSS negative subscale score ¤j©ó PANSS positive subscale score ²Å¦X«æ©Ê±wªÌ¥H¥¿©Ê¯gª¬¬°¥D , ºC©Ê±wªÌ¥Ht©Ê¯gª¬¬°Å㪺°ò½Õ ¨ä¥L¦U¶µÁ{§ÉÀø®ÄªºÀu¦H , ½Ð¤j®a¦Û¦æ¤ñ¹ï ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/8 ¤U¤È 05:00:07²Ä 1110 ½g¦^À³
|
¥»¤½¥q¨üÁÜ°Ñ¥[´I¨¹ÃÒ¨éÁ|¿ì¤§ªk¤H»¡©ú·|(§ó·sªk»¡·|¤é´Á) ¨Æ¹êµo¥Í¤é¡G110/01/19 1.¥l¶}ªk¤H»¡©ú·|¤§¤é´Á¡G110/01/19 2.¥l¶}ªk¤H»¡©ú·|¤§®É¶¡¡G15 ®É 00 ¤À 3.¥l¶}ªk¤H»¡©ú·|¤§¦aÂI¡G¥x¥_¥«ªQ¤s°Ï¥Á¥ÍªF¸ô¤T¬q138¸¹B1(´I¨¹ºî¦XÃÒ¨é¥Á¥Í¤À¤½¥qºtÁ¿ÆU) 4.ªk¤H»¡©ú·|¾Ün°T®§¡G¥»¤½¥q¨üÁÜ°Ñ¥[´I¨¹ÃÒ¨éÁ|¿ì¤§ªk¤H»¡©ú·|(§ó·sªk»¡·|¤é´Á) 5.ªk¤H»¡©ú·|²³ø¤º®e¡G¤º®eÀɮשó·í¤é·|«á¤½§i©ó¤½¶}¸ê°TÆ[´ú¯¸ 6.¤½¥qºô¯¸¬O§_¦³´£¨Ñªk¤H»¡©ú·|¤º®e¡G¦³¡Aºô§}¡G www.syneurx.com/ 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ¡Gªk¤H»¡©ú·|¬ÛÃö²³ø¸ê®Æ¨Ì³W©w¤½§i©ó¤½¶}¸ê°TÆ[´ú¯¸¡C «i©¹ª½«e¤j , »¡±o¬Æ¬O ¤j®a§ë¸ê ¬°±o¬OÅý¥Í¬¡¹L±oºë±m¤@ÂI , ¤£ºÞ¬O¦LÃÒ¦Û¤vªº²´¥ú , ©Î¬O°l¨D°]´I¦Û¥Ñ ·íµM¤]³£§Æ±æ¦¤é¯à¬Ý¨ì¦¨ªG ¤½¥qÀ³¸Ó³£¦³¬Ý¨ì±zªº©IÆ~ , ¤]¬ß±æ¤½¥q¯à°÷§JªA¤jÀô¹Ò , ©Î§ï©¶©öÂá ¥ÎSND-13±ÂÅv¨Ó¾i¦h®×Á{§Éªº³W¹ºÁö¥ß·N¨}µ½ , ¦ýYµLªkªñ´Á¨ú±o±ÂÅv , ¤]´Á«Ý¤½¥q¯à¤j´T¼W¸ê ÅýFDA®Ö㪺Á{§É³£¯à»ôÀY¨Ã¶i , ¸`¬ÙÅýªÑªFµ¥«Ýªº®É¶¡ ¤ß®®ªº¦¨¥æ¶q¤£¤j , Ãø¶iÃø¥X , ¥i¯à¼vÅT¤j³¡¦ì§ë¸êªÌ¶i¾nªº·NÄ@ ªñ´Áªº4132¦b³o¤è±´N°µ±oº¡¦¨¥\ , ¦¨¥æ¶qÂX¼W , ¦ÛµM¨}©Ê´`Àô , ¹ï¼W¸êÀ³¤]·|¦³À°§U ... ... ... ÁÂÁ¤j®a! |
|
|
·|û¡G«i©¹ª½«e10141841 µoªí®É¶¡:2021/1/8 ¤U¤È 02:33:44²Ä 1109 ½g¦^À³
|
²q·Q¤j¦w, ¥¢Â§¤F! ½²±Ð±Â¦b¾Ç³N»â°ìªº¿ïÃD¥\¤O, ¥Ø«e¦b¤U¨S¯à¤O¤]¨S¿³½ìµû½×, ¦ý¬O¦b¸ê¥»¥«³õ¸Ìªº¿ïÃD¥\¤O, ÅãµM©M¾Ç¬É¸Ìªºªí²{¬O¨â¦^¨Æ, ¬Æ¦Üì¦a¥´Âà! ¦pªG¿ïÃD¥i¥H±À¤ÉªÑ»ùªº¸Ü, §Ú·Q¥xÆW¤@°ïªÑ²¼³£½Ä¤W¤d¤¸Ñ¼Ö³¡! ¸Õ·Q, ¬Q¤Ñ¥x¿n¹q¦¬½L565, ½Ð°Ý¬O¾aµÛ¦bªk»¡©Î¬OªÑªF·|¿ïÃDÁ¿¥j¶Ü? ½Í¤F¼Æ¦~ªº±ÂÅv, ¤j¤j¤p¤pªºªÑªFµ¹¤F¤½¥q¦h¤Ö®É¶¡? ¦b¤U§¹¥þ¯à²z¸Ñ·sÃĬãµo®É¶¡ªø, ¦ý¬O¦U¦ìn¤£n½Æ²ß¤@¤U±q2016·¥ú¤W¿³Âd¥H¨Óªº¶i«×ªí? °ÝÃD¦b®Ä²v©M°õ¦æ¤O!®Ú¥»¤@Àô¦©¤@Àô, ¨C¨C¬ã¨s«Ç¿ïÃD, ¤@©ñ¨ìÂi±¤W¶Ò¸ê©Î¬O¦X§@Á`¬O¨B¼iÂÚ¶\ ³o¨Ç¦~¤U¨Ó, ¥i·Q¦Óª¾, ±ÂÅv©Î¥ô¦óªº¦X§@, ¤]¤£¬O¾aµÛ¿ïÃDÁ¿¬G¨Æ¤H®a´NÄ@·N±Ç¿ú¶R¹Ú·Q ¨C¨CªÑªF·|«e, ¤pªºÁ`¬O¥Î¤O¯e©I, ¥¿µø¤½¥qªºÀç¹B»P¸ê¥»¥«³õªº²{¹ê±, Áö»¡©Mª©¤W«e½ú©Î¦³§ý®æ, ªì¤ß«o¤]»PÆp¬ã°ò¥»±ªº¤j¤j¦p¥X¤@Âá, Á`¬O§Æ±æ¤ß®®¯à°÷_§§, §O§Ñ¤F¥u¦³¸ê¥»¤~¯àÄ~Äò¬°¤ß®®¥R¹ê°ò¥»±! ¦Ó¦U¦ìªÑªF, §AÌÁٯ౵¨ü¦h¤ÖªÑªF¿ï¾Ü¥Î¸}§ë²¼? |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/7 ¤W¤È 08:57:03²Ä 1108 ½g¦^À³
|
Long COVID en.wikipedia.org/wiki/Long_COVID Long COVID, also known as chronic COVID syndrome (CCS) and long-haul COVID,[1][2][3] is an informal name for the condition characterised by long-term sequelae¡Xpersisting after the typical convalescence period¡Xof coronavirus disease 2019 (COVID-19). Persistent symptoms include fatigue, headaches, shortness of breath, anosmia (loss of smell), muscle weakness, low fever and cognitive dysfunction (brain fog). ... |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/7 ¤W¤È 07:39:54²Ä 1107 ½g¦^À³
|
¨Dª¾Y´÷¤j ¤½¥q°õ¦æ¬Fµ¦ªº¤è¦¡ , ©Î¦³ÀË°Q§ï¶i¤§³B , ³oÓ¤pªº¦P·N µM¤½¥q¹ï©ó¿ïÃD¿ï§÷ , «h¥O¤H¨ØªA ¤µ¦¤pªº¤S¬Ý¨ì¤@½g³ø¾É ¬O¥ÑÛ´°°ê¤ý¾Ç°|°ò¦]²Õ¬y¦æ¯f¾Ç±Ð±Â©M·Àã¯f¾ÇºaÅAÅU°Ý©Ò¼¶¼g ªøCOVID¡G½Ö¦³·ÀI¡H theconversation.com/long-covid-who-is-at-risk-151797 ¹ï©ó¤j¦h¼Æ¤H¨Ó»¡¡ASARS-CoV-2¡]¤Þ°_COVID-19ªº¯f¬r¡^·P¬V·|¾ÉP»´«×¡Aµu´Á¯gª¬¡A«æ©Ê©I§l¹D¯e¯f¡A¬Æ¦Ü¥i¯à®Ú¥»¨S¦³¯gª¬¡C¦ý¬O¦³¨Ç¤H¦b·P¬V«á·|¥X²{«ù¤[ªº¯gª¬-³oºØ²{¹³³QºÙ¬°¡§ªø´Á·P¬V¡¨ ... ³o¶µ¬ã¨s¹ï200¦W±qCOVID-19¤¤±d´_ªº±wªÌ¶i¦æ¤F©â¼Ë½Õ¬d¡Aµo²{32¢Hªº¤H¤ßŦ¡A33¢Hªº¤HªÍ©M12¢Hªº¤HµÇŦ¦³»´«×¾¹©x·l¶Ë¡C25¢Hªº±wªÌµo²{¦h¾¹©x·l¶Ë¡C ... ¯h³Ò¯gª¬§óÃø±´¯Á¡C³Ìªñªº¥t¤@¶µ¤j³W¼Ò¬ã¨sªí©ú¡A³oºØ¯gª¬¦bCOVID-19¤§«á«Ü±`¨£-µo¥Í¦b¤@¥b¥H¤Wªº¯f¨Ò¤¤-¦ü¥G»P¦´Á¯e¯fªºÄY«µ{«×µLÃö¡C §ó«nªº¬O¡A´ú¸Õªí©ú³QÀˬdªÌªºª¢¯g¤ô¥¨S¦³¤É°ª¡A³oªí©ú¥L̪º¯h³Ò¤£¬O¥Ñ«ùÄò·P¬V©Î§K¬Ì¨t²Î¶W®É¤u§@¤Þ°_ªº¡C³o¶µ¬ã¨s¤¤ªø®Ä¯gª¬ªº¦MÀI¦]¯À¥]¬A¤k©Ê-»PCOVID Symptom App¬ã¨s«O«ù¤@P-¦³½ìªº¬O¡A¥H«e´¿¶EÂ_¥XµJ¼{©M§íÆ{¡C ... ¦ý¬O¡A«Ü²M·¡ªº¬O¡ACOVID-19¤§«áªºªø´Á¯gª¬«Ü´¶¹M¡A¦Ó¥B¦bÃzµo¥»¨®ø°h«Üªø®É¶¡«á¡A¥i¯à»Ýn¬ã¨sªøCOVIDªºì¦]©MªvÀø¤èªk¡C SNB01·Ç³Æ¹ïªì½T¶EªÌ¶i¦æÁ{§É °£¤F±wªÌ¤H¼Æªºì¦]¥~ , ¤£µL [ ¨î¼Ä¾÷¥ý ¨¾±w¥¼µo®É ] ªº¦Ò¶q ¦b¯f¬r¥¼³y¦¨¾¹©x·l®`¤§«e , ´NÄè¼Ä©óµL§Î , ©Î¬O«nªºªvÀøµ¦²¤ ¦Ü©ó±z©Ò´£ªºÄvª§¹ï¤â ¤pªº»{¬° Ävª§¹ï¤â«Ü¦h , ·íµMCNS»â°ì¤ñ°_Àù¯g¤Ö¦h¤F ©Ò¥H¥²¶·¦³©Ò¿ï¾Ü¤~¯à¸`¬Ù®É¶¡ºë¤O , ¤pªº¦Û¤vªº¼Ð·Ç¬O : ¥X¦âªº¤G´ÁÁ{§ÉÀø®Ä©Î¤T´ÁÁ{§É¦¨¥\ ¨ä¥Lªº®É¶¡¥Î¨Ó¤F¸Ñ¦Û¤v©Ò§ë¸ê¤½¥qªº²£«~ ¤pªº¤£¬O¬ì¯Z¥X¨ , ¥i¯à¬y©ó¬ïÆwªþ·| , ÁٽФj®a®ü²[ ÁÂÁ¤j®a! |
|
|
·|û¡G¨Dª¾Y´÷10148579 µoªí®É¶¡:2021/1/6 ¤U¤È 11:30:23²Ä 1106 ½g¦^À³
|
¤p§Ìªþ©M«i©¹ª½«e¤j¡Aªñ¨Ó¤p§Ì´X¦¸¶K¤å¤j¦h¦bÁ¿¤½¥qªºÁô¼~¤è±¡A µL©`ªº¬O¡A§Y¨Ïªþ¤WªvÀøªÍª¢Ävª§¹ï¤âÃĪ«³ø¾É¡A¤]¥¼¨£ª©¤WÃö¤ß¡A ¤j®a³£¬°¤½¥q¦n¡A¦ý¬O«o¦n¹³¹ïÄvª§¹ï¤âµø¦Ó¤£¨£¡A ³o¦¸ªk¤H»¡©ú·|·|¦³¦h¤Ö¦³®Ä¸ê°T¡A¤p§Ì¤w¤£©ê¤Ó¤j§Æ±æ¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/6 ¤U¤È 06:57:34²Ä 1105 ½g¦^À³
|
«i©¹ª½«e¤j ¥¢·q¤F! ¤µ¤Ñ¤S¬Ý¨ì¤@½g¤å³¹ ¬O¦b»¡ ¸²µå¿}¥NÁªº¨â²ÓM¼Ò«¬ ºë¯«¤Àµõ¯gªº°²»¡ www.nature.com/articles/s41380-020-00980-4 Interestingly, many of the listed risk genes and biomarker candidates of schizophrenia are functionally and directly connected to the dynamics of this cell-to-cell passage of glucose [1]. The direct action of glucose and glucose metabolites in regulating cell homeostasis sets glucose metabolism as the ¡¥major in command¡¦ or as the ¡¥operating system¡¦ of cells. Thus, the ¡¥chicken-egg dilemma¡¦ in schizophrenia can be reduced to imbalance in glucose metabolism [33]. It would also prevent us from reaching the end of our tour, which concludes with the fact that glucose levels are significantly increased in the cerebrospinal fluid of ¡¥drug naïve¡¦ schizophrenics [34]. *** Brain Glucose, Insulin Resistance, and Memory in Schizophrenia www.psychiatrictimes.com/view/brain-glucose-insulin-resistance-and-memory-schizophrenia °O¾Ð»Ùê¤wÅã¥Ü¥X·|·l®`ºë¯«¤Àµõ¯g±wªÌªº¥Í¬¡½è¶q¡C³Ìªñªº¤@¶µ¬ã¨sµo²{¡A¯Ø®q¯À©è§Ü¥i¯à¬O¸Ó¤H¸s°O¾Ð³à¥¢ªº®Ú¥»ì¦]¡C *** Impaired Glucose Tolerance and Schizophrenia: It¡¦s Not Just the Medications Steven Dubovsky, MD reviewing Pillinger T et al. JAMA Psychiatry 2017 Jan 11 www.jwatch.org/na43300/2017/01/27/impaired-glucose-tolerance-and-schizophrenia-its-not-just *** Impaired Fasting Glucose Tolerance in First-Episode, Drug-Naive Patients With Schizophrenia ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.160.2.284 CONCLUSIONS: First-episode, drug-naive patients with schizophrenia have impaired fasting glucose tolerance and are more insulin resistant and have higher levels of plasma glucose, insulin, and cortisol than healthy comparison subjects. µM¦Ó www.ncbi.nlm.nih.gov/pmc/articles/PMC5344773/ ªø´Á¥H¨Ó¤H̤@ª½»{¬°¡A¤j¸£¤¤ªº¸²µå¿}Äá¨ú»P¨ã¦³GLUT1©MGLUT3¸²µå¿}Âà¹B³J¥Õªº¯Ø®q¯À§¹¥þµLÃö¡A¨Ã¥B¹ï¯Ø®q¯À«D±Ó·P¡CµM¦Ó¡A²{¦b»{ÃѨìGLUT4¸²µå¿}Âà¹B³J¥Õ¬O¯Ø®q¯À¨üÅé©M¯Ø®q¯À±Ó·P©Ê¸²µå¿}Âà¹B³J¥Õ¡A¨ä¦s¦b©ó¦å¸£«Ì»Ù¡]BBB¡^©M¬Y¨ÇÃþ«¬ªº¸£²ÓM¤¤¡C¦³½ìªº¬O³o¨ÇÂà¹B´I§t¦b°O¾Ð©M¾Ç²ß³B²zµo¥Í¦b°ª³t²vªº°Ï°ì¡C³Ì²×¡A¼W¥[¸£/ CNSªº¸²µå¿}Äá¨ú±N»Ýn¼W¥[GLUT4©Î¯Ø®q¯À¨üÅ骺½Õ¸`¡C *** Current understanding of glucose transporter 4 expression and functional mechanisms. europepmc.org/article/pmc/pmc7672939 ¸£²ÓM¦b¥¿±`¥Í²z±ø¥ó¤U¤£Â_§Q¥Î¸²µå¿}²£¥Í¯à¶q¡C¤j¸£¨C¤Ñ¥i®ø¯Ó¬ù120 g¸²µå¿}¡A¬ù420 kcal¡A¦û¤HÃþ¹ï¶HÄá¤Jªº¸²µå¿}ªº60¢H. ¤j¸£¤¤¸²µå¿}¥NÁªº´î¤Ö¥i¯à¾ÉP»{ª¾¯Ê³´¡C ¯Ø®q¯À¬O®ü°¨°O¾Ð¹Lµ{ªºÃöÁ䦨¤À¡A¯S§O°Ñ»P½Õ¸`®ü°¨»{ª¾¹Lµ{©M¥NÁ¡C¯Ø®q¯À½Õ¸`ªº¸²µå¿}¥NÁ¨ú¨M©ó¤j¸£¤¤ªº°Ï°ì¡C¥Ö½è©M®ü°¨¬O¤j¸£¤¤³Ì±Ó·Pªº°Ï°ì¡C ¥t¤@¤è±¡A¯Ø®q¯À¨ë¿E¥i¥H¼W±j°O¾Ð¤O©M»{ª¾¥\¯à¡C¦p¤j¹«©Ò¥Ü¡A³oºØ¼W±j¥i¯à»Ýn¤j¸£GLUT4©ö¦ì¡C½T©w¤j¸£¤¤GLUT4ªºªí¹FÃÐ¥H¤Î¼vÅTGLUT4ªí¹F©M©ö¦ìªº¦]¯À«D±`«n¡C *** Gallic acid induces GLUT4 translocation and glucose uptake activity in 3T3‐L1 cells febs.onlinelibrary.wiley.com/doi/full/10.1016/j.febslet.2009.11.092 ¦b¥Ø«eªº¤u§@¤¤¡A§Ṳ́w¸gÃÒ©ú¤F¨S¹¤l»Ä¥i¥H¥HAktµLÃö¦ý¹ï´ì°Ò«CÅð¯À ( wortmannin ) ±Ó·Pªº¤è¦¡¼W¥[GLUT4©ö¦ì©M¸²µå¿}Äá¨ú¬¡©Ê¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G«i©¹ª½«e10141841 µoªí®É¶¡:2021/1/6 ¤U¤È 01:57:11²Ä 1104 ½g¦^À³
|
«Ü¼Ö¨£¤½¥q¦b¨C¦~¨Ò¦æªºªÑªF·|¤¤¶¡, ·N¥~¦a¦h¤F³o¤@³õªk»¡·|, ˬO¤@ӫܦnªº¾÷·|ÅýªÑªF»P¤½¥q¥æ¬y·N¨£ ±q¤½§i¤º®e¬Ý¨Ó, ¦ü¥GµJÂI·|µÛ²´©óCOVID-19Ô¿ï·sÃÄSNB01»P¦¬®×¤¤ªºSND-13 ©Z¥Õ»¡¹L©¹ªºªÑªF·|·Pı³£¤£¬O¤Ó¦n, ¦pªG¤£¬O¦p¤Ñ®Ñ¯ëªº¬ì¾Ç¬ã¨s¤À¨É, ´N¬O¹³¥h¦~¤@¼Ë³z¹L¹q¸Ü(ÁÙ¨S¦³µø°T)ªº·s»D¤À¨É, ¦Ñ¸Ü«´£, ÁٽЦU¦ìªÑªF¦^ÂkªÑªFªº±M·~, ¦n¦nÀ˵ø¤½¥qªºÀç¹B©M¥¼¨Óªº°õ¦æpµe ¦Aºë¥©µ´§®ªº³]p, ¨S¦³½T¤Áªº°õ¦æ, ³£¬O¤Ñ¾ô¤U»¡®Ñ! «e¨®¤§Å³¦³: SND-14, SND-51, SNG-12, SNA-1...., ¦U¦ì±¿¤ß¦Û°Ý¦³¦h®t³o¤@ÓSNB01¶Ü? «Ü¥i±¤¦b¤UµLªk«e¥h°Ñ¥[, ¦³´XÓ°ÝÃDÁÙ·Q½Ðª©¤WªºªB¤ÍÀ°¦£½Ð½²¸³¨Æªø¦^µª: 1. SND-13 ¥Ø«e¦¬®×¶i«×, ¤U¤@¦¸´Á¤¤¤ÀªR¹w¦ô®É¶¡? ¦pªG¦¬®×°±º¢, ¦³¨S¦³¬ÛÃö¦]À³ªº°t®M±¹¬I? 2. ¥Ø«e¥i¨£pipelineªº¿ð¤£¦¬®×, Äpµ²ÂI´N¬O¦b¸êª÷, ½Í¤F¼Æ¦~ªº±ÂÅv, ¤é«e¤w²×¤î»PÃö«Y¥ø·~¨Ì¦X¬ù¨óij¸Ñ°£±M§QÅv±ÂÅv(¸Ô¨£12/23¤½§i), ªñ¦~ªº¸êª÷¨Ó·½¦h¥b¬O¨p¤H, ¤½¥q¨s³º¸êª÷¶Ò¶°³¡¤Àªº³W¹º¬O¬Æ»ò? °õ¦æµ{«×¨ìþ¸Ì? À³¸Ó¥²nÅýªÑªFª¾±x 3. SNB01¹wp¦¬®×ªº®Éµ{»P¶O¥Î? ¦³¨S¦³¦P®É¶¡±µ¬¢ªº¦X§@¼t°Ó? ¥H¥Ø«e±b¤W²{ª÷«ÜÅãµMµLªk¦P®É¤ä¼µSNB01»PSND-13, ½Ð°Ý¤½¥q¦b³o¨âªÌ¤§¶¡ªº¨ú±Ë¦w±Æ»PÀu¥ý¶¶§Ç? ¥Ø«e¦b¤U¯à·Q¨ìªº´N¬O³o¨Ç, ÁٽЪѪF±µ¤O! ¦pªG§Æ±æ¤ß®®¦n, ¦b¤U»{¬°ª©¤Wªº¦U¦ì¤j¤jÁÙ¬O±o¤ñ¸û¹ê»Úªº¨Ó¬Ý«Ý¤½¥qÀç¹B, §_«h¤Ñ¾ô¤U»¡®Ñ¤£¹L´N¬O´ê¼ö¾x½}¤F....¥H¥Ø«e½²¸³¨Æªø¼Æ¦¸ªÑªF·|ªºªí²{¬Ý¨Ó, ¤ß®®n¦A«¬B§ë¸ê¤Hªº«H¤ß, ¥i¯àµLªk¥u¾a¬ì¾Ç¯«¸Ü, ¹ê»Ú¤Wªº¸êª÷¶Ò¶°©M°õ¦æ¤O¤~¬O«ÂI! ½²¸³¨Æªø¦b¸ê¥»¥«³õ¤£¬O½²±Ð±Â, ¬O¨Ã´¸êª÷¶Ò¶°, ¤½¥qÀç¹B, ¹êÅç°õ¦æ.....¦U¤è±ªº¸³¨Æªø |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/5 ¤W¤È 08:20:13²Ä 1103 ½g¦^À³
|
¨Ì¹ù¥S¶K¥XªºÁܽШç liawbf.pixnet.net/blog/post/49571169 ¥DÁ¿¤H¬° ½²¸³¨Æªøº[°õ¦æªø ijµ{ : 14:30 ~ 15:00 ¨Ó»«³ø¨ì 15:00 ~ 16:00 ¤½¥q²³ø 16:00 ~ 16:30 ·N¨£¥æ¬y»P Q & A ½Ð¤j®a¿ãÅD³ø¦W°Ñ¥[ ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/4 ¤U¤È 07:38:20²Ä 1102 ½g¦^À³
|
¤@¨ÇCOVID-19ƦsªÌ¦]®ð¨ý©M¨ý¹Dªº³à¥¢¦Ó§xÂZ 2021¦~1¤ë2¤é¡A¤W¤È10:04 | §ó·s©ó2021¦~1¤ë2¤é¤U¤È4:21 www.seattletimes.com/nation-world/some-covid-19-survivors-haunted-by-loss-of-smell-and-taste/?amp=1 §@¬°«aª¬¯f¬r¤Þ°_ªº¯e¯f¡ACOVID-19ªº¨å«¬¯gª¬¤§¤@´N¬O¶åı´î®z¡AºÙ¬°¶åı¥¢½Õ¡C³o¬O¬Y¨Ç±wªÌªº²Ä¤@Ó¯gª¬¡A¦³®É¬O°ß¤@ªº¡C³o¨Ç±wªÌ±`¦ñ¦³¨ýı»Ùê¡A¬ðµM¦Ó¼@¯P¦aµo¥Í¶åı¥¢½Õ¡A´X¥G´N¹³¬O¼·°Ê¶}Ãö¤@¼Ë¡C ¶åıªº³à¥¢¬OµJ¼{©M§íÆ{ªº¦MÀI¦]¯À¡A¦]¦¹¡A¼sªxªº¥¢¯v¯gªº¼vÅT²`²`§xÂZµÛ¤ß²z°·±d±M®a¡CMalaspina©M¨ä¥L¬ã¨s¤Hûµo²{¡Aºë¯«¤Àµõ¯g±wªÌªº¶åı¥\¯à»Ùê³q±`¥ý©óªÀ¥æ¯Ê³´¡A¬Æ¦Ü¦b°·±dÓÅ餤¤]¥X²{ªÀ¥æ°hÁY¡C ¡§±q¤½¦@½Ã¥Íªº¨¤«×¨Ó¬Ý¡A³o½T¹ê«Ü«n¡A¡¨¹F¶ð»¡¡C¡§¦pªG±z¦b¥þ²y½d³ò¤º¦Ò¼{COVIDªº¤H¼Æ¡A§Y¨Ï¥u¦³10¢Hªº¤H¦³§óªøªº®ð¨ý®ø¥¢®É¶¡¡A§Ú̦b½Í½×ªº¤]¥i¯à¬O¼Æ¥H¦Ê¸Upªº¤H¡C¡¨ |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/4 ¤U¤È 06:20:37²Ä 1101 ½g¦^À³
|
¥»¤½¥q¨üÁÜ°Ñ¥[´I¨¹ÃÒ¨éÁ|¿ì¤§ªk¤H»¡©ú·| ¨Æ¹êµo¥Í¤é¡G110/01/13 1.¥l¶}ªk¤H»¡©ú·|¤§¤é´Á¡G110/01/13 2.¥l¶}ªk¤H»¡©ú·|¤§®É¶¡¡G15 ®É 00 ¤À 3.¥l¶}ªk¤H»¡©ú·|¤§¦aÂI¡G¥x¥_¥«ªQ¤s°Ï¥Á¥ÍªF¸ô¤T¬q138¸¹B1(´I¨¹ºî¦XÃÒ¨é¥Á¥Í¤À¤½¥qºtÁ¿ÆU) 4.ªk¤H»¡©ú·|¾Ün°T®§¡G¥»¤½¥q¨üÁÜ°Ñ¥[´I¨¹ÃÒ¨éÁ|¿ì¤§ªk¤H»¡©ú·| 5.ªk¤H»¡©ú·|²³ø¤º®e¡G¤º®eÀɮשó·í¤é·|«á¤½§i©ó¤½¶}¸ê°TÆ[´ú¯¸ 6.¤½¥qºô¯¸¬O§_¦³´£¨Ñªk¤H»¡©ú·|¤º®e¡G¦³¡Aºô§}¡G www.syneurx.com/ 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ¡Gªk¤H»¡©ú·|¬ÛÃö²³ø¸ê®Æ¨Ì³W©w¤½§i©ó¤½¶}¸ê°TÆ[´ú¯¸¡C ³o¬O½²±Ð±Â¥DÁ¿ , ÁÙ¬O«¸°ÆÁ` ? ¥t¥~ ¬Q¤Ñ½Í¨ìªº PDEs §í¨î¾¯ ¤]·|¦¨¬°ªvÀøºë¯«¤Àµõ¯gªº¼Ð¹v¶Ü ? Y¥i¥H , «h NaBen ªº½á§Î¾¯ TA ¤]·|¦³§U©ó¼W¥[Á{§ÉÀø®Ä¶Ü ? PDE Inhibitors for the Treatment of Schizophrenia DOI : 10.1007/978-3-319-58811-7_14 ¼Æ¾Ú¤ä«ùªø´Á¦s¦bªººë¯«¤Àµõ¯g·§©À¡A§Y¥H¤¤¸£¡]¯¾ª¬ÅéD2¡^¦h¤ÚÓi¨t²Î¹L«×¬¡ÅD¬°¯S¼xªº¯e¯f¡C¥t¥~¡A²{¦b¦³¤j¶qÃÒ¾Úªí©ú¡A³q¹LNMDA«¬¨üÅ餶¾Éªº¨¦®ò»Ä¯«¸g¶Ç»¼¦bºë¯«¤Àµõ¯g±wªÌ¤¤¬O¤£¨¬ªº¡A¨Ã¥B¥Ö½è¦h¤ÚÓi©M¨¦®ò»Ä³~®|ªº¬¡©Ê¤£¨¬¬O³oºØÄY«ºë¯«»ÙꪺÃöÁä¯S¼x¡CÁöµM¥Ø«eªº§Üºë¯«¯fÃĪ«-¨ã¦³¯A¤Î¦h¤ÚÓiD2¨üÅé«ú§Ü§@¥Î©Î«e¬ðIJ³¡¤À¿E°Ê§@¥Îªº±`¨£¾÷¨î-¨¬¥H¸Ñ¨M¯e¯fªº¥¿©Ê¯gª¬¡A¨Ò¦p«æ©Ê¤Ûı©M¦k·Q¡A¦ý¥¦Ì¤£¯à¥R¤À§ïµ½½Ñ¦pªÀ¥æ©t¥ßµ¥t©Ê¯S¼x¡A¨Ã¥B·|¶i¤@¨B·l®`»Pºë¯«¤Àµõ¯g¬ÛÃöªº¤£¨}»{ª¾¥\¯à¡C¹ê»Ú¤W¡A»{ª¾»Ùê¬Oºë¯«¤Àµõ¯gªº®Ö¤ß¯S¼x¡C¦]¦¹¡A»Pºë¯«¤Àµõ¯g¦³Ãöªº»{ª¾»Ùê©M¨ä¥L´Ý¾l¯gª¬ªºªvÀø¤´µM¬O¥¼º¡¨¬ªº«nÂå¾Ç»Ý¨D¡C¥Ñ©ó·í«e°ò©ó²ÓMªí±¨üÅ骺ÃIJz¾Ç¤£¯à¸Ñ¨M³o¨Ç®Ö¤ßªº»{ª¾¯gª¬¡A¦]¦¹ªvÀø¶}µoªº³Ì·s¤èªk¶°¤¤©ó²ÓM¤ºªº¹Lµ{¡C¦b³o½gµû½×¤¤ §ÚÌ°Q½×¤FÀôª¬®Ö苷»Ä¡]cNT¡^ÁC»Ä¤Gµw¯×酶¡]PDEs¡^-±±¨î¸£¤¤ÃöÁä²Ä¤G«H¨Ï«H¸¹³q¸ô¬¡©Êªº²ÓM¤º酶ªº«n©Ê¡A¸Ó酶¤w³Q´£Ä³§@¬°·s«¬ºë¯«¤Àµõ¯gªvÀøªº¥Ø¼Ð¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/3 ¤U¤È 08:07:22²Ä 1100 ½g¦^À³
|
¥þ²y¬I¥´¬Ì] ¾¥¦èôÂå®v±µºØ«á¤J°|ªvÀø 2021-01-03 18:08 ¤¤¥¡ªÀ / ¾¥¦èô¥«2¤éºî¦X¥~¹q³ø¾É udn.com/news/story/120944/5144025?from=udn_ch2_menu_v2_main_index ¾¥¦èô½Ã¥Í³¡¦b1¤éµo¥¬ªºÁn©ú¤¤»¡¡G¡uªì¨Bªº¶EÂ_¬O¸£¯áÅ誢¡C¡v¸£¯áÅ誢 ( encephalomyelitis ) ¬O¤j¸£©M¯áÅèµoª¢¡C Activation of aryl hydrocarbon receptor signaling by a novel agonist ameliorates autoimmune encephalomyelitis pubmed.ncbi.nlm.nih.gov/31026283/ Conclusion: Our findings identify GA as a novel Ahr ligand and provide molecular mechanisms elucidating the ameliorative effects of GA on EAE, suggesting that GA is a potential therapeutic agent to control inflammation in autoimmune diseases such as MS. ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/3 ¤U¤È 06:29:16²Ä 1099 ½g¦^À³
|
¥L¤Hªº±M§Q¤å¥ó´¦òUªvÀø¶å¡B¨ýıªº¾÷¨î Methods and compositions for diagnosing and treating hyposmia patents.google.com/patent/WO2014059197A1/en 1. A method of diagnosing a taste or smell disorder in a subject, the method comprising: ¡K 32. The method of any one of claims 2-31 , wherein treating comprises administering a pharmaceutical composition comprising an effective amount of one or more phosphodiesterase ( ÁC»Ä¤Gà酶 ) inhibitors to the subject. ¡K 35. The method of any one of claims 32-34, wherein the one or more PDE inhibitors comprise a non-selective PDE inhibitor, a PDE-1 selective inhibitor, a PDE-2 selective inhibitor, a PDE-3 selective inhibitor, a PDE-4 selective inhibitor, a PDE-5 selective inhibitor, or a combination thereof. 36. A method of treating taste or smell disorders in a subject in need thereof, the method comprising administering an effective amount of an inhibitor of a pro -inflammatory cytokine. ¡K 44. A method of treating a taste or smell disorder in a subject in need thereof, the method comprising administering a pharmaceutical composition comprising an effective amount of an adenylyl cyclase activator ( ¸¢苷»ÄÀô¤Æ酶¿E¬¡¾¯ ) , a guanylyl cyclase activator ( Ðg°òÀô¤Æ酶¿E¬¡¾¯ ), a cAMP analog, a cGMP analog, or a combination thereof. ¡K 47. A method of treating a taste or smell disorder in a subject in need thereof, the method comprising administering a pharmaceutical composition comprising an effective amount of one or more anti-inflammatory cytokines to the subject. ¡K ¤]´N¬O»¡ ªvÀø¨ýı©Î¶åı»Ùê ¥Îªº¬O . phosphodiesterase ( PDE-1 ~ 5 ) inhibitors ©M . inhibitor of a pro -inflammatory cytokine . adenylyl cyclase activator ( ¸¢苷»ÄÀô¤Æ酶¿E¬¡¾¯ ) , a guanylyl cyclase activator ( Ðg°òÀô¤Æ酶¿E¬¡¾¯ ), a cAMP analog, a cGMP analog, . anti-inflammatory cytokines PDE§í¨î¾¯¥i¥H³q¹L§í¨î¨ä¥ÑPDE°¸Ñ¦Ó©µªø©Î¼W±j¥ÑcAMP©ÎcGMP¤¶¾Éªº¥Í²z¹Lµ{ªº§@¥Î¡C ¦]¦¹¡APDE§í¨î¾¯³Q»{¬°¦bÀù¯gªº»²§UªvÀø¤¤¨ã¦³«Ü¤jªºªvÀø»ùÈ¡C PDE§í¨î¾¯¤]³Q¥Î©óªvÀø«D´c©Ê¯e¯f¦pý³Ý¡AªÍ°Ê¯ß°ªÀ£©M«k°_¥\¯à»Ùêµ¥¡C ¦¹¥~¡A¥¦Ì¤w³Q½T©w¬°«a¤ß¯f¡Aè§b¡A§íÆ{¯g©Mºë¯«¤Àµõ¯gµ¥»â°ìªº·s¼ç¦bªvÀø¾¯¡C *** Elucidation of Phosphodiesterase-1 Inhibitory Effect of Some Selected Natural Polyphenolics Using In Vitro and In Silico Methods www.eurekaselect.com/145033/article In conclusion, chlorogenic acid, rutin, gallic acid, and resveratrol could be promising PDE-1 inhibitors and leads to identify new drug candidates against PDE-1-associated disorders. *** In Vitro Inhibition of Phosphodiesterase 3B (PDE 3B) by Anthocyanin-Rich Fruit Juice Extracts and Selected Anthocyanins This study investigated 18 AC-rich juice extracts and pure reference compounds from red fruits for potential inhibitory effects on PDE 3B activity. All extracts comprised high amounts of phenolic compounds, as determined by the Folin¡VCiocalteu assay, ranging from 39.8 ¡Ó 1.5 to 73.5 ¡Ó 4.8 g gallic acid equivalents (GAE)/100 g extract. *** Inhibition of cyclic diadenylate cyclase, DisA, by polyphenols www.nature.com/articles/srep25445 Out of 14 tested polyphenols, tannic acid (TA), theaflavin-3¡¬-gallate (TF2B) and theaflavin-3,3¡¬-digallate (TF3) exhibited inhibitory effects on B. subtilis c-di-AMP synthase, DisA. TF2B and TF3 specifically inhibited DisA but not YybT (a PDE) whilst TA was more promiscuous and inhibited both DisA and YybT. *** tannic acid [Ligand Id: 4319] activity data www.guidetopharmacology.org/GRAC/LigandActivityRangeVisForward?ligandId=4319 Phosphodiesterase PDE5 enzyme inhibition IC50 = 4703 nM ( ? ) *** Application of gallic acid to preparation of phosphodiesterase inhibitor anti inflammatory medicine patents.google.com/patent/CN102389411A/en *** Influence of gallic acid on porcine neutrophils phosphodiesterase 4, IL-6, TNF-£\ and rat arthritis model www.sciencedirect.com/science/article/pii/S2095311914608248 Therefore, the anti-inflammatory effect of gallic acid may be mediated in part through an inhibition on PDE4 activity and further an increase of IL-6 and a decrease of TNF-£\ of neutrophils,¡K *** Differential long-term effects of tannic acid on adenyl cyclase activity and lipolysis in rat adipocytes pubmed.ncbi.nlm.nih.gov/11515719/ On the other hand, tannic acid supplementation decreased both basal and isoproterenol-stimulated lipolysis significantly whereas cyclic AMP production as well as adenyl cyclase activity increased significantly. *** Gallic Acid Inhibits Histamine Release and Pro-inflammatory Cytokine Production in Mast Cells Our findings provide evidence that gallic acid inhibits mast cell-derived inflammatory allergic reactions by blocking histamine release and pro-inflammatory cytokine expression, and suggest the mechanisms of action. Furthermore, in vivo and in vitro anti-allergic effect of gallic acid suggests a possible therapeutic application of this agent in inflammatory allergic diseases. The release of histamine is known to be depressed by an increase in intracellular cAMP content due to the activation of adenylate cyclase or inhibition of cAMP phosphodiesterase (Makino et al., 1987). . The intracellular cAMP content of the mast cells, when incubated with gallic acid, increased in comparison with that of basal cells. These results suggest that the effects of gallic acid on the allergic reaction may be associated with an increase in the intracellular cAMP content of the mast cells as a result of an inhibition of the cAMP phosphodiesterase. TA ©M GA ªº¥\¯àµY·ãº¡¥Ø , Åý¤H²´ªá¼º¶Ã ¥¦Ì¨ì©³¯à¤£¯àªvÀø SARS-CoV-2 ©Ò¤Þ°_ªº¶å¡B¨ýı»Ùê©O ? °£¤Fn§â·s«a¯f¬rª®±þ¥~ ³o¨Ç¿ò¯d¤U¨Óªº¶å¡B¨ýı¨Öµo¯g , ¤W¦Cªº¾÷¨î¯à§_µo¥Í§@¥Î ? ÁÙ¦³ TA ¡BGAªº¿@«×¬O§_¥i¥H²£¥Í®ÄªG ? ³£¬OÃöÁä ·íµMÁÙ¬O¦Ñ¸Ü¤@¥y , ³o¤´«ÝÁ{§ÉÅçÃÒ ½Í¨ì³o¸Ì , ¤£¸T¹ï¤ß®®ªº¹Î¶¤·P¨ì·q¨Ø SNB01´X¥Gn¬Æ»ò¦³¬Æ»ò , ³oÀ³¬O±M·~ , ¦Ó¤£¬O°¸µM ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/2 ¤U¤È 07:40:26²Ä 1098 ½g¦^À³
|
CADENCE-BZ ¨â²Õ¤À¤£¶} , ´N³s D-Ói°ò»Ä¤]¤@¼ËôǦn ¥i±¤ªº¬O , 2013¦~ SBªº¥[¦¨¸ÕÅç¨S¦³ÀË´úD-Ói°ò»Äªº¿@«× , Åý§Ú̵Lªk¤ñ¸û¨ä¶¡ªº²§¦P µM¦Ó ÂÅÂå®v¹Î¶¤¤§«á¤S°µ¤F¨â¶µSBªºÁ{§É¸ÕÅç , ¨âÓÁ{§É³£¦³¶q´ú D-Ói°ò»Ä¿@«× , ÁöµLªkª½±µªº¹ï¤ñ , ¦ý¤]ºâ¬O²á³Ó©óµL¤F ²Ä¤@Ó SB + Clozapine ªvÀøÃøªv©ÊSCZ Sodium Benzoate, a D-amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial DOI : 10.1016/j.biopsych.2017.12.006 ¨ä¤¤ Table 5. Baseline and endpoint DAAO and amino acids levels DAAO protein, ng/mL : SB ²Õ : 1 g Baseline : 46.4 (5.8) Endpoint : 47.5 (7.4) Difference mean (SD) : 1.1 (4.7) SB ²Õ : 2 g Baseline : 49.9 (8.9) Endpoint : 46.8 (11.8) Difference mean (SD) : -3.1 (9.2) Placebo ²Õ : Baseline : 41.9 (6.2) Endpoint : 45.0 (9.1) Difference mean (SD) : 3.0 (6.6) D-serine (ng/mL) : SB ²Õ : 1 g Baseline : 33.8 (8.6) Endpoint : 38.1 (14.2) Difference mean (SD) : 4.4 (8.9) SB ²Õ : 2 g Baseline : 37.2 (12.4) Endpoint : 36.7 (13.4) Difference mean (SD) : -0.5 (15.6) Placebo ²Õ : Baseline : 44.8 (29.2) Endpoint : 50.2 (48.8) Difference mean (SD) : 5.2 (24.6) D-alanine (ng/mL) SB ²Õ : 1 g Baseline : 11.7 (12.5) Endpoint : 11.4 (11.0) Difference mean (SD) : -0.3 (7.8) SB ²Õ : 2 g Baseline : 12.6 (23.9) Endpoint : 18.0 (34.6) Difference mean (SD) : 5.5 (31.4) Placebo ²Õ : Baseline : 10.6 (13.8) Endpoint : 14.9 (21.9) Difference mean (SD) : 4.1 (10.9) ¥t¤@Ó¸ÕÅç SB ªvÀø AD ªº BPSD Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) www.ncbi.nlm.nih.gov/pmc/articles/PMC7039065/ ¨ä¤¤ Table 1 Results of Measures of Serum DAAO, Plasma Amino Acids, and Plasma Antioxidants Over the 6-Week Treatment Between Sodium Benzoate and Placebo Groups DAAO protein, ng/mL : SB ²Õ : Baseline : 46.3 ¡Ó 13.1 Endpoint : 45.7 ¡Ó 16.7 Difference mean (SD) : −0.2 ¡Ó 13.8 Placebo ²Õ : Baseline : 45.1 ¡Ó 17.2 Endpoint : 50.3 ¡Ó 20.7 Difference mean (SD) : 2.8 ¡Ó 20.4 D-Serine, ng/mL : SB ²Õ : Baseline : 55.2 ¡Ó 35.0 Endpoint : 53.1 ¡Ó 25.9 Difference mean (SD) : −2.7 ¡Ó 36.4 Placebo ²Õ : Baseline : 53.4 ¡Ó 27.4 Endpoint : 47.4 ¡Ó 24.3 Difference mean (SD) : −6.1 ¡Ó 19.0 D-Alanine, ng/mL : SB ²Õ : Baseline : 42.4 ¡Ó 39.2 Endpoint : 34.5 ¡Ó 33.2 Difference mean (SD) : −8.1 ¡Ó 51.9 Placebo ²Õ : Baseline : 37.8 ¡Ó 26.2 Endpoint : 36.4 ¡Ó 39.9 Difference mean (SD) : −1.4 ¡Ó 31.7 ¾ã²z¤W±ªº¼Æ¾Ú 1. SB + Clozapine ªvÀøÃøªv©ÊSCZªºÁ{§É¸ÕÅç ( ¬A²Å¤º¼Æ¦r¬°°ò½u¿@«× ) SB 1 g ²Õ : ¸gªvÀø«á DAAO ( 46.4 ) ¤p´T¤É°ª ; D-Serine ( 33.8 ) ¤É°ª ; D-alanine ( 11.7 ) ªñ¥G«ù¥ SB 2 g ²Õ : ¸gªvÀø«á DAAO ( 49.9 ) °§C ; D-Serine ( 37.2 ) ¤p´T°§C ; D-alanine ( 12.6 ) ¤É°ª Placebo ²Õ : ¸ÕÅç«á DAAO ( 41.9 )¤É°ª ; D-Serine ( 44.8 ) ¤É°ª ; D-alanine ( 10.6 ) ¤É°ª 2. SB ªvÀø AD ªº BPSD Á{§É¸ÕÅç ( ¬A²Å¤º¼Æ¦r¬°°ò½u¿@«× ) SB ²Õ : ¸gªvÀø«á DAAO ( 46.3 ) ¤p´T°§C ; D-Serine ( 55.2 ) ¤p´T°§C ; D-alanine ( 42.4 ) ¤j´T°§C Placebo ²Õ : ¸ÕÅç«á DAAO ( 45.1 ) ¤É°ª ; D-Serine ( 53.4 ) °§C ; D-alanine ( 37.8 ) ¤p´T°§C §ÚÌ¥i¥H¬Ý¨ì DAAO¿@«×ªº¤É°¹ï©ó D-Ói°ò»Äªº¼vÅT , ¤pªº§ä¤£¥X¤@Ó³W«ß ¦ý ¦b §Ü©ÊSCZ ©M AD ±wªÌ¤§¶¡ ¦ü¥G¥i¥HÁô¬ù¬Ý¥X DAAO¿@«×¬Ûªñ ( À³¬O¥©¦X? ) , µM¦Ó§Ü©ÊSCZ±wªÌ D-Ói°ò»Äªº¿@«×«h©úÅã¦a§C©ó AD±wªÌ «D±`²Å¦X SCZ ±wªÌ NMDA¥\¯à§C¤Uªº²z½× ¦Ó ¦bÂÅÂå®v¹Î¶¤ªº¥t½g¤@½×¤å¤¤ Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging www.nature.com/articles/s41598-017-13951-7 ¨ä¤¤ Table 1 Demographic characteristics of the overall cohort (n = 397) ¦C¦³°·±dªÌªº¼Æ¾Ú ©M AD±wªÌ¦U¿@«×ªºÁÍ¶Õ DAAO level (ng/mL), mean (SD) : Healthy elderly : 23.9 (11.2) MCI : 32.2 (10.8) Mild AD : 38.1 (14.4) Moderate to severe AD : 41.4 (19.5) D-serine level (ng/mL), mean (SD) : Healthy elderly : 30.8 (11.6) MCI : 44.6 (25.8) Mild AD : 47.5 (29.6) Moderate to severe AD : 50.1 (25.5) D-alanine level (ng/mL), mean (SD) : Healthy elderly : 30.2 (38.0) MCI : 35.1 (34.2) Mild AD : 27.8 (34.3) Moderate to severe AD : 39.0 (41.2) ¤S ¥ÑSBªvÀø AD ªºBPSD ±wªÌªº°ò¥»¯S¼x¤¤ CDR at baseline, n (%) CDR 1 : 28 (57.1) ; 30 (62.5) CDR 2 : 16 (32.7) ; 12 (25.0) CDR 3 : 5 (10.2) ; 6 (12.5) SB ²Õ©M¹ï·Ó²Õ ³£¬O¥H CDR=1 ¬°¥Dnªº²Õ¦¨¦¨û ©Ò¥H¬Oªñ©ó MCI ªº±wªÌ ¦ü¥G©M³Ì«á¤@½g½×¤åªº¼Æ¾Ú ¦³¨ÇÉä®æ ( «eªÌªºD-serine ¤ô¥ °ª©ó ¤¤««×AD±wªÌ ) ¥H¤pªºµ{«× , ·íµM¬Oµ¥«Ýª¾ªÌ¨Ó±Ï´©¤F ¸Ü»¡¦^¨Ó CADENCE-BZªº¸ÕÅç , ¨â²Õ¼Æ¾Ú³£¶K±o«Üªñ SB + Clozapine ªº PANSS total«h¦¨¥\¹F¼Ð ¦ý¬O DAAO level¡BD-serine level¡BD-alanine levelªº¼Æ¾Ú¤@¼Ë²ö°J¤@¬O , Åý¤H°g´b ©Ò¥H , ¨ì©³¬O¬Æ»ò¼Ëªºì¦]¾ÉP¨âªÌ¤£¤@¼Ëªºµ²ªG ? ¬O¤pªº¦b¥»ª©²Ä 1089½g¶K¤åªºì¦] ? ÁÙ¬O¥t¦³¨ä¥L¦]¯À ? ³o¤SÅý§Ú·Q¨ì´Á¤¤¤ÀªR®É DSMBªº¨M©w ¨º´N¬O DSMB ¬°¬Æ»òn§â¤À°t¤ñ¨Ò±q 1 : 3 §ï¬° 1 : 2.5 «á, ¦Ó¤£¨M©w¼W¤£¼W¥[¼Ë¥»¼Æ ? °²¦p DSMB ¦b¬Ý§¹¦A¼W¥[ªº30¤H«á ( ±µªñ¤U¥b¶¥¬qªº 1 / 3 (30/91) ) ¨M©w¼W¥[¼Ë¥»¼Æ ¬J¤w§ó°Ê¤À°t¤ñ¨Ò¤S¼W¥[¼Ë¥»¼Æ , ³o¤£¬O§ó©ì©µ¸ÕÅç¶i«×¤F¶Ü ? ³oÅãµM¬O«Ü¤£²Å¦XÅ޿誺Á|±¹ DSMBªº¦¨û³£¬O¾Ç¦³±Mºëªº±M®a ¥L̤£¥i¯à¥Ç¤F³s§Ú̳£·Q±o¨ìªº¿ù»~ ©Ò¥H , ¥L̬ݨì¤F¬Æ»ò ? ´X¥ó¨Æ³s¦b¤@°_ªÈÄñ¤£²M , ¯u¬O¶Ë¸£µ¬§r ! ¦ýÄ@¦³°ª¤H¥i¥H¸Ñµª , Åý§ÚÌÂç²MÀYºü ! ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2021/1/1 ¤U¤È 06:50:38²Ä 1097 ½g¦^À³
|
ÁÂÁ¹ù¥S¹ï¿D¬w CADENCE-BZ ¸ÕÅçµ²ªGªº³ø¾É©Mµûz liawbf.pixnet.net/blog/post/49544569 ³o¬O¤@½g¦n¤Í¤å³¹ , ½Ð¤j®a§â´¤ªüÀ±ªû¦ò ¦ò½Ï¤é¶}©ñ¦n¤Í¤å³¹ªº´Á¶¡ ¾¨³t¾\Ū ÁÂÁ¹ù¥S ÁÂÁ¤j®a ! ¨Ã¯¬¤j®a·s¦~¦p·N! ¦n¨Æ¦~¦~¨Ó ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/31 ¤W¤È 08:20:27²Ä 1096 ½g¦^À³
|
<< COVID-19 >> ¸ÞÃÔÃø´ú ! ·s«a¯f¬r S1 ³J¥Õ½è¥i¬ï¹L¤p¹«¦å¸£«Ì»Ù , ¤Þµo¸£³¡µoª¢³y¦¨ [ ¸£Ãú ] ¯gª¬ www.genetinfo.com/international-news/item/44525.html |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/30 ¤W¤È 10:15:18²Ä 1095 ½g¦^À³
|
·PÁ ¨Dª¾Y´÷¤jªº¸É¥R ¬Ý¨ìAPN01 ªºÓ®×³ø§i , ¦³µÛÀ~¤HªºÀø®Ä --- ¤@¡B¨â¤Ñ´N¥i¥HÅý«¯g±wªÌ·P¬V¯gª¬©úÅã§ïµ½ ; ¥ÍµØ¬ìªºSilmitasertib ¤]¬OÓ®×Åý«¯g±wªÌ¥i¥H5¤Ñ¥X°| APEIRON Biologics ¤½¥qªº©xºô ¸Ô¦CµÛAPN01¤TÓ¿W¯Sªº MOA www.apeiron-biologics.com/our-work-on-a-potential-drug-candidate-for-covid-19/ . Virus neutralization ( APN01 ¬O¤@ºØ¥Íª«»s¾¯¶Ü ? ) . APN01 can reduce injury to multiple organs including the lung, kidneys and the heart, and reduces disease mediated organ pathology. . APN01 triggers reduction of inflammatory cytokines and chemokines ¤S APN01 ¬ORecombinant Human Angiotensin Converting Enzyme 2 www.ncbi.nlm.nih.gov/medgen/416051 ¤pªº¤£²M·¡¥¦«²Õ®e©ö¶Ü ? ¦¨¥»¶Q¤£¶Q ? ´NAPEIRON Biologics ¤½¥q ¦b2020/12/04 ¤w§¹¦¨¤G´ÁÁ{§É¦¬®×ªº³ø¾É APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01 www.pharmiweb.com/press-release/2020-12-04/apeiron-biologics-patient-recruitment-completed-in-phase-ii-covid-19-clinical-trial-of-apn01 ´£¨ì ¸Ó¸ÕÅ窺¥Dn¥Øªº¬O¨Ï¥Î«I¤J©Ê¾÷±ñ³q®ðµ¥¼Ð·Ç , µû¦ôAPN01¦b«¯gCOVID-19±wªÌ¤¤ªºÁ{§ÉÀø®Ä©M¦w¥þ©Ê¡C¦¸n¥Ø¼Ð¥]¬Aµû¦ôAPN01ªvÀø«á¥i´ú¶qªº¥Íª«¼Ð»xª«ªºÅܤơC ©Ò¥H APN01¬O¥Î¦b«¯g±wªÌªºªvÀø , ¥ÍµØ¬ìªºSilmitasertib¤]¬O¥Î¦b«¯g±wªÌ , ¤£¹LSilmitasertib¬O¤p¤À¤lªº CK2§í¨î¾¯ ¤ß®®ªºSNB01 ¬ã¨s°_¨Ó ( ½Ð°Ñ¤p§Ì¥H«e¶K¤å ) , ¤]¦h¨ã¦³³o¨Ç¥\¯à ¥u¤£¹LSNB01¬O³]p¥Î¦b»´¡B¤¤¯g±wªÌ ( ½T¶E«á48¤p®É¤º ) , ¥B©|¥¼¸g¤HÅéÃÒ¹ê , °ß SNB01¬O¦Û¥D¬ãµo , ¤£¹³«e¤GªÌ³£¬O§ÞÂà¦Û¥L¤H ¤Ï¥¿ , ÃĪ«´N¬O¤ñÀø®Ä ¡B¦¨¥» , ÁÙ¦³±wªÌªº°Ï¹jµ¦²¤ ¨ì©³¤ß®®·s«a·sÃĪºÄvª§¤O¦p¦ó ? ´Nµ¥®É¶¡¨ÓÃÒ©ú ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¨Dª¾Y´÷10148579 µoªí®É¶¡:2020/12/29 ¤U¤È 11:40:05²Ä 1094 ½g¦^À³
|
²q·Q¤j¦³½Í¨ìACE2¨üÅé¤Î·s»D¤À¨É¶åı²§±`¡A ¦ý¬Q¤éGENET¤@«h¥~°ê¥ÍÂå·s»D¡A¤@¼Ë°w¹ï«aª¬¯f¬r(SARS)¡A¤@¼Ë¦³¬ì¾Ç¤Wªº®Ú¾Ú¡A ¤@«¯g¯f±wªýÂ_ACE2¨üÅé«á2¤é¡A¦å²G»PªÍ³¡¤w§ä¤£¨ì¯f¬r¡AÃĪ««Ü¥i¯à2021¦~ªì·Ç³Æ¤W¥«.... www.genetinfo.com/international-news/item/41936.html ¨ä¹êªñ´ÁACE2¨üÅé¬ã¨s¦¨ªG¤£¤Ö¡A¦ý¬Ò¦³¤@©wªº¦¬Ã¬¡A ¦p¤p§Ì¤§«e©Ò»¡¡u¦pµy¦³Àø®Ä¡A®Éµ{§Ö³t§Y¥i¥ý¦WÁn¤j¾¸¡B¿W»â·ÄÌ¡v¡A¤£ª¾SNB1Áٯ঳¦h¤Ö¾÷·|... ¥t¤£ª¾¹D¬°¦ó¤@ª½½ÍTA¥Î©óªvÀø¦¹¦¸ªº¤j¬y¦æªÍª¢¡A¥H¤½¥q¤½¥¬ªº¸ê°T¡A °w¹ï3CLpro+«aª¬¯f¬r©ÎSARS¡A¬Oª½±µ¥i§ä¨ì¤¤¬ã°|2006¦~ªº¦¹«h°T®§¡A www.genomics.sinica.edu.tw/index.php/tw/component/content/article/6-news/news-archives/166-sars ¡uf¨Ã¤TÐüàÃþ¤Æ¦Xª«¡]Benzotriazole esters¡^¹ï©ó3CLpro¨ã¦³¥X¥G·N®Æªº§í¨î®ÄªG¡v¡A ¹ê½è´N¤£ª¾¬O§_¬°¦¹Ãþª«½èªºl¥Íª«¡A¦ý¦Ü¤Ö¦³«e¤H¬ã¨s¥i°Ñ¦Ò¡A¦Ó¦pSNB1¸ÕÅ礣¬O¤j¦n¡A ¤½¥q¦pII´Á¨«§¹¨M©w¤£¨«III´Á¡A³Ì«á¥i¯à¤]µL±qÃÒ¹ê¤F¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/29 ¤U¤È 07:13:22²Ä 1093 ½g¦^À³
|
¬Q¤é¥»ª©²Ä 1092½g¶K¤å , ³ø¾É¤F·s«a¯f¬r¤Þ°_ªº¶åı³à¥¢©MË¿ù , ¤]§â·s«a¯f¬rºÙ¬°¡u¿Ë¯«¸g²Õ´©Ê¯f¬r¡v¡]neurotropic virus¡^. Genet ºô¯¸¤]¦³¬ÛÃö³ø¾É ·s«a¯f¬r¦p¦ó¤Þµo¶åı³à¥¢ ? www.genetinfo.com/international-news/item/44482.html ·s«a¯f¬r¦³Ó«Ü¯S®íªº¯gª¬ , ¨º´N¬O¦³ 80 % ªº±wªÌ·|¸g¾ú¶åı»P¨ýı³à¥¢ ¶V¨Ó¶V¦hªº¬ã¨sÅã¥Ü , ¶åı¯«¸g¤¸¨S¦³ACE2¨üÅé , ¤]¤£¨ü SARS-CoV-2ªº·P¬V , ¦ý¶åı¯«¸g¤¸ªº¤ä«ù²ÓM ¡V sustentacular ²ÓM«o¦³ACE2¨üÅé , ·í¥¦¾D¨ì¯}Ãa®É , «KµLªkºû«ùÂH²G¤¤ÆQÂ÷¤lªº¥¿Å , ¨Ï¯«¸g¤¸µLªk¦V¤j¸£¶Ç°e°T®§ . SNB02 ¥i¥H¶Ü ? PROTECTIVE ACTION OF CERTAIN CHEMICALS AGAINST INFECTION OF MONKEYS WITH NASALLY INSTILLED POLIOMYELITIS VIRUS ¬Y¨Ç¤Æ¾ÇÃÄ«~¹ï·P¬V»óª¢¯áÅè¦Ç½èª¢¯f¬rªºµU¤lªº¨¾Å@§@¥Î rupress.org/jem/article/63/6/877/3429/PROTECTIVE-ACTION-OF-CERTAIN-CHEMICALS-AGAINST . In the present investigation evidence was obtained indicating that nasal instillations of suitable concentrations of sodium alum or tannic acid induce in Macacus rhesus monkeys resistance to the development of poliomyelitis when the virus is introduced by the nasal route. . Experiments designed to elucidate the development of this refractory state in monkeys indicate that it is a result of the action of these chemicals not upon the virus but rather upon the tissues of the host (probably the olfactory mucosa); further evidence in favor of this hypothesis may be found in the observation that several days of treatment are required before resistance is induced. . It was observed, however, that monkeys which were given nasal instillations of alum or tannic acid for 5 days or more may retain the resistance they acquired for 1 or 2 months without any additional treatment (Table V) . As far as could be ascertained, the nasal instillation of tannic acid or alum in man proved thoroughly innocuous beyond some local irritation for a short time. The desirability of testing this procedure as an aid in the prevention of poliomyelitis in man during the months of greatest incidence or during epidemics is quite apparent. µM¦Ó ¡K THE EFFECTS OF TANNIC ACID NASAL SPRAYS ON THE INCIDENCE OF UPPER RESPIRATORY INFECTIONS ( ªþµù : common cold ) DOI:10.1016/S0022-3476(38)80105-0 No significant difference was observed between the treated group and the untreated group. It is probable that blocking of the nasal passages affords effective protection only in those diseases which are caused by strictly neurotropic viruses ( ¿Ë¯«¸g²Õ´©Ê¯f¬r ). THE RAPID INVASION OF THE BODY THROUGH THE OLFACTORY MUCOSA rupress.org/jem/article-pdf/65/2/303/1180910/303.pdf . The results reported elsewhere show that such preliminary treatment gave no protection against pneumococci ( ªÍª¢Ãì²yµß ). . The fact that tannic acid, which prevents the passage of pigment into the olfactory neurones, offers protection against certain viruses, suggests that the latter may enter these olfactory sensory cells as does the pigment. . The experimental results suggest an explanation of the fate of viruses instilled into the nose. If neurotropic viruses ( ¿Ë¯«¸g²Õ´©Ê¯f¬r ) do enter the olfactory neurones like the pigment, they would tend rather to be held here than to pass freely to the tissues and the brain. Experimentally they have not been found in the brain immediately . ( ³o¬O·s«a¯f¬rªº¿Ë¯«¸g¯S©Ê , ©Ò¥H·|¦b¦³¶åı¯«¸gªº»óµÄ¤º°±¯d , ¶i¦Ó·l®`¶åı¯«¸g¤¸¤ä«ù²ÓM , §Î¦¨¶åı»Ùê°ª¹F80 % ªºì¦]¶Ü ( ¯f¬r¤j³¡¤À¥Ñ»óµÄ·P¬V ) ? ) The pantropic viruses ,however, should be able to pass freely out of the olfactory cells and experimentally one such virus has been shown to reach the brain immediately., . Preliminary treatment of the olfactory mucosa with tannic acid does not alter the speed with which this absorption occurs. It does, however, cause an inflammation of the mucosa and appears to prevent the pigment from entering the olfactory sensory cells. ±µ¤U¨Ó , ¤pªº´N¤£²M·¡§@ªÌ¬O¦b»¡ TA ¬O¦³§U©ó®ø«Ú parosmia ? ÁÙ¬O§Uªøparosmia ? ¦³½ÐŪÀ´ªº¤j¤jÀ°¦£¸Ñ»¡ ! ÁÂÁ ! Signs and symptoms, etiologies and clinical course of parosmia + in a series of 84 patients pubmed.ncbi.nlm.nih.gov/10671709/ Products which produced the parosmic perception were identified by nearly all the patients (85%). The most frequently cited products were coffee, perfume, certain fruits (melon, banana, citric fruits), tobacco or chocolate. All these products contain tannic acid, a water-soluble polyphenol with many biological properties (influence feeding habits and metabolism in the rate, antioxidant and antimutagenic properties). Thus acid tannic could induce parosmic perception due to its antioxidant properties susceptible of integrating the P-450 cytochromes of the mucosal cells or olfactory neuroepithelium supporting cells. Åý¤H²´ªá¼º¶Ã¡Bµ²ªG¤S¤£¤@Pªº¤å³¹ Áö¬O¦p¦¹ , µM¤T½g1930sªº¤å³¹³£·t¥ÜµÛ TA ¹ï¿Ë¯«¸g²Õ´©Ê¯f¬r ( neurotropic viruses ) ªº·s«a¯f¬r¥i¯à¦³©Ò§@¥Î ©Ò¥H TA¹ï·s«a¯f¬r©Ò¤Þµoªº¯gª¬¯à§_¨ú±oÀø®Ä ? ÁÙ¦³½w¸Ñ¥¦©Ò±a¨Óªº¯«¸g²§±`¦X¨Ö¯g ? ¦³«ÝÁ{§Éµ²ªG¨ÓÅçÃÒ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/28 ¤U¤È 08:28:38²Ä 1092 ½g¦^À³
|
·s«aÃz¸Þ²§·s¯gª¬ ±wªÌ¨g»D¨ì³½¸{¦½¯ä¨ý Âå¡G2±Ú¸s¬O¤j©v 17:07 2020/12/28 ¤¤®É·s»Dºô §d¬Mêd www.chinatimes.com/realtimenews/20201228004293-260408?ctrack=pc_main_recmd_p19&chdtv ^°ê¦Õ»ó³ï¥~¬ìÂå®v®wº¿¡]Nirmal Kumar¡^«ü¥X¡A³oºØ¡u«D±`©_©Ç¡vªº¯gª¬ºÙ¬°¡u¶åı˿ù¡v¡]parosmia¡^¡C ®wº¿»¡¡A¥ḺN·s«a¯f¬rºÙ¬°¡u¿Ë¯«¸g²Õ´©Ê¯f¬r¡v¡]neurotropic virus¡^¡A¥L»¡³o¥Nªí¯f¬r¥¿¦b¼vÅT»ó¤l³»ºÝªº¯«¸g¡A´N¹³¯«¸g¨t²Î¬ðµM¨ü¨ì½ÄÀ»¡A³o¨Ç¯«¸gµLªkµo´§§@¥Î¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/27 ¤U¤È 08:05:12²Ä 1091 ½g¦^À³
|
°Ñ¦Ò¤@¤U GA §@¬°DAAO§í¨î¾¯ªº¤p¹«¸ÕÅç ³o·|¦³§U©ó NaBen ( SB + TA ) ¼W¥[ D-serine ªº¿@«×¶Ü¡H patentscope.wipo.int/search/en/detail.jsf?docId=WO2016146026&tab=FULLTEXT&_cid=P12-KJ726E-77236-5 ±M§Q¤å¥ó¤¾ªø¡A¬Ý¹Ï¥i²¤ª¾GAªº®ÄªG ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/24 ¤W¤È 11:17:15²Ä 1090 ½g¦^À³
|
¥»ª©²Ä1087¶K¤å , §ÚÌ´£¨ì¤F P2X7¨üÅé¹L«×¬¡¤Æ¬OCOVID-19¯«¸g¯f²z¾Çªº¸o»íº×º ( www.nature.com/articles/s41380-020-00965-3 ) ¦Ó TA ©M GA ³£¦³§í¨î¥¦©Î¥¦ªº¤U´åNLRP3ªº¥\¯à , ©Î¦³¾÷·|ݪvCOVID-19©Ò¨Öµoªº¯«¸g»Ùê ³o¥i¯à¬O²³¦hCOVID-19¸ÕÅ礤·sÃĩүʥFªº ¤]¥i¯à¬O TA °£§í¨î·s«a¯f¬r½Æ»s¥~ ©Ò¨ã¦³ªº¿W¤@µL¤Gªº¯«¸gªvÀø¾÷²z ¤×¨ä·s«a¯f¬r¬ðÅÜÀW¤´ , ¤µ¤é¤S¶Ç¥X«n«D·sÅÜºØ §ó¬ðÅÜ¡B§ó¨ã¶Ç¬V¤O¡I^°êµo²{«n«D·sÅܺدf¬r ±wªÌ¦³Åå¤HÅÜ¤Æ www.chinatimes.com/realtimenews/20201224000892-260408?ctrack=pc_main_headl_p01&chdtv 05:14 2020/12/24 ¤¤®É·s»Dºô °ª¼w¶¶ ¬Ì]¦³¥i¯à³à¥¢¨ä«OÅ@¥\¯à , ÅýÃĪ«ªvÀø¤´¦³¨äªÅ¶¡ §ÚÌ´Á«Ý SNB01 »°§ÖÁ{§É , ¨Ó¬Ý¬Ý¥¦¯à@ªº¼s«× ¤]ų©óP2X7¨üÅé¹ï¯«¸gªº§@¥Î , Åý¤pªºÁp·Q¥¦¬O§_¤]¬O SCZ ©M AD ªºªvÀø¼Ð¹v ? P2X7¨üÅé¦bø¥¾¦°Êª«PCP»¤µoªººë¯«¤Àµõ¯g¼Ò«¬¤¤ªº§@¥Î pubmed.ncbi.nlm.nih.gov/27824163/ §ÚÌÅã¥ÜP2X7Rsªº¿ò¶Ç§R°£©MÃIJz§í¨î§@¥Î´î»´¤Fºë¯«¤Àµõ¯g¼Ë¦æ¬°§ïÅÜ¡C¦bP2rx7 + / +¤p¹«¤¤¡APCP¤Þ°_¹B°Ê¹L«×¡A¨èªO¦L¶H¦æ¬°¡A¦@ÀÙ¥¢½Õ©MªÀ¥æ°hÁY¡C¦bP2X7¨üÅé¯Ê¥F¤p¹«¡]P2rx7-/-¡^¤¤¡AªÀ¥æ¤¬°Ê¼W¥[¡A¦ÓPCP»¤¾Éªº¹L«×¹B°Ê©M¨èªO¦æ¬°¤]±o¨ì½w¸Ñ¡C§Ú̪ºµo²{«ü¥XP2X7R¬Oºë¯«¤Àµõ¯gªº¼ç¦bªvÀø¹v¼Ð¡C P2X7¨üÅé¦bªüº¸¯ý®üÀq¤ó¯f¤p¹«¼Ò«¬¤¤ªº·s§@¥Î pubmed.ncbi.nlm.nih.gov/29934546/ §ÚÌÅã¥Ü¯Ê¥FP2X7R´î¤Ö¤FA£]¯fÅÜ¡A¥i¥H®¾±Ï»{ª¾»Ùê¨Ã§ïµ½AD¤p¹«ªº¬ðIJ¥i¶ì©Ê¡C Á`¤§¡A§Ú̪º¬ã¨s¬ð¥X¤FP2X7R¦bÁͤƦ]¤lÄÀ©ñ¤¤ªº·s«¬¦³®`¥\¯à¡A¨Ã¤ä«ùP2X7R¥i¯à¬OAD¦³§Æ±æªºªvÀø¹vÂIªºÆ[ÂI¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/23 ¤U¤È 01:55:28²Ä 1089 ½g¦^À³
|
·PÁ Cliff ¤j®¦¼w À°§Ú̸ѪR¨Ã´£¨Ñ¤@Ó¤£¤@¼Ëªº«ä¦Ò¨¤«× , Åý§Ú̸£¤O¿EÀú ¬°¦ó 2a ªº¹ï·Ó²Õ¥i¥H±Æ°£¦w¼¢¾¯®ÄÀ³ ? ¦ÓCADENCE-BZ«o¤£¦æ ? ©ÎªÌ»¡ CADENCE-BZªº¹ï·Ó²Õ©Ò§ïµ½ªº´T«× , ¬°¦óBZ²Õ¤£¯à¦AÀA¤W²Kªá¦a¤j´T©Ô¤j©M¹ï·Ó²Õªº®t¶Z §Ú̪¾¹D ºë¯«¤Àµõ¦³©Ò¿×ªº«æ©Ê´Á©MºC©Ê´Á neupsykey.com/acute-and-chronic-schizophrenia/ . ºë¯«¤Àµõ¯gªºº¦¸ªí²{³q±`¬O«æ©Êµo§@¡A¥]¬A¥¿©Ê¯gª¬¡C¦b¬Y¨Ç±¡ªp¤U¡A±wªÌ¤w¦©ó³o¨Ç¯gª¬µo§@¡CµM¦Ó¡A¦b³\¦h±¡ªp¤U¡A±N·|¦³¤@Ó«ùÄò¼Æ¤ë©Î¼Æ¦~ªº«eÅX¶¥¬q¡A¨ä¤¤·|µo¥Í«D¯S©wªº¦æ¬°ÅܤơA¨Ò¦pªÀ¥æ°hÁY©M¥\¯à°§C¡C . ¤@¨Ç±wªÌ±q«æ©Êºë¯«¤Àµõ¯gµo§@¤¤«ì´_¨}¦n¡C¨ä¥L¤H«h¤£¤Ó©¯¹B¡A«á¨ÓÄ~Äòµo®i¬°¤@ºØºC©Ê¯e¯f¡A¨ä¥\¯à©úÅã°§C¡C¥¿©Ê¯gª¬³q±`¦b¦¹Ãþ±wªÌ¤¤«ùÄò¦s¦b¡A¦ýÁ{§Éªí²{³q±`¥Ht©Ê¯gª¬ªº³vº¥¥X²{¬°¥D¾É¡A¦Ó³o¨Ç³q±`¬O³y¦¨´Ý¯eªº³Ì¤jì¦]¡C±w¦³³oºØºC©Ê¯e¯f³QºÙ¬°ºC©Ê©Î´Ý¯d©Êºë¯«¤Àµõ¯g¡C www.schizophrenic.com/articles/schizophrenia/acute-schizophrenia «æ©Êºë¯«¤Àµõ¯g©¹©¹¤ñºC©Êºë¯«¤Àµõ¯g¹ïªvÀø¦³§ó¦n¤ÏÀ³¡C¨ä¤¤¤@Óì¦]´N¬O¡A¨º¨Ç±w¦³«æ©Êºë¯«¤Àµõ¯gªº¤H©¹©¹¦bµo¯f«e¦³°ª¥\¯à¥v ( history of being high-functioning )¡A«Ü¤Ö©Î¨S¦³ºë¯«¤Àµõ¯gª¬¡C¥t¤@Óì¦]¬Oºë¯«¤Àµõ¯gªº¥¿©Ê¯gª¬ ( §Y«æ©Ê±wªÌªº¥Dn¯gª¬ )¹ï²{¦³ÃĪ«ªº¤ÏÀ³§ó¦n¡C ¥t¥~ ¬ü¡B¼w¾ÇªÌªº½×¤å What does the PANSS mean? www.sciencedirect.com/science/article/abs/pii/S0920996405001611?via%3Dihub Being considered ¡§mildly ill¡¨ according to the CGI approximately corresponded to a PANSS total score of 58 , ¡§moderately ill¡¨ to a PANSS of 75 , ¡§markedly ill¡¨ to a PANSS of 95 and severely ill to a PANSS of 116. [[[ ªþµù :¡@ PANSS items are rated on a 7-point scale ¡@(¡@1=absent ( µL ), 2=minimal ( ·¥·L ), 3=mild ( »´«× ), 4=moderate ( ¤¤«× ), 5=moderate severe ( ¤¤««× ), 6=severe ( ««× ) , and 7=extreme ( ·¥««× )) ]]] ¦bªvÀøÃøªv±wªÌ¡A§Y¨Ï¬O¯gª¬¤pªº§ïµ½¡A¦pPANSS´î¤Ö20%©Î§ó¦nªº25% , ¦bÁ{§É¤W¥i¯à¬O«nªº¡CµM¦Ó¡A¦b«æ©Ê¯f±¡ , «DÃøªv±wªÌ50%ªº¼Ð·Ç¡]§YÁ{§É¤W¤jªº§ïµ½¡^¦ü¥G¬OÁ{§É¦³·N¸q§ïµ½ªº§ó«ê·í¤Ï¬M¡A¦]¬°¦¹Ãþ±wªÌ ( ¥H¥¿©Ê¯gª¬¬°¥D ) ³q±`¹ï§Üºë¯«¯fÃĪ«¤ÏÀ³¨}¦n¡C ©Ò¥H §Ú̬O¤£¬O¥i¥H³o¼Ë»¡ ? 2a©Û¶Òªº±wªÌÀ³ÄÝ©óºC©Ê±wªÌ , ¦b¸g¾ú§Üºë¯«¯fÃĪ«ªvÀøéw«á , §Y¤§«e»¡ªº§Üºë¯«¯fÃĪ«¤O®ð©ñºÉ«á , PANSSÁ`¤À¤´°ª¹F90ªþªñªº¥b§Ü©Ê±wªÌ ¦b§Üºë¯«¯fÃĪ«¤O®ð©ñºÉ«á , PANSSÁ`¤À¤´°ª¹F90 , YµL¦³®ÄªºÃĪ«( ¥u¦³¦w¼¢¾¯ ) ¥[¤JªvÀø , ©Î³\PANSSÁ`¤Àµ¥¶q¤Øªº°´T·|¬O¦³ªº ( ¦]¬°®Ú¥»ÅX°Ê¤£¤F¯f±¡ ) »PBZ²Õ¬Û¤ñ , PANSSÁ`¤À´î´T¦b21% , ¤¶©ó 20% ~ 25% ¤§¶¡ , ©Î¥¿¥iÅã¥ÜBZªºÀø®Ä ¦Ó CADENCE-BZªº±wªÌ , ©Î¬OÄÝ©ó«æ©Ê´Á¤¤ÂàºC©Êªº±wªÌ , ¨äPANSSÁ`¤À¦b75ªþªñ , ¬O¬ü¡B¼w¾ÇªÌ©Ò¿×ªº ¡§ moderately ill ¡¨ ¥i¯à¨ä©Û¶Òªº±wªÌ¤´¥¼¹Féw , §Üºë¯«¯fÃĪ«¤´¦³¾l¤Oµo´§Àø®Ä , ¦b«æ©Ê±wªÌ¸û®e©öªvÀøªº±¡ªp¤U ( ¥ÑÁ{§É¦³·N¸qªùÂe³]¬° PANSS´î´T 50% ´N¥iª¾) , §Î¦¨¹ï·Ó²Õ©MBZ²ÕªºPANSSÁ`¤À´î´T³£¦b 25 %ªþªñ ¨º¬°¤°»ò BZ²ÕµLªk¦A´î§ó¦h ? ¤pªº¤]¤£ª¾¹D ©Î³\ , ¥H BZ²ÕªºPANSSÁ`¤À¤w°¨ì57.6¨Ó¬Ý ( ¤p©ó58 , PANSS¨C¶µµû¤À¥§¡§C©ó2¤À ) , ¤w¬O¬ü¡B¼w¾ÇªÌ©Ò¿×ªº ¡§ mildly ill ¡¨ ( »´«×ªº¯fªp ) , ©Î³\¦A´î´N¤ñ¸û§xÃø ? ©Î¦p¦P¦Ò¸Õ¦Ò80¤À¤£¥²ªá«Ü¤j¤O®ð , ¦ýn¹F95¤À´N¨S¦³¨º»ò®e©ö ? ( ©Î³\¤ñ³ë¤£ºÉ¦X©y ) ¦A¬Ý¬Ý SND-13 2b+3 ¥Ñ©xºôªº¸ê®Æ www.syneurx.com/20200726_syneurx.pdf . ®Ú¾Ú¡mºë¯«¯e¯f¶EÂ_»P²Îp¤â ¥U¡n²Ä¤ª© (DSM-V)½T¶E¿©±wºë¯«¤Àµõ¯g¨â¦~¥H¤W • «D¦í°|¯f¤H • ºë¯«¤Àµõ¯g¯f±¡Ã©w¦ý¦³´Ý¾l¯gª¬ • PANSS ¶qªí¤À¼Æ 72-110¤À • ¦~ÄÖ18-45·³ • Á{§É«e¨âÓ¤ë¥H¤ÎÁ{§É´Á¶¡ºû«ù¬Û¦P¤§§Üºë¯«ÃĪ«»P¾¯¶q ¤T¶µ«ÂI • ºë¯«¤Àµõ¯g¯f±¡Ã©w¦ý¦³´Ý¾l¯gª¬ • PANSS ¶qªí¤À¼Æ 72-110¤À ( ¥§¡ 91 ¤À ) • Á{§É«e¨âÓ¤ë¥H¤ÎÁ{§É´Á¶¡ºû«ù¬Û¦P¤§§Üºë¯«ÃĪ«»P¾¯¶q ©M 2a ªº¤J¿ï±ø¥ó¬O§_¬Û¥h¤£»· ? ¥B¥HSPCD¿z¿ï , ¦h¤F¤@¹D°§C¦w¼¢¾¯®ÄÀ³ªºµ{§Ç Y¥Ñ´Á¤¤¤ÀªR®É DSMB ¤w±N¤À°t¤ñ¨Ò±q 1 : 3 §ï¬° 1 : 2.5 ªº¥¿¦V°T®§¨Ó¬Ý ¬O§_¹ï·Ó²Õªº¦w¼¢¾¯®ÄÀ³¥i¥h°£¤j¥b ? ´Nµ¥Á{§Éµ²ªG¨Ó¦LÃÒ ¤pªº»¡ªk©Î¥¢¤§µLÍùÀY ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2020/12/22 ¤W¤È 12:25:49²Ä 1088 ½g¦^À³
|
Cadence BZ Trialªºµ²ªG²×©ó°Ý¥@¡]µù1¡^¡C ¥H¤UÁY¼g¡GBZ=sodium benzoate=f¥Ò»Ä¶u=SND-13 I´º»¡©ú¡G¡]qcmhr.uq.edu.au/research-streams/epidemiology-clinical-trials/epidemiology-and-clinical-trials-research/¡^ ¸ÕÅç©R¦W¥Ñ¨Ó:¬°¦ó¥s°µCADENCE trial¡H ¬ù¿«•³Í¼wÂå®v¡]John Frederick Joseph Cade AO¡^¬O¿D¬wªººë¯«¬ìÂå®v¡A©ó1948¦~º¦¸µo²{¤FºÒ»Ä¾Y¥iªvÀøļÆ{¯g¡C¦³§O©ó·í®Éºë¯«¯fªº¼Ð·ÇÀøªk¹qµjÅËÀøªk©M¸£¥Õ½è¤Á°£³N¡C(From WIKI) 2013¦~¡AJohn McGrath±Ð±Â³Q¿D¬w°ê®a½Ã¥Í»PÂå¾Ç¬ã¨s²z¨Æ·|¡]NHMRC¡^±Â¤©¬ù¿«•³Í¼w¡]John Cade¡^ºë¯«°·±d¬ã¨s¼ú¾Çª÷¡C¸Ó¼ú¾Çª÷±N¨ÏJohn McGrath±Ð±Â¤Î¨ä¹Î¶¤¦b©ø¤hÄõ¦{ªF«n³¡«Ø¥ßÁ{§É¸ÕÅ祥x¡C ³o¨Ç¸ÕÅç²ÎºÙ¬°Cadence¡A±ýÂdzo¨Ç¬ã¨s¨Ó§ïµ½ªì´Áºë¯«¯f±wªÌªºÁ{§É¹w«á¡C ¥Ø«e³W¹º¤F¤TÓÁ{§É¸ÕÅç¡G 1. Cadence BZ Trial ¬Ý¬ÝBZ¯à§_¦³§U©óºë¯«¯f¡H¡]´N¬O²{¦bµoªíµ²ªGªº³o¤@½g¡^ 2. Cadence M Trial ¬Ý¬Ý¼ö±a¤ôªG¡u¤s¦Ë¡v¯à§_¹ïºë¯«¤Àµõ¯g¦³À°§U¡H 3. Cadence SCIT Trial ¬Ý¬ÝªÀ·|»{ª¾¤¬°Ê°V½m(SCIT) ¯à§_¹ïºë¯«¤Àµõ¯g¦³À°§U¡H ¸ÕÅç¥Øªº¡G 1.¦´Áºë¯«¯f¡]Early Psychosis¡^¡]µù2¡^¥H1000 mg/dayªvÀø12¶g«á¡A¬O§_¦bPANSS¤À¼Æ¤W¯à¤ñ¹ï·Ó²Õ¥X²{©úÅ㪺¯gª¬´î¤Ö¡C 2.¦P®É¤F¸Ñ¥[¤WBZ§@¬°»²§UªvÀø«á¬O§_¯à¦P®É¤]§ïÅܤF¥½±éªº¦å²GÓi°ò»Ä¿@«×¦pD-alanine¡BL-alanine¡BD-serine¡BL-serine? ¤èªk¡G ¦h¤¤¤ß¡AÀH¾÷ªºÁ{§É¸ÕÅç¡C2015/8~2018/7¡A¯Ó®É3¦~¡C ¯Ç¤J±ø¥ó¡G 1.15¦Ü45·³¡C 2.Psychotic disorder¡Gschizophrenia, schizophreniform psychosis, delusional disorder, bipolar disorder, psychosis not otherwise specified . 3.¦bªñ¨â¦~¤ºµo¯fªÌ¡A´Á¶¡³sÄòªA¥Î¤F¤@Ӥ몺ÃĪ̡C 4.PANSS¤À¼Æ¤j©ó55¤ÀªÌ¡C ±Æ°£±ø¥ó¡G 1.¹ïBZ¹L±Ó©Î¹ï¹ª«¨¾»G¾¯¹L±ÓªÌ 2.¯f±¡»ÝÃB¥~ªvÀø©Î»Ý¦í°|ªÌ 3.µLªk¥Î^»y·¾³qªÌ 4.¥Ø«eÃh¥¥¤¤¡B÷¨Å¤¤©Î·Ç³ÆÃh¥¥ªÌ 5.¤w¥[¤J¨ä¥LÁ{§É¸ÕÅçªÌ 6.µLªk²z¸Ñ¥»¸ÕÅç¨BÆJ©Îµ{§ÇªÌ ¾¯¶q¡G BZ 500mg,¤@¤Ñ¨â¦¸¡A¬°´Á12¶g¡C µ²ªG¡G ºn¥Ø¼Ðªº¸ÕÅç²ÕPANSS Total¤À¼Æ¨Ã¥¼»P¹ï·Ó²Õ²£¥ÍÅãµÛ®t²§¡F¦bPANSSªº¦U¤À¶µ¤]¤@¼Ë¡F¥H¤Î¥ô¦ó¦¸n¥Ø¼Ð¡A¥]¬A¦å²G®ò°ò»Ä¿@«×¤]¨S®t²§¡C µL½×¬O¥Hintention- to-treat¤ÀªRªºµ²ªG¡]Table 2¡^©Î¬Oper-protocol¤ÀªRªºµ²ªG¡]eTable 3¡^¡A¨â²Õ³£¨S¦³ÅãµÛ®t²§¡C ¨â²Õ¦b¦U¶µµû¦ôªº¼Æ¾Ú½Ð¬Ý²q·Q¤j¡G²Ä1086½g¶K¤å¡C °Ñ»PӮפÀªR¡G 2015¦~8¤ë~2018¦~7¤ë¡F100¦ì¤J³ò¡F¦ý¦]¨ä¤¤1¦ì³Qµo²{¤w¦Û¦æªA¥Î¹LBZ¡A©Ò¥H³Qç°£¡C³Ñ¤U99¦ì¶i¦æÀH¾÷¤À²Õ¡C¥§¡¦~ÄÖ21.4·³¡A¨k vs¤k=73¦ìvs 26¦ì¡C³o99¤H¤¤¡A83¦ì(83%)¦³ºë¯«¤Àµõ¯g¡A16¦ì(16%)¬O±¡·P©Ê¯e¯f(Biopolar disorder¡K)¡A³o16¦ì±¡·P©Ê¯e¯f±wªÌ·í¤¤¡A«á¨Ó¸g¹LÀH¾÷¤À²Õ«á¡A¦³7¦ìªA¥Î¤FBZ¡A9¦ìªA¥Î¤F¦w¼¢¾¯¡C °Ñ¥[®É±wªÌªº¥ÎÃĤÀªR¡F ¥HAripiprazole(¦³25¦ì¡^¡BOlanzapine(¦³26¦ì¡^¨âºØ§Üºë¯«ÃĪ«³Q³Ì¦h¤HªA¥Î¡A¨ä¤¤¦³9¦ìÁÙªA¥ÎºÒ»Ä¾Y¡]ªvļ¯g¡^¡C¦Ó2013¦~½²¸³&ÂÅ¥D¥ô¨º½g¬OHaloperidol¸û¦h¦ì¦bªA¥Î(¦³18¦ì¡FCADENCE¶È1¦ì)¡C¨âÓ¸ÕÅç¶È¦³¥|ºØ§Üºë¯«ÃĪ«¬Û¦P¡GAmisulpride¡BHaloperidol¡BQuetiapine¡BRisperidone¡C ¦b2013¦~½²¸³&ÂÅ¥D¥ô¨º½g¸ÕÅ窺¨Æ«á¤ÀªR(Post hoc)¤¤¡Aµo²{ì¤wªA¥ÎHaloperidol©ÎRisperidoneªÌ¥[¤WBZ«á¯S§O¦³®Ä¡Cì¤wªA¥ÎRisperidoneªÌ¡]BZ²Õvs¹ï·Ó²Õ=6¦ìvs 7¦ì¡^ANS¡BGAF¡BQOLS¤ÎCGIªº¤À¼ÆÅãµÛ¦a¤ñ¹ï·Ó²Õ¦n¡F¦ýHDRS¶µ¥Ø¤À¼Æ«h¨S¯S§O¡Cì¤wªA¥ÎHaloperidolªÌ¡]BZ²Õvs¹ï·Ó²Õ=9¦ìvs 9¦ì¡^¥[¤WBZ«á¡A¦bSANS¡BGAF¡BQOLS¤ÎHDRSªº¤À¼ÆÅãµÛ¦a¤ñ¹ï·Ó²Õ¦n¡F¦ýCGI¶µ¥Ø¤À¼Æ«h¨S¯S§O¡C¦Ó¦bCADENCE-BZ¸ÕÅ礤¡Aì¤wªA¥ÎRisperidoneªÌ¡ABZ²Õvs¹ï·Ó²Õ=7¦ìvs 10¦ì¡Fì¤wªA¥ÎHaloperidolªÌ¡ABZ²Õvs¹ï·Ó²Õ=1¦ìvs 0¦ì¡F¼vÅT¤£¤@¦Ó¨¬¡C CADENCE-BZ¸ÕÅ礤¡ABZ²Õvs¹ï·Ó²Õ=49¦ìvs 50¦ì¡C ¦¬®×Ó®×¥¿¦bªA¥Îªº±¡ºü½Õ¸`¾¯¦³¤TºØ¡GLamotrigine¡BLithium carbonate(¾YÆQ)¤Îsodium valproate(«Ò©ÞÄA)³£¸òļ¯gªvÀø¦³Ãö¡C BZ²Õ¦³39¦ì¥uªA¥Î§Üºë¯«ÃĪ«¡A¥t¦³3¦ì¥uªA±¡ºü½Õ¸`¾¯¡A¥t7¦ìݪA§Üºë¯«ÃĪ«¤Î±¡ºü½Õ¸`¾¯¡AªA¥Î±¡ºü½Õ¸`¾¯ªº¤ñ¨Ò¬°20.4%(10/49)¡C¹ï·Ó²Õ¦³43¦ì¥uªA¥Î§Üºë¯«ÃĪ«¡A¥t¦³1¦ì¥uªA±¡ºü½Õ¸`¾¯¡A¥t6¦ìݪA§Üºë¯«ÃĪ«¤Î±¡ºü½Õ¸`¾¯¡AªA¥Î±¡ºü½Õ¸`¾¯ªº¤ñ¨Ò¬°14%(7/50)¡CÁöµM¹ï·Ó²Õ¤¤ªA¥Î±¡ºü½Õ¸`¾¯ªº¤ñ¨Ò§C©óBZ²Õ(14% vs 20.4%)¡A¦ý®Ú¾Ú2000¦~M Tohen et al¬°´Á¥§¡12¶gªº¬ã¨s¡]µù3¡^¡Aµo²{±¡·P©Ê¯e¯f(Bipolar¡Bschizoaffective disorders¡K¡K)¦bªvÀø¤¤¤ñºë¯«¤Àµõ¯g±wªÌ¸û§Ö±o¨ì¯gª¬¤Wªº½w¸Ñ¡A©Ò¥HÃø¥Hºë½T¤F¸Ñ²VÂø¤F±¡·P©Ê¯e¯fӮתº¬ã¨sµ²ªG·|¨ü¨ì¦p¦óªº¤zÂZ¡H ¦bCADENCE-BZ³ø§iªº°Q½×¤¤¡AÁÙ´£¨ì¦¬®×¦~ÄÖ¤ñ2013¦~½²¸³&ÂÅ¥D¥ô¨º½g¸ÕÅç¡]µù4¡^ªº¦~ÄÖ¬°§C¡A¥§¡21.4·³(2013¦~½²¸³¡G37.3·³)¡Fµo¯f®É¶¡¦b³Ìªñ¨â¦~¤º¡A¦Ó2013¦~¨º½g¦¬®×ªÌ¯fµ{¸û¤[¡A¬Æ¦ÜÁÙ¦³¤w²£¥Í§ÜÃĩʪ̡AÄݺC©Êºë¯«¤Àµõ¯gӮסC¨º»ò¡A¬O§_¯à¦bµo¯f«e¨â¦~¤º´N±o¨ìéw¯f±¡¦Ó§â¶EÂ_½T©w¤U¨Ó¤´¬OÅܼơC ¤å¥½§@ªÌ´£¨ìCADENCE-BZ¸ÕÅ窺±ø¥ó¨îªº±´°Q¡G 1.°lÂÜ´Á¶È12¶g¥i¯à¤Óµu¡A¦³¬ã¨s´£¥X¥i¯ànªø¹F6-12Ó¤ë¤~¯àÅý¤@¨Ç¤pªº¥¿±°T¸¹¡AÅã¥Ü¦beffect size¤W¡C 2.¦w¼¢¾¯®ÄÀ³¤Ó°ª¡C 3.Ãö©ó¥½±é¦å²G¤¤ªº¯S©wÓi°ò»Ä¿@«×ªºÅܤơA§@ªÌ»{¬°¥iÂǥѷsªº¬ã¨s¨Ó§ä¥X¥¿½T·s¾¯¶q¡A§âªA¥ÎBZӮתº¯S©w¦å²GÓi°ò»Ä¿@«×¨q¥X¨Ó¡A¦]¬°¥Lı±oDAAO »Ã¯À¨Ã¦s©ó¨x»P¤j¸£¡AªA¥ÎBZ«áÀ³¸Ó¤£¥u¼vÅT¸£¤¤¿@«×¦Ó¤w¡A¤]·|¼vÅT¨ì¨x¡A©Ò¥HÀ³¸Ó¥i¦b¦å²G¤¤¬Ý¨ì¯S©wÓi°ò»Ä¿@«×ÅܤơC µù: 1.¡uEffect of Sodium Benzoate vs Placebo Among Individuals With Early PsychosisA Randomized Clinical Trial¡v¡]2020¡FJames G, Scott et al¡^¡]jamanetwork.com/journals/jamanetworkopen/fullarticle/2772735¡^ 2.©Ò¿×Psychosis¬OÓ¼sªxªº²ÎºÙ¡A³q±`«ü·|¦³¤Ûı(Hallucinations)©Î¦k·Q(Delusions)ªººë¯«¯f¡Aºë¯«¤Àµõ¯g(schizophrenia)¶È©~¨ä¤@¡C 3.¡uThe McLean¡VHarvard First-Episode Project: 6-Month Symptomatic and Functional Outcome in Affective and Nonaffective Psychosis. ¡v(2000;Mauricio Tohen et al)¡]pubmed.ncbi.nlm.nih.gov/11018220/¡^ ¯gª¬§ï¶iªº§ÖºC¡Gmaj. affective disorder(81%)¡Fnon-affective psychosis(74%)¡Fschizoaffective disorder(70%)¡F¦Óschizophrenia¤~36%¡C 4.¡uAdd-on Treatment of Benzoate for SchizophreniaA Randomized, Double-blind, Placebo-Controlled Trial of D-Amino Acid Oxidase Inhibitor¡v¡]2013; Hsien-Yuan Lane et al¡^¡]jamanetwork.com/journals/jamapsychiatry/fullarticle/1746121¡^ ¦n©_: 1. 2013¦~½²¸³&ÂÅ¥D¥ô¨º½g¸ÕÅ窺¦¬®×³]p¬O¦p¦ó±Æ°£¦w¼¢¾¯®ÄÀ³ªº¡H |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/21 ¤U¤È 07:08:44²Ä 1087 ½g¦^À³
|
¤W¬P´Á¬Ý¨ì¤@½g½×¤å Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology P2X7¨üÅé¹L«×¬¡¤Æ¬OCOVID-19¯«¸g¯f²z¾Çªº¸o»íº×º www.nature.com/articles/s41380-020-00965-3 SARS-CoV-2·P¬V»¤¾Éªº²ÓM¥~ATP¤ô¥¤É°ª¥i¯à·|IJµoP2X7¨üÅ骺¹L«×¬¡¤Æ¡A±q¦Ó¾ÉPNLRP3ª¢¯g¤pÅé¨ë¿E¡A§@¬°¯«¸g¤J«I©MÀH«áªº¯«¸gª¢¯g¹Lµ{ªºÃöÁ䤶½è¡C¦b³oºØ±¡ªp¤U¡AP2X7¨üÅé«ú§Ü§@¥Î¥i¯à¬O¹w¨¾©ÎªvÀøCOVID-19±wªÌ¯«¸g¨t²Î¨Öµo¯gªº¦³«e³~µ¦²¤¡C ¤U¦Cªº³o½g½×¤å ¬O§_¤]¦b»¡©ú TA Âǥѧí¨î Cl- , ¦Ó®ø«ÚP2X7 receptor ¤¶¾ÉªººØºØ§@¥Î ? ATP-Gated P2X7 Receptors Require Chloride Channels To Promote Inflammation in Human Macrophages www.jimmunol.org/content/202/3/883 We find that antagonists of PLA2 and Cl− channels abolish P2X7 receptor¡Vmediated current facilitation, membrane permeabilization, blebbing, phospholipid scrambling, inflammasome activation, and IL-1£] release. Facilitation of P2X7Rs is prevented by inhibition of PLA2 and Cl− channels Importantly, tannic acid and A01 significantly reduced ATP-induced Cl− influx (Fig. 5C). ¥t¥~ §Ú̦b¥»ª©²Ä1083¶K¤å ¤]»¡¹L www.frontiersin.org/articles/10.3389/fimmu.2020.580593/full ¨S¹¤l»Ä¹ïNLRP3ª¢©ÊÅ鬡¤Æªº§í¨î§@¥Î¨Ï¨S¹¤l»Ä¦¨¬°ªvÀø»PNLRP3¬ÛÃöªº¯e¯f¡]¨Ò¦p¿}§¿¯f¡Aµh·©Mªüº¸¯ý®üÀq¤ó¯f¡^ªº¦³§l¤Þ¤Oªº·sÔ¿ïªÌ¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/20 ¤U¤È 06:50:58²Ä 1086 ½g¦^À³
|
Cadence - BZ ªº¦w¼¢¾¯²ÕÀø®Ä¶W°ª, ³o¬O쥻ÃĪ«ªºÀø®Ä? ÁÙ¬O¦w¼¢¾¯®ÄÀ³? PANSS Total ¤À¼Æ: Cadence ¡V BZ ¹ï·Ó²Õ : 74.7 => 56 , ¥§¡®t: 18.7 , §ïµ½ 25.03 % BZ ²Õ : 75.9 => 57.2 , ¥§¡®t: 18.7 , §ïµ½ 24.64 % SND-13 2a : ¹ï·Ó²Õ : 87.3 => 81.4 , ¥§¡®t: 5.9 , §ïµ½ 6.76 % BZ ²Õ : 90.3 => 71.7 , ¥§¡®t: 18.6 , §ïµ½ 20.60 % PANSS Positive subscale¤À¼Æ: Cadence - BZ ¹ï·Ó²Õ : 17.6 => 12.9 , ¥§¡®t: 4.7 , §ïµ½ 26.70 % BZ ²Õ : 19.1 => 12.6 , ¥§¡®t: 6.5 , §ïµ½ 34.03 % SND-13 2a : ¹ï·Ó²Õ : 20.4 => 18.8 , ¥§¡®t:1.6 , §ïµ½ 7.84 % BZ ²Õ : 20.6 => 15.3 , ¥§¡®t:5.3 , §ïµ½ 25.73 % PANSS Negative subscale¤À¼Æ: Cadence - BZ ¹ï·Ó²Õ : 19.1 => 15.3 , ¥§¡®t: 3.8 , §ïµ½ 19.90 % BZ ²Õ : 18.2 => 16.0 , ¥§¡®t: 2.2 , §ïµ½ 12.09 % SND-13 2a : ¹ï·Ó²Õ : 24.8 => 23.1 , ¥§¡®t:1.7 , §ïµ½ 6.83 % BZ ²Õ : 26.1 => 20.8 , ¥§¡®t:5.3 , §ïµ½ 20.31 % PANSS general psychopathology subscale¤À¼Æ: Cadence - BZ ¹ï·Ó²Õ : 38.0 => 27.8 , ¥§¡®t: 10.2 , §ïµ½ 26.84 % BZ ²Õ : 38.6 => 28.4 , ¥§¡®t: 10.2 , §ïµ½ 26.42 % SND-13 2a : ¹ï·Ó²Õ : 42.2 => 39.6 , ¥§¡®t:2.6 , §ïµ½ 6.16 % BZ ²Õ : 43.6 => 35.7 , ¥§¡®t:7.9 , §ïµ½ 18.12 % CGI : Clinical Global Impression Cadence - BZ ¹ï·Ó²Õ : 4.1 => 3.2 , ¥§¡®t: 0.9 , §ïµ½ 21.95 % BZ ²Õ : 4.3 => 3.6 , ¥§¡®t: 0.7 , §ïµ½ 16.28 % SND-13 2a : ¹ï·Ó²Õ : 4.5 => 4.3 , ¥§¡®t:0.2 , §ïµ½ 4.44 % BZ ²Õ : 4.6 => 3.5 , ¥§¡®t:1.1 , §ïµ½ 23.91 % GAF : Global Assessment of Functioning Cadence - BZ ¹ï·Ó²Õ : 52.0 => 63.3 , ¥§¡®t: 11.3 , §ïµ½ 21.73 % BZ ²Õ : 52.7 => 61.2 , ¥§¡®t: 8.5 , §ïµ½ 16.13 % SND-13 2a : ¹ï·Ó²Õ : 41.4 => 45.2 , ¥§¡®t:3.8 , §ïµ½ 9.18 % BZ ²Õ : 40.6 => 51.5 , ¥§¡®t:10.9 , §ïµ½ 26.85 % HDRS : Hamilton Depression Rating Scale Cadence - BZ ¹ï·Ó²Õ : 8.7 => 4.6 , ¥§¡®t: 4.1 , §ïµ½ 47.13 % BZ ²Õ : 10.2 => 5.3 , ¥§¡®t: 4.9 , §ïµ½ 48.04 % SND-13 2a : ¹ï·Ó²Õ : 6.3 => 5.2 , ¥§¡®t:1.1 , §ïµ½ 17.46 % BZ ²Õ : 7.1 => 3.8 , ¥§¡®t:3.3 , §ïµ½ 46.48 % QOLS : Assessment of Quality of Life score Cadence - BZ ¹ï·Ó²Õ : 18.8 => 88.9 ( ¼Æ¾Ú¦³°ÝÃD??? ¤£¥i¯à³o»ò°ª,ÁÙ¬O 28.9 ? ) , ¥§¡®t: ??? , §ïµ½ ??? % BZ ²Õ : 19.6 => 86.3 ( ¼Æ¾Ú¦³°ÝÃD??? ¤£¥i¯à³o»ò°ª,ÁÙ¬O 26.3 ? ) , ¥§¡®t: ??? , §ïµ½ ??? % SND-13 2a : ¹ï·Ó²Õ : 16.4 => 20.8 , ¥§¡®t:4.4 , §ïµ½ 26.83 % BZ ²Õ : 15.4 => 26.8 , ¥§¡®t:11.4 , §ïµ½ 74.03 % Cadence ¡V BZ ¤J¿ï¼Ð·Ç : (1) onset of a psychotic disorder within the last 2 years; (2) diagnosis of psychotic disorders according to the Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition (DSM-IV), which include schizophrenia, schizophreniform psychosis, delusional disorder, bipolar disorder and psychosis not otherwise specified; (3) age between 15 and 45 years; (4) treatment with antipsychotic medications for a period of at least one continuous month within the 2-year period as in ¡§(1)¡¨; (5) PANSS total score of at least 55 (i.e. those who have at least moderate symptoms) SND-13 2a¤J¿ï¼Ð·Ç : Patients were enrolled in this study if they (1) were physically healthy and had all laboratory assessments (including routine urine and blood tests, biochemical tests, and electrocardiography) within normal limits, (2) were aged 18 to 65 years, (3) satisfied DSM-IV criteria for schizophrenia confirmed by the Structured Clinical Interview for DSM-IV, (4) remained symptomatic but without clinically significant fluctuation and if the antipsychotic doses were unchanged for at least 3 months and would be maintained during the period of the 6-week trial, (5) had a minimum baseline total score of 60 on the Positive and Negative Syndrome Scale (PANSS), µM¦Ó SND-13 ¬O«ç¼Ëªº¤J¿ï¼Ð·Ç©O ? Inclusion Criteria: . Male/female subjects between 18 and 45 years of age . Physician confirmed DSM-V diagnosis of schizophrenia for the past 2 years based on subject¡¦s history and confirmed by psychiatric evaluation and MINI International Neuropsychiatric Interview For Schizophrenia and Psychotic Disorders, version 7.0 (MINI, Version 7.0) . The subject¡¦s schizophrenia condition is clinically stable with residual symptoms. Residual symptoms will be defined as a total score of ≤110 and ≥ 60 of PANSS per Visit 1 evaluations . An unchanged antipsychotic medication regimen for at least eight (8) weeks prior to screening into the study and expected to remain unchanged during the study (longer for depot or long-acting antipsychotics: ten (10) months for Aripiprazole and Paliperidone; six (6) months for Olanzapine pamoate monohydrate; and at least 6 times duration of the reported half life or minimum four (4) months for other depot or long-acting antipsychotics) ¤j®a¥H¬°³oÓ³]p¦p¦ó©O? ³Ì«án»¡ªº¬O? ³o½g½×¤å¦Ü¤Ö¦³¨âÓ¦a¤è»~´Ó ²Ä¤@Ó ¬O eTable 3 in Supplement 2 cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938577/zoi200798supp2_prod_1604346454.25792.pdf?Expires=2147483647&Signature=HkYDS0ehW7x9JHQW1OTvKUSJ~gMZ54y1tCzkuihf2nJrTVQKT-9-QqFQHP0RSCPwDRGWIqBe12YjKbYl6LvKP~GU5HzP0vdXCMz39ETyAmVJY~wz1uU~uMR~cuMuXfdKSNnpGgxszSGqpkEm9foMYGy6LBwGN~6bQ0vhI5TUhd6midnqMhayvH68Bu8lF~AE9pVH9vs2ur3eAa4MUvcX6VyNXxISGF4D3RVz1Y2p-KlSOV1BtCFJKxyivFxtLcJpvI~ZLp3amYE6XdNtQNRp1OnDvDxdDXEWV43skbZ8BhsNJGeDNW1CjbtEIQhzMeeh8DxZEQAI1ML112l00HX3MA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA ªí®æ¤¤ ¦³¨âÓPANSS positive symptom subscale score ²Ä¤GÓÀ³§ï¬° PANSS negative symptom subscale score ¥t¥~ Assessment of Quality of Life score °ò½u®Éªº¼ÆȬO20ªþªñ ( Table 1 ) , ªvÀø«á°¨¤W¸õ¨ì80´X ( Table 3 ) , Å㦳»~´Ó? ¦A¨Ó Á{§É³]pªº»¡©ú¤£°÷²M·¡ ? ¾ÉP¥~¤H¤@ÀYÃú¤ô , ¬Æ©Î»~§P? ¦A¬Ý¬Ý Table 3 ªº¼Æ¾Ú Difference in score Äæ¦ì ¦ü¥G¬OFinal visit ªº¼ÆȬ۴î , Åý¤H¤£¯à²z¸Ñ ¦]¬°³o¼Ë , Åý¤pªº¤S·Q¥h¤F¸Ñ Significance test ªº tÈ Äæ ©M p value Äæ ¥H¥¦ªº tÈ , ¥ÎEXCEL²Îp¤½¦¡¥hºâ±oªºp value ©Mªí¦CªÌ¬Û¦P ¦ý tÈ «ç»ò¨Ó ? Table 3 ªº t È«Ü©Ç , ¤×¨ä¬O¥¿t²Å¸¹¬O§_¶Ã¤F®M ? ) t ¤£¬Oµ¥©ó ( ¨â²Õ¥§¡®t ) / SQRT ( pooled Åܲ§¼Æ * ( 1 / ¸ÕÅç²Õ¼Ë¥»¼Æ + 1 / ¹ï·Ó²Õ¼Ë¥»¼Æ )) ÁÙ¬O¥t¦³§óºë·Çªººâªk ? ¦³¤j¤j¥i¥HÀ°¤pªº¸Ñ»¡¤@¤U¶Ü? ¥ý¦æÁÂÁ¤F ! ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/20 ¤U¤È 03:03:00²Ä 1085 ½g¦^À³
|
¿ÕµØ7.7»õ¬ü¤¸¦¬ÁÊCadent ¨Ó·½¡G·s®öÂåÃÄ·s»D¡@2020-12-18 ½sĶ丨½dªFªF med.sina.com/article_detail_100_2_93791.html ¤é«e¡A¿ÕµØ«Å¥¬¥¿¦b¥H2.1»õ¬ü¤¸ªº»ù®æ©M¥¼¨Ó¥i¯àªº5.6»õ¬ü¤¸¨½µ{¸O¥I´Ú¡A¦¬ÁÊÁ`³¡¦ì©ó°¨ÂĽѶë¦{¼C¾ôªºCadent Therapeutics¡C ¦¹¦¸¦¬ÁÊ¡A¿ÕµØ±N¾Ö¦³Cadent§¹¾ãªº¯«¸g¬ì¾Ç²£«~½u²Õ¦X¡A¥]¬ANMDAr¶µ¥Ø¡C¸Ó¶µ¥Ø¦³¨âӮ֤ߪºÁ{§É¸ê²£¡ACAD-9303¥¿¦b¶}¾v¥Î©óºë¯«¤Àµõ¯gªºNMDAr¶§©ÊÅܺc½Õ¸`¾¯¡A¦ÓMIJ-821¬ONMDArtÅܺc½Õ¸`¾¯¡A¤w©ó2015¦~±ÂÅvµ¹¿ÕµØ¤½¥q¡CMIJ821¥Ø«e³B©óII´Á¸ÕÅ礤¡A¸ÓÃĪ«¥i¥H¿ï¾Ü©Ê¦a½Õ¸`»P§íÆ{¯g¬ÛÃöªºNMDA¨üÅ骺¤l¶°¡C¿ÕµØÁÙ±NÀò±oCAD-1883ªº¥þ³¡Åv§Q¡A³o¬O¤@ºØ³B©óÁ{§É¶¥¬qªºSK³q¹D¶§©ÊÅܺc½Õ¸`¾¯¡A¥¿¦b°w¹ï¹B°Ê»Ùê¡]¨Ò¦p¤p¸£¦@ÀÙ¥¢½ÕSCA¡^¶}µo¡C §ïµ½AD±wªÌ»{ª¾«ü¼Ð³Ð·s¤fªAÀøªk¹F¨ì2b/3´ÁÁ{§É¥Dn²×ÂI ¨Ó·½¡GÃÄ©ú±d¼w¡@2020-12-17 med.sina.com/article_detail_100_2_93675.html AB Science¤½¥q¶}µoªº°¨ÁÉ´À¥§¬O¤@ºØ¹T®ò»Ä¿E酶 ( tyrosine kinase ) §í¨î¾¯¡C¥¦¨ã¦³Âù«§@¥Î¾÷¨î¡A¤@¤è±¡A³q¹L¯S²§©Ê§í¨îc-Kit¡BLyn¡B©MFyn³J¥Õ¿E酶ªº¬¡©Ê¡A¥¦¥i¥H§í¨îªÎ¤j²ÓM¡]mast cells¡^ªº¿E¬¡¡CªÎ¤j²ÓM¬O¯«¸g°h¦æ©Ê¯e¯f¡Bª¢¯g©Ê¯e¯f©M¸~½F¾Ç¤¤ªº«n¹vÂI¡C¥¦Ìªº¿E¬¡¤¶¾Éªºª¢¯g¤ÏÀ³¥i¯à¬Oªüº¸¯ý®üÀq¯f¯e¯fµo¥Íªº¦]¯À¤§¤@¡C ¦¹¥~¡A°¨ÁÉ´À¥§ÁÙ¯à°÷³q¹L§í¨îMCSFR-1¬¡©Ê¹v¦V¥¨¾½²ÓM/¤p½¦½è²ÓM¡C³o¨Ç²ÓM¦bªüº¸¯ý®üÀq¯fªºª¢¯g¤ÏÀ³¤¤¤]°_¨ì«n§@¥Î¡C ³o¨Ç¾÷Âà SND-51 ¥i¯à¤]¦³ ? 1. Tannic acid, a potent inhibitor of epidermal growth factor receptor tyrosine kinase pubmed.ncbi.nlm.nih.gov/16567414/ In the present study, tannic acid was found to strongly inhibit tyrosine kinase activity of epidermal growth factor receptor (EGFr) in vitro (IC50 = 323 nM). In contrast, the inhibition by tannic acid of p60(c-src) tyrosine kinase (IC50 = 14 microM) and insulin receptor tyrosine kinase (IC50 = 5 microM) was much weaker. 2. Gallic Acid Inhibits Histamine Release and Pro-inflammatory Cytokine Production in Mast Cells academic.oup.com/toxsci/article/91/1/123/1672576 Our findings provide evidence that gallic acid inhibits mast cell-derived inflammatory allergic reactions by blocking histamine release and pro-inflammatory cytokine expression, and suggest the mechanisms of action. Inhibitory Effect of Gallic acid on Production of Chemokine and Growth Factor in Mouse Macrophage Stimulated by Lipopolysaccharide www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001469970 GA significantly inhibited the production of interferon-inducible protein (IP)-10, keratinocyte-derived chemokine(KC), and vascular endothelial growth factor (VEGF) in LPS-induced RAW 264.7 cells at the concentration of 25, 50, 100, 200 uM (p<0.05). GA significantly inhibited the production of monocyte chemoattractant protein-1(MCP-1) and macrophage-colony stimulating factor(M-CSF) in LPS-induced RAW 264.7 cells at the concentration of 50, 100, 200 uM (p<0.05). drugcentral.org/drugcard/5039 §í¨îFynªº IC50 , ¡Vlog[M] = 7.66 ¬ù 21.9 nM ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/9 ¤U¤È 08:13:40²Ä 1084 ½g¦^À³
|
SND-51 ݪv AMD ( ¦Ñ¦~©Ê¶À´³ÅÜ©Ê , age-related macular degeneration ) ? AD ¨ã¦³ AMD ¦X¯f¯gªº±wªÌ¥i¯à¦b 50 % ¥H¤W ? ( 1. ¦Ñ¦~©Ê¶À´³ÅܩʦX¨Öªüº¸¯ý®üÀq¤ó¯fªº¦X¨Ö¯g¡G²Õ´¯f²z¾Ç¯f¨Ò¹ï·Ó¬ã¨s pubmed.ncbi.nlm.nih.gov/31568508/ AD¯f¨ÒªºAMDµo¥Í²v¡]53.0¢H¡^ 2. ªi¦h¾¤¦U¦è¯Z¤ú¸Ç¦¨¦~¤H¤¤»P¦~ÄÖ¬ÛÃöªº¶À´³Åܩʦbªüº¸¯ý®üÀq¤ó¯f¤¤ªº±w¯f²v www.aaopt.org/detail/knowledge-base-article/prevalence-of-age-related-macular-degeneration-in-alzheimers-disease-among-hispanics-adults-in-puerto-rico-339197-3234053 The proportion of AMD in subjects with AD (56.6%) ) ¤µ¤é¥Xª©ªº½×¤å ¼g¹D µÇ¯À-¦åºÞºò±i¯À¨t²Î·l®`¥¨¾½²ÓM¯×½è¥NÁ¡A«P¶i¤p¹«¼Ò«¬¤¤»P¦~ÄÖ¦³Ãöªº¶À´³ÅÜ©Ê www.nature.com/articles/s42003-020-01483-2 ¤@ºØ°À£ÃÄ¡A¦åºÞºò±i¯ÀII 1«¬¨üÅé¡]AT1R¡^ªýº¢¾¯¡A¸Ñ¨M¤F¥¨¾½²ÓM¤¤¯×½è¥NÁªº¥NÀv¥¢½Õ¡A¨Ã°fÂà¤FHFD¤p¹«ªºRPEª¬ºA©Mµøı¥\¯à¡CAT1R«H¸¹¥i¯à¬O¥¨¾½²ÓM¬ÛÃöªº°I¦Ñ¯e¯f¡]¨Ò¦pAMD¡^ªº¥¼¨ÓªvÀø¹v¼Ð¡C ¦Ó ³æ¹ç»Ä³q¹LMAPK¨Ì¿à¾÷¨î¤U½Õ¦åºÞºò±i¯À1«¬¨üÅé www.ncbi.nlm.nih.gov/pmc/articles/PMC3286191/ §Ú̪ºµo²{º¦¸ÃÒ©ú¤FTA§í¨îAT1R°ò¦]ªºªí¹F©M²ÓM¤ÏÀ³ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/9 ¤U¤È 06:20:24²Ä 1083 ½g¦^À³
|
ªüº¸¯ý®üÀq¯g·s¹vÂI³q¸ô¡X¡XDrp1-HK1-NLRP3 ¨Ó·½¡GÂåÃÄÅ]¤è¡@2020-12-09 med.sina.com/article_detail_103_2_93302.html ¨S¹¤l»Ä³q¹L¼W±jNrf2«H¸¹¶Ç¾É¨Ó§í¨îNLRP3ª¢©ÊÅé¿E¬¡©Mä¤`¡A±q¦Ó´î»´µh·©ÊÃö¸`ª¢ 2020¦~12¤ë7¤é www.frontiersin.org/articles/10.3389/fimmu.2020.580593/full Á`¤§¡A§Ú̪ºµ²ªGªí©ú¡A¨S¹¤l»Ä¥i¥H¼W±jNrf2ªí¹F¡A±q¦Ó°§CmtROSªº²£¥Í¡A±q¦Ó¨¾¤îNLRP3ª¢©ÊÅ骺¿E¬¡©Mä¤`¡A¨Ã´î¤Ö¥¨¾½²ÓM¤¤IL-1£]ªº¤Àªc¡Cµ²ªG¶i¤@¨BÃÒ©ú¤F¨S¹¤l»Ä¥i¥H³q¹L§í¨îIL-1£]ªºªí¹F¨Ó´î»´MSU»¤µoªºµh·©ÊÃö¸`ª¢¡C¨S¹¤l»Ä¹ïNLRP3ª¢©ÊÅ鬡¤Æªº§í¨î§@¥Î¨Ï¨S¹¤l»Ä¦¨¬°ªvÀø»PNLRP3¬ÛÃöªº¯e¯f¡]¨Ò¦p¿}§¿¯f¡Aµh·©Mªüº¸¯ý®üÀq¤ó¯f¡^ªº¦³§l¤Þ¤Oªº·sÔ¿ïªÌ¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/8 ¤W¤È 09:06:27²Ä 1082 ½g¦^À³
|
www.genetinfo.com/international-news/item/40959.html p38 MAPK §í¨î¾¯ FLT3 §í¨î¾¯ SNB01¬O¶Ü ? 1. Pre-treatment with tannic acid inhibits the intracellular IL-8 production by chitosan in a human oral epithelial cancer cell line www.jstage.jst.go.jp/article/omp/13/4/13_4_135/_pdf These investigations showed the pre-treatment effects of TA on IL-8 production to be mainly mediated through the inhibition of the p38 MAPK pathways. 2. Gallic acid targets acute myeloid leukemia via Akt/mTOR-dependent mitochondrial respiration inhibition 10.1016/j.biopha.2018.05.158 MV411 cells express the FLT3-ITD mutation, which is found in a high proportion of AML patients We demonstrate that gallic acid induces apoptosis of AML cells with FLT3-wildytpe or FLT3-ITD mutation MV411 cells which harbour FLT3-ITD mutation are more sensitive to gallic acid than THP-1 cells which is non-FLT3-ITD. Interestingly, we noted that AML cells with FLT-3-ITD are more sensitive to gallic acid compared to AML cells with non-FLT-3-ITD . ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/4 ¤U¤È 06:05:41²Ä 1081 ½g¦^À³
|
ÁÂÁ¹ù¥S¦n¤å liawbf.pixnet.net/blog/post/49551641 liawbf.pixnet.net/blog/post/49552333 liawbf.pixnet.net/b331 ¥»¥H¬°¾Y¤£¯àªø´ÁªA¥Î , ³»¦hªA¥Î´XÓ¤ë´N±o¶¡Â_ µM¥»¤å§@ªÌ¦b¯Ã¬ù®É³ø¼¶¤å´yz¦o©MļÆ{¯g¾Ô°«20¦~ªº·³¤ë , ¦³¿³½ìªº¤j¤j½Ð°Ñ¦Ò ¡¥I Don¡¦t Believe in God, but I Believe in Lithium¡¦ My 20-year struggle with bipolar disorder. By Jaime Lowe June 25, 2015 www.nytimes.com/2015/06/28/magazine/i-dont-believe-in-god-but-i-believe-in-lithium.html For two decades since then, I have been taking lithium almost continuously. It has curbed my mania, my depression and, most significant, ... As long as I take those three pink lithium-carbonate capsules every day, I can function. ... ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/12/1 ¤W¤È 09:15:53²Ä 1080 ½g¦^À³
|
½Ö¹G¦º¤F¥xÆW¤j±M¥Í¡H«C¤Ö¦~¦Û±þ¦º¤`¼Æ¡B¦º¤`²vÂùÂù³Ð10¦~·s°ª 2020-12-01 08:00 §d©|°a www.storm.mg/article/3247062 SARS-CoV-2 and the risk of Parkinson¡¦s disease: facts and fantasy November 27, 2020 www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30442-7/fulltext As many as 65% of people with COVID-19 present with hyposmia, which is also a common premotor symptom in Parkinson¡¦s disease. www.genetinfo.com/international-news/item/43580.html www.genetinfo.com/international-news/item/43492.html |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/11/30 ¤W¤È 11:30:34²Ä 1079 ½g¦^À³
|
³o«h³ø¾É¹ïSAGEªº¨âÀÉ·sÃĦ³©Ò¤¶²Ð 31»õ¬ü¤¸¶}µo¬ð¯}©Ê§íÆ{¯g©M¹B°Ê»ÙêÀøªk´ñ°·¹F¦¨¬ãµo¦X§@ ¨Ó·½¡GÃÄ©ú±d¼w¡@2020-11-30 med.sina.com/article_detail_100_2_92798.html ÁÂÁ¤j®a! |
|
|
·|û¡GªNô10148223 µoªí®É¶¡:2020/11/29 ¤W¤È 11:20:15²Ä 1078 ½g¦^À³
|
¯uªº«Ü¨ØªA²q·Q¤jªº¥]®e¤ß»P±M·~µ{«×¡I ¨Dª¾Y´÷¤j»¡ªº¤]¤£¿ù,±o½T®É¶¡´N¬O¤ß®®ªº³Ì¤j¼Ä¤H,¦ý¦b¤U¤]ÁÙ¬O¬Û«H¬ì¾Çªº¨¤«×,SNB01¦pªG¨S¦³«Ü¤£¿ùªº§í¨î¯à¤O,¬Û«H¤½¥qÀ³¸Ó¤£·|¯S§O¶]¥h¯S§O¬ã¨s,¬JµM¬Ì±¡ÄY«¼vÅTSND¨t¦C¦¬®×,¨º»ò´N°®¯Ü¸òµÛ¤j³¡¶¤¤@°_§Ü¬Ì¥B¬ãµo²{¦¨ªºSNB01,¦Ó¥B¥Ø«e¶i«×¤]¦p¤½¥qÁ¿ªº,FDA¥un¤½¥q¸É¤W¤j¹«¬r²z¹êÅç,¬Û«HÀ³¸Ó¤£·|¤Ó¤[!¦A@¤ßµ¥µ¥§a. ¦n°s¤]»Ýn®É¶¡µo»Ã¤~·|¿@¡B¾J¡B»¡I ¥H¤W¡I |
|
|
·|û¡G¨Dª¾Y´÷10148579 µoªí®É¶¡:2020/11/29 ¤W¤È 01:39:58²Ä 1077 ½g¦^À³
|
ÁÂÁ²q·Q¤jªº¦^ÂФΤÀ¨É¡A Áö¬Û«H¤½¥qªº³W¹º¬O´Â¹ï¤½¥qµo®i¦³¯qªº¸ô¦b¨«¡A¦ý¬O¼~¤ßªº¬O®Éµ{ªº±±¨î¡A ¤p¤½¥q´N¬On¦³ÃÄ¥X¨Ó¡A¥HÃÒ©ú¦Û¤vªº¯à@¡A¦ýSND¨t¦C®É¶¡¤@¦A¹L¥h¡A©|µL¨ãÅ馨ªG¡A ¤p§Ì»{¬°SND-13¦hªá±¼ªº®É¶¡¤w¤£¥u1¦~¡A®Éµ{ªº´x±±¤£¦n¡A¥Õ¥ÕÅýÄvª§ªÌ¦h¤F¤@¨Ç¾÷·|¡A SNB1¯à¤£¥Ç¬Û¦P¿ù»~¶Ü¡A¥O¤H¼~¤ßªº¡A¦]¥@¬É¤W¦UÃļt¸ê·½¤j¶q§ë¤J¡A¤p§Ì·¥¬Û«H·|¦³¯S®ÄÃÄ¥X¨Ó¡A ¯S®ÄÃĤ£¤@©w¬OSNB1¡A¦ý¦pµy¦³Àø®Ä¡A®Éµ{§Ö³t§Y¥i¥ý¦WÁn¤j¾¸¡B¿W»â·ÄÌ¡F ®Éµ{¸¨«á¤Ó¦h¡A§Y¨Ï³Ì«á¥X¨Ó¦³¨ÇÃĮġA¦ý¤£¤ñ¥L¤H®É¡A®£©È¬O¸¨¤J¥Õ¦£¤@³õ¡C ¥H¾ú¨Ó©ÒÆ[¹î¡A¦U¦ì»{¬°þºØ¾÷·|§ó¤j¤@ÂI¡H |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/11/28 ¤U¤È 03:17:47²Ä 1076 ½g¦^À³
|
¨Dª¾Y´÷¤j ¤£ºÞ¤½¥q«ç»ò³W¹ºµo®i , §Ú·Q³£¬O¥H¹ï¤½¥q¦³¯qªº¹D¸ô¦b¨« ¥u¬O¦³®ÉÔ , §Ú¤]·|·Q©Ò¦³FDA®Ö㪺Á{§É³£¤@°_°µ¤£¬O«Ü¦n¶Ü ? ... ¥xÆWªº¦³¿ú¤H¤D¦Ü°ê¥~¸êª÷ , Ãø¹D³£¤£´±§â³¡¤À¿ú©ñ¦b¤@ӫܦ³¦¨¥\¾÷·|ªº¤½¥q¶Ü ? ÁÙ¬O¤@¤Á³£¦b¤½¥qªº´x´¤¤¤ ? ¬Q¤Ñ¤Sµo¥Í¤@¥ó 31 »õ¬ü¤¸ªº®×¤l , ¨â®a³£¬O§Ú̦ռô¯à¸Ôªº¤½¥q ¬O Biogen ¤ÓºÆ¨g ? ÁÙ¬O¤¤¼Ï¯«¸gªº·sÃÄ¤Ó¯Ê ? Biogen bets on depression drug in $ 1.5 billion deal with Sage Therapeutics Biogen»P Sage Therapeutics ¹F¦¨ 15 »õ¬ü¤¸ªº¥æ©ö¡A©ãª`§íÆ{¯gÃĪ« cn.reuters.com/article/biogen-sage/biogen-sage-therapeutics-enter-1-5-billion-deal-to-develop-sell-neurological-treatments-idINKBN2871LK 2020¦~11¤ë27¤é9:36 ±ß¤W ¸ô³zªÀ- ¨â®a¤½¥q¶g¤ªí¥Ü¡ABiogen Inc.±NÁʶRSage Therapeutics 6.5»õ¬ü¤¸ªºªÑ¥÷¡A¨Ã¤ä¥I8.75»õ¬ü¤¸ªº¹w¥I´Ú¡A¥H¦@¦P¶}µo©M¾P°â¥Î©óªvÀø§íÆ{¯g©M¨ä¥L¯«¸g¨t²Î¯e¯fªºÀøªk¡C ³oµ§¥æ©ö±N¨Ï¦Ê°·¤½¥qÀò±ozuranolone¡]SAGE-217 , ¤@ºØ°w¹ï««×§íÆ{¯g¡]MDD¡^©M²£«á§íÆ{¯gªº¤fªAÀøªk¡^¥H¤ÎSAGE-324¡]°w¹ïìµo©Ê¾_Ÿ©M¨ä¥L¯«¸g¨t²Î¯e¯fªº¬ãµo¡^¡C ®Ú¾Ú¨óij±ø´Ú¡ABiogen±N¥H¨CªÑ104.14¬ü¤¸ªº»ù®æÁʶR¬ù620¸UªÑ·sµo¦æªºSageªÑ²¼¡A¸ûSage¶g¤T¦¬½L»ù·¸»ù26¢H¡C °£¤F15.25»õ¬ü¤¸ªº²{ª÷¥~¡ASageÁÙ±N¦³¸ê®æÀò±o°ª¹F16»õ¬ü¤¸ªº¼ç¦b¨½µ{¸O¥I´Ú¡C ¦Ê°·¤½¥q±N¦b¬ü°êÁp¦X¾P°â³o¨ÇÃĪ«¡A¨ÃÀò±o¦b°ê¥~¾P°â¸ÓÃĪ«ªº±M¦³Åv¡A¦ý¦b¤é¥»¡A¥xÆW©MÁú°ê«h¨S¦³¨Ï¥ÎzuranoloneªºÅv§Q¡C Sage Therapeutics ªº pipeline : www.sagerx.com/programs-research/pipeline/ ³o´N¬O¨â´Ú·sÃĪº»ùÈ , Ãø¹D§Ú̳o¨Ç¤ß®®ªÑªF , ´N¥u¦³¬y¤f¤ôªº¥÷ ? ¤Ï¬M¦b¥«³õªº»ùÈ´N¥u¦³³o¼Ë ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¨Dª¾Y´÷10148579 µoªí®É¶¡:2020/11/27 ¤U¤È 11:40:53²Ä 1075 ½g¦^À³
|
¦³¤@½g¨S¤H°Q½×¡A¦ýÅý¤p§Ì«Ü¼~¤ß¡ASSRIÃþ§Ü§íÆ{ÃÄ¡A°µ¬°ªÍª¢¦´ÁªvÀøÃĪ«ªº³ø¾É www.genetinfo.com/international-news/item/43408.html ½Ð°Ñ¦Òkinmen3015¤jªº¤µ¦~ªÑªF·|µ§°O¡uSNB1ªºÃĪ«¬O±q¤½¥q즳¤@Ó¤jªºProgram¤¤ªº¼Æ¤QºØ¦X¦¨¤Æ¦Xª«¡A µo²{¦³§í¨î·s«a¯f¬r½Æ»s§@¥Îªº¾÷Âà¡AÓ¤H¸ÑŪ»y·N¡A´N¬O«´¦X¡¨¬ì¾Çªº¥»½è¡¨¡A¤£¬O¦]¬°²{¦b¼öªù³oÓ¡A ´NÀ³´º±À¥X¡v¡F ¬O§_«Ü¦³¬Û¦ü·P¡A¦P¼Ë¬O¾Ç²z¤WÀ³¥Î¡A¨ã¦³«Ü±jªº§Üª¢¬¡©Ê¡A¦ý¤£¦Pªº¬O¡A³o¨Ç¤w¬O²{¦³ÃĪ«¡A ±qÅ¥¨ì¤½¥qn¶i¦æSNB1¡A¤p§Ì´Nı±oÀ³¸ÓÁÙ¬On¥Hìºë¯«ÃþÃĪ«¦¬®×¬°«¡A¤p§Ìªº¼~¤ß±¦³´X¶µ¡A 1.³o¸Ì¤£¥u¤@¶µ¤w¸g§¹¦¨¤p«¬¸ÕÅç¡A¦ÓSNB1¦¬®×³£ÁÙ¥¼¶}©l¡C 2.¥H®É¶¡ÂI¨Ó¬Ý¡A¦b¤£ª¾¹Dªº¦a¤è¥H¬ì¾Ç©Ê¤ÀªR(¨Ò¦p¥ý«e¦³³ø¾É¶W¯Å¹q¸£§ä¥X¦h¶µÔ¿ïÃĪ«)¡A ¤w¦³¤Ó¦hªì¨B¬ã¨s§¹¦¨¡A®É¶¡¬O§_¤´µM¯¸¦b¤ß®®³o¡H©|¥B¬OÁÙ¥¼¦³¯u¥¿«Ü¦³®ÄªºÃĪ«¥X²{¤§±¡§Î¡A ¦p¯u¥¿«Ü¦³®ÄªºÃĪ«¥X²{¤F¡AªÑªF¬O§_ÁÙ¤ä«ù¡B¤½¥q¬O§_ÁÙnÄ~Äò§¹¦¨SNB1¡H 3.¤p«¬¸ÕÅç¬Ý¨Ó¦³®Ä¡A¦ý¤´»Ý¤j«¬¬ã¨s¡A¦pSNB1¹J¨ì¤@¼Ëª¬ªp¡A¬O§_¦³¨¬°÷¸êª÷¡B¤H¤O¸ê·½¥i¤ä¼µ¤j«¬¬ã¨s¡H ¹ï·sÃĤ½¥q¨Ó»¡¡A®É¶¡¤´¬O³ÌÄ_¶Qªº¡A¤½¥qªº²Ä¤@¶µÃĪ«¨ì©³¦ó®É¥i´Á¤¤¤ÀªR¡H(ªp¥BÁÙ¥u¬O´Á¤¤¤ÀªR) ¥t¼Ú¬ü¬Ì±¡¸û¤µ¦~ªÑªF·|®É§óÄY«¡A¤£ª¾þ¦ì¥ý¶i¥i¥H«üÂI¡AFDA´N¬Ì±¡¼vÅTÁ{§É¸ÕÅç¡A ¬O§_¦³¦]À³¤§¹D¡A¥i¥HÀ°§U·sÃĤ½¥qªº¤°»ò¶µ¥Ø¡H |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/11/27 ¤U¤È 12:57:52²Ä 1074 ½g¦^À³
|
´ª¥Xªü¯÷®üÀq¯g´c¤ÆªºÃöÁ䨤¦â ¤¤¬ã°|¦³¤jµo²{ 11:142020/11/27 ¤¤®É·s»Dºô ±ç´f©ú www.chinatimes.com/realtimenews/20201127002067-260418?ctrack=pc_main_headl_p04&chdtv ¤¤¥¡¬ã¨s°|¹Î¶¤ªñ´Áµo²{¨Ã¥BÃÒ¹ê¡A«P¨Ïªü¯÷®üÀq¯g§ó¥[´c¤Æªº¥t¤@ºØ¤j¸£¤¤ªº³J¥Õ½èTDP-43¡C ¦@®¶µ¥¤è¦¡´x´¤TDP-43©MA£]ªº¤¬°Ê°Ï°ì¡A§Æ±æ´M§ä¥i±æ¬ð¯}TDP-43¡B¸Ñ¨Mªü¯÷®üÀq¯g¡Bº¥á¯g¤Î¬ÛÃö¸£¯«¸g°h¤Æ¯e¯fªº¾÷·|. ³o¬O¬Æ»ò·N«ä ? doi.org/10.1021/acs.jafc.5b05432 Gallic acid (GA) caused a dose-dependent decrease in TDP-43 ( A315T ) mediated paralysis. ??? |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/11/27 ¤W¤È 08:17:23²Ä 1073 ½g¦^À³
|
ÁÂÁ¹ù¥S¦n¤å³sµo liawbf.pixnet.net/blog/post/49542461 liawbf.pixnet.net/blog/post/49544601 liawbf.pixnet.net/blog/post/49547421 liawbf.pixnet.net/blog/post/49548315 liawbf.pixnet.net/blog/post/49548605 |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/11/16 ¤W¤È 10:50:25²Ä 1072 ½g¦^À³
|
CNS¥«³õÂX±iI«á¡Gù¤ó¦³±æ¶W¶V´ñ°·¿ÕµØ¾ÌÂǨâ´Ú²£«~¡§½Äº]¡¨ ¨Ó·½¡G·s®öÂåÃÄ·s»D¡@2020-11-16 ½sĶ丨ªiªi¦w med.sina.com/article_detail_100_2_92018.html 2019¦~¡A³B¤èÃÄ©M«D³B¤èÃÄ¡]OTC¡^¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¯e¯f¬ÛÃö²£«~ªº¥þ²y¾P°âÃBÁ`p860»õ¬ü¤¸¡C ¾¨ºÞCOVID-19¤j¬y¦æµ¹¥«³õ±a¨Ó¤F¤£½T©w©Ê¡A¦ý¤ÀªR®a«ü¥X¡ACNS²£«~¥«³õ±N¦b2022¦~ÂX¤j¨ì1010»õ¬ü¤¸¡A¨ì2025¦~±N¼W¦Ü1310»õ¬ü¤¸¡]¹Ï1¡^¡C ¦b2019¦~¡A¦hµo©Êµw¤Æ¯g¡]MS¡^Àøªkªº¥«³õ¥÷ÃB³Ì°ª ¦b2019¦~ªº¤¤¼Ï¯«¸g¨t²Î¥«³õ±Æ¦W¤¤¡A§Üºë¯«¯fÃĪ«±Æ¦W²Ä¤T¡A¶È¦¸©ó¡§¨ä¥L¤¤¼Ï¯«¸g¨t²ÎÃĪ«¡¨¡A¥«³õ¥÷ÃB¬°13%¡]¹Ï1¡^¡C¾Ú¹w´ú¡A³oÃþÃĪ«±N¦b2022¦~©M2025¦~«O«ù³o¤@¦a¦ì¡A¦Ó±j¥ÍªºÀR¯ßª`®g¾¯«¬ºë¯«¤Àµõ¯gÃĪ«Invega Sustenna¡]paliperidone palmitate¡^¬O¸Ó»â°ìªºªø´Á¾P°â±À°ÊªÌ¡A¦¦b2009¦~´NÀò±o§åã¡C¦b³o¤@»â°ìªº·s¿³²£«~¤¤¡AAcadia»sÃĥΩ󩬪÷´Ë¯fªº§Üºë¯«¯fÃÄNuplazid¡]pimavanserin¡^ªº¾P°âÃB¼Wªø³Ì§Ö¡A¦b2025¦~¹F¨ì25»õ¬ü¤¸¾P°âÃB¡C 2019-2025¦~´Á¶¡¡A§Ü§íÆ{ÃIJ£«~ªº¾P°âÃB±N±q52»õ¬ü¤¸¤W¤É¨ì86»õ¬ü¤¸¡]¹Ï1¡^¡A³o¬O¥Ñ©ó³Ìªñ§å㪺·s«¬²£«~¦p¤j¶ï»sÃÄRexulti¡]brexpiprazole¡^¾P°âªº±À°Ê¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/11/16 ¤W¤È 10:29:34²Ä 1071 ½g¦^À³
|
¹ù¥S¬°¼y¯¬ÃÄ®v¦ò¸t½Ï , ¯S§O¶}©ñ¦n¤Í¤å³¹¦Ü17¤é ¥t¥~ ´X½g¤å³¹¨Ñ°Ñ The depressor axis of the renin¡Vangiotensin system and brain disorders: a translational approach doi.org/10.1042/CS20180189 RAS³Q»{¬°¥Dn¥Ñ¨âÓ¶b²Õ¦¨¡G¥H¦åºÞºò±i¯À¡]Ang¡^II /¦åºÞºò±i¯ÀÂà´«酶 ( ACE )/ AT1¨üÅ鬰¥Nªíªº¤ÉÀ£¶b¡A¥H¤Î¥HAng-¡]1-7¡^/¦åºÞºò±i¯ÀÂà´«酶2 ( ACE2 )/ Mas¨üÅé¥Nªíªº°À£©M«OÅ@¶b¡C¾¨ºÞRAS¦b¹q¸Ñ½èúA©M¦åÀ£½Õ¸`¤¤°_µÛÃöÁä§@¥Î¡A¦ý¥¦Ì¤]»P¸£¥\¯à¦³Ãö¡A¥]¬A»{ª¾¡A°O¾Ð¡AµJ¼{©M§íÆ{¥H¤Î¤@¨Ç¯«¸g¨t²Î¯e¯f¡CRASªº¤ÉÀ£¶b¹L«×¬¡°Ê»P¤¤·©M¤@¨Ç¸£³¡¯e¯f¦³Ãö¡A¨Ò¦p»{ª¾»Ùê¡Aè§b©Mªüº¸¯ý®üÀq¤ó¯g©Î©¬ª÷´Ë¤ó¯f¡C .. Hyperactivity of the pressor axis of the RAS, mediated by Ang II activation of the AT1 receptor has been implicated in the pathogenesis of AD . .. In addition, an increased ACE expression and activity has been reported in AD . .. Overactivation of the brain pressor axis of the RAS has been implicated in the etiology of stress-associated anxiety disorders . .. The development of anxiety has been associated with activation of AT1 receptors, central AT2 receptor may have a role in attenuating stress-associated anxiety . .. Ang-(1¡V7) can modulate anxiety and depression-like behaviors . .. It suggests that increasing ACE2 activity is anxiolytic. .. Reduction in the central angiotensin function has both antidepressant-like and anxiolytic-like actions . .. Results showed an important trend in favor of the depressive symptom-reducing effects of ACEis, as assessed by the Hospital Anxiety and Depression Rating Scale . Thus, ACEi and ARBs ( AT1 receptor blockers ) may be considered as potential treatment against mood disorders Neuropsychiatric Properties of the ACE2/Ang-(1-7)/Mas Pathway: A Brief Review pubmed.ncbi.nlm.nih.gov/31868143/ ACE2 / Ang-¡]1-7¡^/ Mas³~®|¥i¯à³q¹L¤¤¼Ï©M¥~©P³\¦h¥i¯àªº¥Í¤Æ¾÷¨îªí²{¥X§ÜµJ¼{©M§Ü§íÆ{§@¥Î¡A Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system ³q¹L§í¨î¦åºÞºò±i¯À¨t²Î§ïµ½ªüº¸¯ý®üÀq¤ó¯fªº¯gª¬ www.sciencedirect.com/science/article/pii/S1043661818319509 §Ú̵o²{§í¨î¦åºÞºò±i¯ÀÂà¤Æ酶¡]ACE¡^ªº¤¤¼Ï©ÊACE§í»s¾¯¥i©µ½wAD¹êÅç¼Ò«¬¤¤ªº¯«¸gÅÜ©Ê¡AAbeta´³¶ô§Î¦¨©Mtau¹L«×ÁC»Ä¤Æªº¯gª¬¡C .. ACE©M/©ÎAT1¨üÅ骺¿ò¶Ç©MÃIJzªº§í¨î , ¨ã¦³ª½±µªº§Ü°I¦Ñ§@¥Î¡A¨Ã©µªø¤F¹êÅç¼Ò«¬ªº¹Ø©R .. ¤j¶q¬ã¨sªí©ú¡AACE©MAT1¨üÅ骺§í¨î ¥i§ïµ½2«¬¿}§¿¯fªº¯gª¬¨Ã§ïµ½¯Ø®q¯À©è§Ü¡CAD±wªÌªº¤j¸£ªº¯S¼x¦b©ó¯Ø®q¯À©è§Ü©M¥NÁºî¦X¼x»P¼W±j«¬ªºA£]´³¶ôªº¿n²Ö¬ÛÃö¡C¦]¦¹¡A§ïµ½¯Ø®q¯À©è§Ü³Q»{¬°¬OAD¤¤·s¿³ªºªvÀø¹vÂI . .. ¿ò¶Ç¯Ê³´©M¦åºÞºò±i¯À¨t²Î¡]ACE¡^©M¨ä¥L¦¨¤Àªº§í¨î§@¥Îªí©ú¡AACE§í¨î¨ã¦³ª½±µªº§ÜªÎD§@¥Î .. ¦b±w¦³ADªº±wªÌ¤¤¡A°ª¦åÀ£»P»{ª¾¥\¯à¤U°¡A¦æ¬°¯gª¬©M®ü°¨¸²µå¿}§C¥NÁ¦³Ãö .. ACE§í¨î¾¯©MAT1¨üÅé«ú§Ü¾¯¹ï§íÆ{¯gªº¯gª¬®ÄªG¿n·¥ .. ³q¹LACE§í¨î¾¯©M/©ÎAT1«ú§Ü¾¯§í¨îACE-AT1¨üÅé¶b , ¥i¾ÉP¦³Ãö»{ª¾©Mè§b¯gª¬ªº§ó¦nµ²ªG Increasing brain angiotensin converting enzyme 2 activity decreases anxiety-like behavior in male mice by activating central Mas receptors pubmed.ncbi.nlm.nih.gov/26767952/ Glutamate Within the Marmoset Anterior Hippocampus Interacts with Area 25 to Regulate the Behavioral and Cardiovascular Correlates of High-Trait Anxiety MarmosetµU®ü°¨¤ºªº¨¦®ò»Ä»P°Ï°ì25¬Û¤¬§@¥Î¡A¥H½Õ¸`¦æ¬°©M¤ß¦åºÞ¬ÛÃöªº°ª¯S½èµJ¼{¡C www.jneurosci.org/content/39/16/3094 ÃIJz¾Ç¤W , ´£°ª¨¦®ò»ÄªºaHipp (anterior hippocampus ) ¥i¥H°§C°ª«×µJ¼{ªºMarmosetµUªºµJ¼{¤ô¥¡C ¦b³o¸Ì¡A§ÚÌÃÒ©úMarmosetµUªºµJ¼{¼W¥[»P®ü°¨¨¦®ò»Ä´î¤Ö¦³Ãö¡A¦Ó°ª©Ê®æµJ¼{ªºµU¤l®ü°¨¨¦®ò»ÄÄÀ©ñªº¼W¥[ , «h¨Ï¹ï¼ç¦b«Â¯Ùªº²§±`¦æ¬°©M¤ß¦åºÞ¤ÏÀ³¥¿±`¤Æ¡C °ª¯S½èµJ¼{ªº¤H©ö±wµJ¼{©M§íÆ{¯g ¶V¨Ó¶V¦hªºÃÒ¾Úªí©ú , ±¡·P»Ùꪺ¯f²z¥Í²z¥iÂk¦]©ó®ü°¨¨¦®ò»Ä¯à¥\¯àªº°§C¡C Á`¦Ó¨¥¤§¡A§Ṳ́w¸gÃÒ©úaHipp¨¦®ò»Ä¯à¥\¯à§C¤U¬OMarmosetµU°ª¯S¼x-µJ¼{ªí«¬ªºÃöÁä¹w´ú¦]¤l¡A¨Ã¥B³q¹LÃIJz¤W¨Ï³oºØ¥\¯à§C¤U¥¿±`¤Æ D-Serine as the gatekeeper of NMDA receptor activity: implications for the pharmacologic management of anxiety disorders www.nature.com/articles/s41398-020-00870-x D-serine is a dynamic gatekeeper of NMDAR function in forebrain regions that are implicated in the pathophysiology of fear and anxiety-related disorders. We highlight the potential utility of D-serine or molecules that augment D-serine availability as a means to enhance extinction learning, as well as improving cognition and mood. The latter strategy could be accomplished by increasing release or blocking reuptake via the aforementioned transporters or inhibiting the breakdown of D-serine by DAO (Table 2). ¦Ó biblio.ugent.be/publication/8022799/file/8022864.pdf P.93 IC50 ( §í¨î ACE ) Tannic acid : 0.23 mM Gallic acid : 3.7 mM Pyrogallol : 1.12 mM Tannic Acid Down-Regulates the Angiotensin Type 1 Receptor Through a MAPK-Dependent Mechanism ³æ¹ç»Ä³q¹LMAPK¨Ì¿à¾÷¨î ¤U½Õ¸`¦åºÞºò±i¯À1«¬¨üÅé(AT1R) www.ncbi.nlm.nih.gov/pmc/articles/PMC3286191/ Under normal conditions, exposure of cells to TA resulted in the down-regulation of AT1R-specific binding in concentrations ranging from 12.5¡V100 £gg/ml (7.34¡V58.78 £gM) over a time period of 2¡V24 h with no change in receptor affinity to angiotensin II (AngII). The inhibitory effect of TA on AT1R was specific and reversible. Inhibitory effect of catechin-related compounds on renin activity www.medicinabiomolecular.com.br/biblioteca/pdfs/Biomolecular/mb-0624.pdf Renin is a crucial enzyme in the renin-angiotensin system, and the inhibition of its activity is considered as a useful approach to the treatment of hypertension. Gallic acid exert renin inhibition with an IC50 value of 890.71 £gM ( 151.53 £gg/mL ) . ¦Ü©ó¼@±¡«ç»ò½s , «h¦³¿à¤j®aªº·Q¹³ µMµ²§½¦p¦ó¨« , ÁÙ¬OnÁ{§Éªí²{¨Ó¥D¾É ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/11/8 ¤W¤È 11:24:13²Ä 1070 ½g¦^À³
|
¥D³õÀu¶ÕÃø§K¶Ü? §Æ±æ¥Î¬ì¾ÇªºÃÒ¾Ú¨Ó¸ÑÀø®ÄºÃ¼{ ªüº¸¯ý®üÀqÃijQFDA±M®a·|¹ý©³§_¨M ¨Ó·½¡G ¬ü¤¤ÃÄ·½¡@2020-11-08 med.sina.com/article_detail_103_1_91586.html ¥»¶g¤TFDA¤½¶}¤F¤º³¡±M®a¹ï´ñ°·/½Ã§÷¯»ª¬³J¥Õ§ÜÅéaducanumabªº¤W¥«¥Ó½Ðµ¹¥X«D±`¿n·¥ªºµû»ù¡A»¡Á{§É¼Æ¾Ú«D±`¦³»¡ªA¤O¡B¨Ã§_»{¸£¤ô¸~°Æ§@¥Î°_¨ì´¦ª¼§@¥Î¡C¦ý¨ä¤¤¤@Ó²Îp¾Ç®a´£¥X¤£¦P·N¨£¡A»{¬°§Y¨Ï°ª¾¯¶q²Õ¤]ÃÒ¾Ú¤£°÷§¹µ½¡C¤µ¤Ñ¦b¥~³¡±M®a²Õ°Q½×·|¤WFDA¯«¸gÃĪ«t³d¤HªºÁ¿¸Ü¦³ÂI¯¸¥x¹L«×¶ûºÃ¡A¥O±M®a½èºÃ¨ä°Ê¾÷¡C³Ì«á±M®a²Õ¥H8²¼¤Ï¹ï¡B1²¼ÃÙ¦¨¡B2²¼¤£½T©w§_»{aduªºEmerge¸ÕÅçÃÒ©ú³oÓÃĪ«¦b¤¤»´«×AD±wªÌªºÀø®Ä¡A7¡G0¡G4§_»{¤@´ÁÁ{§É103¸ÕÅ窺¼Æ¾Ú¡C¥t¥~´XÓ°ÝÃD¤]¬Ot±¦^µª¡A¦p10¡G1½èºÃ§âEmerge§@¬°¥DnÃÒ¾Úªº¦X²z©Ê¡C FDA panel rejects Biogen¡¦s new Alzheimer¡¦s drug There¡¦s not enough evidence that the experimental drug known as aducanumab works, government health advisors said Friday. 2020¦~11¤ë7¤é¡A¬ü°ê¤¤³¡¼Ð·Ç®É¶¡¤W¤È7:11 www.nbcnews.com/health/aging/fda-panel-rejects-biogen-s-new-alzheimer-s-drug-n1246818 |
|
|
·|û¡G¤p³ì10135960 µoªí®É¶¡:2020/11/6 ¤U¤È 02:43:22²Ä 1069 ½g¦^À³
|
¤j¼t«ùÄò¥[³t ªü¯÷®üÀq¯g¦³±Ï¤F Biogen·sÃÄÃÒÀø®Ä ªÑ»ù¨gº¦44¢H 14:272020/11/05 ¤¤®É·s»Dºô ¤ý·¶°· Facebook Messenger Line Weibo Twitter Telegram ½Æ»s³sµ² Biogen·sÃÄ¥i±æ¦¨¬°º´ÚÀòFDA®Ö㪺ªü¯÷®üÀq¯g¥ÎÃÄ¡C(¹F§Ó¼v¹³shutterstock) Biogen·sÃÄ¥i±æ¦¨¬°º´ÚÀòFDA®Ö㪺ªü¯÷®üÀq¯g¥ÎÃÄ¡C(¹F§Ó¼v¹³shutterstock) Facebook Messenger Line Weibo Twitter Telegram ½Æ»s³sµ² ¦r¯Å³]©w¡G¤p¤¤¤j¯S ¥þ²y¶W¹L3000¸Uªü¯÷®üÀq¯g±wªÌ¦³±Ï¤F¡C¬ü°ê¥Í§Þ»sÃĤ½¥qBiogen·sÃÄ¡uaducanumab¡vÀø®Ä¤wÀò¬ü°êFDA(¹«~ÃÄ«~ºÊ·þºÞ²z§½)»{¥i¡A³ø§i¤¤¬Æ¦Üµ¹¤©¡u¨¬¥HÀò±o®Öã¡vµû»ù¡A¦³¾÷·|¦¨¬°º´ÚÀò±o¸Ó³æ¦ì®Ö㪺ªü¯÷®üÀq¯g¥ÎÃÄ¡ABiogen©P¤T¦b¨º´µ¹F§JªÑ»ù¼Éº¦43.97%¡A¦¬355.63¬ü¤¸¤]¬O2018¦~7¤ë25¤é¥H¨Ó·s°ª¡C ªü¯÷®üÀq¯g¬O¯Ó¶O¤w¶}µo°ê®aªÀ·|¸ê·½³Ì¦hªº¤@ºØ¯e¯f¡A¥ú¬ü°ê´N¦ôp¦³570¸U¦W±wªÌ¡CFDA³ø§iºÙ¦³¹ê½èÃÒ¾Ú(substantial evidence)Åã¥Üaducanumab¦³®Ä¡AÁöµMBiogen¦b2¦¸Á{§É¹êÅ礤¥u¦³1¦¸¦¨¥\¡A¦ýFDA¥H¡u°·¥þ¥B¦³«D¤Z»¡ªA¤O¡v¨Ó§Î®e¸Ó¦¸¹êÅç¡A¨Ãªí¥Ü¥Ó½ÐªÌ´£¨Ñ¤F¥R¤Àªº¦³®ÄÃÒ¾Ú¡A¨¬¥HÀò±o®Öã¡C ³o¥÷³ø§i¤£¬O³Ì²×¨M©w¡AFDA³Ì§Ö©ú¦~3¤ë¤~·|¨M©w¬O§_§åãaducanumab¤W¥«¡C®Ú¾ÚBiogen»¡ªk¡AaducanumabÁöµMµLªk°fÂà¯fµ{¡A¦ý¯à¦¨¥\°§C¸£¤¤B«¬Ãþ¾ý¯»³J¥Õ(amyloid beta¡A©Î²ºÙA£]¡þAbeta¡A³Q»{¬°¬O¤Þµoªü¯÷®üÀq¯gªºÃöÁ䪫½è)§t¶q¡AÅãµÛ°§C±wªÌ¥¢¥h°O¾Ð¡B»y¨¥»P¦æ°Ê¯à¤Oªº³t«×¡C Biogen±Mª`©ó¯«¸g¨t²Î¯e¯f¡B¦ÛÅé§K¬Ì©Ê¯e¯f¡BÀù¯gµ¥»â°ìÃĪ«¶}µo¡A¥h¦~¢²¤ë¸Ó¤½¥q´¿¼È°±¢±³õªü¯÷®üÀq¯gÃĪ«Á{§É¹êÅç¡A¦]¬°ÃĪ«Ãø¥Hµo´§§@¥Î¡A¦ý7Ó¤ë«á¤Sµo²{´£°ª¾¯¶q«áÃĪ«½T¹ê¯à¦³®ÄªG¡CFDA¤]»{¬°¥h¦~´£«eµ²§ôªº¹êÅç©M¤µ¦~¥¼¯àÃÒ©ú®Ä¥Îªº¨º¦¸¹êÅç¡A¤£§«Ãª¹ï¦¨¥\¹êÅ窺¼Æ¾Ú¸ÑŪ¡C °£Biogen¡A¥¿¦b¬ãµoªü¯÷®üÀq¯gÃĪ«ªº¨ä¥L¤½¥q¤]¨ü¯q¡A¨Ò¦p§¨Ó(Eli Lilly)¤]¦¬ÀòÂù¦ì¼Æº¦´T¡A¸õ°ª13.44%¡A¦¬148.59¬ü¤¸¡Cȱo¤@´£ªº¬O¡A§¨Ó¦P®É¤]¬O¬ü°ê½Þ°¦¹}®Æ²K¥[ª«°öªL(Paylean)»s³y°Ó¡A¦Ó°öªL¤¤§t¦³µÜ§J¦h¤ÚÓi¡A¶}©ñ§t¦³µÜ§J¦h¤ÚÓi¬ü°ê½Þ¦×¶i¤f¥¿«ùÄò¦b¥xÆW¤Þ°_ª§Ä³¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/11/5 ¤U¤È 04:43:21²Ä 1068 ½g¦^À³
|
Biogen ªüº¸¯ý®üÀq¯fÀøªk¶i¤JÃöÁä¼fµû¶¥¬q FDA±M®aªº¬Ýªk¬O¤°»ò? ¨Ó·½¡GÃÄ©ú±d¼w¡@2020-11-05A- med.sina.com/article_detail_100_2_91400.html ¡m¦ÛµM¡n¼öij¡Gªüº¸¯ý®üÀq¯fªº®Ú·½¬O¡K¡K·L¥Íª«·P¬V¡H ¨Ó·½¡G ¾Ç³N¸g½n¡@2020-11-05 med.sina.com/article_detail_103_1_91435.html |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/31 ¤U¤È 06:15:40²Ä 1067 ½g¦^À³
|
¥»¶K¤å¤¾ÂØ¥BµLÃöªÑ»ù , «Ø½ÐµL¿³½ìªÌ²¤¹L , ÁÂÁ ! J&J ©xºô©ú¦C¥¦¦³¿³½ìªº»â°ì¦Ó±ý´M¨D¦X§@¹Ù¦ñ ¦h¦~«e , §Ṳ́]´¿¸g´£¹L , ¥¦¦bSCZ»â°ì¶}¥Xªº±ø¥ó www.janssen.com/neuroscience/schizophrenia ·s¿oªººë¯«¤Àµõ¯gÄpª¬ªvÀø , ¤×¨äª`«¦b»{ª¾¯Ê·l©Mt©ÊÄpª¬¤è±ªºÁ{§É2b´Á©Î§ó«áºÝªºÁ{§É Åý§ÚÌÁp·Q¨ìSND-11 ~ 13 ¦ü¥GÆZ²Å¦Xªº , ¤£²M·¡¤½¥q¦³¨S¦³¸òJ&J ±µÄ²¹L ¤£¹L , ¤S¬Ý¤F¥L̦b [ Discovery ] ªº´yz www.janssen.com/neuroscience/discovery ¦b¾ãÓ¯«¸g¬ì¾Ç»â°ì¡AJanssen¬ã¨s¤Hû¥¿¦b±´¯Á¯«¸g°h¦æ©Ê¯e¯f©M¯«¸gª¢©Ê¯e¯f¡]¥]¬A¬ðIJ¥i¶ì©Ê©M²ÓM¼u©Ê¡^¤è±ªº·s¿³¬ì¾Ç¡C³Ìªñªº¬ã¨s¤w±N¯«¸g¤¸¥i¶ì©Ê©M²ÓM¼u©Ê»P¾Ç²ß¡A°O¾Ð¡A»{ª¾©M±¡ºüÁpô¦b¤@°_¡C§Ú̪¾¹D¯«¸gºë¯«¯f©M¯«¸g°h¦æ©Ê¯e¯f¬O¥Ñ¯«¸g¤¸¥i¶ì©Ê©M²ÓM¼u©Ê¯ÅÁp¤ÏÀ³²§±`¤Þ°_ªº¡C ¤Sı±o f¥Ò»Ä¾Y ¥i¯à§ó¶Kªñ ¦]¬° ¥Ñ2013 ¦~Husseini K Manji --- Global Therapeutic Head for Neuroscience , Johnson & Johnson ªººtÁ¿¤Û¿O¤ù Bipolar Disorder: Harnessing Brain Plasticity for Improved Overall Outcomes www.bbrfoundation.org/sites/default/files/pdfs/april-2013-webinar-slides.pdf ½Í¨ì Chronic lithium robustly regulates regional Bcl-2 levels ( p.18 ) Lithium ¡V via its effects on ¡§neurotrophic molecules¡¨ appears to enhance neuronal resilience ( p.20 ) Targeting synaptic plasticity and cellular resilience has the potential for markedly improved treatments ( p.24 ) ¦Ó Neuroplasticity and cellular resilience in mood disorders www.nature.com/articles/4000811 ¥O¤H«HªAªº¬O¡A¼W¥[CNS Bcl-2ªº¤ô¥¥i¯à¥Nªí¤F¤@ºØ«D±`¦³®Äªº¯«¸gÀç¾iµ¦²¤¡A¥i¥H¼W±j²ÓMªº¼u©Ê ¾Y±j¯P¤W½ÕÃöÁä²ÓM«OÅ@³J¥Õbcl-2 ¾Y¹ï¦¨¼ô¤¤¼Ï¯«¸g¨t²Îbcl-2©MGSK-3£]ªº±j°·§@¥Îªí©ú¡A¥¦¥i¯à¨ã¦³«nªº¯«¸g«OÅ@¯S©Ê¡C ¾Y¼W¥[®ü°¨¯«¸gµo¥Í Four weeks lithium treatment alters neuronal dendrites in the rat hippocampus academic.oup.com/ijnp/article/16/6/1373/753845 ¯«¸g¥i¶ì©Ê²z½×±j¯Pªí©ú¡A¾Y¹ï¯«¸g¤¸¥i¶ì©Ê¨ã¦³¦hºØ¥B±j¤jªº§@¥Î¡A³o¨Ç§@¥Î»P¨äªvÀø§@¥Î¦³Ãö. ¨Ò¦p¡A¤À¤l¥Íª«¾Ç¬ã¨sªí©ú¡A¾Y·|¤W½Õ°Ñ»P¯«¸g¤¸¥i¶ì©Êªº¤À¤l¡A¸£·½©Ê¯«¸gÀç¾i¦]¤l ( BDNF )¡FB²ÓMCLL /²O¤Ú½F2¡]Bcl-2¡^©M¯«¸g¥Íªø¦]¤l¤w±o¨ì³Ì¼sªxªº¬ã¨s¡C¾YÁÙ³QÃÒ©ú¥i¥H¼W±jÀôª¬³æÁC»Ä¸¢苷¤ÏÀ³¤¸¥óµ²¦X³J¥Õ¡]CREB¡^ªº¬¡¤Æ¡ACREB¬O°Ñ»P¯«¸g¥i¶ì©Êªº¦hºØ³J¥Õ½èªº°ò¦]ªí¹F¤¤ªº¥DnÂà¿ý¦]¤l¡CCREB©M¤Wz³J¥Õ¦b¾ð¬ðª¬¼W¥Í¡A¬ðIJ§Î¦¨©M¬ðIJ¥i¶ì©Ê¤¤°_ÃöÁä§@¥Î¡C²ÓM¬ã¨sªí©ú¡A³o¨Ç¤À¤l³q¹L¨ë¿E¦¨¤H¯«¸gµo¥Í ( neurogenesis : ¬O«ü¯«¸g¤¸ªº¥Í¦¨ ) ¨Ã«OÅ@¯«¸g¤¸§K¨ü¯«¸g¬r©Ê·l¶Ë©M²§±`ä¤`¹Lµ{¨Ó¤W½Õ¬ðIJ¥i¶ì©Ê . ¤S J&J ©xºô [ Depression and Treatment-Resistant Depression ] ¶µ¤U ¦C¦³ • Novel therapeutic agents that have fast onset of action, good safety and tolerability profiles, and that address common co-morbidities (for example, anxiety and substance abuse) o Glutamatergic modulators o Neuroactive cytokines ( ¤pªº¤£²M·¡³o¬O¬Æ»ò ? ¤£ª¾¬O§_¦b»¡¯«¸gª¢©Êªº¬ÛÃö²ÓM¦]¤l ? ) o Molecules that positively impact synaptic plasticity and cellular resilience • Phase 2 and later-stage opportunities with defined mechanism of action and superior efficacy over standard of care ¦b [ Bipolar Depression ] ¶µ • Novel therapeutic agents that provide rapid improvement in bipolar depression and in suicidal patients and that produce long-term stabilization of mood and prevent recurrences ³o¤@¶µ¬JµM¦bÁ¿ MDD ¡BTRD ÁÙ¦³BD ( Âù¬Û±¡·P»Ùê ) §ÚÌ´N®³ SNG-12 ©M ¦Ù®ò»Ä¾Y ¨Ó¤ñ¹ï SNG-12 ¬O¥¿¦VªºGlutamatergic modulators ©Ò¥H¹ï¼W¶isynaptic plasticityÀ³¤]·|¦³¥¿±®ÄªG ¦ý¹ïcellular resilienceªº§@¥Î¤£²M·¡ , ¤£¹L¦b¤@¶µ±M®aªºµû½×¤¤ , ¼g¹D ( ¨S¦³¸ÕÅç¦õÃÒ ) Alternatively, sarcosine might activate synaptic NMDARs to increase resilience ¡K [ ºK¦Û : ¼W±j©Î§í¨îNMDA-§ïµ½§íÆ{¯g www.jwatch.org/na32767/2013/11/15/enhance-or-inhibit-nmda-and-improve-depression ] ¤S °²Y Neuroactive cytokines ¬O¦b»¡¯«¸gª¢©Êªº¬ÛÃö²ÓM¦]¤l ¨º»ò SNG-12 ¤]¥i¥H§Üª¢©Ê Metabotypes with properly functioning mitochondria and anti-inflammation predict extended productive life span in dairy cows www.nature.com/articles/srep24642 In general, common effects of biogenic amines such as carnosine, sarcosine and spermidine are anti-inflammatory, anti-oxidative and anti-ageing. ¦Ù®ò»Ä¡]N-¥Ò°ò¥Ì®ò»Ä¡^¬O¥Ì®ò»Ä¥NÁªº¤¤¶¡²£ª«¡A¥ÑÂßÅé©Ò¦³²ÓM²£¥Í¡C§@¬°¿¯¹¸É¥R¾¯¡A¦Ù®ò»Ä¥i«P¶i¯«¸g«OÅ@§@¥Î¡A¡K¡A¼W±j¯Ø®q¯À±Ó·P©Ê¡C ¦b§íÆ{¯g±`¨£ªº¦X¨Ö¯g ( µJ¼{©MÃĪ«ÀݥΠ) ¤è± SNG-12 ¥i¥HªvÀøµJ¼{ ; ÃĪ«ÀݥΤ豩Υu¯à²o±jªþ·| Inhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of Depression DOI:doi.org/10.1016/j.biopsych.2013.02.020 Citalopram °£¤F§Ü§íÆ{¥~ , ¤]¨ã§ÜµJ¼{ªº®ÄªG en.wikipedia.org/wiki/Citalopram Citalopram may be used off-label to treat anxiety Citalopram is well tolerated and as effective as moclobemide in social anxiety disorder. ( ªþµù : Moclobemide is a Reversible Inhibitor of Monoamine oxidase-A (RIMA) drug primarily used to treat depression and social anxiety. ) µM¦Ó sarcosine ¦b§Ü§íÆ{©MµJ¼{¤è±³£Àu©óCitalopram Do specific NMDA receptor subunits act as gateways for addictive behaviors? onlinelibrary.wiley.com/doi/full/10.1111/gbb.12348 ¥Ñ©ó¥Ì®ò»Ä¦ìÂIªº¿E°Ê§@¥Îªº°§C¦Ó¾ÉPNMDAR¥\¯à°§C¡A¼W¥[¤F¦æ¬°±Ó¤Æªº¼vÅT¡A«ì´_¥¿±`NMDAR¥\¯à¦ü¥G¥i¥H¨¾¤î³oºØ¦¨Å}¬ÛÃö¦æ¬°¡C Á`¤§¡A³o¨Çµ²ªGªí©ú¡A§ïÅÜNMDAR»²§U¦]¤lªº½Õ¸`¥i¥H±j¯P¼vÅT¦¨Å}¬ÛÃöªº¦æ¬°¡A¦Ó¥B¤£¦P¤ô¥ªºNMDAR¥\¯à¥i¯à¨ã¦³¤£¦Pªº§@¥Î¡C ¨ó¦P¿E°Ê¾¯NMDAR½Õ¸`¾¯ÁÙ¥i³q¹L¨ä¥L¾÷¨î´î¤Ö¦¨Å}¦æ¬°¡C ¾¨ºÞ¨Ï¥ÎNMDAR¿E°Ê¾¯¨Ó«P¶iÃĪ«´£¥Üªº®ø·À¦b·§©À¤W¤´µM«Ü¦³§l¤Þ¤O¡A¦ý¬O¦b¤@¨Ç¤HÅé¬ã¨s¤¤¯Ê¥F¦³®Ä©Ê¥i¯à¤Ï¬M¤F§JªA©M§í¨î«D±`±j¯Pªº¦¨Å}°Ê¾÷ªº§xÃø . D-Àôµ·®ò»Ä¡A¦Ù®ò»Ä©MD-µ·®ò»Ä´î¤Ö¤F¥i¥d¦]»¤¾Éªº±ø¥ó¦ì¸m°¾·Rªºªí¹F journals.sagepub.com/doi/abs/10.1177/0269881110388333 Although D-cycloserine (30 mg/kg) abolished cocaine (10 mg/kg)-induced CPP, sarcosine (300 and 600 mg/kg) and D-serine (600 mg/kg) diminished the expression of such a cocaine memory. Sarcosine (600 mg/kg) and D-serine (600 mg/kg) did not affect the storage of this cocaine memory. It was of interest to note that D-cycloserine facilitated the extinction of cocaine-induced CPP in a fast and early-onset manner, while sarcosine and D-serine decreased cocaine-induced CPP expression in a delay-onset manner. In addition to D-cycloserine treatment, our results indicate that long-term treatment with D-serine and sarcosine may afford a therapeutic advance in suppressing the expression of cocaine-associated memory. Glycine Transport Inhibition for Nicotine Dependence in Schizophrenia grantome.com/grant/NIH/R01-DA022276-03 ¦Ù®ò»Ä¥i´î»´¥Òf»¤¾Éªº¹B°Ê¤£¨ó½Õ¡A°O¾Ð¤O´î°h©MÅé·Å¹L§C¡A¦ý¤£·|¨ë¿E¤p¹«ªº¸£¨ë¿E¼úÀy¡C europepmc.org/article/pmc/pmc3509804 Á`¤§¡A¥»¬ã¨sÃÒ©ú¤F«æ©Ê¥Òf ( ±j¤O½¦¥D¦¨¤À )¼ÉÅS¾¯¶q¨Ì¿à©Ê¦a¦bNMRI¤p¹«¤¤¤Þ°_¹B°Ê¤£¨ó½Õ¡AÅé·Å¹L§C©MÃѧO°O¾Ð»Ùê¡A¨Ã«P¶i¤FC57BL6 / J¤p¹«ªº¸£¨ë¿E¼úÀy¡C¦Ù®ò»Ä¬O¤@ºØ¤º·½©Ê®ò°ò»Ä¡A¬ONMDA¨üÅ骺¨ó¦P¿E°Ê¾¯¡A¬OGlyT1ªºÄvª§©Ê§í¨î¾¯¡A¥i°fÂàNMRI¤p¹«¤¤¥Òf»¤¾Éªº¹B°Ê»Ùê¡AÅé·Å¹L§C©M°O¾Ð¤O´î°h¡A¦ý¤£¯à°fÂà¥Òf»¤¾ÉªºC57BL / 6J¤p¹«¤j¸£¨ë¿Eªº«P¶i§@¥Î¡C¤£¦Pªº¯«¸g³q¸ô©M¯«¸g»¼½è¨t²Î¥i¯à·|¾ÉP¹ï¥Òfªº¤£¦P¦æ¬°¤ÏÀ³¡K¡C¦]¦¹¡A¦Ù®ò»Ä¥i¯à¨ã¦³³q¹L¾·~©Î¬G·N±µÄ²¹w¨¾«æ©Ê¥Òf¤¤¬rªº¼ç¤O¡C ²¢µæÆP¤Îf¥Ò»Ä¶u½Õ¸`K¥L©R¤§¦Û§Úµ¹ÃļW±j§@¥Î¤Î´_µo¦æ¬° ndltd.ncl.edu.tw/cgi-bin/gs32/gsweb.cgi/login?o=dnclcdr&s=id=%22106TCU00229002%22.&searchmode=basic K¥L©R¦¨Å}°ÝÃD¤éÁÍÄY«¡A´M§äªvÀøªºÃĪ«¬°«n½ÒÃD¡CK¥L©R»¤¾Éªº¦æ¬°¼W±j®ÄÀ³³Q»{¬°»PNMDA¨üÅé¥\¯à³QK¥L©R§í¨î¦³Ãö¡CGlycine¡AD-serine¬ONMDA¨üÅ鬡¤Æªº¦@¦PP®Ä¾¯¡A²¢µæÆP¬°glycineªºl¥Íª«¡Ff¥Ò»Ä¶u¬°D-«¬Ói°ò»Ä®ñ¤Æ酶§í¨î¾¯¡A¥i¼W¥[D-serine¦b¸£¤¤ªº¿@«×¡Cµ²ªGÅã¥Ü²¢µæÆP¥i¨ú¥Nglycine¦X¨Öglutamate¤Þ°_NMDA¨üÅé½Õ¸`ªº¿³¾Ä©Ê³õ°ì¹q¦ì¡A¦Óf¥Ò»Ä¶u¦X¨Öglutamateªº°_®Ä®É¶¡«h¸ûªø¡F¦bK¥L©R¹S½à°O¾Ð®ø°£(extinction)¡B±j¢§ÙÂ_(forced abstinence)´Á¶¡µ¹ÃĩΫe³B²z ²¢µæÆP¤Îf¥Ò»Ä¶u¬Ò¥i´î½wK¥L©R³VÃĦ欰´_µo¡FµM¦Ó¡A³o¨âӤƦXª«¬Ò¤£¼vÅT¹ª«ªº¼W±j®ÄÀ³»P³V¹¦æ¬°¡A¨âªÌ¨ã¦³Á{§ÉªvÀøK¥L©R¦¨Å}ªº¼ç¤O¡C ²¢µæÆP¬°glycineªºl¥Íª« , ¦³ªvÀøK¥L©R¦¨Å}ªº¼ç¤O , SNG-12¬Oglycineªº¤¤¶¡¥NÁª« , ¬O§_¤]¨ã¦³³oºØ¥\¯à©O ? ¥Ñ¥H¤Wªº¤åÄm¬Ý°_¨Ó ¦ÙÓi»Ä ( SNG-12 ) ¥i¯à¦³¦pJ&J©xºô©Ò´M¨Dªº¤TÓ§@¥Îªº¤À¤l¥\¯à o Glutamatergic modulators --- ¦ÙÓi»Ä¬O¼W±j¨¦Ói»Ä¯àªº¤Æ¦Xª« , ¥i¥H¼W¶i»{ª¾¥\¯à , ¤£¹³§Ü«ú¾¯¦³·l®`»{ª¾ªººÃ¼{ , ³oÀ³¸Ó¬O½²±Ð±Â¿ï¥Îªº¤Æ¦Xª«¦h¬O¼W±jNMDA ¥\¯àªº¥D¦]§a? o Neuroactive cytokines ( ¬O«ü¯«¸gª¢©Êªº¬ÛÃö²ÓM¦]¤l¶Ü ? ) --- ¦ÙÓi»Ä¤]¨ã¦³§Üª¢§@¥Î o Molecules that positively impact synaptic plasticity and cellular resilience --- ¦ÙÓi»Ä¦³¼W¶i synaptic plasticity ©M/©Î cellular resilience ªº¥\¯à ³o¤TºØ¤À¤l©Î¤Æ¦Xª«·íµM¥²¶·¨ã³Æ§Ü§íÆ{ , ÁÙ¦³¥iªvÀø§íÆ{¯g±`¨£ªº¦X¨Ö¯g ( µJ¼{©MÃĪ«ÀݥΠ) ¦ÙÓi»Ä¥i¥H§Ü§íÆ{¦Û¤£«Ý¨¥ , ÁÙ¯à§Ü¦Û±þ·N©À ¥t¥~§Ṳ́]¬Ý¨ì¤F , ¦ÙÓi»Ä¥i¥H§ÜµJ¼{ , ©Î¥i¯àªºªvÀøÃĪ«ÀݥΠ¥i»¡¬O¶°¦hºØ§@¥Î©ó¤@¨ , ©Î«D±`²Å¦XJ&Jªº»Ý¨D? Y¦b¥[¤W¾Y °£¤F«e±»¡ªº ¤W½Õ¯«¸g¥i¶ì©Ê ¡B¼W¶i²ÓMªº¼u©Ê ¡B¯«¸g«OÅ@©M¼W¥[®ü°¨¯«¸gµo¥Í ¤§¥~ ²{¦b´NÅý§Ų́ӬݬݾYªº¤åÄm Effects of lithium on cytokine neuro-inflammatory mediators, Wnt/£]-catenin signaling and microglial activation in the hippocampus of chronic mild stress-exposed rats pubmed.ncbi.nlm.nih.gov/32454056/ Chronic Li treatment ameliorated stress induced-behavioral changes, reduced microglial activation and enhanced the hippocampal expression of Wnt/£]-catenin signaling pathway. CONCLUSION: This work highlights that Li-induced inhibition of GSK-3£] with subsequent accumulation of £]-catenin could impede pro-inflammatory microglia activation which is a key pathological hallmark associated with depression. Wnt/£]-catenin signaling represents a promising therapeutic target, not only for alleviation of depression, but also for a wide array of neurological disorders. ¾Y¦bÂù¬Û±¡·P»Ùꤤªº¼ç¦b§@¥Î¾÷²z link.springer.com/article/10.1007%2Fs40263-013-0039-0 ¤j¶q¬ã¨s³ø§iªí©ú¡A¾Y¥i¦³®ÄªvÀø«æ©Êļ¨g¯g¥H¤Îªø´Áºû«ù±¡ºü©M¹w¨¾¯gª¬¡C¾Y¨ã¦³¿W¯Sªº§Ü¦Û±þ©Ê¯à¡A¨Ï¨ä»P¨ä¥L¸Õ¾¯°Ï¤À¶}¨Ó¡CÃö©ó»{ª¾¡A¬ã¨sªí©ú¾Y¥i¥H´î¤Ö±wªÌªº»{ª¾¯à¤O¤U°¡CµM¦Ó¡A³o¨Çµo²{»Ýn¨Ï¥Î¯«¸g¤ß²z¾Ç©M¥\¯à©Ê¯«¸g¼v¹³±´°w¶i¦æ¶i¤@¨B¬ã¨s¡C¦³½ìªº¬O¡A¾Y¦ü¥G¥i¥H«O¯d©Î¼W¥[¯A¤Î±¡ºü½Õ¸`ªº¤j¸£µ²ºcªºÅé¿n¡A¨Ò¦p«eÃB¸¥Ö¼h¡A®ü°¨©M§ö¤¯®Ö¡A¥i¯à¤Ï¬M¤F¨ä¯«¸g«OÅ@§@¥Î¡C Role of Inflammation in Suicide: From Mechanisms to Treatment www.nature.com/articles/npp2016116 Administration of lithium, which exhibits anti-inflammatory effects through inhibition of GSK3, has been found effective in decreasing depressive-like and aggressive behavior in animal models (Beurel and Jope, 2014) and reducing suicidal attempts and suicide completion in patients with bipolar as well as unipolar depression (Baldessarini et al, 2006; Guzzetta et al, 2007). ¾Y¹ïª¢¯gªº¼vÅT pubs.acs.org/doi/abs/10.1021/cn500038f ¾Y¬OªvÀøÂù¬Û±¡·P»Ùꪺ¦³®ÄÃĪ«¡C¶V¨Ó¶V¦hªºÃÒ¾Úªí©ú¡Aª¢¯g¦bÂù¬Û±¡·P»Ùꪺµo¯f¾÷¨î¤¤°_§@¥Î¡A¾Y¨ã¦³§Üª¢§@¥Î¡A¥i¯à¦³§U©ó¨äªvÀø¥\®Ä¡C¥»¤åÁ`µ²¤F¬ã¨s¾Y¹ï«Pª¢©M§Üª¢¤¶½èªº¼vÅTªº¬ã¨s¡C¤@¨Ç¶×Á`¼Æ¾Úªí©ú¾Y¨ã¦³§Üª¢§@¥Î¡]¨Ò¦p¡A§í¨îÀô®ñ¦X酶2ªºªí¹F¡A§í¨î¥Õ¤¶¯À¡]IL¡^-1£]©M¸~½FÃa¦º¦]¤l-£\ªº²£¥Í¡A¥H¤Î¼W±jIL-2©MIL-10ªº¦X¦¨¡^ ¡^¡C¾¨ºÞ¦p¦¹¡A¤´¦³¤j¶q¼Æ¾Úªí©ú¡A¦b¬Y¨Ç¹êÅç±ø¥ó¤U¡A¾YÁ٨㦳«Pª¢¯S©Ê¡]¨Ò¦p¡A»¤¾ÉIL-4¡AIL-6©M¨ä¥L«Pª¢²ÓM¦]¤lªº¦X¦¨¡^¡C Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB/c mouse strain doi: 10.1016/j.brainresbull.2006.03.007 Abnormalities of NMDA receptor-mediated neurotransmission are involved in the pathophysiology of schizophrenia, Alzheimer¡¦s disease, substance abuse and seizure disorders. Double- Blind and Placebo-Controlled Study of Lithium for Adolescent Bipolar Disorders With Secondary Substance Dependency citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.477.3099&rep=rep1&type=pdf Conclusions: Lithium treatment of BP with secondary SDD in adolescents was an efficacious treatment for both disorders. These results warrant replication with a long-term maintenance phase. The mean 6-year interval between the onset of BP and onset of SDD strongly argues for earliest recognition of BP. Lithium Pharmacology and a Potential Role of Lithium on Methamphetamine ( ¥Ò°ò¦w«D¥L©R ) Abuse and Dependence DOI : 10.2174/2589977511666190620141824 Conclusion: It is possible that lithium treatment reduces the amount of newly synthesized phosphatidylinositol, potentially preventing or reversing neuroadaptations contributing to behavioral sensitization induced by methamphetamine. In addition, it is suggested that exposure to repeated doses of methamphetamine induces hyperactivation of glycogen synthase kinase-3£] in the nucleus accumbens and in dorsal hippocampus, resulting in a long-term alterations in synaptic plasticity underlying behavioral sensitization as well as other behavioral deficits in memory-related behavior. Therefore it is clear that glycogen synthase kinase-3£] inhibitors can be considered as a potential candidate for the treatment of methamphetamine abuse and dependence. ¾Y¡G±q±¡ºüéw¾¯¨ì¤½»{ªº»{ª¾¼W±j¾¯ ? www.ncbi.nlm.nih.gov/pmc/articles/PMC5020816/ ³æ»ù¶§Â÷¤l¾Y¡]¨ä¥Î©óºë¯«¯f¾Çªº¾ú¥v¥i¥H°l·¹¨ì1940¦~¥N¥½¡^¤´µM¬OªvÀøÂù¬Û±¡·P»Ùê¡]BD¡^±wªÌªº¤@½uÃĪ«¡C¥¦¥i¦³®ÄªvÀø¤¤«×¦Ü««×«æ©Êļ¨g¡A¹w¨¾¤Ï´_µo§@ªºÄ¼¨g©M§íÆ{µo§@¡A¨Ã°§C¦Û±þ·ÀI¡C¥¦ÁÙ¥i¥H¼W±j§Ü§íÆ{ÃĦbªvÀø««×§íÆ{¯g¤¤ªº§@¥Î¡]Albertµ¥¡A2014¡^¡C Lithium Carbonate Augmentation of Antidepressant Treatment An Effective Prescription for Treatment-Refractory Depression jamanetwork.com/journals/jamapsychiatry/article-abstract/493225 §Ú̱o¥Xªºµ²½×¬O¡A±NºÒ»Ä¾Y²K¥[¨ìµL¤ÏÀ³ªº±wªÌªºªø´Á§Ü§íÆ{ªvÀø«á¡A½T¹ê·|¼W±j§Ü§íÆ{§@¥Î¡C ļÆ{¯g±wªÌ¾Yªº¨Ï¥Î»P¯«¸g»{ª¾¥\¯àªºÃö«Y pubmed.ncbi.nlm.nih.gov/32349118/ Epub 2020¦~4¤ë29¤é §Ú̱´°Q¤F¾YÀøªk¦b¤£¦P®É¶¡¹ï¯«¸g»{ª¾¥\¯àªº¼vÅT¡C»P¥¼ªA¥Î¾YªºBD±wªÌ¬Û¤ñ¡A°ò½u®É¨S¦³®t²§¡CÀH³X®É¡AÁ`Åé»{ª¾«ü¼Æ±o¤ÀÅãµÛ§ïµ½¤F¯«¸g»{ª¾[F = 31.69; p <0.001]¡ACVLT¸ÕÅç1-5 [F = 29.81¡Fp <0.001]¡ACVLT©µ¿ð¥l¦^[F = 15.27; p <0.001]©MTMT-B [F = 6.64¡Ap = 0.012]¡C¾îÂ_±©MÁaÂ_±¬ã¨s¡]°w¹ï88¦ì±wªÌªº¤@³¡¤À¡^ªí©ú¡A¾Y¥i¯à¹ïBD±wªÌªº¯«¸g»{ª¾¥\¯à¦³¯q¡A¨Ã¥B¦Ü¤Ö¦bªvÀø¤W¨Ï¥Î¾Y¦ü¥G¤£·|©úÅã·l®`»{ª¾¡C §Ų́Ӧ۾îºI±©MÁa¦V¤ÀªRªº¼Æ¾Úªí©ú,¾Y¥i¯à¦³§U©óBD±wªÌªº¯«¸g»{ª¾¥\¯à,¦Ó¥B¦Ü¤Ö¦bªvÀø®É,¾Y¦ü¥G¤£·|ÅãµÛ·l®`»{ª¾¡C³o¥i¯à¹ïÁ{§ÉÂå¥Í»P¯f¤H°Q½×³oºØÃĪ«¦bªvÀø±¡ºüéwªº§Q¹ú¤è± , ¦³µÛ«nªº¼vÅT¡C ´â¤Æ¾Y¹ïAPP / PS1¤p¹«ªº»{ª¾¯q³B»P£]-¾ý¯»¼Ë³J¥Õªº¸£²M°£²v´£°ª¦³Ãö www.sciencedirect.com/science/article/abs/pii/S0889159118300552 ¬y¦æ¯f¾ÇÃÒ¾Úªí©ú¡A»P³B¤è¨ä¥L±¡ºüéwÃĪ«ªº¤H¬Û¤ñ¡A³B¤è¾YªºÄ¼Æ{¯g±wªÌªí²{¥X¸û§Cªºªüº¸¯ý®üÀq¤ó¯f¡]AD¡^·ÀI¡CAD¤¤¤j¸£A£]ªº²M°£²v°§C¡AµM´â¤Æ¾Y¡]LiCl¡^°§C¤F¤j¸££]-¾ý¯»¼Ë³J¥Õ¡]A£]¡^ªº¤ô¥¡C LiClªºªvÀø«ì´_¤FAPP / PS1¤p¹«¤¤Æ[¹î¨ìªºªø´ÁªÅ¶¡°O¾Ð¯Ê³´¡]«ì´_¨ì»PWT¤p¹«¬Û¦üªº°kÁ×¼ç¥ñ¤ô¥¡^¡A¦ýLiCl³B²z¨Ã¥¼¼vÅTµu´Á°O¾Ð¯Ê³´¡C ¾Y¹ï»´«×»{ª¾»Ùê¦Ñ¦~¤Hªºªø´Á¾YªvÀøªºÁ{§É©M¥Íª«¾Ç®ÄÀ³¡GÀH¾÷Á{§É¸ÕÅç www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/clinical-and-biological-effects-of-longterm-lithium-treatment-in-older-adults-with-amnestic-mild-cognitive-impairment-randomised-clinical-trial/EF9931A98FFD7FA99F2202C19063EF77 Results Participants in the placebo group displayed cognitive and functional decline, whereas lithium-treated patients remained stable over 2 years. Lithium treatment was associated with better performance on memory and attention tests after 24 months, and with a significant increase in CSF amyloid-beta peptide (A£]1−42) after 36 months. ( ¾YªvÀø 2 ¦~ ) Conclusions Long-term lithium attenuates cognitive and functional decline in amnestic MCI, and modifies Alzheimer¡¦s disease-related CSF biomarkers. The present data reinforces the disease-modifying properties of lithium in the MCI¡VAlzheimer¡¦s disease continuum. Molecular Mechanisms of Lithium Action: Switching the Light on Multiple Targets for Dementia Using Animal Models www.frontiersin.org/articles/10.3389/fnmol.2018.00297/full ¥[¤F¾Y , ¦n¤£¦n©O? George Washington University School of Medicine, Bipolarªº±M®a¾ÇªÌ¦³Å³©ó¾Yªº¦n , ¦ý¦b¬ü°ê¥¼¨£¥R¤À§Q¥Î¦Ó±M¤å±À¼s ¦³Ãö¾Yªº·s·s»D¡G¬ü°ê¥¼¥R¤À§Q¥ÎªºªvÀø¤èªk www.ncbi.nlm.nih.gov/pmc/articles/PMC5854802/ ³æ¬Û§íÆ{¯gªº«æ©Ê©M¹w¨¾§@¥Î ¤j¶q¼Æ¾Úªí©ú¡A»P¦w¼¢¾¯¬Û¤ñ¡A¾Y¥iÅãµÛ¼W±j§Ü§íÆ{ÃĪº§@¥Î¡CÂA¬°¤Hª¾ªº¬O¡A¸Ó¤H¸s¦b¹w¨¾´_µo©Ê³æ¬Û§íÆ{¯gµo§@©M¹w¨¾¦Û±þ¤è±ªº¼Æ¾Ú±j«× ¾Y¨ã¦³§Ü¦Û±þ§@¥Î¡A§Y¨Ï¦b¶¼¥Î¤ô¤¤ªº·L¶q§t¶q¤]¬O¦p¦¹ ·í¥HªvÀø¾¯¶q¨Ï¥Î®É¡A¾Y¨ã¦³¤ä«ù¨ä§Ü¦Û±þ§@¥Îªº³Ì¨Î¼Æ¾Ú ¾Y¥i°§Cè§b¯gªº·ÀI ¾YªºÁ{§É¨Ï¥Î»P¦Ñ¦~è§b¯gªºµo¥Í²v¸û§C¬ÛÃö¡]Kessingµ¥¡A2010¡FNunesµ¥¡A2013¡^¡C¦¹¥~¡AÀu¨qªº¾YÅTÀ³ªÌ«O¯d¤F»{ª¾¡]Rybakowski©MSuwalska¡A2010¦~¡^¡C¾YªvÀøªº±wªÌ¤ñ«D¾YªvÀøªº±wªÌ¨ã¦³§ó¦nªºµøı°O¾Ð ¾Y¨ã¦³¯«¸gÀç¾i©M¯«¸g«OÅ@§@¥Î ¾Y»P®ü°¨©M¥Ö½èÅé¿nªº¼W¥[¦³Ãö¡C³o¥i¯à¬O°ò©ó¨ä¼W¥[¯«¸g«OÅ@¦]¤lBDNF©MBCl-2¨Ã°§Cä¤`¡]²ÓM¦º¤`¦]¤l¡^BAX©MP53ªº¯à¤O¡]Malhiµ¥¡A2013¡FRowe©MChuang¡A2004¡^¡C¥¦¼W¥[¯«¸gµo¥Í©M¯«¸g½¦½èµo¥Í¡C ¾Y¼W¥[ºÝ²Éªø«× ¾Y¼W¥[¤FºÝ²Éªºªø«×¡AºÝ²Éªº«O¦s¹ï©óºû«ù¨Åé©Mºë¯«°·±d¦ÜÃö«n¡C¾Y¹ïºÝ²Éªº¼vÅT¬OºÝ²É©µªø酶¡]ºÝ²É酶¡^¬¡©Ê¼W¥[ªºª½±µµ²ªG¡]Martinssonµ¥¡A2013¡^¡C¦³¾Yªº®É¶¡¶Vªø¡AºÝ²Éªºªø«×¶V¥¿±` ¦³½ìªº¬O¡A¾Y¦ü¥G³Ì¾A¦X¥H¤U±¡ªpªº±wªÌ¡GÂù¬Û±¡·P»Ùꪺ¸g¨åªí²{¡F±¡ºü©ÎÂù¬Û±¡·P»Ùꪺ¶§©Ê®a±Ú¥v; ¡K¥H¤Î±w¦³µJ¼{¯g©Îª«½è¦X¨Ö¯g ( substance comorbidity ) ©Î±¡ºü¤£¨ó½Õªº¦k·Q±wªÌ. ½²±Ð±Â¹ï¾YªºÀ³¥Î°_¦Ó¤O¦æ , ¥¿©Ò¿×^¶¯©Ò¨£¤@¦P J&J ¯«¸g¾Ç¬ãµo¹Î¶¤¸Ô¦C¤F³Ì·s¬ãµo¤è¦V , ¨Ã´M¨D¦X§@¹Ù¦ñ ½²±Ð±Â§â¤ß®®ì¥ýªº¥Dn¤Æ¦Xª« --- f¥Ò»Ä¶u ¡B¦Ù®ò»Ä ( sarcosine ) ¨ÓÓÃIJz±M·~ªº³Ð·N°t¹ï , Åܦ¨f¥Ò»Ä¾Y ¡B¦Ù®ò»Ä¾Y , ¨Ã¥B³£¤wÀò±o¬ü°ê±M§Q ¥ý¤£½×¬O§_¦³¾÷·|©MJ&J ¦¨¬°¦X§@¹Ù¦ñ ? ¥[¶i¨Ó¾Y , ¬O§_·|¦h¤è± ( ¦p J&J ©Ò´£¶µ¥Ø ) ¦a§ó¼W±jÀø®Ä ? ¤×¨ä¦b¼W¶i»{ª¾¤è± ²¦³º , J&J»¡ [ ³Ìªñªº¬ã¨s¤w±N¯«¸g¤¸¥i¶ì©Ê©M²ÓM¼u©Ê»P¾Ç²ß¡A°O¾Ð¡A»{ª¾©M±¡ºüÁpô¦b¤@°_¡C ] ¬Û«H¤j®a¦h«Ü·Qª¾¹D ÁöªÑ»ù³QÀ£§í , ¦ý§Ṳ́´¤£¯à©Ù·À¤½¥q´£¤É°ò¥»±ªº§V¤O ÁÂÁ¤߮®¹Î¶¤ ! ¤j®a¥[ªo ! ¤pªº°ò¥»¥\«Ü®t , ¦³½Ð¤j®a§V¤OªÈ¥¿ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/27 ¤U¤È 12:57:59²Ä 1066 ½g¦^À³
|
¤ß®®¤µ¤é¨ú±of¥Ò»Ä¾Y¦@´¹©M¥Î³~ªº¬ü°ê±M§Q Co-crystals of lithium benzoate and uses thereof United States Patent 10,815,184 October 27, 2020 ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/26 ¤W¤È 08:30:15²Ä 1065 ½g¦^À³
|
SNB01¯u¬O¤@Ó¿ùºî½ÆÂø ½L®Ú¥æ¿ùªº¾÷¨î ¤pªº¦b¥»ª©²Ä801½g¶K¤å´£¨ì . powerful anti-fibrotic effect of tannic acid in cultured human lung fibroblasts ( §ÜªÍÅÖºû¤Æ ) . ³æ¹ç»Ä¬OACE§í¨î¾¯ ; ¦åºÞºò±i¯ÀÂà´«酶¡]ACE¡^§í¨î¾¯¦³§U©ó©ñÃP¦åºÞ¡A±q¦Ó¦³§U©ó°§C¦åÀ£¡C¤Ï¹L¨Ó¡A³o´î¤Ö¤F¤ßŦªº¤u§@¶q¡C³Ìªñªº¤@¶µ¬ã¨sµo²{ACE§í¨î¾¯ÁÙ¦³¨ä¥L¦n³B¡C¬ã¨s¤Hûµo²{ACE§í¨î¾¯¥iÅãµÛ°§CªÍª¢·ÀI¡C . ¦h×ôÃþ¤Æ¦Xª«¬OACE§í¨î¾¯ ©M ACE2¿E°Ê¾¯ , ¦ý§@ªÌ¨S¦³¯S§Oªí©ú³æ¹ç»Ä¬OACE2¿E°Ê¾¯ ; ¦åºÞºò±i¯ÀÂà´«酶¡]ACE¡^»Pý³Ý¡AºC©Êªý¶ë©ÊªÍ¯e¯f¡]COPD¡^¡A«æ©Ê©I§lµ~¢ºî¦X¼x¡]ARDS¡^¥¿¬ÛÃö¡A¨Ã¦bªÍ¤¤°ªªí¹F¡CACE2¬OACEªº©è§Ü酶¡A³QÃÒ©ú¹ïªÍ¡A¤ß¦åºÞ¯e¯f¨ã¦³«OÅ@§@¥Î¡C . ³æ¹ç»Äµ¹Ãįà°÷ÅãµÛ§í¨îTNF-£\¡AIL-1£]©MIL-6ªº¤ô¥ , §ïµ½¤p¹«¹ï¯×¦hÁÞ»¤¾Éªº±Ñ¦å¯g©M«æ©ÊªÍ·l¶Ë ACE§í¨î¾¯¦³³o»ò¦h¦n³B , ¦ý¤]¥i¯à´£¤ÉACE2ªºªí²{¶q , GA ¤S·|µ²¦XACE2ªý¤î¯f¬r¶i¤J²ÓM ©Ò¥H , SNB01·|¦³«ç¼Ëªºªí²{? ¤]µÛ¹ê¥O¤H¦n©_ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/26 ¤W¤È 07:47:16²Ä 1064 ½g¦^À³
|
www.genetinfo.com/international-news/item/39236.html ¨ä¤¤´£¨ì ADAM17 ¦A¨Ó¬ïÆwªþ·|¤@¤U www.spandidos-publications.com/10.3892/ol.2013.1632 Western blot analysis demonstrated that the expression of ADAM17, EGFR, p‑Akt and p‑Erk was suppressed by gallic acid in the HeLa and HTB‑35 cell lines. europepmc.org/article/pmc/pmc3003697 Western blot analysis showed that expression of ADAM17, p-Akt and p-Erk was suppressed by gallic acid in both U87 and U251n cell lines. These data suggest that suppression of ADAM17 and downregulation of PI3K/Akt and Ras/MAPK signaling pathways may contribute to gallic acid-induced decrease of invasiveness. Gallic acid may be a valuable candidate for treatment of brain tumor. GA ¥i¥H§í¨îÀù²ÓM¤Wªº ADAM17 GA ªº¿@«×ÁÙ¦³¾÷²z¬O§_¤]¥i¥H§í¨î¦]SARS-CoV-2©Ò³y¦¨ªº ADAM17 ¹Lªí¹F ? ¤´«ÝÁ{§ÉÃÒ¹ê ©Î³\¤j®a¤´°O±o GA ¥i¥H©M ACE2µ²¦X , ªý¤î·s«a¯f¬r¤J«I²ÓM ¤]¥i¥H¸g¥Ñ RdRp §í¨î¯f¬r½Æ»s §Æ±æSNB01ªº¿@«×¨¬¥H¹F¨ì³o¨Ç¾÷¨îªº¥\¯à , ¨Ó®i²{SNB01§Ü¯f¬rªº¹ê¤O ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/25 ¤U¤È 07:23:50²Ä 1063 ½g¦^À³
|
¸É¥R¥t½g¤]¬OÃö©ó¤fªA GA ¹ï APP/PS1 ¤p¹«ªvÀø¦¨ªGªº½×¤å , Åã¥Ü¥X¥i«½Æªºµ²ªG Gallic acid disruption of A£]1¡V42 aggregation rescues cognitive decline of APP/PS1 double transgenic mouse • DOI¡G 10.1016 / j.nbd.2018.11.009 One of the most interesting findings of the present study was that GA not only significantly improved cognitive deficits of the 4-month-old APP/PS1 mice, but also significantly ameliorated cognitive deficits of the 9-month-old AD mice, suggesting GA can be used to prevent and treat AD. Together we show that GA may have multiple targets including inhibit A£] aggregation, increase synaptic strength, reduce inflammation and partially block intracellular calcium influx. These data shed new light on possible mechanisms of GA function and support the view that GA is a promising drug candidate to delay and treat AD in humans. Future studies of GA¡¦s clinical benefits are warranted. ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/25 ¤W¤È 10:17:35²Ä 1062 ½g¦^À³
|
¹ù¥S¤À¨Éªº ³q¹L¾v§¨ª¬¤À¤l§í¨î¾¯³æ¹ç»Ä¥]»q¯×½èÅé¦b²ÓM¾Ç¤W´î¤ÖTau»E¶°ªº·sµ¦²¤ pubs.acs.org/doi/abs/10.1021/acschemneuro.0c00508 ¦®¦bÄÄzTA¯×½èÅé³q¹LBBB ªºµ¦²¤ , ¨Ã»¡©ú We found that TA exhibited significant affinity to the Tau peptide, while its moiety GA did not. We introduced tannic acid (TA), a polymeric plant polyphenol, and its moiety, gallic acid (GA), as the references. We showed that tannic acid, a multibranched hydrophilic molecule, could tightly bind with the target peptide chain to form a hairpinlike molecular framework, and it effectively inhibited Tau aggregation in vitro. ¥t¥~ , ¦b¥L½g½×¤å¸Ì Molecular hairpin: a possible model for inhibition of tau aggregation by tannic acid pubmed.ncbi.nlm.nih.gov/23442089/ «h»¡ We demonstrated that TA could competently inhibit the in vitro aggregation of tau peptide R3, corresponding to the third repeat unit of the microtubule-binding domain, with an IC50 of 3.5 £gM, while GA¡¦s inhibition was comparatively piddling (with an IC50 of 92 £gM). ¥H«e , §Ṳ́À§O¤]´£¹L¤é¥»¾ÇªÌªº¨âÓ¸ÕÅç , ³o¨â½g½×¤åªºµoªí®É¶¡³ºµM®t¤F 8 ¦~ ²{¦b§â³o¨â½g½×¤å©ñ¦b¤@°_¨Ó¬Ý , ¥i¥H¤ñ¸û TA ©M GA ¹ï APP/PS1Âà°ò¦]¤p¹«ªºªvÀø®ÄªG Tannic Acid Is a Natural £]-Secretase Inhibitor That Prevents Cognitive Impairment and Mitigates Alzheimer-like Pathology in Transgenic Mice www.ncbi.nlm.nih.gov/pmc/articles/PMC3307267/ ±q6Ó¤ë¤jªº¤p¹«¶}©lªA¥Î6Ӥ몺TA , ¥i¥H¹w¨¾Âà°ò¦]¬ÛÃöªº¦æ¬°»Ùê¡A¥]¬A¬¡°Ê¹L«×¡A¹ï¶HÃѧO°§C©MªÅ¶¡°Ñ¦Ò°O¾Ð¯Ê³´¡A¦ý¤£·|§ïÅÜ«DÂà°ò¦]¤p¹«ªº¦æ¬°¡C . ¤fªA³æ¹ç»ÄªvÀø¥i´î»´PSAPP¤p¹«ªº¹L«×¬¡ÅD©M»{ª¾»Ùê . ³æ¹ç»ÄªvÀø§ïµ½¤F¸£¾ý¯»¼ËÅܩʪº¤p¹«¼Ò«¬¤¤ªºA£]¯f²z . ³æ¹ç»ÄªvÀøªºPSAPP¤p¹«¸£¾ý¯»¼Ë³J¥ÕAPP¥NÁªº§í¨î . ³æ¹ç»Ä´î¤Ö¯«¸g¤¸¼Ë²ÓM¤¤A£]ªº²£¥Í¨Ã§í¨î¾ý¯»¼Ë³J¥ÕAPP¥NÁ . ³æ¹ç»Ä¥i´î»´PSAPP¤p¹«ªº¯«¸gª¢¯g Gallic Acid is a Dual £\/£]-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice www.jbc.org/content/early/2020/09/10/jbc.RA119.012330.full.pdf Beginning at 12 months, we orally administered GA (20 mg/kg) or vehicle once daily for 6 months to APP/PS1 mice that have accelerated Alzheimer-like pathology. At 18 months of age, GA therapy reversed impaired learning and memory as compared with vehicle and did not alter behavior in wild-type littermates. . Oral GA therapy fully remediates impaired learning and memory in APP/PS1 mice . GA attenuates £]-amyloid pathology in APP/PS1 brains . Oral GA therapy has dual effects on £\- and £]-secretases GA therapy upregulates £\-secretase and downregulates £]-secretase activity . GA attenuates neuroinflammation and oxidative stress in APP/PS1 brains In conclusion, we report that administering 6- month oral GA therapy to the APP/PS1 mouse model of cerebral amyloidosis completely remediates behavioral deficits, ameliorates cerebral amyloidosis, and reduces A£] abundance. GA treatment further alleviates neuroinflammation and stabilizes oxidative stress. If the APP/PS1 mouse model reflects the clinical syndrome, then dietary supplementation with GA represents a viable therapeutic modality for AD. TA ©MGA ªºªvÀø®ÄªG¦ü¥G¤j¦P¤p²§ GA ¦h¤F¤@¶µ upregulates £\-secretase activity , TA «h¨S¦³ §Ú̪¾¹D £]-secretase ¤ñ¸û¦h , ¸û¤Ö±µÄ² £\-secretase en.wikipedia.org/wiki/Alpha_secretase ´£¨ì . £\-¤Àªc酶ªºµõ¸Ñªý¤î¤F¾ý¯»¼Ë£]ªº§Î¦¨ . £\¤Àªc酶ªº¬¡©Ê»P¾Ç²ß©M°O¾Ð§Î¦¨ªº½Õ±±¦³Ãö ¹ï©óªvÀø AD , ¦b¤HÅé·|¤£·|¦³ TA + GA ªº®ÄªG ´Á«Ý ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/24 ¤W¤È 08:36:51²Ä 1061 ½g¦^À³
|
¹ù¥S¤À¨É ¤¤°ê(¤j³°)ªº¬ãµo ¤¤°êÅܱj¤F ¹ï§Ü AD ÃĪ«¬ãµo§ó§Ö¤F liawbf.pixnet.net/blog/post/49528215 ÁÂÁ¹ù¥S ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/24 ¤W¤È 07:34:45²Ä 1060 ½g¦^À³
|
¤½¥q¨p¶Ò¸êª÷¹B¥Î²Îp 108Q3 : 36,736,468 108Q4 : 44,368,144 109Q1 : 44,706,776 109Q2 : 52,923,875 109Q3 : 62,237,249 ( ¸û¤W©u¬ù¼W¤d¸U , ¬O¦¬®×¶i«×¼W¥[ ? ÁÙ¬OSNB01¤j¹«¬r²z¸ÕÅ窺©e¿ì¶O ? ) ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¤p·10148067 µoªí®É¶¡:2020/10/23 ¤U¤È 01:41:16²Ä 1059 ½g¦^À³
|
¤ß®®©O¡H ÁÙ¦bµ¥¤j¹«ªº¬rª«¹êÅç¶Ü¡H IND¤@´ÁÁÙ¨S°_°Ê¡H ¥t¤HÃø¹L😫 |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/23 ¤U¤È 12:21:29²Ä 1058 ½g¦^À³
|
¹ù¥S³sµ²¤¤¬ã°|³¯»ö²ø¬ã¨sûªº¬ì´¶ºtÁ¿ ¯«¸g¨t²Îªºµoª¢»P°h¤Æ liawbf.pixnet.net/blog/post/49528005 ÁÂÁ¹ù¥S ÁÂÁ¤j®a! ¥t¥~¤À¨É¤@«h·s»D ( ³o¬O¦h±j ? ³o»ò¦³»ù®æ ! ) 3.5»õ¬ü¤¸«e´Á¥I´Úù¤ó¦X§@¶}µo¤fªA§Ü¯f¬rÀøªk ¨Ó·½¡GÃÄ©ú±d¼w¡@2020-10-23 med.sina.com/article_detail_100_2_90720.html ¤µ¤é¡Aù¤ó¡]Roche¡^©MAtea PharmaceuticalsÁp¦X«Å¥¬¡AÂù¤è¤w¹F¦¨¤@¶µ¦X§@¨óij¡A±NÁp¦X¶}µo¡B¥Í²£©M±À¼sAtea¤½¥qªº¦b¬ã¤fªA§Ü¯f¬rÃĪ«AT-527¡CAT-527¬O¤@´Ú¯f¬rRNA»E¦X酶¤p¤À¤l§í»s¾¯¡C·s»D½Z«ü¥X¡A¥¦¤£¦ý¥i¥H§@¬°¤fªAÀøªkªvÀø¦í°|COVID-19±wªÌ¡A¦Ó¥B¥i¯à¦¨¬°«D¦í°|±wªÌªººÓ¤fªAªvÀø¿ï¾Ü¡C¥¦Á٨㦳§@¬°¼ÉÅS«á¹w¨¾©ÊªvÀøªº¼ç¤O¡C AT-527¬O¤@ºØ¤fªAáIËï®Ö苷»Ä«eÅéÃĪ« , ³oºØ°ª¿ï¾Ü©ÊáIËï®Ö苷»Ä«eÅéÃĪ«ªº³]p¡AÅý¥¦¥i¥H¯S²§©Ê§í¨î¯f¬rªºRNA¨Ì¿à©ÊRNA»E¦X酶 ( RdRp ). ¦pªGAT-527Àò±oºÊºÞ§åã¡AAtea±Nt³d¨ä¦b¬ü°êªº±À¼s¡Aù¤óÀò±o¤FAT-527¦b¬ü°ê¥H¥~±À¼sªº¿W®aÅv¯q¡]ªvÀøCOVID-19¡^¡CAtea¤½¥qÀò±o°ª¹F3.5»õ¬ü¤¸ªº«e´Á¥I´Ú¡A¨Ã¥B¥i¥HÀò±o«áÄò¨½µ{¸O¥I´Ú¡C ªþµù : AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic www.biorxiv.org/content/10.1101/2020.08.11.242834v2 ¥»¤å¤¤¡A§Ú̳ø§i¤FAT-511¡]AT-527ªº´åÂ÷ÆP§Î¦¡¡^¹ï´XºØ«aª¬¯f¬r¡A¥]¬ASARS-CoV-2¡]COVID-19ªºP¯f¦]¤l¡^ªº¦³®ÄÅé¥~¬¡©Ê¡C¦b¥¿±`¤H®ð¹D¤W¥Ö²ÓM¡]HAE¡^¤¤¡A§í¨îSARS-CoV-2½Æ»s90¢H¡]EC 90¡^©Ò»ÝªºAT-511ªº¥§¡¿@«×¬°0.5 µM . ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/23 ¤W¤È 08:33:09²Ä 1057 ½g¦^À³
|
¹ï¤£°_ ! §ï¤@¤U Remdesivir ( ·ç¼w¦è³ ) ¬OºÓÀò±oFDA§å㪺COVID-19ªvÀøÃĪ« time.com/5903121/remdesivir-fda-covid-19/ 10¤ë22¤é¡A¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]FDA¡^§åã¤FºÓ¥Î©óªvÀøCOVID-19ªºÃĪ«¡C ¦N§Q¼w¤½¥qªº Remdesivir ¬O¤@ºØÀR¯ßª`®gªº§Ü¯f¬rÃĪ«¡A²{¤w§åã¥Î©ó¦í°|COVID-19ªº¥ô¦ó¤H¡C¥¦³q¹Lªý¤î¯f¬r½Æ»s¨Óµo´§§@¥Î¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/23 ¤W¤È 08:25:22²Ä 1056 ½g¦^À³
|
Remdesivir ( ·ç¼w¦è³ ) ¬OºÓÀò±oFDA§å㪺COVID-19ªvÀøÃĪ« time.com/5903121/remdesivir-fda-covid-19/ 10¤ë22¤é¡A¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]FDA¡^§åã¤FºÓ¥Î©óªvÀøCOVID-19ªºÃĪ«¡C Remdesivir¬O¤@ºØÀR¯ßª`®gªº§Ü¯f¬rÃĪ«¡A²{¤w§åã¥Î©ó¦í°|COVID-19ªº¥ô¦ó¤H¡C¥¦³q¹Lªý¤î¯f¬r½Æ»s§ó¦h¦Û¨ªº¥\¯à¨Óµo´§§@¥Î¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/22 ¤U¤È 12:49:37²Ä 1055 ½g¦^À³
|
¤ß®®¤µ¤éÂX¥RDAAO§í¨î¾¯ªº¬ü°ê±M§Q¥Ó½Ð ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/20 ¤W¤È 08:35:33²Ä 1054 ½g¦^À³
|
¤¤·¤Þµo¥¢´¼¯g?! °ê½Ã°|¸ÑÁ¼¥Íª«¼Ð°O¹w´ú·ÀI ¼¶¤å°OªÌ§d°ö¦w¤é´Á2020-10-19 news.gbimonthly.com/tw/article/show.php?num=2709 ¤µ(19)¤é¡A°ê½Ã°|¯«¸g¤Îºë¯«Âå¾Ç¬ã¨s¤¤¤ß¼B¥ÉÄR¬ã¨sû¡A»PªL¤fªø©°Âå°|¥¢´¼¯g¬ì³¯©É§gÂå®v¦X§@¡A¤ÀªR¯Ê¦å©Ê¤¤·¯f±wªº»{ª¾¥\¯àª¬ªp¤Î¬ÛÃö¥Í²zÅܤơCµ²ªGµo²{¡A¤¤·«á¿©±w¥¢´¼¯g¯f±w¦å¼ß¤¤ªºD«¬Ói°ò»Ä®ñ¤Æ酶(D-amino acid oxidase, DAO)¡A¸û¤¤·«áµL¥¢´¼¯gªº¯f±w©Î°·±dªÌ¡A¨ä¿@«×ÅãµÛªº¼W°ª¡A¨Ï±oDAO¥i±æ§@¬°¹w´ú¥¢´¼·ÀIªº¥Íª«¼Ð°O¡C¦¹¬ã¨s¤wµoªí¦b¡mFrontiers in Neurology¡n¡C ½×¤å³sµ² A Post-hoc Study of D-Amino Acid Oxidase in Blood as an Indicator of Post-stroke Dementia www.frontiersin.org/articles/10.3389/fneur.2019.00402/full ¤¤·¬Oè§bªº«n¦MÀI¦]¯À¡C¬y¦æ¯f¾Ç¬ã¨sªí©ú¡A¤¤·±wªÌè§bªºµo¥Í²v«Ü°ª¡C·í«e©|µL¥Î©ó¶EÂ_¤¤·«áè§b¡]PSD¡^ªº¦³®Ä¥Íª«¼Ð»xª«¡CD-®ò°ò»Ä®ñ¤Æ酶¡]DAO¡^¬O¤@ºØ¶À¯À¨Ì¿à©Ê酶¡A¼sªx¤À§G©ó¤¤¼Ï¯«¸g¨t²Î¡CDAO·|®ñ¤ÆD-®ò°ò»Ä¡A¸Ó¹Lµ{·|²£¥Í¯«¸g¬r©Êªº¹L®ñ¤Æ²B¨Ã¾ÉP¯«¸gÅÜ©Ê¡C DAAO ( D-amino acid oxidase ) ¦n¼ôªº¦W¦r SND-14 ©M SND-51 ¥i¥H¥Î¨ÓªvÀø©Î¹w¨¾¶Ü ? 2019¦~ ®ý¦¿¤j¾Ç¾ÇªÌµoªíªº½×¤å f¥Ò»Ä¶u³q¹L§í¨î¯«¸g¤¸ä¤`©M´î¤Ö½u²ÉÅ餶¾Éªº®ñ¤ÆÀ³¿E¦b¤j¹«¸£¥X¦å¼Ò«¬¤¤´î»´Ä~µo©Ê¸£·l¶Ë¡G¥i¯à¯A¤ÎDJ-1 / Akt / IKK /NF£eB³~®| www.frontiersin.org/articles/10.3389/fnmol.2019.00105/full ´N»¡¤F f¥Ò»Ä¶u ¥i¥H´î»´ ¤j¹«¸£¥X¦å¼Ò«¬¤¤Ä~µo©Ê¸£·l¶Ë . NaB§ïµ½ICH ( ¸£¥X¦å ) «áªºµu´Á¯«¸g¦æ¬°¨Ã´î¤Ö¸£¤ô¸~ . ICH«áµ¹¤©NaB§ïµ½ªø´Á¯«¸g¦æ¬° . NaBªºµ¹ÃÄ¥i°§C®ñ¤ÆÀ³¿E¨Ã§ïµ½½u²ÉÅé¥\¯à . ICH«á¥ÎNaB´î¤Ö½u²ÉÅ餶¾Éªº²ÓMä¤` ¦Ó¨Æ¹ê¤W ¦b¤ß®®ªº±M§Q¤å¥ó [ Compositions containing tannic acids and uses thereof ] ªº [ Claims ] ¤¤ patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=9&f=G&l=50&co1=AND&d=PTXT&s1=%22Tsai%3B+Guochuan+Emil%22.INNM.&OS=IN/%22Tsai;+Guochuan+Emil%22&RS=IN/%22Tsai;+Guochuan+Emil%22 ¨äªvÀø¿ï¶µ¤¤´N¦C¦³ stroke ( ¤¤· ) Å㨣 ½²±Ð±Â¤ß®®¹Î¶¤ªº¥ý¨£¤§©ú ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/19 ¤U¤È 01:39:02²Ä 1053 ½g¦^À³
|
§¨Ó13»õ¬ü¤¸¦¬ÁÊ «OÅ@¯«¸g¶b¬ð³Ð·sÀøªk 2020.10.16 Àô²y¥Í§ÞÂø»x°OªÌ/§õªLÀõ ½sĶ www.gbimonthly.com/2020/10/81409/ ¬ü°ê®É¶¡15¤é¡A§¨Ó¡]Eli Lilly)«Å¥¬¦¬Áʯ«¸g¯e¯fªvÀø·s³Ð¤½¥qDisarm Therapeutics¡A±N¤ä¥I1.35»õ¬ü¤¸ªº¹w¥I´Ú¡A¥¼¨Ó¨½µ{¸Oª÷¦³±æ°ª¹F12»õ¬ü¤¸¡ADisarm¸Õ¹ÏÃÒ©ú¥i³z¹L«OÅ@¶b¬ð¨ÓªvÀø¯«¸g¨t²Î¯e¯f¡A§¨Ó±N¥Ø¼Ð©w¦b¦hµo©Êµw¤Æ¯g(MS)¡B¦ÙµäÁY©Ê°¼¯Áµw¤Æ¯g(Amyotrophic lateral sclerosis, ALS)©M©PÃ䯫¸g¯e¯f¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/18 ¤U¤È 07:27:40²Ä 1052 ½g¦^À³
|
GA ¹ï©ó AD ªº¹«Åé¤fªA¹êÅç---¶°²³¾÷¨î©ÒÅã¥Üªº®ÄªG ¤é¥»¾ÇªÌ·sªñªº¬ã¨s ( 2020¦~9¤ë10¤é ) Gallic Acid is a Dual £\/£]-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice. ¨S¹¤l»Ä¬O¤@ºØÂù«£\/£]-¤Àªc酶½Õ¸`¾¯¡A¥i°fÂà»{ª¾»Ùê¨Ã¸É±Ïªüº¸¯ý®üÀq¯f¤p¹«ªº¯f²z europepmc.org/article/med/32913125 www.jbc.org/content/early/2020/09/10/jbc.RA119.012330.full.pdf §Ú̬ã¨s¤FGA¦b¬ðÅÜ«¬¤H¾ý¯»¼Ë£]³J¥Õ«eÅé/¦¦Ñ¯À1¡]APP / PS1¡^Âà°ò¦]AD¤p¹«¼Ò«¬¤¤ªº§@¥Î¡C±q12Ó¤ë¶}©l¡A§Ų́C¤Ñ¤fªA¤@¦¸GA¡]20 mg / kg¡^©Î½á§Î¾¯¡A«ùÄò6Ó¤ë¡A¥HªvÀø¨ã¦³¥[³tªüº¸¯ý®üÀq¤ó¼Ë¯fª¬ªºAPP / PS1¤p¹«¡C»P½á§Î¾¯¬Û¤ñ¡AGAªvÀø¦b18Ó¤ë¤j®É¥i°fÂà¾Ç²ß©M°O¾Ð»Ùê¡A¨Ã¥B¤£·|§ïÅܳ¥¥Í«¬¦PºÛ¥Jªº¦æ¬°¡C¸gGAªvÀøªºAPP / PS1¤p¹«´î»´¤F¸£¾ý¯»¼ËÅÜ©Ê¡A¥]¬A¸£¹ê½è©M¸£¦åºÞ£]¾ý¯»¼Ë¨I¿nª«¡A¨Ã´î¤Ö¤F¸£¾ý¯»¼Ë£]³J¥Õ¡C´î¤Ö¾ý¯»¼Ë³J¥Õ¥Í¦¨©M¼W¥[«D¾ý¯»¼Ë³J¥Õ¥Í¦¨APPªº¹Lµ{¦P®É²£¥Í¦³¯q§@¥Î¡C¦¹¥~¡A´î»´¤F¸£³¡ª¢¯g¡A¯«¸g½¦½è¼W¥Í©M®ñ¤ÆÀ³¿E¡C§ÚÌÅã¥Ü¡AGA¥i¦P®É´£°ª£\-©M°§C£]-¤Àªc酶ªº¬¡©Ê¡A§í¨î¯«¸gª¢¯g¨Ãéw¸£³¡®ñ¤ÆÀ³¿E¦bADªºÁ{§É«e¤p¹«¼Ò«¬¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/18 ¤U¤È 04:48:22²Ä 1051 ½g¦^À³
|
SND-51 »P BPSD ²Ä¤@½g¤å³¹¦®¦bÄÄz¥þ¨©Êª¢¯g¦b³o¨Ç«D»{ª¾¯gª¬ ( ©Î¬°BPSD ) ªºµo¯f¾÷²z¤¤°_µÛ«n§@¥Î¡C ªüº¸¯ý®üÀq¯fªº¥þ¨©Êª¢¯g¡A¦å¸£«Ì»Ù¯Ü®z©Ê©M»{ª¾/«D»{ª¾¯gª¬¡G»Pµo¯f¾÷¨î©MªvÀøªº¬ÛÃö©Ê www.ncbi.nlm.nih.gov/pmc/articles/PMC4114193/ ªüº¸¯ý®üÀq¤ó¯f¡]AD¡^¬Oè§b¯gªº³Ì±`¨£§Î¦¡¡A¨ä¯S¼x¬O¶i¦æ©Ê»{ª¾»Ùê¡C°£¤F¸g¨åªº¯«¸g¯f²z¾Ç¯S¼x¡]¦p¾ý¯»¼Ë´³¶ô©M¯«¸gìÅÖºûÄñµ²¡]NFT¡^¡^¤§¥~¡AAD¤j¸£¤¤ÁÙ°O¿ý¤F¬¡¤Æ§K¬Ì²ÓMªº¿n²Ö¡A³o´£¥Ü¤F¯«¸gª¢¯g¦bADµo¯f¾÷²z¤¤ªº§@¥Î¡C°£¤F»{ª¾¯à¤O¤U°¥~¡Aè§b±wªÌ¡]¥]¬A±w¦³ADªº±wªÌ¡^ÁÙ¸g±`Æ[¹î¨ìļ°Ê¡A§ðÀ»¡A§íÆ{©Mºë¯«¯fµ¥«D»{ª¾¯gª¬¡A³o¨Ç¯«¸g¤ß²z¯gª¬µ¹Å@²z¤Hû±a¨Ó¨I«t¾á¡C³o¨Ç¯gª¬³q±`ªí²{¬°¬ðµMµo§@¡A¨ÃÀHµÛ®É¶¡¦Óªi°Ê¡A¦b³\¦h±¡ªp¤U¡A¥¦Ì¬O¥Ñ©P³ò¾¹©xªº·P¬VIJµoªº¡Aªí©úª¢¯g¦b³o¨Ç«D»{ª¾¯gª¬ªºµo¯f¾÷²z¤¤°_µÛ«n§@¥Î¡C BPSDªºªí²{³q±`»P©P³ò¾¹©xªº·P¬V¡]¦pªÍª¢©Î§¿¸ô·P¬V¡^¦³Ãö¡]Holmes and Butchart¡A2011¡^¡A³oªí©úª¢¯g¥i¯à¦b³o¨Ç»Pè§b¬ÛÃöªº¦æ¬°»Ùꪺµo¯f¾÷²z¤¤°_«n§@¥Î¡C«nªº¬O¡A©P³ò·P¬V¤ÞµoªºÄY«¯«¸g¤ß²z¯gª¬¥i¥H¦b¨S¦³²Óµßª½±µ±q©P³ò¾¹©xÂX´²¨ì¤j¸£ªº±¡ªp¤Uµo®i¥X¨Ó¡]van Gool et al¡C¡A2010¡^¥B¨S¦³±Ñ¦å¯gªº¸ñ¶H¡]Ebersoldtµ¥¡A2007¡^¡C¤@¶µ«e¤©Ê¹ï·Ó¬ã¨sªí©ú¡A±µ¨üÆbÃö¸`¤â³Nªº¦Ñ¦~¤Hè§b¯g»P³N«áĸ¦k¤§¶¡¦³«Ü±jªºÁpô¡A³oªí©ú¥~©P¤z¹w¤Þ°_ªº¥þ¨©Êª¢¯g»Pè§b¯g¬ÛÃöªººë¯«¯gª¬¤§¶¡¦s¦bÁpô¡]Katµ¥¡A2008¡^¡CµM¦Ó¡A¥Ø«e¡A©|¥¼´£¥X¨Ïè§b±wªÌ©ö¨ü·P¬VIJµoªº¯«¸g¤ß²z¾Ç¯gª¬ªº¨ãÅé¾÷¨î¡C ³ø¾ÉºÙ¡A»P¦~»´¤p¹«¬Û¤ñ¡ALPS»¤¾Éªº©P³òª¢¯g¤Þ°_¦Ñ¦~¤p¹«§óÄY«ªº¯«¸gª¢¯g©M¬ÛÃöªº¦æ¬°»Ùê¡A³oªí©ú¦~ÄÖ¬ÛÃöªº¯«¸gª¢¯g¤ÏÀ³ªº¼ç¦b¼W±j¥i¯à·|¼vÅT©P³ò§K¬Ì¨t²Î¿E¬¡«á¹ï¦æ¬°°ÝÃDªº±Ó·P©Ê¡] Godboutµ¥¡A2005¦~; Godbout©MJohnson¡A2009¦~¡^¡C¦Ñ¦~è§b¯gªºAPPÂà°ò¦]¤p¹«¬O¤H©Ò¦@ª¾ªº¦UºØ¦æ¬°°ÝÃD¡A¦p±Þ©]¸`«ß¯¿¶Ã©M¼W¥[«I²¤Ã¨§b¯f¤HÃþ¦üBPSD¡]Vloeberghsµ¥¤H¡A2004¦~¡A2007¦~¡^¡A³o¥i¯à¬O¤@Ó¦³»ùȪº¤u¨ã¡A¥Î©ó¬ã¨s§ó¨ãÅ骺¾÷¨îADªº¯«¸g¤ß²z¯gª¬¡C ²Ä¤G½g¬OÂÅ¡BªLÂå®vªº¤å³¹ À³¦b»¡©ú DAAO§í¨î¾¯¥i¯à¥Î©óBPSD ªºªvÀø The Role of N-Methyl-D-Aspartate Receptor Neurotransmission and Precision Medicine in Behavioral and Psychological Symptoms of Dementia www.frontiersin.org/articles/10.3389/fphar.2019.00540/full#ref28 ¼W±jNMDA¯«¸g¶Ç»¼¥i¥H§ïµ½Ã¨§b¯g©Mºë¯«¤Àµõ¯gªº°O¾Ð©M¦æ¬°¯gª¬¡]Goussakovµ¥¡A2010¡FLaneµ¥¡A2013¡^¡CBPSDªºÁ{§É¯S¼x¡A¦p¤Ûı¡A¦k·Q¡A¨¥»y²V¶Ã©M¦æ¬°¤£¦w¡AÃþ¦ü©óºë¯«¤Àµõ¯gªº¥¿©Ê¯gª¬¡C»Pºë¯«¤Àµõ¯gªºt©Ê¯gª¬¬Û¦üªºªÀ¥æ°hÁY¡A§Nºz¡A¥¢»y©Mºë¯«¿ù¶Ã¡A¦bºë¯«¤Àµõ¯g±wªÌ¤¤¤]¸g±`¥X²{¦æ¬°¡AºÎ¯v©Î±¡·P°ÝÃD¡C ȱoª`·Nªº¬O¡AG72¡]t³dD-µ·®ò»Ä¥NÁªºD-®ò°ò»Ä®ñ¤Æ酶¿E¬¡¾¯DAOA¡^°ò¦]¤¤ªº³æ®Ö苷»Ä¦hºA©Ê¡]rs2153674¡^»PAD±wªÌªººë¯«¯f¯gª¬¬ÛÃö¡]Di Mariaµ¥¡C ¡A2009¦~¡^¡C¥t¥~¡A¦bAD±wªÌ¤¤¡ANMDARsªº¥Ì®ò»ÄÃѧO¦ìÂIªº¿Ë©M¤O»PµJ¼{±¡ºü¡]BPSDªº¤@Ó°ì¡^¦³Ãö¡]Tsangµ¥¡A2008¡^¡C¦]¦¹¡A¤w³QÃÒ©ú¥i¦³®ÄªvÀøºë¯«¤Àµõ¯g¡A§íÆ{¯g©M¨ä¥Lºë¯«¯f¯gª¬ªºNMDAR¼W±j¾¯¤]¥i¥Î©óªvÀøBPSD¡C ¦¹¥~¡A¸£·l¶Ë«á24©M48 h¨ë¿ENMDAR¥i¥H´î»´¯«¸g¥\¯à¯Ê·l¨Ã§ïµ½»{ª¾¯à¤O¡A³o·N¨ýµÛNMDAR¥\¯à¹ï©ó¨È«æ©Ê©ÎºC©Ê¤¤·ªº¯«¸g×´_¦ÜÃö«n¡]Biegon et al¡C¡A2004¡^¡C«ez¬ã¨sªí©úDAAO§í¨î¾¯¥i¯à¥Î©óªvÀøBPSD¡C §Æ±æSND-51¦b³o¨âºØ¾÷¨îªºÁp¦XªvÀø¤U , ®i²{ÅãµÛªºÀø®Ä ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/18 ¤U¤È 04:29:37²Ä 1050 ½g¦^À³
|
GA ¬OÂ\Àú©ó©ó SNB01¡BSND-11¡BSND-13¡BSND-14 ¤Î SND-51 ¤§¶¡ ? ÁÙ¬OÁa¾î¨ä¤W? Cyclooxygenase-2 inhibition improves amyloid-£]-mediated suppression of memory and synaptic plasticity www.ncbi.nlm.nih.gov/pmc/articles/PMC2628581/ «DÍrÅéÃþ§Üª¢ÃÄ¡]NSAIDs¡^¥i¨Ïªüº¸¯ý®üÀq¤ó¯fªºµo¯f²v°§C¦h¹F80¢H . §í¨î¬ðIJCOX-2¬¡©Ê¨¬¥H«ì´_³Q¥i·»©Ê¦X¦¨A£]42¯}Ãaªºªø®Éµ{¼W±j§@¥Î¡C . ªýÂ_COX-2¨¬¥H«ì´_Tg2576¤p¹«ªº°O¾Ð . ¦³½ìªº¬O¡A°O¾Ð¥\¯àªº§ïµ½»P«e¦C¸¢¯ÀE2¡]PGE2¡^¤ô¥¦¨¤Ï¤ñ¡C§ÚÌ«ØijNSAIDsªý¤îCOX 2¤¶¾Éªº¾ð¬ð´Æ¤ºªºPGE 2ªº¥Í²£¡A±q¦Ó¨¾¤îA£]¹ï¬ðIJ¥i¶ì©Ê©M°O¾Ð¥\¯àªº¦³®`¼vÅT¡C . §Ú̪ºµ²ªG¹w´ú¡A¦b¥Ñ©óª¢¯g©Î¨¦®ò»Ä¤Þ°_ªºCOX-2¤É°ª¤§«e¡A¦b¨ã¦³¥¿±`COX-2¤ô¥ªºÓÅ餤±Nµo²{NSAIDªº¥Dn¥\®Ä¡CÂX¤j¹ï«DÍrÅé§Üª¢ÃįA¤Î¬ðIJ©M¸£¥\¯àªº¼vÅTªº¬ã¨s¥i¯à·|«·s¤Þ°_¤H̹ï«DÍrÅé§Üª¢ÃĨä¥L¼ç¦b«OÅ@¾÷¨îªº¿³½ì¡A±q¦ÓÂX¤j¶}µo°w¹ïªüº¸¯ý®üÀq¤ó¯fªº¦w¥þ¹w¨¾ÃĪ«ªº¥i¯à©Ê¡C Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer¡¦s disease model mice www.ncbi.nlm.nih.gov/pmc/articles/PMC4939702/ ¨´¤µ¬°¤î¡A¥Dn¦bª¢©Ê¯«¸g½¦½èCOX / PGE 2 «H¸¹¶Ç¾ÉªºI´º¤U¡A¤w¸g¦bNSAIDs¹ïªüº¸¯ý®üÀq¤ó¯f¼Ò«¬¤p¹«ªº¹w¨¾§@¥Î¤¤¶i¦æ¤F¬ã¨s ¡] Keene µ¥ ¡A2010 ¡F Shi µ¥ ¡A2012 ¡F Woodling µ¥¡C ¡C ¡A2014 ; Johanssonªº ¡Cµ¥¤H ¡A2015¦~ ¡^¡C§Ú̪º¬ã¨sµo²{¤F«DÍrÅé§Üª¢ÃĦb½Õ¸`ªüº¸¯ý®üÀq¤ó¯f¤p¹«¼Ò«¬ªº¯«¸g¤¸¥\¯à¤è±¨ã¦³¥X¥G·N®Æªº¦³¯q§@¥Î¡A¨ä¤¤«DÍrÅé§Üª¢ÃÄ¥i¹w¨¾ªüº¸¯ý®üÀq¤ó¯f¼Ò«¬¤p¹«ªº¦´Á°O¾Ð¯Ê³´¡A¦Ó¹ïª¢¯g©Î¾ý¯»¼Ë£]肽¥NÁ¨S¦³©úÅ㪺¼vÅT¡C ¦b§Ú̪º¬ã¨s¤¤¡A¥¬¬¥ªâ ( ibuprofen ) ¦bAPP-PS1¤p¹«¤¤®¾±Ï®ü°¨¥h¥ÒµÇ¤W¸¢¯À¤ô¥¬°¥h¥ÒµÇ¤W¸¢¯À»P»{ª¾»Ùꤧ¶¡ªºÁpô´£¨Ñ¤FÃB¥~ªº¤ä«ù¡A¨Ã´£¨Ñ¤F¤@ºØÃB¥~ªº¯«¸g¤¸¾÷¨î¡ANSAID¥i¥H³q¹L³oºØ¯«¸g¤¸¾÷¨î¨Ó¹w¨¾¦Ñ¦~è§b¯g¡C ¦b¬y¦æ¯f¾Ç¬ã¨s¤¤¡A«DÍrÅé§Üª¢ÃĬO»P¹w¨¾ªüº¸¯ý®üÀq¤ó¯f¦³Ãöªº¥DnÃĪ«Ãþ§O¡] t¡¦Veld µ¥¤H ¡A2001 ¡F Vlad µ¥¤H ¡A2008 ¡F Breitner µ¥¤H ¡A2011¡^ ¡^¡CµM¦Ó¡A¦b¶EÂ_±w¦³ªüº¸¯ý®üÀq¤ó¯fªº±wªÌªºÁ{§É¸ÕÅ礤¡ANSAIDs©MCOX§í¨î¾¯ªº¥¢±Ñªí©ú¤@¥¹µo¥Í»{ª¾»Ùê¡ACOX§í»s§@¥Î¥i¯à´NµL®Ä¡] Candelario-Jalil¡A2009 ©M Heneka et al¡C ¡A2015 ºîz ¡^¡C NSAID¬O§_¥i¥Î©óªvÀøªüº¸¯ý®üÀq¤ó¯f©Î»´«×»{ª¾»Ùê¡H www.frontiersin.org/articles/10.3389/fnagi.2010.00019/full Non-Steroidal Anti-Inflammatory Drugs and Cognitive Function: Are Prostaglandins ( «e¦C¸¢¯À ) at the Heart of Cognitive Impairment in Dementia and Delirium ( ĸ¦k )? www.researchgate.net/publication/51656063_Non-Steroidal_Anti-Inflammatory_Drugs_and_Cognitive_Function_Are_Prostaglandins_at_the_Heart_of_Cognitive_Impairment_in_Dementia_and_Delirium °£¤F¹ïªÍ³¡¡B¤ß¦Ù·l¶Ëªº«Â¯Ù¡AªZº~ªÍª¢ÁÙ¸g±`¾ÉP¯«¸g¯gª¬ technews.tw/2020/06/17/covid-19-neurology/ ¬ã¨s«ü¥X¡A¦h¹F 65% ªº±wªÌ¸g¾ú¤Fĸ¦k¡]delirium¡^ªºÅéÅç Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement www.ncbi.nlm.nih.gov/pmc/articles/PMC7242189/ ĸ¦k¦ü¥G¬OSARS-CoV-2·P¬Vªº«n«á¿ò¯g¡C°£¤Fĸ¦kªº¨å«¬¯S¼x¥~¡A¥»¯f¨Ò¨t¦C±wªÌÁÙªí²{¥X©úÅ㪺ļ°Ê¡Aºò±i©Î»øµw¡A°·§Ñ¡A¥¢»y©M©úÅ㪺¥þ¨©Êª¢¯g¤ÏÀ³¡C³oºØ¯gª¬¸s¤Þµo¤F¤@ӺðݡA§Y¦bCOVID-19¤¤¬Ý¨ìªºÄ¸¦k¬O§_¶Èªí©ú©ö¨ü¶Ë®`ªº±wªÌ±w¦³ÄY«ªº¥þ¨©Ê¯e¯f¡A©ÎªÌSARS-CoV-2¬O§_¥i¥H³q¹Lª½±µ©Î¶¡±µ³~®|¿W¯S¦a¹v¦V¥Ö¼h¤Uµ²ºc¡C¬°¤F½T©w·P¬VSARS-CoV-2ªº¼ç¦b¤¤¼Ï¯«¸g¨t²Î§@¥Î¡A¶i¤@¨B¬ã¨s¦ÜÃö«n¡C¦P®É¡AÂå°|À³®Ú¾Ú·í«e¤åÄm¡A¦Ò¼{±Nºë¯«ª¬ºAÅܤƲK¥[¨ì´ú¸Õ¼Ð·Ç¦Cªí¤¤¡C Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients ccforum.biomedcentral.com/articles/10.1186/s13054-020-03200-1 Delirium/neurological symptoms could be secondary to systemic inflammatory reaction to SARS-CoV-2. Systemic inflammation and delirium: important co-factors in the progression of dementia. europepmc.org/article/med/21787328 ¦h¦~¥H¨Ó¤wª¾¥þ¨©Êª¢©Ê·l¶Ë¥i¥H¦V¤j¸£µo¥X«H¸¹¡A¥H»¤¾É¤¤¼Ï¯«¸g¨t²Î¡]¤¤¼Ï¯«¸g¨t²Î¡^¥\¯àªº§ïÅÜ¡A³q±`ÂkÃþ¬°¯e¯f¦æ¬°ºî¦X¼x¡C³o¨ÇÅܤƬO³q¹L¥þ¨©M¤¤¼Ï¯«¸g¨t²Î²ÓM¦]¤l©M«e¦C¸¢¯À¦X¦¨¤¶¾Éªº¡C·íè§b¯g±wªÌ¾D¨üÃþ¦üªº¥þ¨ª¢©Ê·l¶Ë®É¡Aĸ¦k¬O±`¨£ªº«áªG¡C NSAID¹ï©óAD»{ª¾ªº¼vÅT , ²z½×©MÁ{§É²£¥Í²ö°J¤@¬Oªºµ²ªG ÅãµM ADªº§Î¦¨¦]¯À¿ùÁa , ©Î«D³æ¤@¾÷¨î©Ò¯à³º¨ä¥\ GA ¤]¨ã¦³ NSAID ªºÃIJz ( COX-1 ¡BCOX-2 §í¨î¾¯ ) , ¬O§_¦b¨ä½Ñ¦h¾÷¨î¤¤¦AÀA¤W²Kªá ? ´Á«Ý¦³§ó¥¿±ªºµ²ªG ¤S ¬Û·í¤ñ¨ÒªºCOVID-19±wªÌ·|²£¥ÍDelirium ( ĸ¦k ) ¤£ºÞ¬O¥ÑSARS-CoV-2«Iŧ¤j¸£ÁÙ¬O¥þ¨ª¢©Ê©Ò¤Þ°_ GA ©Î³\©Î¦h©Î¤Ö¦³¨äªvÀø¥\¯à ? ¦ýµL½×¬O§_¦³®Ä , §ÚÌÁÙ¬O´Á«Ý¥¦¦b»´¯g±wªÌªºªvÀø¤W¨ú±o¦¨¥\ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/17 ¤U¤È 01:07:52²Ä 1049 ½g¦^À³
|
¹ù¥Sªº¦n¤Í°Q½× /liawbf.pixnet.net/blog/post/49523987?utm_source=PIXNET&utm_medium=Blog_login#_=_ ¥t¥~ , ¤pªº¬Q¤Ñ¬Ý¨ì¤@½gCOVID-19ªº¬ÛÃö½×¤å ¸g¥Ñ GA ( gallic acid ) ©M PGE-2 ªº³sµ² , ³º§â SNB01 ©M SND-13 ¦ê°_¨Ó Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms science.sciencemag.org/content/early/2020/10/14/science.abe9403 ½Õ¬d³Q½T©w¬°¦hºØ«aª¬¯f¬r¬Û¤¬§@¥ÎªÌªº¥iÃĪ«¹v¦V ¦b³oÓ¶¤¦C¤¤¡A§ÚÌ°w¹ï¦b¦¹³B½T©wªº¡A¦b«aª¬¯f¬r®è¤¤¦@¦³ªº¹v¼Ð¡A±´°Q¤FÃĪ«ªº¨Ï¥Î¡Aµo²{³o¨Ç¹v¼Ð¦b¿ò¶ÇÂZ°Ê¿z¿ï¤¤¨ã¦³¥\¯à¬ÛÃö©Ê¡C¯S§O¬O¡A§Ṳ́ÀªR¤F«e¦C¸¢¯ÀE¦X酶2«¬§í¨î¾¯¡]PGES-2¡A¥ÑPTGES2½s½X¡^©Msigma«Dªü¤ùÃþ¨üÅé1¡]sigma-1¡A¥Ñ½s½XSIGMAR1¡^ PGES-2¬O¨Ó¦Û©Ò¦³¤TºØ¯f¬rªºNsp7ªº¬Û¤¬§@¥Î¦]¤l¡]¹Ï4D¡^¡A¬OSARS-CoV-2ªº¨Ì¿à©Ê¦]¤l¡]¹Ï5F¡^¡C¥¦³QFDA§å㪺³B¤è---«DÍrÅé§Üª¢ÃÄ(NSAID) indomethacin ©Ò§í¨î¡C ( ªþµù Indometacin : Indometacin inhibits both cyclooxygenase-1 ( COX-1 ) and cyclooxygenase-2 ( COX-2 ) , commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins ( PGEs ).ºK¦Û en.wikipedia.org/wiki/Indometacin ) GA ¤]¬O COX-1 , 2 ¿ï¾Ü©Ê§í¨î¾¯ , ©Î¤]¥i¥H§í¨î PGES-2 ? Kinetics and docking studies of a COX-2 inhibitor isolated from Terminalia bellerica fruits pubmed.ncbi.nlm.nih.gov/20441561/ We report here the inhibitory effects of GA, with an IC(50) value of 74 nM against COX-2 and 1500 nM for COX-1 Taken together, our studies indicate that GA is a selective inhibitor of COX-2. Being a small natural product with selective and reversible inhibition of COX-2, GA would form a lead molecule for developing potent anti-inflammatory drug candidates. ¦³½ìªº¬O , COX-2 §í¨î¾¯¸g¬ã¨s¹ï©óºë¯«¤Àµõ©M««×§íÆ{ªºªvÀø , ¤]¦³¦³¯qªºµ²ªG SND-13 ¦³ TA §U°} , §Æ±æ·|¦³ 1 + 1 > 2 ªº®ÄªG COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence pubmed.ncbi.nlm.nih.gov/20047157/ In addition, immunological imbalance results in the increased production of PGE2 in schizophrenia and depression, as well as increased COX-2 expression in schizophrenia. There is evidence indicating that anti-inflammatory therapy may have beneficial effects in schizophrenia and major depression (MD). COX-2 inhibitors have been tested in animal models and in preliminary clinical trials, demonstrating favorable activity compared with placebo, both in schizophrenia and MD. ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/15 ¤U¤È 01:13:10²Ä 1048 ½g¦^À³
|
¡mCOVID-19ªvÀø¡n¤HÃþ±N»P¯f¬rÄ~Äò¦@¦s¡A§¨Ó(Eli Lilly)°õ¦æªø»¡ ¦bªvÀø¤W¦hµÛ¾¥¤~¬O¥¿½Tªº¦]À³¤§¹D www.genetinfo.com/international-news/item/42302.html |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/14 ¤W¤È 10:46:32²Ä 1047 ½g¦^À³
|
¸É¥R³ø¾É Tannin found in persimmons fights COVID-19, Japan team says www.asahi.com/ajw/articles/13736334 The team said the ¡§active¡¨ virus count was reduced to less than one ten-thousandth in solutions that contain the tannin, showing that it is effective against the virus. But the tannin can no longer render the virus ineffective when the content of the tannin is diluted to a certain level, according to the team. Ito, who has studied the antibacterial actions of persimmon tannin, said it can be assumed that the tannin sticks to the surface of the coronavirus and prevents it from entering cells inside the mouth and throat. Persimmon tannin has also been reported to be effective against the flu and the norovirus, according to Ito. |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/14 ¤W¤È 10:35:52²Ä 1046 ½g¦^À³
|
¤µ¦~¥V¤Ñ¦MÀI¤F¡I¬ü°ê¶W¹L20¦{ªñ¤é·s¼W¯f¨Ò³Ð·s°ª 2020-10-14 09:30 ¸gÀÙ¤é³ø / ½sĶ©u´¹´¹¡þºî¦X¥~¹q udn.com/news/story/120944/4933792?from=udn_ch2cate6638sub120944_pulldownmenu_v2 µØ²±¹y¶l³ø³ø¾É¡A¬ü°ê¦è³¡©M¤¤¦è³¡ªº¦h¦{ªñ¤é³q³ø·s«aªÍª¢·s¼W½T¶E®×¨Ò³Ð·s°ª¡A³o¬O¬Ì±¡§Ö³t¶Ç¼½ªº°T¸¹¡A¥i¯à¹w¥Üªø´Á¥H¨Ó²³¤H¾á¤ßªº¤Ñ®ð§N·|¼W¥[·P¬V·ÀI¡C ±M®a¾á¤ß¡A³o¹w¥Ü¤µ¦~¥V¤Ñ¬V¬Ì¤H¼Æ±N¥X²{§ó¤jªº¼W´T¡A¨ì®É®ðÔ¸û°®Àê¡A¥B¥Á²³«Ý¦b«Ç¤ºªº®É¶¡§óªø¡A·|¥[³t¯f¬r¶Ç¼½¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/14 ¤W¤È 08:39:52²Ä 1045 ½g¦^À³
|
¤t´¶Æg¹LªºÂ§¨Ó§ÜÅéÃÄ ²Ä3´ÁÁ{§É¸ÕÅç¾D³Û°±¡IªÑ»ù®À 2020-10-14 07:40 ¸gÀÙ¤é³ø / ½sĶ©u´¹´¹¡þºî¦X¥~¹q udn.com/news/story/6811/4933702 ¦¹«e¤£¨ì24¤p®É¡A¼b¥Í¤½¥q¡]Johnson & Johnson¡^¤~¦]¬°¤@¦W¬ã¨s°Ñ»PªÌ¦]¬°¨Å餣¾A¯f¯g¡A¼È°±·s«a¯f¬r¬Ì]Á{§É¸ÕÅç¡C ¥t®Ú¾Ú¸ô³z¤Þz¤£¨ã¦W®ø®§¨Ó·½ªº¿W®a³ø¾É¡A¹«~ÃĪ«ºÞ²z§½¡]FDA¡^µo²{¡A¥[³t¥Í²£¨âºØ·s«a§ÜÅéÃĤ§¤@ªºÂ§¨ÓÃļt¡A¦³ÄY««~ºÞ°ÝÃD¡C Àˬd¤Hû¥h¦~11¤ë³y³X¦ì©ó¯Ã¿A¦è¦{¥¬Äõ©_³ù¡]Branchburg¡^ªºÂ§¨Ó¤u¼t¡Aµo²{¦h¶µ»sµ{ªº¸ê®Æ¾D§R°£¥B¥¼¸g¬d®Ö¡CFDA±N¦¹¤@°ÝÃD¦C¬°³ÌÄY«¯Å§O¹H³W¡A¶}¥ß©x¤è¦æ°Ê«ü¥Ü¡]OAI¡^ªº³qª¾¡A·N¨ý¡u¹H³WÄY«¥B¹ï¤½½Ã¦³«¤j¼vÅT¡A¥²¶·¥[¥H×¥¿¡v¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/13 ¤U¤È 07:25:11²Ä 1044 ½g¦^À³
|
Fruit Punch: Japanese Researchers Find Tannin-Rich Persimmon Juice Weakens Coronavirus www.nippon.com/en/blog/m00155/ Professors Itō Toshihiro and Yano Hisakazu of NMU announced at a press conference on September 15 that the research team they lead was able to neutralize the coronavirus in samples of human saliva by adding high concentrations of persimmon tannins. In tests, researchers found that after 10 minutes, the concoction had reduced the virus to one ten thousandth of its original potency, rendering it nearly harmless. ¦ý³oÓ³æ¹ç¬O³æ¹ç»Ä¶Ü¡H |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/13 ¤U¤È 04:11:55²Ä 1043 ½g¦^À³
|
Alkermes±À«äı¥¢½Õ·sÃÄ´î½w¼W«°Æ§@¥Î¡B§ó¬Æ§¨Ó ÀòFDA©eû·|¤ä«ù 2020.10.12 Àô²y¥Í§ÞÂø»x / °OªÌ §d°ö¦w ½sĶ www.gbimonthly.com/2020/10/81011/ Alkermes©Ò¶}µoªºALKS 3831¡A¬O²V¦X¤Folanzapine©Msamidorphan¨âºØ¥D¦¨¤Àªº·sÃÄ¡C¨ä¤¤¡Aolanzapine¬O§¨ÓÀò§åÃÄZyprexaªº¥Dn¦³®Ä¦¨¤À¡A¦P®É¤]¬OªvÀø«äı¥¢½Õ¯gªº´¶¹MÃĪ«¡A«o¦³µÛ¼vÅT±wªÌ¥NÁ¡BÅ髼W¥[ªº°Æ§@¥Î¡FSamidorphan«h¬O°w¹ïolanzapine°Æ§@¥Î´£¥Xªº¸Ñ¤è¡A¦ý¥¦¤]¦P®É¬O¤@ºØ¾~¤ùÃþª«½è«ú§Ü¾¯(opioid antagonist)¡B¦³µÛª«½èÀݥΪººÃ¼{¡A¦¨¬°FDA¼f®ÖÃÄÃÒªº«n¦Ò¶q¡C ALKS 3831 ¥u°w¹ïolanzapine°Æ§@¥Î´£¥Xªº¸Ñ¤è ¦ÓSND-11 ~ 13 ¹ï²{¤µºë¯«¤Àµõ¥ÎÃÄ°µ´¶¹Mªº¥[¦¨ªvÀø , ¤£¥u´M¨D´î§C°Æ§@¥Î , §ó¥[±jt©Ê¯gª¬©M»{ª¾¯Ê·lªºªvÀø ¬Ý¨ì ALKS 3831 ¥O¤H¤£³Ó®D¼N? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2020/10/13 ¤W¤È 08:22:45²Ä 1042 ½g¦^À³
|
·P®¦²q·Q¤jªº¦^ÂСA±z´£¨Ñªº¸ê®Æ«Ü¦³»ùÈ¡AÅý§ÚÄÀºÃ¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/13 ¤W¤È 08:16:02²Ä 1041 ½g¦^À³
|
¬h¸¤M¡GÁ{§É¸ÕÅçªí©ú¬¥¤Ç¨º³-§Q¦«¨º³¤£¯à¦³®ÄªvÀø·s«a±wªÌ ¨Ó·½¡G ¥Íª«¨¦¡@§@ªÌ¡G towersimper¡@2020-10-12 med.sina.com/article_detail_103_1_90154.html ®Ú¾Ú´º³Í¥Í§Þ¬Q¤éªº«°T www.genetinfo.com/investment/company-news/item/42217.html ¬¥¤Ç¨º³¹ïSARS-CoV-2 3CLpro ªº IC50 = 486·L¼¯º¸ ´X¤Ñ«e¥Xª©ªº½×¤å Biochemical screening for SARS-CoV-2 main protease inhibitors journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0240079&type=printable We could additionally confirm tannic acid (4, Fig 3A), which has an IC50 of 3 £gM for SARS-CoV Mpro [10], as a SARS-CoV-2 Mpro inhibitor with an IC50 of 2.1 £gM. Tannic acid, a hydrolysable tannin, is a polyphenolic compound formed by a glucose moiety and gallic acid. Several enzymes have been shown to be inhibited by tannic acid, including proteases [27]. Due to these properties, tannic acid was used successfully in this work as a positive control. ¤S¤ß®®¤½¥q©xºô´£¨Ñªº SNB01 ¹ï SARS-CoV-2 Mpro ( 3CLpro ) ªº EC50 < 0.77 £gM ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/12 ¤W¤È 11:10:25²Ä 1040 ½g¦^À³
|
¡u¦Û¤v¦n¹³¦³¥¢´¼¯g¡v¡I·s«a±wªÌ±d´_«á³à¥¢°O¾Ð¤O 2020-10-12 11:01 Áp¦X³ø / ½sĶJ¹ÚÞ³¡þ§Y®É³ø¾É udn.com/news/story/120944/4928508 ¤w¸g´À¼Æ¦Ê¦W·s«aªÍª¢±d´_ªÌ¬Ý¯fªºªÛ¥[ô¦è¥_¬ö©ÀÂå°|¯«¸g·P¬V¯e¯f¬ì¥D¥ô¬_©Ô¥§§J¡]Igor Koralnik¡^ªí¥Ü¡A¤w¸g¦³¼Æ¸U¤H¥X²{³oºØ²{¶H¡C µM¦Ó¡AÃö©ó¸£Ãúªº¬ã¨s¤~¥¿¶}©l¡Cªk°ê8¤ë¤@¥÷¦³Ãö120¦W¦í°|±wªÌªº¬ã¨s«ü¥X¡A±wªÌ±d´_«á¼Æ¤ë¡A34%±wªÌ¥X²{°O¾Ð³à¥¢¡B27%±wªÌ¦³ª`·N¤OÃø¥H¶°¤¤²{¶H¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/12 ¤W¤È 07:29:42²Ä 1039 ½g¦^À³
|
§Ü¼~Æ{ÃĪA¥Î¤H¼Æ¼É¼W ¤k¦h©ó¨k 2020-10-12 01:41 Áp¦X³ø / °OªÌªô©y§g¡þ¥x¥_³ø¾É udn.com/news/story/7266/4928016?from=udn_ch2_menu_v2_main_index °·«O¸p²Îp¡A°ê¤ºªA¥Î§Ü¼~Æ{ÃĪ«¤H¼Æ³v¦~Ãk¤É¡A¥h¦~¹F¤@¦Ê¤T¤Q¤EÂI¤C¸U¤H , ¹L¥h¤¦~¤º¼W¥[¹O¤Ü¸U¤H¡A³t«×³v¦~¥[§Ö¡A¤k©Ê¼W¥[¤H¼Æ¬O¨k©Êªºªñ¨â¿¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/10/11 ¤W¤È 08:24:39²Ä 1038 ½g¦^À³
|
¾å¦à¤j ©Î³\±N¨ÓSNB01Á{§É¦¨¥\«á , ´N·|´M¨D±ÂÅv¹ï¶H?! ¥t¥~¨â«h³ø¾É¨Ñ°Ñ COVID-19 ·s«aªÍª¢±N ¬y·P¤Æ ? www.genetinfo.com/international-news/item/41763.html ^°ê»P¦L«×¬ã¨s : ·s«aªÍª¢¤Þµo¯«¸g»Pºë¯«¯e¯f ? ȱoÂå¬É«µø www.genetinfo.com/international-news/item/41887.html Y¨â«h³ø¾Éªº²{¶H¦¨¯u , SNB01ªº¬ãµo´NÅã±o§ó¬°¦³²z©M¦³§Q ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2020/10/8 ¤W¤È 10:27:59²Ä 1037 ½g¦^À³
|
¥i¥H¸õ¹LPhase I¡Aª½±µ°µII¡A III ´Á¡AÀ³¸Ó«Ü¤Ö§a¡H ©Ò¥HÀ³¥i¥H½Í¥X¦n±ø¥ó,¤£¬O¶Ü? |
|
|
·|û¡G¾å¦à10141996 µoªí®É¶¡:2020/10/8 ¤W¤È 10:19:40²Ä 1036 ½g¦^À³
|
¦³¤@°ÝÃD½Ð±Ð¦U¦ì¤j¤j¡G SNB01 ¥H¥Ø«e¤½¥q°]¤O»P¸ê·½¡A ¨p¦Û¥H¬°³Ì¦X²zªº¤èªk¬O±ÂÅv¥X¥h¡A ®³Åv§Qª÷»P¥¼¨Ó¤§¤À¬õ¡C SNB01 ¦pªG¯u¦p½²¸³©Ò»¡¡A¾Ì¥Lªºreputation, À³¤£Ãø§ä¨ì¦n¤½¥q¡A½ÍÓ¦ndeal¡A¨ä»ùÈ»sÃĤ½¥q³Ì¤F¸Ñ¡C ¤§«á±Mª`©óì¨Ó¤§¬ãµo¡C ³o¬Ý¨Ó¤~³Ì¦X²z¡A ¤£ª¾²q·Q¤j¡B¹ù¤j¡BCliff¤j ¬Ýªk¦p¦ó¡H |
|
|
·|û¡G¤p³ì10135960 µoªí®É¶¡:2020/9/30 ¤W¤È 11:38:43²Ä 1035 ½g¦^À³
|
¤jÃļt¶}µo³t«×³£«Ü§Ö www.moneydj.com/KMDJ/News/NewsViewer.aspx?a=079adc0e-6aa2-44c3-aea4-7b70439492a2&c=MB010000 Regeneron¸ÕÅ禳275¦W«D¦í°|±wªÌ°Ñ»P¡A§ÜÅéÃĨó§U§K¬Ì¤ÏÀ³¸û®zªº±wªÌ¡B©Î¬O¯f¬r§t¶q·¥°ªªº±wªÌ¡A°§C¯f¬r¶q¨Ã§ïµ½¯f¯g¡CYancopoulos»¡¡A³oÅã¥Ü·sÃĦb³Ì¢¤Á»Ýnªº¯f±w¨¤W¡A¦¨®Ä³Ì©úÅã¡Cªì©l®É¯f¬r§t¶q³Ì°ªªº±wªÌ¡AÅ餺¯f¬r¶q¤j´î99%¡A¯gª¬¤]¦b¤»¤Ñ¤º¸Ñ°£¡CªA¥Î¦w¼¢¾¯ªº±wªÌ¡A¯gª¬¦Ü¤Ön12¤Ñ¤~·|§ïµ½¡C Regeneron PharmaceuticalsÃļt°ª¼hChristos Kyratsous»¡¡G¡u§ÜÅé¯àªý¤î¶Ç¬V©Ê¡A³o¬O¨Æ¹ê¡v¡CRegeneron¥¿¦b´ú¸Õ²V¦X¨âºØ§ÜÅ骺Âû§À°sÀøªk¡A¬Û«H¨âºØ§ÜÅé¤ñ¤@ºØ§ÜÅé§ó¯àªý¤î¯f¬r°k¶h¡C¸Ó¤½¥qªº¬ã¨s¼Æ¾Ú±N¦b®L¥½©Î¬îªì¤½¥¬¡C°£¦¹¤§¥~¡A§¨Ó(Eli Lilly)¡Bªü´µ¯S±¶§Q±d(AstraZeneca)¡B¦w¶i(Amgen)¡B¸¯Äõ¯À¥v§J(GlaxoSmithKline)³£¦b¬ã¨s¦¹ºØÀøªk¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/24 ¤W¤È 11:41:29²Ä 1034 ½g¦^À³
|
ÁÂÁ¹ù¥S¤À¨É DelveInsight ©ó2020/9µoªíSCZ¦Ü2030ªº¥«½Õ³ø§i liawbf.pixnet.net/blog/post/49509283 ¥t¥~ ù¤ó«Å¥¬¨äTau§ÜÅésemorinemab ¦b¤@Ó¥s°µTAURIELªº¤G´ÁÁ{§É¥¢±Ñ med.sina.com/article_detail_103_1_89600.html AD¬O¦h¦]¯À¯e¯f¡A¯gª¬¤]¤£¶È©ó¥¢´¼¡BÁÙ¦³ºë¯«¤è±©M¥¢¯vµ¥¯gª¬¡C¯»ª¬³J¥Õ¬OAD³Ì©úÅ㪺¯f²z¯S¼x¡A...Tau»PAbeta¤]¦³¤@©wÃöÁp¡ATau¬OAbeta¬r©Êµo§@¥²nªº»²§U³J¥Õ¡C¥t¥~³o¨âÓ³J¥Õ³£»P¤¤¼ÏÅK¥NÁ¦³Ãö¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/20 ¤W¤È 08:24:32²Ä 1033 ½g¦^À³
|
ÁÂÁ¹ù¥S¤À¨É ¤é¥»ÔÃ¥ÉÂå¬ì¤j¾Ç¯«¸g¯f²z¾Ç Mori ±Ð±Âªº¬ã¨s ( ¦n¤Í©w ) ³o¬O¦³Ãö TA GA ªvÀø AD ªñ10¦~¨Óªº¨t¦C¬ã¨s liawbf.pixnet.net/blog/post/49504905 ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/19 ¤W¤È 09:10:13²Ä 1032 ½g¦^À³
|
½÷·ç ( Pfizer ) ¤]nµo®i§Ü¯f¬r·sÃÄ Pfizer¡¦s novel COVID-19 antiviral heads to clinical trials ½÷·ç·s«¬COVID-19§Ü¯f¬rÃĪ«¶i¤JÁ{§É¸ÕÅç The small molecule targets coronavirus 3CL protease and is active against multiple coronaviruses in cell studies ¸Ó¤p¤À¤l¹v¦V«aª¬¯f¬r3CL³J¥Õ酶¡A¦b²ÓM¬ã¨s¤¤¹ï¦hºØ«aª¬¯f¬r¨ã¦³¬¡©Ê by Bethany Halford SEPTEMBER 17, 2020 »sÃÄ°Ó½÷·ç¤½¥q¤w¸g¶}©l¹ïPF-07304814¶i¦æ1´ÁÁ{§É¸ÕÅç PF-07304814§t¦³¤@ÓÁC»Äà°ò¹Î¡A¨Ï¸Ó¤Æ¦Xª«¥i·»¨Ã³Q²Õ´¤¤ªºÆP©ÊÁC»Ä酶µõ¸Ñ¡A±q¦ÓÄÀ©ñ¥X¬¡©Ê§Ü¯f¬r¾¯PF-00835231¡C ¹³¹p©i©õ³ ( remdesivir ) ¤@¼Ë¡APF-07304814 ¥²¶·ÀR¯ßª`®g¡C ¸¦»«®Ú¤j¾ÇªºÃĪ«¤Æ¾Ç®aThanigaimalai Pillaiyar¶}µo¤F«aª¬¯f¬r§í¨î¾¯¡A¥L»¡ PF-00835231 ¼sªxªº§Ü¯f¬r¬¡©Ê¬Ý°_¨Ó«Ü¦³§Æ±æ¡A¦ý¥L«ü¥X¡A¹wpªº¦³®Ä¾¯¶q¡]500²@§J/¤Ñ¡^«Ü°ª¡C ½×¤å¦b¦¹ www.biorxiv.org/content/10.1101/2020.09.12.293498v2.full «Ü©êºp , ¤pªºÃª©óª¾ÃÑ , µLªk«ü¥X EC50 ¬O¦h¤Ö ½÷·ç¤w¸g¦b¶}µo¬Ì] , ¬°¦óÁÙnµo®i§Ü¯f¬rÃĪ« ©Î³\¥ý«eªº¤ÀªR³ø¾É , ¥i¬°»¡©ú ¥»ª©²Ä1029½g¶K¤å ¤@¤åŪÀ´¡G·s«a¬Ì]ªº«OÅ@®Ä¤O¤£¥u¬O¤£·|±o¯f¨º»ò²³æ ¨Ó·½¡GÃÄ©ú±d¼w¡@2020-09-16 med.sina.com/article_detail_103_2_89142.html ¦Ó¦b¦¹¤§«e¡A¤µ¦~6¤ë©³¡AFDA´¿ªí¥Ü¡A¤@¥¹¬Ì]³QÃÒ©ú¬O¦w¥þªº¡A¦Ü¤Ö¦³50%ªº¦³®Ä©Ê¡A¥¦´N¥i¥H³Q§åã¦b¬ü°ê¨Ï¥Î¡C¨º»ò¡A50%ªº¦³®Ä©Ê·N¨ýµÛ¤°»ò¡H ®Ú¾Ú¬ü°ê¯e¯f±±¨î»P¹w¨¾¤¤¤ß¡]CDC¡^ªº¼Æ¾Ú¡A¦Û2010¦~¥H¨Ó¡A©u¸`©Ê¬y·P¬Ì]ªº¥\®Ä¤¶©ó19¢H¦Ü60¢H¤§¶¡¡C 50%ªº¦³®Ä©Ê¡AÅ¥°_¨Ó¥i¯à·|Â÷¤j®aªº´Á±æ¬Û¶Z¬Æ»·¡A¦ý±µºØCOVID-19¬Ì]¹ïÓ¤H©MªÀ°Ïªº¼ç¦b¦n³B¡A¨ä¹ê¨Ã¤£©ó¦³®Ä©Ê¡C«X¥è«X¦{¥ß¤j¾Ç¤½¦@½Ã¥Í¾Ç°|±Ð±ÂBill Miller³Õ¤hªí¥Ü¡A¡§¡]¦³®Ä©Ê¬° 50% ªº¡^COVID-19¬Ì]¡A¥i¯à·|°§C¨ä¥L 50% ªº±wªÌªº¯f±¡ÄY«µ{«×¡C¡¨³o¥i¯à·N¨ýµÛ±µºØªÌ§Y«K¬V¤WCOVID -19¡A¤]¤£¤Ó¥i¯à»Ýn¦í°|¡A¤£»Ý¤J¦í«¯gºÊÅ@¯f©Ð¡A©ÎªÌ¯à°÷§K©ó¦]¬°¬V¤WCOVID-19¦Ó¦º¤`¡CMillerÂå¥Í»{¬°¡A¬y·P¬Ì]´N¬O³o¼Ë¡C±µºØ¬y·P¬Ì]ªÌ¤¤¡A¤j¦h¼Æ¥i¯à¤´µM·|¬V¤W¬y·P¡A¦ý¦b«Ü¦h±¡ªp¤U¡A§Y«K¬O¬V¤W¬y·P¡A³o¨Ç±µºØ¬Ì]ªÌªºÄY«µ{«×¡A¤]n¤ñ¥¼±µºØ¬Ì]ªÌn»´¡C ½÷·ç³oÀɧܯf¬r·sÃÄ , ¦]¬°¥ÍÅé§Q¥Î²vªº¦]¯À , ¥²¶·±ÄÀR¯ßª`®gªº¤è¦¡ SNB01 ÁöµM¤´¦³¥ÍÅé§Q¥Î²v¤ñ¸û®tªº°ÝÃD , ¦ý¸g¤½¥qªºµû¦ô¤´±Ä¤fªAµ¹ÃÄ , ©Î³\¦b©ó¨âÓì¦] ? SNB01¦b¥NÁ¤§«á , ¨ä¥NÁª«¤´¨ã¦³§Ü¯f¬r®ÄªG¦hºÞ»ô¤U©M¤fªAµ¹ÃĤ~¬O§Ü¯f¬rÃĪ«ªº¤ý¹D ? ¬JµM¤j¼t°£¤F¬Ì]¥~ , ¨Ìµo®i§Ü¯f¬r·sÃÄ , À³¸Ó¬O§Ü¯f¬rÃĪ«ªº¥«³õG¯Ç¤´¦³¤£¤pªÅ¶¡§a ? §ÚÌ´Á«ÝSNB01¯àµo´§·¥¨ÎªºÃÄ®Ä , ¦b¤G´Á´Á¤¤¤ÀªR´N¥iµ²§ôÁ{§É¥Ó½ÐÃÄÃÒ , ºÉ§Ö³yºÖ±wªÌ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/18 ¤W¤È 07:10:38²Ä 1031 ½g¦^À³
|
¹ù¥S¤À¨É ¼Ú¶§¤åsÂå®v AD + BPSD ªvÀøªºÂ²³øÀÉ liawbf.pixnet.net/blog/post/49505351 ÁÂÁ¹ù¥S ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/17 ¤W¤È 09:21:30²Ä 1030 ½g¦^À³
|
¹ù¥S¬°¬ö©À ¤j»}¤jÄ@ ¦aÂäýµÐÂÄ ¶ê±I¤é ¯S§O¶}©ñ¦n¤Í¤å³¹¦Ü9/18 ÁÂÁ¹ù¥S ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/16 ¤W¤È 10:34:17²Ä 1029 ½g¦^À³
|
¤@¤åŪÀ´¡G·s«a¬Ì]ªº«OÅ@®Ä¤O¤£¥u¬O¤£·|±o¯f¨º»ò²³æ ¨Ó·½¡GÃÄ©ú±d¼w¡@2020-09-16 med.sina.com/article_detail_103_2_89142.html ¦Ó¦b¦¹¤§«e¡A¤µ¦~6¤ë©³¡AFDA´¿ªí¥Ü¡A¤@¥¹¬Ì]³QÃÒ©ú¬O¦w¥þªº¡A¦Ü¤Ö¦³50%ªº¦³®Ä©Ê¡A¥¦´N¥i¥H³Q§åã¦b¬ü°ê¨Ï¥Î¡C¨º»ò¡A50%ªº¦³®Ä©Ê·N¨ýµÛ¤°»ò¡H ®Ú¾Ú¬ü°ê¯e¯f±±¨î»P¹w¨¾¤¤¤ß¡]CDC¡^ªº¼Æ¾Ú¡A¦Û2010¦~¥H¨Ó¡A©u¸`©Ê¬y·P¬Ì]ªº¥\®Ä¤¶©ó19¢H¦Ü60¢H¤§¶¡¡C 50%ªº¦³®Ä©Ê¡AÅ¥°_¨Ó¥i¯à·|Â÷¤j®aªº´Á±æ¬Û¶Z¬Æ»·¡A¦ý±µºØCOVID-19¬Ì]¹ïÓ¤H©MªÀ°Ïªº¼ç¦b¦n³B¡A¨ä¹ê¨Ã¤£©ó¦³®Ä©Ê¡C«X¥è«X¦{¥ß¤j¾Ç¤½¦@½Ã¥Í¾Ç°|±Ð±ÂBill Miller³Õ¤hªí¥Ü¡A¡§¡]¦³®Ä©Ê¬°50%ªº¡^COVID-19¬Ì]¡A¥i¯à·|°§C¨ä¥L50%ªº±wªÌªº¯f±¡ÄY«µ{«×¡C¡¨³o¥i¯à·N¨ýµÛ±µºØªÌ§Y«K¬V¤WCOVID -19¡A¤]¤£¤Ó¥i¯à»Ýn¦í°|¡A¤£»Ý¤J¦í«¯gºÊÅ@¯f©Ð¡A©ÎªÌ¯à°÷§K©ó¦]¬°¬V¤WCOVID-19¦Ó¦º¤`¡CMillerÂå¥Í»{¬°¡A¬y·P¬Ì]´N¬O³o¼Ë¡C±µºØ¬y·P¬Ì]ªÌ¤¤¡A¤j¦h¼Æ¥i¯à¤´µM·|¬V¤W¬y·P¡A¦ý¦b«Ü¦h±¡ªp¤U¡A§Y«K¬O¬V¤W¬y·P¡A³o¨Ç±µºØ¬Ì]ªÌªºÄY«µ{«×¡A¤]n¤ñ¥¼±µºØ¬Ì]ªÌn»´¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/14 ¤U¤È 07:40:19²Ä 1028 ½g¦^À³
|
¹ù¥SÀ°§Ṳ́ÀªR SNB01 ¥i¯àªºªvÀøÀu¶Õ ( ¦n¤Í©w ) liawbf.pixnet.net/blog/post/49502901 ÁÂÁ¹ù¥S ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/13 ¤U¤È 06:05:41²Ä 1027 ½g¦^À³
|
¤T½gNATURE ½×¤å½à¤ß 1. Enhancing microtubule stabilization rescues cognitive deficits and ameliorates pathological phenotype in an amyloidogenic Alzheimer¡¦s disease model ¦b¤Þ°_¾ý¯»¼ËÅܩʪºªüº¸¯ý®üÀq¤ó¯f¼Ò«¬¤¤¡A¼W±j·LºÞéw©Ê¥i¥H®¾±Ï»{ª¾¯Ê³´¨Ã§ïµ½¯f²zªí«¬ www.nature.com/articles/s41598-020-71767-4 §Ú̵û¦ô¤FADªº¾ý¯»¼Ë³J¥Õ¥Í¦¨¼Ò«¬¤¤¸£º¯³z·LºÞéw¾¯®J©YÅð¯ÀD¡]EpoD¡^ªº¼vÅT ¦b¯f²zµo§@¤§«e¡A¹ï¤TÓ¤ë¤jªºAPP / PS1¤p¹«¨C¶gª`®gEpoD¡A«ùÄò3Ó¤ë¡C³B²z¹Lªº¤p¹«ªºÁC»Ä¤Ætau¤ô¥ÅãµÛ°§C¡C¦¹¥~¡A¥çµo²{¤FÅãµÛªº»{ª¾§ïµ½©M¬ðIJ©M¯«¸g¯f²z¾Çªº§ïµ½ ¦]¦¹¡A·LºÞéw¾¯¥i³Qµø¬°´îºCtau©MA£]¯f²z¾Ç¶iµ{ªºªvÀø¾¯¡C ¦]¦¹¡A·LºÞ ( MT ) -¹v¦V¸Õ¾¯¬O¥Î©óªvÀø¯«¸gÅܩʯe¯fªº¦³§l¤Þ¤OªºªvÀøÔ¿ï¡C¨Æ¹ê¤W¡A¹³µµ§üÖJÃþ©Î®J³ÕÅð¯À¡A¦b§ÜÀù¤ÆÀø¤¤¨Ï¥Î¤£¦PªºMT-éw¤Æ¦Xª«¡A³Ìªñ¤w¦b¬Y¨ÇÁ{§É«e¬ã¨s¤¤¨Ï¥Îªº£n³J¥Õ¯f¯gªºÂà°ò¦]¼Ò«¬µû¦ô. ±qCa¯ó¤¤¤ÀÂ÷ªº×ôÃþ¤Æ¦Xª«³q¹L°®ÂZÀù²ÓM¨t¤¤ªº·LºÞ°Ê¤O¾Ç¡A®t²§©Ê¦a»¤¾ÉS©MG2 / M´Á²ÓM¶g´Á°±º¢¨ÃIJµo²ÓM¦º¤`¡C www.mdpi.com/1420-3049/22/4/666/htm ¦b¥ÎEG ( ¨S¹¤l»Ä¤Aà ) ³B²zªºHep3B²ÓM¤¤¡A§ÚÌÆ[¹î¨ì·LºÞéw¦b²ÓM®Ö©P³ò¡A»Pµµ§ü¾J³B²zªº²ÓM¬Û¦ü¡A¦ýµ{«×¸û¤p¡C¾¨ºÞÀË´ú¨ì¸û§Cªºº·¥ú±j«×¡A¦ý¦b¥ÎTA³B²zªº²ÓM¤¤¤]Æ[¹î¨ì¤F³o¨Çµ²ºc¡C³o¬O²Ä¤@¥÷´yzEG¹ïÀù²ÓM·LºÞéw§@¥Îªº³ø¾É¡C¦¹¥~¡A¾¨ºÞ¦³¨Ç·LºÞ¬Ý¤W¥h¥¿±`¡A¦ýGA³B²zªº²ÓMÅã¥Ü¥X·LºÞ³J¥Õ¤À´²«H¸¹¡Aªí©úGA¹ï·LºÞéw©Ê¦³»´·Lªº¼vÅT¡C 2. Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging www.nature.com/articles/s41467-020-18405-9 Caspase Functions in Cell Death and Disease cshperspectives.cshlp.org/content/5/4/a008656.full Tannic acid inhibits NLRP3 inflammasome-mediated IL-1£] production via blocking NF-£eB signaling in macrophages pubmed.ncbi.nlm.nih.gov/30126633/ ( in vitro ) Here, we reported that tannic acid inhibited NLRP3 inflammasome activation by blocking NF-£eB signaling to suppress IL-1£] secretion. We found that the BMDMs (bone marrow-derived macrophages cells) pre-treated with tannic acid blocked caspase-1 cleavage and inhibited IL-1£] secretion in a NLRP3-dependent manner, and suppressed NF-£eB signaling activation by inhibiting NF-£eB/P65 nuclear localization, suggesting that tannic acid inhibited NLRP3 inflammasome activation. 3. Increased blood BACE1 activity as a potential common pathogenic factor of vascular dementia and late onset Alzheimer¡¦s disease www.nature.com/articles/s41598-020-72168-3 Tannic Acid Is a Natural £]-Secretase Inhibitor That Prevents Cognitive Impairment and Mitigates Alzheimer-like Pathology in Transgenic Mice* www.ncbi.nlm.nih.gov/pmc/articles/PMC3307267/ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¥[¯Z¤H¥Í10148422 µoªí®É¶¡:2020/9/10 ¤U¤È 04:50:18²Ä 1026 ½g¦^À³
|
·PÁ¦ÌÄ_¤jªº¦^À³¡C ¦³¨Ç¹êÅçÁÙ¬On©e¥~³B²z¡C ©Ò¥H¦³¨Ç¤jÃļt³t«×«Ü§Öªº¡A¬Ý¨ÓÀ³¸Ó³£¦³¦Û¤vªº¤H°¨¨Ó°õ¦æ¥þ³¡ªº¹êÅç¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/10 ¤U¤È 04:07:58²Ä 1025 ½g¦^À³
|
¹ù¥Sµ¹§Ų́â³õ¦³Ãö COVID-19 ªººtÁ¿ 1.§Ü¯f¬rÃĪ«ªvÀø 2.¯f¬r¾Ç¸ÑªR liawbf.pixnet.net/blog/post/49500491 ¥t¥~ÁÙ¦³¦n¤Í©wªº SNB01 VS. Antroquinonol liawbf.pixnet.net/blog/post/49499771 ÁÂÁ¹ù¥Sªº¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2020/9/10 ¤W¤È 07:54:27²Ä 1024 ½g¦^À³
|
¾Ú¤p§Ì¤F¸Ñ³oÓ¹êÅç¬O©e°UCRO°µªº ¥Ø«eCRO±µ®×¶q¤w¸g±Æ¨ì2~3Ó¤ë«á¤F ©Ò¥HnªáÂI®É¶¡.... |
|
|
·|û¡G¥[¯Z¤H¥Í10148422 µoªí®É¶¡:2020/9/9 ¤U¤È 10:23:49²Ä 1023 ½g¦^À³
|
«D¬ÛÃö¬ì¨t, ½Ð±Ð¦U¦ì¦³¸gÅ窺¤j¤j, ¶È»Ý¸É¥R¤@¶µ¤j¹«¤Q¥|¤Ñ¬r²z¹êÅç ³oÓnªá¥|Ó¤ë¶Ü? 14¤Ñ¥[¾ã²z¤ÀªR¸ê®Æ, »Ýn³o»ò¤[³á? Ãø¥H·Q¹³. ÁÂÁ |
|
|
·|û¡Gªü¤Ñ10149120 µoªí®É¶¡:2020/9/9 ¤U¤È 02:38:33²Ä 1022 ½g¦^À³
|
¤j¦P¥S §AÁÙ¦n§a ³o¤£¬O»D¶Ü¡H... |
|
|
·|û¡G§õ¤j¦P10150456 µoªí®É¶¡:2020/9/9 ¤W¤È 10:34:42²Ä 1021 ½g¦^À³
|
³o¤]¤Ó¼F®`¤F¡I ÁÂÁ³¯ÀR¤j¤@»y¹D¯}SNS¨t¦C²£«~ªº²Õ¦XÀu¶Õ¡AÅý¤pªº¬íÀ´¥¦ÌªººëµØ ¡u ¤ß®®¥ÍÂå°£¤F«ùÄò±q¤W¦ì®Ú·½©ÊªºNMDA¾÷Âà¶}µo¼s®Äªº³Ð·sªvÀø¥~¡A¥tµo²{SND5¨ã¦³¼W±jSND1ªº®ÄªG¡A§Y¦P®É¬I¤©§C¾¯¶qªºSND1»PSND5«K¥i¹F¨ì©Î¶W¶V°ª¾¯¶qSND1ªº®ÄªG¡A ¹EµÛ¤â¬ãµo¬J¦³¤¤¼Ï¯«¸gÃĪ«»PSND1¡BSND5¶i¦æ²Õ¦Xªº¥i¦æ©Ê¡C¡v ¡u ºë¯«¤Àµõ¯g¡Bªü¯÷®üÀq¥¢´¼¯g¡B««×¼~Æ{¯g¬O¤¤¼Ï¯«¸gÃĪ«¥«³õ¤T¤jªvÀø»â°ì¡A¤ß®®¤w¦b¦¹¤T¤j»â°ì¿ï©w¦X¾A·sÃĪ«»PSNS1-7¶i¦æ¶}µo¡C ¡v xn--ces829a09dg1a.greenclean.com.tw/index.html ì¨Ó¦p¦¹ ¬O¤@ºØ¡u ¬J¦³¤¤¼Ï¯«¸gÃĪ«»PSND1¡BSND5¶i¦æ²Õ¦X ¡vªº NME ÃĪ« ¦A¦¸·PÁ³¯ÀR¤jªº«ü¾É ¤]ÁÂÁ¤j®a ¡I |
|
|
·|û¡Gªü¤Ñ10149120 µoªí®É¶¡:2020/9/9 ¤W¤È 08:53:28²Ä 1020 ½g¦^À³
|
ªü´µ¯S±¶§Q±d¼È°±·s«a¬Ì]¸ÕÅç ªÑ»ù¤U®À8% news.cnyes.com/news/id/4522540 |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/8 ¤U¤È 03:34:11²Ä 1019 ½g¦^À³
|
¹ù¥S¶Ç¹F¬ã°Q·|°T®§ ¥xÆW¯«¸g¬ì¾ÇÁp¦X¾Ç³N¬ã°Q·| ( 9/11 ~ 9/13 ) Åwªï¤j®a¥h´Â¸t ¬ã°Q·|¦³«GÂI liawbf.pixnet.net/blog/post/49499073 ÁÂÁ¹ù¥S ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/8 ¤U¤È 12:53:56²Ä 1018 ½g¦^À³
|
¤ß®®¤µ¤é¤S¨ú±o¬ü°ê±M§Q United States Patent 10,765,651 September 8, 2020 Co-crystals of substituted glycine and uses thereof ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/7 ¤U¤È 08:18:13²Ä 1017 ½g¦^À³
|
¤pªº¥u¬O¶¢¶¢À°¤j®a¬d¬d¸ê®Æ ´£¨Ñµ¹¤j®a°Ñ¦Òªº¤H ¼ÖÆ[¬£¤]½} ¿Ë½Ã¶¤¤]½} ¨º¤]³£¥u¬OÓ¤H¹ï¨Æª«ªº»ùȪºµûÂ_ ´N¦p¦P¤pªº²{¦b¤ß¸Ìªº»´·T SNB01¥Ø«eªºÄvª§¹ï¤â ¥HÃöÁä¦r [ mild SARS-CoV-2 ] ·j´M , ¦@75¶µ clinicaltrials.gov/ct2/results?cond=mild+SARS-CoV-2&term=&cntry=&state=&city=&dist= 1. KB109 Not Applicable Camostat mesilate Phase 2 Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the treatment of COVID-19. KB109 Not Applicable Cannabidiol 2 3 CBD¤wÅã¥Ü¦³§Æ±æ§@¬°¤îµh¾¯¡A§ÜÅå³ÖÃÄ¡A¦Ù¦×ÃP¦¢ÃÄ¡A§ÜµJ¼{ÃÄ¡A§Üºë¯«¯fÃÄ¡A¨Ãªí²{¥X¯«¸g«OÅ@¡A§Üª¢¡A©M§Ü®ñ¤Æ¬¡©Ê¡A Remdesivir 3 Favipiravir 2 3 ³Ìªì³Q§åã¥Î©ó§ÜÃĩʬy·PªºªvÀø¡C7¡A9©Òzªº§Ü¯f¬r¹v¼ÐªºRNA¨Ì¿à©ÊRNA»E¦X酶¡]RdRp¶i¦æ¡^酶¡A¨ä¬O¥²nªº¯f¬r°ò¦]²ÕªºÂà¿ý©M½Æ»s Tafenoquine 2 tafenoquineªº§@¥Î¾÷²z©|¤£©ú½T Tafenoquine¥Î©óªvÀø©M¹w¨¾16·³¥H¤W±wªÌªºVivaxºÄ¯e´_µo¡CTafenoquine¤£¾A¦XªvÀø«æ©Ê¶¡¤éºÄ¯e Favipiravir 3 Favipiravir 2 Favipiravir 3 11 ¯Ê Niclosamide 2 Niclosamide¬O¤@ºØ§ÜįÂÎÃÄ¡A¥Î©ó§ÜtapeÂηP¬V¡C¥¦¥i¯à³q¹L¹q¤l¶Ç¿éÃì»PATP¦X酶ªº¸Ñ°¸Áp§@¥Î¡C¸ÓÃöÁä¥NÁ³~®|ªº¯¿¶Ãªý¤î¤F¤TÁC»Ä¸¢苷¡]ATP¡^ªº²£¥Í¡AATP¬O¬°¥NÁ´£¨Ñ¯à¶qªº¥²»Ý¤À¤l¡C Hydroxychloroquine 1 2 ßm´â喹§í¨îACE2ªº¥½ºÝ¿}°ò¤Æ¡AACE2¬OSARS-CoV©MSARS-CoV-2¹v¦V¶i¤J²ÓMªº¨üÅé¡C9¡A8 ACE2¤£¬O¦b¿}°ò¤Æªºª¬ºA¥i¥H¸û¤Ö¦³®Ä¦a»PSARS-CoVªº-2¨ë¬ð³J¥Õ¬Û¤¬§@¥Î¡A¶i¤@¨B§í¨î¯f¬r¶i¤J Indomethacin 吲哚¬ü¨¯ªº¥Dn§@¥Î¬O½w¸Ñ¯kµh¡A´î»´µo¿N¡A¸~µÈ©MÀ£µh¡A±q¦Ó§í¨îÃþ·ÀãÃö¸`ª¢ªºª¢¯g¡C Zithromax¬°¤F½Æ»s¡A²Óµß»Ýn¥Ñ®ÖÁÞÅé³J¥Õ6±Ò¥Îªº³J¥Õ½è¦X¦¨ªº¯S©w¹Lµ{¡Cªü©_Åð¯À»P²Óµß50S®ÖÁÞÅé¨È°òªº23S rRNAµ²¦X¡C¥¦³q¹L§í¨î³J¥Õ½èªº¦X¦¨ªºÂà肽/©ö¦ì¨BÆJ©M³q¹L§í¨î50S®Ö¿}Åé¨È°òªº²Õ¸Ë°±¤î²Óµß³J¥Õ½è¦X¦¨ Hydroxychloroquine 1 Azithromycin 2020¦~3¤ë¡Aªk°ê¬F©²¸ê§U¤F¤@¶µ¤p«¬¬ã¨s¡A¥H¬ã¨sªü©_Åð¯À©M§ÜºÄ¯eÃĪ«ßm´â喹Áp¦XªvÀøCOVID-19ªº¤èªk¡Cµ²ªG¬OªÖ©wªº¡A©Ò¦³±µ¨üÁp¦X¥ÎÃĪº±wªÌ¦bªvÀø«áªº6¤Ñ¤º³£Àò±o¤F¯f¬r¾Çªv·U¡A¦ý¬O»Ýn¶i¦æ§ó¤jªº¬ã¨s Hydroxychloroquine 2 Ciclesonide ¿}¥Ö½è¿E¯À¡A¨Ò¦pciclesonide¡A¥i¥H§í¨îª¢¯g³¡¦ìªº¥Õ²ÓM®û¼í¡A¤zÂZª¢¯g¤ÏÀ³ªº¤¶½è¡A¨Ã§í¨îÅé²G§K¬Ì¤ÏÀ³¡C¿}¥Ö½è¿E¯Àªº§Üª¢§@¥Î³Q»{¬°»PÁC¯×酶A2§í¨î³J¥Õ¡A¯×¥Ö½è¿E¯À¦³Ãö¡A«áªÌ±±¨îµÛ¦³®Äªºª¢¯g¤¶½è¡]¦p«e¦C¸¢¯À©M¥Õ¤T²m¡^ªº¥Íª«¦X¦¨¡C Leflunomide 1 ¥Î©óªvÀø¬¡°Ê©ÊÃþ·ÀãÃö¸`ª¢¡]RA¡^ªºÅé¼x©M¯gª¬¡A¥H§ïµ½¨Åé¾÷¯à¨Ã´î½w»P¸Ó¯e¯f¬ÛÃöªºµ²ºc©Ê·l¶Ëªºµo®i¡C ¨Ó¬t¦Ì¯S¤]¬O¹T®ò»Ä¿E酶§í»s¾¯¡C¹T®ò»Ä¿E酶¿E¬¡«H¸¹¶Ç¾É³~®|¡A¾ÉPDNA×´_¡Aä¤`©M²ÓM¼W´Þ¡C§í¨î¹T®ò»Ä¿E酶¥i¥H³q¹L¹w¨¾¸~½F²ÓM×´_¨ÓÀ°§UªvÀøÀù¯g¡C Chloroquine 2 3 ´â喹¤£·|¼vÅT²ÓMªí±ACE2ªºªí¹F¤ô¥¡A¦ý·|§í¨îACE2ªº¥½ºÝ¿}°ò¤Æ¡AACE2¬OSARS-CoV©MSARS-CoV-2¹v¦V¶i¤J²ÓMªº¨üÅé¡C13¡A14 ACE2¤£¬O¦b¿}°ò¤Æªºª¬ºA¥i¥H¸û¤Ö¦³®Ä¦a»PSARS-CoVªº-2¨ë¬ð³J¥Õ¬Û¤¬§@¥Î¡A¶i¤@¨B§í¨î¯f¬r¶i¤J Hydroxychloroquine 3 Pyronaridine 2ým«£ÖJ¤w³Q¬ã¨s¥Î©óªvÀøºÄ¯e Artesunate «C»Uµ[à¥NÁ¬°¬¡©ÊDHA¡C8 DHAªº¤º¹L®ñ¤Æª«¾ô»P¦å¬õ¯À¤ÏÀ³¡A²£¥Í¦Û¥Ñ°ò¡A¦b©Ò¦³¬õ²ÓM¶¥¬q³£§í¨îºÄìÂΪº³J¥Õ½è©M®Ö»Ä¦X¦¨¡C8¡A7¤ÏÀ³»P³o¨Ç¦Û¥Ñ°ò¤]¥i¾ÉP±H¥Í³J¥ÕªºÖJ°ò¤Æ¡A¨Ò¦p¶t¸¢苷¤TÁC»Ä酶©MEXP1¡A½\¯Ö¥Ì肽S-Âಾ酶¡C1¡A7 Lianhua Qingwen 3 ½¬ªá²M½E 21 Antroquinonol 2 °ê¹© Hydroxychloroquine 1 Camostat mesylate 2 Nitazoxanide 3 ³Ìªñ¡A¥Ñ©ó¸ÓÃĨ㦳§í¨î¦hºØRNA©MDNA¯f¬r½Æ»sªº¯à¤O3¡A¦]¦¹¤w³Q¬ã¨s¬°¼sÃЧܯf¬rÃÄ¡C ²×¤î Ivermectin 0 ¥Î©óªvÀø¦]½uÂαH¥ÍÂÎÃþ©T½uÂΡ]Strongyloides stercoralis¡^¦Ó¤Þ°_ªº¸z¹D¡]§Y¥¼¼½´²ªº¡^¶ê½uÂίf¡C ¥ìºûµß¯À¤]³Q»{¬°¬O¯«¸g»¼½è£^-®ò°ò¤B»Ä¡]GABA¡^ªº¿E°Ê¾¯¡A±q¦Ó¯}Ãa¤FGABA¤¶¾Éªº¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¯«¸g¬ðIJ¶Ç»¼¡C Bactek-R 3 BACTEK R§K¬Ì¨ë¿E¾¯ ¾AÀ³¯g¡G ¤ÏÎ`©I§l¹D·P¬V¡]»óÄuª¢¡A«|ª¢¡A¤¤¦Õª¢©MªÍª¢¡^ Peginterferon Lambda-1a 2 Peginterferon lambda-1a¥¿¦bÁ{§É¸ÕÅçNCT01754974¤¤¶i¦æ¬ã¨s¡]Peginterferon Lambda-1a»PPeginterferon Alfa-2a¥H¤Î§Q¤Ú³ªL¦b1«¬°ò¦]«¬¤þ«¬¨xª¢±wªÌ¤¤ªº¦w¥þ©Ê©M¦³®Ä©Ê¬ã¨s¡^ Withdrawn Withdrawn 31 LY3819253 2 LYCoV555¡A¤]ºÙ¬°LY3819253¡A¬O¤@ºØ¦X¦¨³æ§J¶©§ÜÅé¡]mAb¡^¡A¨ä·½¦Û¬ü°ê²Ä¤@§å±qCOVID-19¤¤«ì´_ªº±wªÌ±Ä¶°ªº¦å²G¼Ë¥»¤§¤@¡C1¡A2 LY-CoV555¬O¤¤©MªºIgG1³æ§J¶©§ÜÅé°w¹ïSARS-CoVªº-2°v¡]S¡^³J¥Õ¡A¨ä³Q´yz¬°ªý¤î¯f¬r¶i¤J¤HÃþ²ÓM¡C1 LY3832479 ¡K Nitazoxanide 2 3 liposomal lactoferrin 2 3 ¡K Colchicine 2 ¬î¤ô¥PÆP¥i¥Î©ó¹w¨¾©MªvÀøµh·µo§@ ¬î¤ô¥PÆPªº½T¤Á§@¥Î¾÷²z©|¥¼§¹¥þ½T¥ß¡A¦ý¬O¥i¯à¬O¥Ñ©ó¤U´å§í¨î·LºÞ³J¥Õ¯}Ãa¤Þ°_ªºª¢¯g¦Óµo¥Í¡C2¬ã¨sªí©ú¬î¤ô¥PÆP·|¯}Ãa¦s¦b©ó³æ®Ö²ÓM©M¤¤©Ê²É²ÓM¤¤ªºª¢¯g¤pÅé½Æ¦Xª«¡A³q±`·|¾ÉP¥Õ¤¶¯À-1¡]¤@ºØ«nªºª¢¯g¤¶½è¡^¬¡¤Æ¡C3°£¤Wz§@¥Î¥~¡A¬î¤ô¥PÆPÁÙ¥i¥H°®ÂZ¤¤©Ê²É²ÓMªºÖߪþ©M¶Ò¶°¡A¶W®ñ¤Æª«ªº²£¥Í¡ARhoA / Rho®ÄÀ³¿E酶¡]ROCK¡^³~®|¥H¤Î¤@ºØ®Ö¦]¤l£e£E¡]NF-£e£E¡^³~®|¡A´î»´ª¢¯g¡C Immunofree 2 3 ¡K Reginmune ¡K ¯Ê YinHu QingWen 2 3 ¡K Artemisinin 2 «C»U¯À¤w¥Î©ó¬ã¨sªvÀøºë¯«¤Àµõ¯g¡AºÄ¯e¡A´c©ÊºÄ©M´c©ÊºÄìÂΪº¸ÕÅç Artesunate «C»Uµ[à¥Î©óÄY«ºÄ¯eªºªì©lªvÀø¡C8¥@¬É½Ã¥Í²Õ´«Øij±N«C»Uµ[à§@¬°ÄY«ºÄ¯eªº¤@½uªvÀø¡C6«C»Uµ[઺¶}µo¬O¥X©ó¹ï«C»U¯À§ó¿Ë¤ô©Êl¥Íª«ªº»Ý¨D¡C5 Diagnostic Test Diagnostic Test 41 Diagnostic Test Bromhexine Hydrochloride 0 ÆQ»Ä·Í¤v·s¬O·Í¤v¨¯ªºÆQ»ÄÆQ§Î¦¡¡A¬O¤@ºØ¨ã¦³Öß²G·»¸Ñ¬¡©Êªº«P¤Àªc¾¯¡Cµ¹ÃÄ«á¡A·Í¤v·s¥i¼W¥[·»酶Å鬡©Ê¡A¨Ã¼W±j©I§l¹D¤¤»Ä©ÊÖߦhÁÞ»E¦Xª«ªº¤ô¸Ñ¡C³o¼W¥[¤F©I§l¹D¤¤¼ß²GÖß²Gªº²£¥Í¡A³o¨Ï·ðÅܵ}¨Ã¥B°§C¤FÖß²GÖ߫סC³o¦³§U©ó¨ä¤Àªc¹B°Ê§@¥Î¡A¨Ã¨ÏÅÖ¤ò§ó®e©ö±N·ð±qªÍ¤¤Âà¹B¥X¨Ó¡C³o¼Ë¥i¥H²M°£©I§l¹D¤¤ªºÖß²G¡A¨Ã¥B¥i¥HÀ°§UªvÀø»P²§±`Öß²G¡A¹L¦hªºÖß²G¤Àªc©MÖß²G¹B¿é»Ù꦳Ãöªº©I§l¨t²Î¯e¯f¡C Arbidol Hydrochloride Granules ¡K INOpulse 3 ¤@®ñ¤Æ´á¬O¤HÅé³\¦h²ÓM²£¥Íªº¤Æ¦Xª«¡C¥¦³q¹L»PM½è³¾苷»ÄÀô¤Æ酶ªº¦å¬õ¯À³¡¤Àµ²¦X¡A¿E¬¡³¾苷»ÄÀô¤Æ酶¨Ã¼W¥[²ÓM¤ºÀô³¾苷3¡¦¡A5¡¦-³æÁC»Ä઺¤ô¥¨Ó©ñÃP¦åºÞ¥·Æ¦Ù¡AµM«á¾ÉP¦åºÞµÎ±i¡C§l¤J®É¡A¤@®ñ¤Æ´á·|¾ÉPªÍ¦åºÞÂX±i¡C Telemedicine»·µ{ÂåÀø 0 ¯Ê APL-9 1 2 ¡K Nitazoxanide 2 3 Leronlimab 2 Leronlimab©ÎPRO-140¬OCytoDyn¶}µoªº¤H³æ§J¶©§ÜÅé¡C4¥¦©ó2001¦~¦b¤åÄm¤¤º¦¸´yz¡C1¸Ó§ÜÅé»PCCR5µ²¦X¡A¥i¥Î©óªvÀøHIV¡AÀù¯g©M«¯gCOVID-19±wªÌ LeronlimabÁÙ³Q¬ã¨s¥Î©óªvÀø«¯gCOVID-19ªº±wªÌ¡A¦]¬°¥¦¹ï´î»´²ÓM¦]¤l·¼É©M¹w¨¾§K¬Ì¤¶¾Éªº·l¶Ë¨ã¦³§@¥Î Chloroquine 4 Hydroxychloroquine Azithromycin 3 ªü©_Åð¯À 51 Nitric Oxide 2 Withdrawn Iodine Complex 1 2 ¤wª¾¤À¤l¸K·|§í¨îN-¥Ò°ò-n-¨Èµv°ò脲»¤¾Éªº¨Å¸¢ÀùPÀù§@¥Î¨Ã«P¶i¨äµo®i¡A¨Ï7,12-¤G¥Ò°òf¨Ã¡]a¡^蒽»¤µoªº¤j¹«¨Å¸¢¸~½F°h¤Æ¡A¨Ã¤wÃÒ©ú¨ã¦³¦³¯q§@¥Î¦b¤H©ÊÅÖºûÅn©Ê¨Å¸¢Àù¤¤¡C Favipiravirµ¥ 3 hydroxychloroquine in combination with camostat mesylate 3 Hydroxychloroquine in combination of Azithromycin 3 Interferon Alfa-2b 1 2 Rintatolimod Û¥L²ö¼w¥H°Ó«~Ampligen¥X°â¡A¬O¤@ºØ¥Î©óªvÀøºC©Ê¯h³Òºî¦X¯g¡]CFS¡^ªºÃĪ«¡C[1]§C±j«×ÃÒ¾Úªí©ú¥¦¥i¥H´î»´CFS¯gª¬¡C[1] ¥¦¬O¤@ºØ§K¬Ì½Õ¸` ©ÊÂùÃìRNAÃĪ« Nitric Oxide 2 Telephone interview Rivaroxaban 2 §Q¥ï¨F¯Z¬Oª½±µ»P¦]¤lXaµ²¦Xªº§Ü¾®¾¯¡C¦¹«á¡A¥¦¦³®Ä¦aªý¤î¤F¾®¦å¯ÅÁp¤ÏÀ³ªºÂX¼W¡A±q¦Ó¨¾¤î¤F¦å®êªº§Î¦¨¡C a Specific Plant Based Dietary Supplement 2 Vitamin D3 61 Nigella Sativa 1 2 Ivermectin Zinc Bucillamine 3 ¥¬¥d©ú¤w³Q¥Î©ó¬ã¨sªvÀø©M¹w¨¾µh·©MÃþ·ÀãÃö¸`ª¢ªº¸ÕÅ礤 Prolectin-M 0 ¡K Vitamin D 0 Ivermectin 2 N-acetylcysteine 4 ¤A酰¥b¯Ö®ò»ÄÁ٨㦳¤@¨Ç§Üª¢§@¥Î¡A¥i¯à¬O³q¹L®Ö¦]¤l£e¿E酶ªº®ñ¤ÆÁÙì¿E¬¡¨Ó§í¨îNF-£eB¡A±q¦Ó½Õ¸`²ÓM¦]¤lªº¦X¦¨¡C Withdrawn Withdrawn Camostat Mesilate 2 Artemisia Annua Leaf 71 Human umbilical cord mesenchymal stem cells + best supportive care 1 ¤HÃþÂÀ±a¶¡¥R½è·F²ÓM PF-07304814 1 ¡K Hydroxychloroquine 3 Lopinavir/ Ritonavir Hydroxychloroquine 0 NİCaS 0 ¡K ¤pªº¤]¤£·Q¦h°µµû½× ¥u§Æ±æ¤j®a¦h¦h§å§P ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/7 ¤W¤È 11:02:39²Ä 1016 ½g¦^À³
|
¬ðµMµo²{ ²³ø¸ê®Æ P.8 ªºÁ{§É³]p¤¤ ¤G´ÁÁ{§É«áªº´Á¤¤¤ÀªR , ³]¦³²×¤îÁ{§É¤T±ø¥ó---1.¥¼¨£Àø®Ä 2.Àø®Ä·¥¨Î 3.¦w¥þºÃ¼{ ¥u¦³¦b³£¥¼²Å¦X¤T¶µ´£«eµ²§ô±ø¥ó , ¤~¶i¦æ²Ä¤T´ÁÁ{§É ³o¤£´N¬O»¡ , ¤G´ÁÁ{§ÉYÀø®Ä·¥¨Î ( À³»PFDA½Í§´ , Àø®Ä¦b¤@ÓªùÂe±ø¥ó¤§¤W ) , ´N¥i¥Ó½ÐÃÄÃÒ ? ªGY¦p¦¹ , ´N¬O¦n´Îªº³]p ¦ÓÃĮĩO ? ¤½¥qªºSNB01¬ãµo¶i«×»¡©ú , ¶È¶È´£¤Î§í¨î3CL Proªº¥\¯à ÁöµM§Ṳ́£ª¾SNB01¬O¦ó¤Æ¦Xª« , ¦ý®Ú¾Ú¤åÄm¨Ó²q´ú , ©Î¬°TAªºªñ¿Ë ¥H«e , §ÚÌ°Q½×¤FTA©M¥¦ªº¥NÁª«ªººØºØ¥\¯à ¥]¬A 1. ³æ¹ç»Ä¦Û¨¦³§í¨î3CL proªº¥\¯à------§í¨î½Æ»s ¦p¤½¥q¸ê®Æ©Ò¥Ü SNB01 : EC50 < 0.77£gM ; CC50 > 50£gM ; SI > 100 2. ¨S¹¤l»Ä§@¬°COVID-19 RNA¨Ì¿à©ÊRNA»E¦X酶 ( RdRp )¡]PDB ID 6M71¡^ªº§í¨î¾¯------§í¨î½Æ»s¡C www.researchsquare.com/article/rs-25850/v1 3. GA§í¨î¯f¬r½Æ»s©Î¶i¤J²ÓM link.springer.com/article/10.1007/s13337-020-00598-8 ¨S¹¤l»Ä¨ã¦³¹ïACE2¨üÅ骺ÅãµÛµ²¦X¿Ë©M¤O¡A¦]¦¹¥i¥Î©óACE2¤¶¾ÉªºSARS-CoV-2§í¨î DOI: 10.26434/chemrxiv.12325844 SARS-CoV-2 main protease ; SARS-CoV-2 receptor binding domain ; human furin protease ( the spike protein of SARS-CoV-2 ) These targets are chosen because of their role in the process of penetration of the virus into human cells and its multiplication. 4. ¾Ff¤T×ô ( PY ) ¬í±þ¯f¬r www.ncbi.nlm.nih.gov/pmc/articles/PMC7411974/ »P³æ¿W¨Ï¥Îªº¥ô¦ó¦¨¤À¤Æ¦Xª«¤£¦P,´I§t¾Ff¤T×ôªº(Fr 1C)§ó§Ö³t¡B§ó¦³®Ä¦a·À¬¡©Ò¦³¯f¬r¡C§Ú̵o²{,25£gg/mLªºFr 1C¦b10 ¬í¤º·À¬¡¤F> 99.6% ªºSARS-CoV-2 ( ´î¤Ö >= 2.33 log10 TCID50/mL)¡CFr 1C ¤¤Â_¯f¬r°ò¦]²Õ©M³J¥Õ½è¡C¨ä¤¤¬r±þ¯f¬rªºÃöÁ䤸¯À¬Ogalloyl groups ©M pyrogallol moieties 5. EA ´N¬O¶W±jªºCK2§í¨î¾¯ , ¬O¥ÍµØ¬ì°õ¦æªø¤f¤¤ªºCOVID-19ªºP©R®zÂI pubmed.ncbi.nlm.nih.gov/16610779/ Using a virtual screening approach, we have identified the ellagic acid, a naturally occurring tannic acid derivative, as a novel potent CK2 inhibitor. At present, ellagic acid represents the most potent known CK2 inhibitor (K(i) = 20 nM). ³Ìªñ , ¤pªº¤SŪ¨ì±ÀÂ˥͵جìCK2§í¨î¾¯ªº¾Ç³N³æ¦ì¼gªº½×¤å The Global Phosphorylation Landscape of SARS-CoV-2 Infection www.sciencedirect.com/science/article/pii/S0092867420308114?via%3Dihub#! ªí©ú We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies. We found pharmacological inhibitors of CK2, p38 MAPK signaling, PIKFYVE, and CDKs to possess strong antiviral efficacy. ³q¹L§Ç¦C¹w´ú¥i½Õ±±³o¨Ç¦ìÂIªº³»¯Å¿E酶®a±Ú¥]¬A¹T³J¥Õ¿E酶II¡]CK2¡^¡A²ÓM¶g´Á³J¥Õ¨Ì¿à©Ê¿E酶¡]CDK¡^©M³J¥Õ¿E酶C¡]PKC¡^µ¥¡]¹Ï2 C¡^¡A³oªí©ú³o¨Ç¿E酶¥i¯à¦³§U©ó¯f¬r½Æ»sªº½Õ±±¡C 6. §í¨îPKC : The effect of plant phenols on the expression and activity of phorbol ester-induced PKC in mouse epidermis. europepmc.org/article/med/17196728 ( ªþµù : ¦òªià¡]phorbol esters¡^¬O¤@Ãþ¯à«P¶i¸~½F¥Íªøªº¦³¾÷¤Æ¦Xª«¡A¦³®É·|³Q¨Ï¥Î¦b¥Íª«¾Ç¹êÅç·í¤¤¡A§@¬°¤G酰¥ÌªoªºÃþ¦üª«¡A¿E¬¡³J¥Õ¿E酶C¡]protein kinase c¡^) The most potent inhibitor of PKC translocation and activity was tannic acid. Tannic acid ( TA ) decreased the activities of all three PKC classes by approximately 94% in the membrane fraction in comparison with the TPA treated group of animals. 7. §í¨îp38 MAPK : 7-1 Pre-treatment with tannic acid inhibits the intracellular IL-8 production by chitosan in a human oral epithelial cancer cell line www.jstage.jst.go.jp/article/omp/13/4/13_4_135/_pdf These investigations showed the pre-treatment effects of TA on IL-8 production to be mainly mediated through the inhibition of the p38 MAPK pathways. 7-2 Tannic acid prevents macrophage-induced pro-fibrotic response in lung epithelial cells via suppressing TLR4-mediated macrophage polarization link.springer.com/article/10.1007/s00011-019-01282-4?shared-article-renderer TA pre-treated CM showed diminished activation of MAPK in epithelial cells. 7-3 Tannic acid protects against experimental acute lung injury through downregulation of TLR4 and MAPK ³æ¹ç»Ä³q¹L¤U½ÕTLR4©MMAPK¨¾¤î¹êÅç©Ê«æ©ÊªÍ·l¶Ë pubmed.ncbi.nlm.nih.gov/30246289/ In both preventive and therapeutic approaches, TA attenuated LPS-induced histopathological alterations, lipid peroxidation, lung permeability, infiltration of inflammatory cells, and the expression of proinflammatory mediators. In addition, in-vitro study showed that TA treatment could reduce the expression of proinflammatory mediators. Further studies revealed that TA-dampened inflammatory responses by downregulating the LPS-induced toll-like receptor 4 (TLR4) expression and inhibiting extracellular-signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) activation. 8. §í¨îCDKs : 8-1 Octyl gallate and gallic acid isolated from Terminalia bellarica regulates normal cell cycle in human breast cancer cell lines www.sciencedirect.com/science/article/abs/pii/S0753332217347455 Both OG & GA exhibited decreased MCF-7 & MDA-MB-231 survival and induced apoptosis, with IC50 value of OG and GA as 40 £gM and 80 £gM respectively. No toxic effect was observed on normal breast cells (MCF-10A). The compounds inhibited cell cycle progression by altering the expression of the cell cycle regulators (Cyclin D1, D3, CDK-4, CDK-6, p18 INK4, p21Waf-1 and p27 KIP). 8-2 Gallic acid causes inactivating phosphorylation of cdc25A/ cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells mct.aacrjournals.org/content/molcanther/5/12/3294.full.pdf gallic acid caused a decrease in CDK4, CDK6, and CDK2 protein albeit at different levels following different treatment times 8-3 Tannic acid inhibits the Jak2/STAT3 pathway and induces G1/S arrest and mitochondrial apoptosis in YD-38 gingival cancer cells www.spandidos-publications.com/10.3892/ijo.2015.3098 TA inhibited the expression of G1 phase modulators CDK-4, CDK-6, cyclin D1 and cyclin E. 8-4 Tannic acid-induced apoptosis in FaDu hypopharyngeal squamous cell carcinoma www.kijob.or.kr/journal/article.php?code=67417 The expressions of various cyclins, including cyclin D1 and cyclin-dependent kinases (CDK-1 and CDK-2), were down-regulated at low doses of TA, µY·ãº¡¥Øªº¥\¯à , ¼C«ü¤@ӥؼÐ---®ø·À¯f¬r©óµL§Î SNB01 Àø®Ä¬O§_·¥¨Î , ´£«e¥Ó½ÐÃÄÃÒ ??? ©ú¦~Q1¨£¯u³¹ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/6 ¤U¤È 07:41:11²Ä 1015 ½g¦^À³
|
¤½¥q·s»D½Zªº«GÂI ,¤pªº»{¬°¦b©ó¥O¤H´ÜÆgªºÁ{§É³]p©Mµ¦²¤ [[[ SNB011 Á{§É¸ÕÅç±Ä½Õ¾ã¦¡(adaptive)¤G/¤T´ÁÁ{§É³]p¡AÂùª¼¡BÀH¾÷¤À°t¡B¦w¼¢¾¯¹ï·Óªº¦h¤¤¤ß¬ã¨s¡A¥Dn¦¬®×±ø¥ó¬° PCR ½T¶E¥¼º¡ 48 ¤p®É¥B²Å¦X»´«×·s «a¯e¯f¯gª¬ªÌ¡C¥Dnµû¦ô«ü¼Ð¬° TTSCR (Time to Sustained Clinical Resolution)¡A§Y¹F¨ìÁ{§É½w¸Ñ©Ò»Ýnªº®É¶¡¡A¦¸n«ü¼Ð¥]¬A±Ä¼Ë¤§¯f¬r§t¶q¡CÁ{§É¸ÕÅç±N¤À¨â¶¥¬q¡A²Ä¤@¶¥¬q(§Y¤G´ÁÁ{§É) ³W¹º¦¬®× 90 ¤H . ]]] ¥Ø¼Ð«ü¦V»´¯g±wªÌ©Î°ª¦MÀô¹ÒªÌ , ©Î±ÄªvÀø»P¹w¨¾¨Ã« , Ãþ¦ü¤µ¤éªº§J¬y·P(Tamiflu) , ±N¥«³õ·¥¤j¤Æ [[[ ¦Ü©óªvÀø»´¯g¯f±w¤Î¹w¨¾¨ä¯f±¡¥[««h©|µL¨}¤è¡A«æ»Ý¦³®ÄÃĪ«¥H¾¨¦ªvÀø¡A´î¤Ö¯f±w´c¤Æ¦¨«¯g¤§¥i¯à¡A¨ÃªýÂ_°§C¶Ç¼½³t«×¡CÃþ¦P Pentarlandir(TM) ¨¾ªv·s«a¯e¯fªºµ¦²¤¡A¨Ï¥Î§J¬y·P(Tamiflu)¨¾ªv¬y·P¡AÀ³©ó¯gª¬¥X²{ 48 ¤p®É¤º¶i¦æªvÀø¡A¬Æ¦Ü¦b°ª¦MÀIªºÀô¹Ò¤U¹w¨¾©Ê¨Ï¥Î¡C ]]] ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GJY10150115 µoªí®É¶¡:2020/9/6 ¤U¤È 02:34:47²Ä 1014 ½g¦^À³
|
ÁÂÁ²q·Q¤j´£¨Ñ°T®§ òÏÃ¥´ «ùÄò«e¶i ¤£¿à |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/6 ¤U¤È 01:43:27²Ä 1013 ½g¦^À³
|
Cliff ¤j®¦¼w§i¶D¤pªº ¤½¥qªº©xºô¦³SNB01ªº¬ãµo¶i«×»¡©ú www.syneurx.com/2020/09/06/snb01/ ¦b¦¹·PÁ¤½¥q¹Î¶¤ªº§V¤O³Ð·s¬ãµo¥B§ïÅÜ·®æ , ´Á¬ßÃĮĨôµÛ³yºÖ¤HÃþ , ¨ÃÂÇ¥H´£¤É¤½¥qª¾¦W«× ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/6 ¤W¤È 08:54:51²Ä 1012 ½g¦^À³
|
¹ù¥SÁܬùŪ®Ñ·| liawbf.pixnet.net/blog/post/49497479 ÁÂÁ¹ù¥S¼ö±¡Á|¿ì ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/3 ¤U¤È 07:43:58²Ä 1011 ½g¦^À³
|
§ÚÌ«Ü®¥³ß¥ÍµØ¬ìÃĮĨôµÛ ÁöµM¤ß®®¤£¬O¥HªvÀøSARS-CoV-2¬°¥D¥´ , ¦ý¤ß®®ªºSNB1À³¸Ó¤]·|«Ü¤£¿ù ¤µ¤Ñ¬Ý¨ìÀô²y¥Í§Þªº³ø¾É É«IBM¶W¯Å¹q¸£! ¬ü¬ì¾Ç®aµo²{ ½w¿E肽·¼É¥i¯à¤~¬OCOVID-19µoª¢¥D¦] 2020.09.03Àô²y¥Í§ÞÂø»x/°OªÌ ´^±ê²[½sĶ www.gbimonthly.com/2020/09/78868/ ¥Ø«e³\¦hÃö©óCOVID-19ªº¬ã¨s³£¶°¤¤¦b²ÓM¿E¯À·¼É(cytokine storm)¤W¡A¤£¹LJacobson»{¬°¡A½w¿E肽¥i¯à¤~¬O¨Ï³\¦h¯f¬rµo¯fªºÃöÁä¡A¡¨½w¿E肽·¼É(bradykinin storm)¡¨¥i¥H¸ÑÄÀCOVID-19±wªÌ©Ò¸g¾úªº¦hºØ¯gª¬¡A¥]§t¡GªÍ³¡²§±`¿n²G¡B¦Ù¦×¯kµh¡B¯h³Ò¡Bäú¤ß¡B¹Ã¦R¡B¸¡Âm¡BÀYµh©M»{ª¾¥\¯à¤U°¡C Jacobson¤]ªí¥Ü¡A¨ÏCOVID-19´c¤Æ¥i¯à¬O½w¿E肽·¼É¦Ó¤£¬O²ÓM¦]¤l·¼É¡A¤£¹L²{¦b¦b±wªÌ¤¤Æ[¹î¨ìªº¡A¥i¯à¬O¨âªÌ¿ùºî½ÆÂø¤Þ°_ªº«áªG¡C TA ©M GA ³£¥i¥H´î°²ÓM¦]¤l , ¥i¯à¤]¥i¥H§í¨î½w¿E肽 ( bradykinin ) ? 1. Tannic acid modulates excitability of sensory neurons and nociceptive behavior and the Ionic mechanism ³æ¹ç»Ä½Õ¸`·Pı¯«¸g¤¸ªº¿³¾Ä©Ê©M¶Ë®`·P¨ü¦æ¬°¥H¤ÎÂ÷¤l¾÷¨î pubmed.ncbi.nlm.nih.gov/26134502/ ³æ¹ç»Ä¤j¤j´î»´¤F½w¿E肽»¤¾Éªº¤j¹«¯kµh¦æ¬°¡C³æ¹ç»Ä¥i¥Î©óªvÀøª¢¯g©Ê¯kµh¡A¨Ò¦p°©Ãö¸`ª¢¡A·Àã©ÊÃö¸`ª¢©M¿N¶Ë¯kµh¡C 2. Pharmacological effects of gallic acid in health and diseases: A mechanistic review europepmc.org/article/PMC/6528712 As shown in Figure 2, gallic acid can extinguish the flames of inflammation via different mechanisms. It decreases the expression and release of pro-inflammatory and inflammatory mediators, such as bradykinin ( ½w¿E肽 ) , substance P, COX-2, NF-£eB, IL-2, IL-4, IL-5, IFN-£^, and TNF-£\. The compound also inhibits the phagocyte- or polymorphonuclear (PMN)-mediated inflammatory responses by scavenging ROS and decreasing the myeloperoxidase (MPO) activity (69-73). 3. Inhibition of bradykinin by gallates ¨S¹¤l»Äà¹ï½w¿E肽ªº§í¨î§@¥Î pubmed.ncbi.nlm.nih.gov/5433993/ ¦Ó¥t½g¤å³¹«hÄÄzbradykinin ( ½w¿E肽 )©M AD ªºÃö«Y ½w¿E肽B1¨üÅé°Ñ»P¤p½¦½è²ÓM¿E¬¡¡GÅé¥~©MÅ餺¬ã¨s www.researchgate.net/publication/316436898_Involvement_of_the_Bradykinin_B1_Receptor_in_Microglial_Activation_In_Vitro_and_In_Vivo_Studies The importance of brain inflammation to Alzheimer¡¦s disease (AD) pathogenesis has been accepted of late, with it currently being held that brain inflammation aggravates AD pathology. One important aspect of brain inflammation is the recruitment and activation of microglia, a process termed microgliosis. Kinins and bradykinin (BK), in particular, are major pro-inflammatory mediators in the periphery, although all of the factors comprising the kinin system have also been described in the brain. Moreover, it was shown that the amyloid £] (A£]) peptide (a component of AD plaques) enhances kinin secretion and activates BK receptors that can, in turn, stimulate A£] production. ³o¦P®É¤]»¡©ú¤F SND-51 ªvÀø AD ªº¥tºØ¾÷¨î? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GYendis10145808 µoªí®É¶¡:2020/9/3 ¤U¤È 06:51:02²Ä 1010 ½g¦^À³
|
§O¤H¥i¯àÃÄÃÒ³£®³¨ì¤F¤ß悦ÁÙ¨S¦³nIND ¥ÍµØ¬ì (6492-TW) ¤µ (3) ¤éªí¥Ü¡AºX¤U³Qµø¬°ªvÀø·s«aªÍª¢¼ç¤O·sÃÄ Silmitasertib Àò¬ü°ê FDA ®Öãºò«æ¤HÅéÁ{§É¸ÕÅç«á¡Aº¦ì·s«aªÍª¢«¯g¨ü¸ÕªÌ¥ÎÃÄ²Ä 5 ¤Ñ«á¡A¨Å骬ªp©úÅã¦nÂà¡A¹wp©ú¤Ñ¥X°|¡C ¥ÍµØ¬ìªí¥Ü¡Aº¦ì¨ü¸ÕªÌ¬° 64 ·³¨k©Ê¡A¬ü°ê®É¶¡ 8 ¤ë 16 ¤éº«×½T¶E¡A8 ¤ë 20 ¤é¦í°|«á¶}©l±µ¨ü°ªÀ£®ñ®ðªvÀø¡A´Á¶¡±µ¨ü¹L 5 ºØÃĪ«ªvÀø¡A¥]¬A·ç¼w¦è³¡BÃþ©T¾J¦a¶ë¦ÌªQ¡B§Ü¥Í¯À Ceftriaxone¡B§Ü¥Í¯À Azithromycin ¤Î§Ü¾®¦å¾¯ Enoxaparin¡A¥Ñ©ó¯f±¡¥¼¦nÂà¡A¦b¨S¦³¨ä¥LÃĪ«¿ï¾Ü¤U¡A¨Ï¥Î¥ÍµØ¬ìªº Silmitasertib¡C ¥ÍµØ¬ì«ü¥X¡A¨ü¸ÕªÌ 8 ¤ë 29 ¤éº¦¸ªA¥Î Silmitasertib «á¡A@¨ü©Ê¨}¦n¥B¥i²æÂ÷®ñ®ð³]³Æ¡B¥¿±`¦Û¥D©I§l¡A¥ÎÃÄ²Ä 4 ¤Ñ®É¡AÁ{§É¥D«ùÂå®vµû¦ô¡A±wªÌ¤w¹F¥X°|¼Ð·Ç¡AªvÀø²Ä 5 ¤Ñ´X¥G§¹¥þ±d´_¡A¹wp¦b¬ü°ê®É¶¡ 9 ¤ë 3 ¤é¥X |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/3 ¤W¤È 10:30:02²Ä 1009 ½g¦^À³
|
¹ù¥S¥D°Ê¥XÀ» , ´Á¸ó¥X²Ä¤@¨B , ¬°¤ß®®¥´ÅT²Ä¤@¯¥ ! Åwªï°]¸g§ë¸ê¦³ÃöÂø»x/ºô¯¸ÁܽZ liawbf.pixnet.net/blog/post/49496021 ¦³½Ð¬ÛÃö¤H¤h±À¤¶ , ÁÂÁÂ! ¤]ÁÂÁ¹ù¥S¬°¤ß®®ªº¥I¥X ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/9/2 ¤W¤È 07:29:39²Ä 1008 ½g¦^À³
|
¥Í§Þ·~¯Ê¿ú °êµo°òª÷¡G§ä§Ú 04:102020/09/02 ¤u°Ó®É³ø Ĭ¨q¼z ¥Í§Þ·~¦pªG¨S±o¨ì´Iª¨ª¨«C·ý¡A©¹©¹¼µ¤£¨ì²{ª÷Âॿ¡A«Ü¥i¯à¿ú´N¿N§¹¤F¡A°êµo·|°Æ¥D©e¾GsZ1¤é»¨®ð¦aªí¥Ü¡A¥Í§Þ·~¸êª÷¤W¦p¦³°ÝÃD¡A¥L¥Nªí°êµo°òª÷¸ÛÀµÁܽФj®a¡u¨Ó§ä§ÚÌ¡v¡A¥L»¡¡u°êµo°òª÷¯Ê®×·½¡v¡A¡uÅwªï¤j®a¨Ó§ä§ÚÌ¡v¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/31 ¤U¤È 06:16:10²Ä 1007 ½g¦^À³
|
GSK3£] inhibition restores cortical gamma oscillation and cognitive behavior in a mouse model of NMDA receptor hypofunction relevant to schizophrenia www.nature.com/articles/s41386-020-00819-0 ¾Y¬°GSK3£]§í¨î¾¯ , ¨Ì·Ó³oÓ¬ã¨s , ¨ºf¥Ò»Ä¾Y·|¤£·|¤ñf¥Ò»Ä¶u§ó¦³Àø®Ä ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/31 ¤W¤È 09:55:42²Ä 1006 ½g¦^À³
|
¹ù¥S¬°·P©À¤j¶Õ¦ÜµÐÂĸt½Ï¤é , ¯S¶}©ñ¦n¤Í¤å³¹¤T¤Ñ¦Ü9/2 ½Ð¤j®a§â´¤¾÷·| ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/31 ¤W¤È 08:23:07²Ä 1005 ½g¦^À³
|
¥ÍµØ¬ìªº«°T ©Î³\¥i´£¨ÑSNB01°Ñ¦Ò ... 5.µo¥Í½t¥Ñ: (1)¬°´£¨Ñ·s«aªÍª¢±wªÌªvÀø¤è®×¡A¥ÍµØ¬ì¦X§@¹Ù¦ñ-¬ü°ê³ìªv¨È¦{¥ý¶i¬ã¨s©M±Ð¨|¤¤¤ßÂåÀø¾÷ºc(Center for Advanced Research & Education, Gainesville, Georgia)¤w¦V¬ü°ê¹«~ÃĪ«ºÊ·þºÞ²z§½FDA(U.S. Food and Drug Administration)¥Ó½Ð¥Ñ¬ã¨sªÌ¥D¾É(Investigator-Initiated Trial, IIT)ªº·s«aªÍª¢¤G´Á¤HÅéÁ{§É¸ÕÅç¡A¥ÍµØ¬ì·sÃÄSilmitasertib±N¦bÀò±o¬ü°êFDA®Öã«á±Û§YªvÀø·s«aªÍª¢±wªÌ¡C¸ÕÅç³W¹º¦p¤U¡G a.¦¬ªv¤H¼Æ: ³W¹º¥ý¦¬ªv10¦ì·s«aªÍª¢±wªÌ¡C b.µ¹ÃĤè®×: ¯f±w±N¥H¤fªA¤è¦¡¡A±µ¨ü14¤Ñªº¤@Ó§¹¾ãÀøµ{§Ç¡C (2)¥»¶µ·s«aªÍª¢¤G´Á¤HÅéÁ{§É¸ÕÅç¥ÑDr. Christopher P. Recknort³d¥D«ù¡A¦¹ÂåÀø¾÷ºc´¿¨ó§U¬ü°ê¤@®a¥Íª«§Þ³N¤½¥q§¹¦¨·s«aªÍª¢¤G´ÁÁ{§É¸ÕÅç¡A¦]¦¹¬ü°ê³ìªv¨È¦{¥ý¶i¬ã¨s©M±Ð¨|¤¤¤ßÂåÀø¾÷ºc¹ï©ó·s«a±wªÌ¦¬®×©M°õ¦æ¸ÕÅç¤w¦³Â×´I¸gÅç¡A¹w´Á¥i¥[³t§¹¦¨¥ÍµØ¬ìªvÀø·s«a±wªÌÁ{§É¸ÕÅç¡C¦pSilmitasertib¹ï·s«a±wªÌ¨ã¥¿¦VÀø®Ä¡A¥ÍµØ¬ì±N©M¬ü°êFDA°Q½×ª§¨úºò«æ¨Ï¥Î±ÂÅvEUA¡A¦P®É°Q½×¼Ï¯Ã©Ê¸ÕÅç³W¹º(Pivotal Trial)¡A´Á¯à¦¤é¨ú±oÃÄÃÒ¤W¥«¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/30 ¤U¤È 08:28:26²Ä 1004 ½g¦^À³
|
ªiÄõ¾ÇªÌÀ°§Ú̾ã²z¦³ÃöAD+BPSD¨Ì¾÷Âà¤ÀÃþªºÁ{§É·sÃÄ ¥¿©Ò¿×ª¾¤vª¾©¼¤] Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates www.ncbi.nlm.nih.gov/pmc/articles/PMC7048860/ ¨ä¤¤¦³Ãö SND-51ªº¤¶²Ð ¦C¦bDAAO§í¨î¾¯ D-®ò°ò»Ä®ñ¤Æ酶§í¨î¾¯ ¶¡±µ±±¨î¨¦®ò»Ä¯à¯«¸g¶Ç»¼ªº¤@ºØ¦³½ì¤èªk¬O§í¨îD-®ò°ò»Ä®ñ¤Æ酶¡]DAAO¡^ªº¬¡©Ê¡CD-®ò°ò»Ä®ñ¤Æ酶½Õ¸`¤j¸£¤¤D-®ò°ò»Äªº¤ô¥¡A¦b¬Y¨Çºë¯«¯e¯f¤¤¡ADAAOªº¬¡©Ê©Mªí¹F±o¨ì¼W±j[ 140 ]¡CDAAOªº¹L«×¬¡¤Æ°§C¤FNMDA¨üÅ骺¤º·½©Ê¿E°Ê¾¯d-µ·®ò»Äªº§Q¥Î²v¡CN-¥Ò°ò-D-¤Ñ¥V®ò»Ä¥\¯à»Ùê¤S»Pºë¯«¤Àµõ¯g©MAD¦³Ãö[ 141 ]¡Cd-®ò°ò»Ä®ñ¤Æ酶§í¨î¾¯³Qµo²{µo´§§Üºë¯«¯f¬¡©Ê©M§ïµ½»{ª¾¥\¯à¦bAD [ 142¡A143]¡C¥Ø«e¡ASyneuRx International Corp.¥¿¦b¶}µo¤@ºØÄvª§©ÊªºDAAO«ú§Ü¾¯¡A¤Æ¦Xª«SND-51¡A¥Î©óªvÀøè§b¯g©Mºë¯«¯f¡CSND-51°_·½©ó´Óª«¡]¤Æ¾Çµ²ºc©|¥¼¤½¶}¡^¡A¨Ã¥B¦b°Êª«¼Ò«¬¤¤¤Þµo§Üºë¯«¯f©M§ÜµJ¼{¬¡©Ê¡A¨Ã§ïµ½¤FªÅ¶¡°O¾Ð[ 144 ]¡CSND-51²{¦b¤w¸g¶i¤JII´ÁÁ{§É¸ÕÅç¡A¨Ã¥B¥¿¦bµû¦ô¨ä¦bè§b©Mºë¯«¯fªvÀø¤¤ªºÀø®Ä[ 145 ]¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2020/8/29 ¤U¤È 11:53:50²Ä 1003 ½g¦^À³
|
2020/8/4 ¦ó¤j¤@³Õ¤h»PôÛ¤ñ¨È¤j¾Ç¹Î¶¤µoªí§Ü·s«a¯f¬rÃĪ«ªº¤@½g³ø§i¡A¥Zµn¦bbioRxiv¡G ¡uLead compounds for the development of SARS-CoV-2 3CL protease inhibitors¡v ¡]www.biorxiv.org/content/10.1101/2020.08.03.235291v1.full¡^ ´£¨ì¤F¤TÓ¤p¤À¤l¬ãµo¤¤·sÃÄ¡Gcompound 4¡BGC376¡BMAC-5576¡A¸òSNB01¦P¼Ë¬O§@¥Î¦b¦P¤@Ó³J¥Õ酶¤W¡]SARS-CoV-2 3CL protease¡^¡C compound 4 EC50¡G3.023 ¡Ó 0.923 µM GC376 EC50¡G 4.481 ¡Ó 0.529 µM ¡]SNB01 EC50¡G¡H¡^ ¦ó¤j¤@±N§ÞÂ൹¤¤¸Îªº·sÃĽs¸¹¬O2-43¡A¬O¤@ºØ³æ®è§ÜÅé¡A¤À¤l¶q¤j«Ü¦h¡A·íµM¦¨¥»¡BÃÄ»ù³£·|¸û°ª¡A¥B¥²¶·±Ä¥Îª`®g¤è¦¡µ¹ÃÄ¡C¨Ì·Ó¦ó³Õ¤h8/27ªº»¡ªk¡A¸Õ¹L«Ü¦h¤£¦Pªº·s«a¯f¬r®è³£¦³®Ä¡A´Â¥u¥´¤@¾¯´N¦³®Äªº¤è¦V¬ãµo¡A¦Ó¥B¥i¥Î©óªvÀø»P¹w¨¾¡C¬ãµo¸ê®Æ¥Zµn©ó¤µ¦~¤C¤ëªºNature¤W¡A¦W®ð»·°ª©óbioRxiv¡C ¥Ø«e°ê»Ú¶¡¦³¦h®aª¾¦WÃļt¥¿´ÂµÛ¥H¦hºØ³æ®è§ÜÅéÃĪ«¨Ó¬ãµo§Ü·s«a¯f¬rÂû§À°sÀøªk¡C¡uRegeneron ¥¿¦b´ú¸Õ²V¦X¨âºØ§ÜÅ骺Âû§À°sÀøªk¡A¬Û«H¨âºØ§ÜÅé¤ñ¤@ºØ§ÜÅé§ó¯àªý¤î¯f¬r°k¶h¡A¬ã¨s¼Æ¾Ú±N¦b®L¥½©Î¬îªì¤½¥¬¡C°£¦¹¤§¥~¡A§¨Ó¡]Eli Lilly¡^¡Bªü´µ¯S±¶§Q±d¡]AstraZeneca¡^¡B¦w¶i¡]Amgen¡^¡B¸¯Äõ¯À¥v§J¡]GlaxoSmithKline¡^³£¦b¬ã¨s¦¹ºØÀøªk¡C¡v¡]technews.tw/2020/08/05/next-big-covid-19-treatment-may-be-manufactured-antibodies/¡^ ¥t¥~2020/7/17¦³¤@½g¨Ó¦Û¬ü°ê®aÂàĶ¬ì¾Ç«P¶i¤¤¤ß(The National Center for Advancing Translational Sciences, NCATS)ªº³ø§i¡A¹B¥Î°ª³q¶q¿z¿ï¤èªk§ä¥X¤@°ï¥i¯à¥i¥H§í¨îSARS-CoV-2 3CL proteaseªºÔ¿ïÃĪ«¡A ¡uIdentification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening¡v ¡]www.biorxiv.org/content/10.1101/2020.07.17.207019v2#disqus_thread¡^ Table 1¤ÎSupplementary Table 1ªþ¤F¦UÓ·sÃIJM·¡ªºIC50¡BEC50¤Î²ÓM¬r©Ê¥i¥H°Ñ¦Ò¡C³o¨Ç·sԿ令¤À¥¼¨Ó·|¤£·|¶i¤JÁ{§É©|¥¼¥iª¾¡C ¬ü°ê®aÂàĶ¬ì¾Ç«P¶i¤¤¤ßÁõÄÝ©ó¬ü°ê°ê¥ß½Ã¥Í¬ã¨s°|(National Institutes of Health, NIH)¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/29 ¤U¤È 03:49:20²Ä 1002 ½g¦^À³
|
¬Q¤Ñ´£¨ì¹v¦V¨x²ÓM¥Íªø¦]¤l¡]HGF¡^ªº NDX-1017 ALZFORUM §@³o¼Ëªº¤¶²Ð www.alzforum.org/therapeutics/ndx-1017 NDX-1017¬O¤@ºØ¥i¬ï³z¤j¸£ªº¤p¤À¤l¡A¥i³q¹L¨x²ÓM¥Íªø¦]¤l¡]HGF¡^/ MET¨üÅé¨t²Î¿E¬¡«H¸¹¶Ç¾É¡CHGF«P¶i¯«¸g¤¸ªº¼W´Þ©M¦s¬¡¡A¼W±j®ü°¨¬ðIJ¥i¶ì©Ê¡A¨Ã¼W±j¾Ç²ß©M°O¾Ð¡]Akimotoµ¥¡A2004¡FKatoµ¥¡A2012¡^¡CNDX-1017¥¿¦b¶}µo¬°¨C¤é¤@¦¸ªº¥Ö¤Uª`®g¡C NDX-1017±N©w¶q¸£¹q¹Ï¡]qEEG¡^©M¨Æ¥ó¬ÛÃö¹q¦ì¡]ERP¡^±¹¬Iµû¦ô¬°¸£³¡º¯³z©M¥Ø¼Ð°Ñ»Pªº«D«I¤J©Ê¼Ð»xª«¡C¸£¹q¹Ï¦÷°¨±j«×»P¾Ç²ß¡A°O¾Ð©M°õ¦æ¥\¯à¬ÛÃö¡A¦ÓERP P300©µ¿ð¬O»{ª¾³B²z³t«×ªº¼Ð»x¡C¦b±w¦³ADªº¤H¤¤¡A¦÷°¨¥\²v·|°§C¡AP300©µ¿ð·|©µªø¡C¦b¸Ó¸ÕÅ礤¡A¾Ú³ø¾ÉNDX-1017¦b°·±d¤H¤¤¤Þ°_¾¯¶q¬ÛÃöªº¦÷°¨¥\²v¼W¥[¡F¦bAD²Õ¤¤¡A¦h¦¸µ¹ÃÄ¥i§ïµ½£^¥\²v©Mp300©µ¿ð¡C¸Ó¸ÕÅ礣¥]¬A»{ª¾µû¦ô¡C ¦ÓGA¤]¥i¥H¼W±jªº HGF , ¦³¦ó¥\¯à? 1. ¨x²ÓM¥Íªø¦]¤l ( HGF ) ¥i¼W±j®ü°¨NMDA¹q¬y©M¬ðIJ¥i¶ì©Ê pubmed.ncbi.nlm.nih.gov/15450362/ ¥~¥ÎHGF¼W±j®ü°¨CA1°Ïªº¬ðIJªø´Á¼W±j¡]LTP¡^¡A¦ý¤£¼vÅTªø´Á§íÆ{¡C§Ú̶i¤@¨Bµo²{¡AHGF¦b¤Á¤ù©M¤ÀÂ÷ªº¯«¸g¤¸¤¤³£¼W¥[¤FN-¥Ò°ò-D-¤Ñ¥V®ò»Ä¨üÅ餶¾Éªº¹q¬y¡C³oºØ¼W±j«Ü¥i¯à¬OLTP¼W±jªº°ò¦¡C 2. ¯«¸g¨t²Î¤¤¨x²ÓM¥Íªø¦]¤lªº¹Lªí¹F¼W±j¤p¹«ªº¾Ç²ß©M°O¾Ð¯à¤O pubmed.ncbi.nlm.nih.gov/22535512/ ³o¨Çµ²ªGªí©ú¡AHGFªº¹Lªí¹F¾ÉPµu´Á©Mªø´Á°O¾Ðªº¼W±j¡CWestern¦L¸ñ¤ÀªRÅã¥Ü¡A»P³¥¥Í«¬¹ï·Ó¬Û¤ñ¡AHGF-Tg¤p¹«®ü°¨¤¤N-¥Ò°ò-D-¤Ñ¥V®ò»Ä¡]NMDA¡^¨üÅé¨È°òNR2A©MNR2Bªº¤ô¥¤É°ª¡A¦ýNR1¨S¦³¤É°ª¡Aªí©úNR2A©MNR2Aªº¤W½ÕNR2B¥i¯à¥NªíHGF¼W±j¾Ç²ß©M°O¾Ðªí²{ªº¤@ºØ¾÷¨î¡C³o¨Çµ²ªGªí©ú¡A¾Ç²ß©M°O¾Ð¥\¯àªº½Õ¸`¬OHGFªº«n¥Í²z¥\¯à¡A¦³§U©ó¥¿±`ªºCNS¥i¶ì©Ê¡A§ÚÌ´£¥XHGF§@¬°°ª¸£¥\¯àªº·s«¬½Õ¸`¾¯¡C 3. ¶WÁn¤¶¾ÉªºHGF°ò¦]Âಾ¦b¤p¹«¼Ò«¬¤¤½w¸ÑAbeta»¤¾Éªº»{ª¾»Ùê pubmed.ncbi.nlm.nih.gov/18288214/ ¨x²ÓM¥Íªø¦]¤l¡]HGF¡^¬O¿W¯Sªº¦h¥\¯à¥Íªø¦]¤l¡A¨ã¦³µo´§¯«¸gÀç¾i§@¥Î©M»¤¾É¦åºÞ¥Í¦¨ªº¼ç¦b§@¥Î¡C¦b³o¶µ¬ã¨s¤¤¡A§Ú̦bµù¤JAbetaªº»{ª¾¥\¯à»Ùê¤p¹«¼Ò«¬¤¤¡A¨Ï¥Î¶WÁn¤¶¾Éªº°ò¦]Âಾ¨ì¤j¸£¤¤¡A¬ã¨s¤F¤HÃþHGF½è²ÉDNA¹Lªí¹Fªº¼vÅT¡C§ÚÌÃÒ©ú¦b¦æ¬°´ú¸Õ¤¤¡AHGF°ò¦]Âಾ¥iÅãµÛ´î»´¤p¹«¤¤Abeta»¤¾Éªº»{ª¾»Ùê¡CHGFªº³o¨Ç¦³¯q§@¥Î¥i¯à¬O¥Ñ©ó¡]1¡^®ü°¨¾¦ª¬¦^¤¤¦åºÞ±K«×ªºÅãµÛ«ì´_¡A¡]2¡^BDNF¤W½Õ¡A¡]3¡^®ñ¤ÆÀ³¿EÅãµÛ°§C©M¡]4¡^¬ðIJ¼W±j¡C¥]¬A°ò¦]ªvÀø¥H¼W¥[HGF¤ô¥ªºÃĪ«ªvÀø¤èªk»P§ÜAbetaªvÀø¬Ûµ²¦X¥i¯à¬OªvÀøADªº·sªvÀø¿ï¾Ü¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/28 ¤W¤È 10:57:57²Ä 1001 ½g¦^À³
|
·s¾U¤½¥q¤½§GIPOp¹º¥þ·s«ä¸ô¬D¾Ôªüº¸¯ý®üÀq¯f¯à§_¦¨¥\¡H ¨Ó·½¡G ³ÐŲ¶×¡@2020-08-28 med.sina.com/article_detail_100_1_88104.html Athira¤½¥q«h±Ä¥Î¤F¤@ºØ¤£¦Pªºµ¦²¤¡A¥L̤O¹Ï³q¹L¿E¬¡ÃöÁä©Ê¤j¸£¯«¸gÀç¾i¦]¤l¡A«ì´_¥á¥¢ªº¯«¸g³s±µ¡A©ÎªÌ²£¥Í·sªº¯«¸g³s±µ¡A¥H¦¹¨Ó¥Ã¤[§ïÅܯe¯fªº¶iµ{¡CAthira¤½¥q¥D¥´ªºÔ¿ïÃĪ«NDX-1017¯à¹v¦V¨x²ÓM¥Íªø¦]¤l¡]HGF¡^»P¨ä¨üÅéMET¡A«P¶i¯«¸g¤¸ªº¼W´Þ©M¥Í¦s¡A¸Ñ¨M¯«¸g°h¦æ©Ê¯fÅܹLµ{ªº¼ç¦b¾÷¨î¡A±q¦Ó§ïµ½¤j¸£¯«¸g²ÓM¤§¶¡ªº³s±µ¡C¦bAthira¤½¥qªºIb´ÁÁ{§É¸ÕÅ礤NDX-1017¤]®i¥Ü¿n·¥ªºÀø®Ä¯S¼x¡C Athira¡¦s lead drug, coded NDX-1017, activates a key neurotrophic pathway in the brain, the hepatocyte growth factor (HGF). ¨Æ¹ê¤W , GA ¤]¥i¥H¼W±j HGF ¤Þ¾Úªº¨Ó·½ , ¬O¤é¤H¦b2001¦~¥Ó½Ð±M§Qªº¸ÕÅçµ²ªG patentimages.storage.googleapis.com/9a/11/6f/477b865396febc/EP1283037A1.pdf Example 3 : Enhancing Activity for HGF Production of Gallic Acid [0072] The enhancing activity for HGF production of gallic acid was assayed in the same manner as in Example 1. Here, gallic acid was added so as to have a final concentration of 0, 1, 10 or 100 µM. The results are shown in Table 3. As shown in Table 3, gallic acid enhanced HGF production. ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/28 ¤W¤È 08:02:59²Ä 1000 ½g¦^À³
|
¤¤¸Î°_º¦¦Ü¤µ¤w¶W¹L50% , Genetºô¯¸À°§Ú̾ã²zªk»¡·|ªºnÂI , ¥i¥H´£¨Ñ¤j®a°Ñ¦Ò www.genetinfo.com/investment/featured/item/41160.html www.genetinfo.com/investment/featured/item/41161.html |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/26 ¤U¤È 12:22:32²Ä 999 ½g¦^À³
|
ªüº¸¯ý®üÀq¯g¦b¬ãÃĪ«½LÂI¡G±q§Ü£]¾ý¯»¼Ë³J¥Õ¨ì°ò¦]Àøªk¡I ¨Ó·½¡G·s®öÂåÃÄ·s»D¡@2020-08-26 ½sĶ| newborn med.sina.com/article_detail_103_2_87973.html ªüº¸¯ý®üÀq¤ó¯gÃĪ«µo²{°òª÷·|½T«H¡AªvÀøADªºµª®×¦b©óÁp¦X¨Ï¥Î¦hºØÃĪ«¡A©Î¬O¦b¤@Ó¤À¤l¤¤¨ã¦³¦hºØ§@¥ÎªºÃĪ«¡C³o¤Ï¬M¥XAD¬O¤@ºØ·¥¨ä½ÆÂøªº¯e¯f¡A¦³¦hºØ¯f¦]©M¯f²z¾Ç¡C . ¾ý¯»¼Ë³J¥Õ¹vÂI . tau¹vÂI . ¯«¸g«OÅ@¾¯ . §Üª¢ . ¥NÁ³~®| ¤@¨Ç¬ã¨s¤Hû»{¬°AD¥i¥H³QºÙ¬°¡§3«¬¿}§¿¯f¡¨¡A¦]¬°¦³¨Ç§Î¦¡ªºAD¦ü¥G»P¯Ø®q¯À©è§Ü¦³Ãö¡A¯Ø®q¯À©è§Ü¬O2«¬¿}§¿¯fªº¥Dn°ÝÃD¡C2«¬¿}§¿¯f±wªÌ¦ü¥G§ó®e©ö±w¤W¦Ñ¦~è§b¯g©Î¦åºÞ©Êè§b¯g¡C . ·F²ÓM©M°ò¦]Àøªk SND-51 ¦³¦h¤Ö§@¥Î³~®| ? |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/25 ¤U¤È 04:01:42²Ä 998 ½g¦^À³
|
½²±Ð±Â¿ï¥ÎSND-51 ¨Ó°µ¬°ªvÀø AD+BPSDªº¸ÕÅçÃĪ« , ¥²¦³¨ä®Ú¾Ú ±M§Q¤å¥ó¤º®e¦³«Ü¦hȱo¸Ô¾\±o¦a¤è ( patentscope.wipo.int/search/en/detail.jsf?docId=US214328240&tab=PCTDESCRIPTION&_cid=P10-KE9NKY-29276-6 ) ¥H«e , §Ú̽ͤF«Ü¦h³æ¹ç»Ä¦b¹«Åé¤WªvÀøADªº¬ã¨sµ²ªG °ß¹ï BPSD «h¤Ö´£¤Î ¹ù¥S¹ï¦¹µÛ¾¥¤£¤Ö , ¤j®a¥i«e©¹«·Å½Æ²ß liawbf.pixnet.net/blog/category/2061906 ¤£¹L , ¹ù¥Sªº¦h½g¤j¤å³£¬O¦n¤Í©w , «D¦n¤Íªº¤j¤j®£µLªkªY½à ¤µ¤é , ¤pªº§ä¤F¦h½g¤å³¹ , ¸Õ¹Ï²Ê²¤¦a¬ïÆwªþ·|SND-51¹ïªvBPSDªº¥i¯à®ÄªG ¦ý¥H¤pªºª¾ÃѤô¥ , ®£©È·|¦]¤Þµo¾÷¨îªº¤£¦P¦Ó¦³±i«a§õÀ¹¤§¼{ , ¦³½Ð¤j®a¤£§[«ü¥¿ÀË°Q ¶À¥¿¥Âå®v ¹ïBPSDªº¤¶²Ð ¥¢´¼¯g¤§¦æ¬°ºë¯«¯gª¬ ( Behavioral and Psychological Symptoms of Dementia , BPSD ) : www.sop.org.tw/sop_journal/Upload_files/20_1/02.pdf «D»{ª¾¯gª¬¥]¬A¤F¼~Æ{¡BµJ¼{¡B¦k·Q¡B¤Ûı¡B¦æ¬°»Ùê¤Î¨ä¥Lºë¯«¯f¯gª¬¡A¥H«eºÙ¤§¬°¦æ¬°»Ùê [4]¡A¦]¬°¤£¯à¥]²[¾ãÅéºë¯«¯gª¬¡A¬G°ê»Ú¦Ñ¦~ºë¯«Âå¾Ç·| ¡]International Psychogeriatric Association¡A ²ºÙIPA¡^¦b 2000 ¦~¤w§â¥¦§ïºÙ¬°¦æ¬°ºë¯«¯gª¬¡]Behavioral and Psychological Symptoms of Dementia¡A²ºÙ BPSD¡^[5]¡A¬G±Ä¥Î BPSD ¨Ó¥Nªí¥¢´¼¯g¤§«D»{ª¾¯gª¬¡C . AD ¦ñÀH¼~Æ{¯gªºµo¥ÍÀW²v¦U®a³ø§i¬Û·í¤Àª[¡A¤@¯ë¦Ó¨¥¦b 40-50% ¤§¶¡ . ¤@¯ë¦Ó¨¥¡AAD ¦k·Q¯gª¬¥X²{ÀW²v¤j¬ù¦b 10-70%¤§¶¡¡A¥§¡¤¶©ó 30-38%¥ª¥k . ¿ù»{µo¥Íªº¤ñ¨Ò¦b 30-55%¤§ ¶¡ . ¦b°ê¥~ªº³ø§iÅã¥Üªü¤ó±wªÌ¦³ 7-49%¥X²{¤Ûı¡A¨ä¤¤¥Hµø¤Ûı³Ì¬°±`¨£¡A¨ä¦¸¬°Å¥¤Ûı . ¤j¬ù 80% ªº¥¢´¼¯g±wªÌ¨ã¦³¤@ºØ¥H¤W¤§¦æ¬°»Ùê¡A¥BÀHµÛ¥¢´¼¯g¤§¯fµ{·UÄY«¡A¨ä¥X²{¦æ¬°»Ùꤧ¼Æ¶q¤]·U¦h . ¦æ¬°»Ùê¥]¬A¿Eļ¦æ¬°¡B§ðÀ»¦æ¬°¡Bº© ¹C¡B¶¼¹§ïÅÜ¡BºÎ¯v»Ùê¡B¥¢¸T¦æ¬°¡B³g¹¦æ¬°¡B«ÂЦ欰¡B©Ç²§¦æ¬°¡B¼É¤O¦æ¬°¡BÓ¤H½Ã¥ÍÅÜ®t¦æ¬°¡B¤£«ê·íªº©Ê¦æ¬°µ¥. . ¤é¸¨¯gÔ¸s(Sundowning or Sundown syndrome)¡G ³Ìªñ¦³¨Ç¾ÇªÌ§â¤é¸¨¯gÔ¸s·í°µ¥t¤@ºØ BPSD¡A¥LÌ©w¸q¦¹¯gª¬¬°¦b¤U¤È¨ì¶À©ü¡A¤j¬ù±q 3 pm ¨ì 11 pm ¥X²{ªººë¯«²V¶Ã¤Î¿Eļ¦æ¬°³£ºÙ¤§¿×¤é¸¨¯gÔ¸s¡C ¦Óµû¦ôBPSD ©Ò¥Îªº¶qªí¦³ BEHAVE-AD ©Î NPI BEHAVE-AD ¶qªí¤À¬° 7 ¤jÃþ , ¥]¬A : 1. ¦k·Q 2. ¤Ûı 3. ¬¡°Ê»Ùê 4. ¼É¤O¶É¦V 5. ¤é©]¸`«ß»Ùê 6. ±¡·P»Ùê(¼~Æ{) 7. µJ¼{©M®£·W º¥ý , ½Ð¤j®a¥ý¬Ý¤@½g¤å³¹ ³B²zè§b¯gªº¦æ¬°©M¤ß²z¯gª¬ªº³Ì¨Î¹ê½î www.ncbi.nlm.nih.gov/pmc/articles/PMC5518961/ BPSD¯f¦]ªº¥Íª«¾ÇÆ[ÂI : . ¤w¸gµo²{¯«¸g¶Ç»¼©M¯«¸g½Õ¸`ªºÅܤƻPBPSD¬ÛÃö¡C¦bAD¤¤¡AÃB¸©Mù®¥Ö½èªºÁxÆP¯à¬¡°Ê ( cholinergic activity ) ªº§ïÅÜ¥i¯à»P²§±`ªº¹B°Ê¬¡°Ê©M§ðÀ»©Ê¦æ¬°¦³Ãö¡C ( ªþµù : Cholinergic deficits contribute to behavioral disturbance in patients with dementia pubmed.ncbi.nlm.nih.gov/11094098/ Clinical trial data indicate that cholinomimetics improve noncognitive behaviors. »P¹ï·Ó²Õ¬Û¤ñ¡AAD¤¤ChAT¬¡©Ê°§C¡A¦ý¨S¦³¨ä¥L¯«¸g¤Æ¾Ç¼Ð»xª«°§C¡CChAT¬¡©Êªº³à¥¢»P»{ª¾»Ùê¬ÛÃö¡CChAT¬¡©Ê°§CÁÙ»PÃB¸¥Ö½è©Mù®¸¥Ö½èè§b±wªÌªº¹L«×¬¡°Ê¼W¥[¬ÛÃö ) . ¦bDLB ( ¸ô©öÅéè§b ) ¤Ûµø¦ü¥G»Pù®¸¥Ö¼hÁxÆP¯à¤£¨¬ ( cholinergic deficits ) ±¾¹_¡C . ¦bAD¤¤¡A¾Ú³ø¾É«I²¤»Pù®¸¥Ö½è¤¤¦h¤ÚÓi¿@«×°§C¦³Ãö¡C . §Nºz»PAD¦h¤ÚÓi¯à¥\¯à»Ùê¬ÛÃö¡C §Nºz¬O¯«¸g°h¦æ©Ê¯e¯f±wªÌªº¯S¼x»P¤@©wµ{«×ªº¦h¤ÚÓi¯à¯«¸g¤¸¥á¥¢¬ÛÃö¡C . ¦bADÄY«¨¦®ò»Ä·l¥¢ ( Severe glutamate loss ) ¥i¯à¾ÉPºë¯«¯f¯gª¬¡C . ¦bÄY«AD¤¤µo²{ÃB¸©Mù®¥Ö½èªºGABAÅãµÛ°§C¥H¤Î°ªªºGABA¦å¼ß¿@«×¡A³o»P§íÆ{©M§Nºz¦³Ãö¡C . ÁxÆP酶§í¨î¾¯¥i§ïµ½»´«×¦Ü¤¤«×è§b¯gªº±¡·P¯S¼x¡CÁxÆP酶§í¨î¾¯©M¬üª÷è¥i¥H¦³®ÄªvÀøBPSD¡C ¥t¥~ , ¤p§Ì§ä¨ìªvÀøªº¬ÛÃö¤å³¹¦p¤U , ½Ð¤j®a¦Û¦æ¹ï·Ó³s±µ 1. §Ü¼~Æ{ Antidepressant Effect and Modulation of the Redox System Mediated by Tannic Acid on Lipopolysaccharide-Induced Depressive and Inflammatory Changes in Mice ³æ¹ç»Ä¤¶¾Éªº®ñ¤ÆÁÙì¨t²Îªº§Ü§íÆ{§@¥Î¤Î¨ä¹ï¯×¦hÁÞ»¤¾Éªº¤p¹«§íÆ{©Mª¢¯gÅܤƪº½Õ¸`§@¥Î link.springer.com/article/10.1007/s11064-020-03064-5 TA¦b³oºØ«æ©Ê§íÆ{¼Ë¦æ¬°°Êª«¼Ò«¬¤¤Åã¥Ü¥X³\¦h¯«¸g«OÅ@¯S©Ê¡A¨Ã¨ã¦³§Ü®ñ¤Æ¡A§Üª¢©M§Ü§íÆ{§@¥Î¡C¦]¦¹¡A¸Ó¤Æ¦Xª«¥i¬°§íÆ{¯gªºªvÀø´£¨Ñ¥t¤@ºØªvÀø¤èªk¡C 2. §ÜµJ¼{ Effect of gallic acid on chronic restraint stress-induced anxiety and memory loss in male BALB/c mice ¨S¹¤l»Ä¹ï¶¯©ÊBALB / c¤p¹«ºC©Ê§ô¿£À³¿E¤Þ°_ªºµJ¼{©M°O¾Ð³à¥¢ªº¼vÅT www.ncbi.nlm.nih.gov/pmc/articles/PMC6312671/ GA¹ïÀ³¿E¤Þ°_ªº±¡ºü©M°O¾Ð»Ù꦳«OÅ@§@¥Î¡C 3. ¨¾¤î»{ª¾»Ùê¨Ã§ÜPSAPP¤p¹«ªº¦æ¬°»Ùê( behavioral impairment ) ©MAD¼Ë¯fª¬ Tannic Acid Is a Natural £]-Secretase Inhibitor That Prevents Cognitive Impairment and Mitigates Alzheimer-like Pathology in Transgenic Mice ³æ¹ç»Ä¬O¤@ºØ¤ÑµMªº£]-¤Àªc酶§í»s¾¯¡A¥i¨¾¤î»{ª¾»Ùê¨Ã´î»´Âà°ò¦]¤p¹«ªºªüº¸¯ý®üÀq¤ó¯g¼Ë¯fª¬ www.ncbi.nlm.nih.gov/pmc/articles/PMC3307267/ §Ú̪º¼Æ¾Úªí©ú¡A´Óª«¨Ó·½ªº¦h×ôTA¹ï§ÜPSAPP¤p¹«ªº¦æ¬°»Ùê( behavioral impairment ) ©MAD¼Ë¯fª¬¡C³o¨Ç¦³¯q§@¥Î³q¹L´î¤Ö¥H¤U¤è±¦Óµo¥Í¡G¸£A£]¯f²z¾Ç¡A£]-CTFªºµõ¸Ñ¡AsAPP-£]¡ABACE1³J¥Õªí¹F©M¬¡©Ê¥H¤Î¯«¸gª¢¯g¡C¦pªG³o¨ÇÂà°ò¦]¼Ò«¬¤¤ªºA£]¯f²z¾Ç¥NªíÁ{§Éºî¦X¼x¡A¨º»ò§Ú̪º¼Æ¾Ú´N¼W¥[¤F¸É¥RTA¶¼¹¥i¯à¥Nªí¼ç¦bªº¦w¥þ¦³®ÄªºAD¹w¨¾ªº¥i¯à©Ê¡C 4. GAªº§Ü§íÆ{©MµJ¼{ Histopathological Analysis from Gallic Acid Administration on Hippocampal Cell Density, Depression, and Anxiety Related Behaviors in A Trimethyltin Intoxication Model. ¨S¹¤l»ÄºÞ²z¹ï¤T¥Ò°ò¿ü¤¤¬r¼Ò«¬¤¤®ü°¨²ÓM±K«×¡A§íÆ{©MµJ¼{¬ÛÃö¦æ¬°ªº²Õ´¯f²z¾Ç¤ÀªR¡C europepmc.org/article/med/26862525 µ²ªG¡GGAªº¨Ï¥Î´î»´¤F¦æ¬°´ú¸Õ¤¤ªºµJ¼{©M§íÆ{±¡ºü¡CGA³B²z¤j¹«ªºCA1¡ACA2¡ACA3©MDG®ü°¨°Ïªº²ÓM±K«×°ª©ó¥Í²zÆQ¤ô³B²zªº¤j¹«¡Cµ²½×¡GGA¹ïTMT©ÒP®ü°¨ÅܩʪºªvÀø§ïÅܤF®ü°¨²ÓMªº¥á¥¢¨Ã§ïµ½¤F§íÆ{µJ¼{ª¬ºA¡C 5.§Üºë¯«¤Àµõ¯g(1)¥¿©Ê¯gª¬¡G¦k·Q¡B¤Ûı¡B»yµLÛ¦¸¡B ¤Ï±`ªº¦æ¬°¡B¿E°Ê¤£¦w¡C (2)t©Ê¯gª¬¡G¯Ê¤Ö·P±¡¡BµLªk»¡¸Ü¡B¯Ê¤Ö·F«l¡B ¹ï©ó¦³½ìªº¬¡°Ê¨S¦³´r®®·P¡B°Ê§@½wºC¡C Protective effect of gallic acid in experimental model of ketamine-induced psychosis: possible behaviour, biochemical, neurochemical and cellular alterations ¨S¹¤l»Ä¦b´âÓi଻¤µoªººë¯«¯f¹êÅç¼Ò«¬¤¤ªº«OÅ@§@¥Î¡G¥i¯àªº¦æ¬°¡A¥Í¤Æ¡A¯«¸g¤Æ¾Ç©M²ÓM§ïÅÜ link.springer.com/article/10.1007/s10787-017-0366-8?shared-article-renderer . ¨S¹¤l»Ä¥i´î¤Ö¯×½è¹L®ñ¤Æ¨Ã«ì´_Á`¸£³J¥Õ¡C¦¹¥~¡A¨S¹¤l»ÄÅãµÛ°§C¤F¤p¹«¤¤ªº¦h¤ÚÓi¤ô¥¡AAChE¬¡©Ê©Mª¢©Ê¿E¼W¡]¦å²MTNF-£\¡^¡A¨Ã¼W¥[¤FGABAªº¤ô¥©M¼W¥[ªº½\¯Ö¥Ì肽¡C¬ã¨sªí©ú¡A¨S¹¤l»Ä¥i¥H§ïµ½¤p¹«ªººë¯«¯f¯gª¬©M¥Í¤ÆÅܤơAªí©ú¹ïºë¯«¯f¨ã¦³«OÅ@§@¥Î¡C . NMDA¨üÅé³q¹L¼W¥[GABAÄÀ©ñ¹ï¦h¤ÚÓi¯«¸g¶Ç»¼¦³§í¨î©Ê±±¨î;¦]¦¹,NMDA¨üÅé(NMDARS)¥\¯à¤£¥¿±`¬O³y¦¨¦h¤ÚÓi¬¡©Êªº²§±`(Kumarµ¥¤H,2017¦~)¡C«eÃB¥Ö¼h©MÃä½t¨t²Îªº¦h¤ÚÓi¥\¯à»Ùê¦bºë¯«¯f¤¤°_µÛ«n§@¥Î . GA³Qµo²{¬O¦³®Äªº§Ü´âÓi଻¤µoªººë¯«¯f¯g¥¿©Ê¯gª¬,¦]¬°¥¦¾¯¶q¨Ì¿à¦a´î®zlocomotors activity¡C¤Wzµ²ªGÁÙ±o¨ì¥Í¤Æªº¤ä´©,¨ä¤¤´âÓiର§CGABA¤ô·Ç,¼W¥[¦h¤ÚÓi¤ô·Ç,³o³QGAªvÀø°fÂà¡C . ´âÓiଵ¹ÃĦb±j¨î´åªa´ú¸Õ¤¤¼W¥[¤F¤£°Ê´Á ( immobility period ) ,³oªí©ú¬Oºë¯«¯f¯gªºt©Ê¯gª¬¡C¥»¬ã¨s»{¬°,ªø´Áµ¹ÃÄGA¯à¦³®Ä´î¤Ö¤p¹«ªº¤£°Ê´Á¡C . ¦¹¥~,¦b¥Í¤Æ¬ã¨s¤¤,´âÓiାÉP¤A酰ÁxÆP酶¬¡©ÊÅãµÛ¼W¥[,ªø´ÁGAªvÀø°§C¤F¸Ó¬¡©Ê,±q¦ÓÅã¥Ü¥X¾Ç²ß©M°O¾Ð¹Lµ{ªº¼W±j¡C¡C³o¨Çµ²ªGI«áªº°²³]¾÷¨î¥i¯à¬OGA¦³®Ä´î¤Ö¹ï¤AñQÁxÆP酶¬¡©Êªº¼vÅT,¾ÉP¬ðIJ¤AñQÁxÆPªº¿é¤J¼W¥[,±q¦Ó¶i¤@¨B¼W¥[¨¦¯Ö¥Ì肽¯«¸g¶Ç»¼©M¼W±jNMDAR¥\¯à¡C 6.§ÜÁxÆP酶©M¿}§¿¯f ³æ¹ç»Ä§@¬°¤ÑµM§Ü®ñ¤Æ¾¯¡Gµo²{¬O¦³®Äªº¥NÁÂ酶§í¨î¾¯¡A¥Î©ó¿}§¿¯f©Mªüº¸¯ý®üÀq¤ó¯fªº·sªvÀø¤èªk pubmed.ncbi.nlm.nih.gov/30974029/ ¦b³o¶µ¬ã¨s¤¤¡A³æ¹ç»Ä¤Æ¦Xª«¹ï¤A酰ÁxÆP酶¡]AChE¡^¡A£\-¿}苷酶¡A£\-¾ý¯»酶©M¤B酰ÁxÆP酶¡]BChE¡^ªí²{¥XÀu²§ªº§í¨î§@¥Î¡C ±M§Q¤å¥ó§i¶D§ÚÌ , TA¬ODAAO§í¨î¾¯ patentscope.wipo.int/search/en/detail.jsf?docId=US214328240&tab=PCTDESCRIPTION&_cid=P10-KE9NKY-29276-6 ¹ù¥S¥H«eÀ°§Ṳ́¶²Ðªº¤@¨t¦C¦³ÃöBPSDªº¤å³¹ , ¤]´£¤Î GA ¤]¬ODAAO§í¨î¾¯ , ¨Ã¥H¾¯¶q¨Ì¿à¤è¦¡´£°ª°O¾Ð¤Î»{ª¾ ¦P®ÉGA ¥i¥Ñ TA¥NÁ¦ӱo ³o¤]´N¥O¤H¦³²q´ú·Q¹³ªÅ¶¡ TAªºG ( galloyl moieties ) ¶V¦h , ©Î³\¥NÁ¦¨GAªº¿@«×¤]´N¶V°ª , ©Ò¥HÀø®Ä¤]´N¶V¦n ? ¬O§_´N¬O³oÓ¹D²z©O? ±q¤£¦Pªº¤Þµo¾÷¨î©Ò°µªº¹«Åé¬ã¨s , ¤£ª¾¬O§_¯à»P¤ÞP BPSDªº¥Íª«¾Ç¹B§@¦³©Ò³sµ² ? ´Á«Ý SND-51ªº¤G´ÁÁ{§É»°§Ö¶i¦æ , ¬Ý¯à¤£¯à½Æ»s¹«Å骺¬ÛÃö¬ã¨s «¢! ·íµM§ó§Æ±æ¯à°µÓ¶W¦³Àø®Äªº¹Ú , ¬Ý¯à¤£¯à¦A®³ÓAD+BPSD »â°ìªºBTD ©MÃÄÃÒ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/25 ¤W¤È 10:08:41²Ä 997 ½g¦^À³
|
º¦¸½T»{¡I±d´_ªÌ¥i¦A¦¸·P¬V·s«a¯f¬r §K¬Ì¤OÁٯണ¨Ñ«OÅ@¶Ü¡H ¨Ó·½¡GÃÄ©ú±d¼w¡@2020-08-25 med.sina.com/article_detail_103_2_87901.html ³o¦¸¡A»´ä¤j¾Çªº¬ã¨s¤Hû³q¹L¹ï±wªÌ¨â¦¸·P¬V«áÀò±oªº¼Ë¥»¶i¦æ°ò¦]²Õ´ú§Ç¡Aµo²{¤F¨â¦¸·P¬Vªº·s«a¯f¬r®è¦b°ò¦]²Õºc¦¨¤W¦³ÅãµÛ°Ï§O¡A±q¦Ó½T»{¤F³o¤@±wªÌ¨ü¨ì¤F·sªº¯f¬r®èªº·P¬V¡C ·s«a¯f¬r·P¬V¨ì©³¯à°÷¬°¨¾¤î¦A«×·P¬V´£¨Ñ¦hªø®É¶¡ªº«OÅ@¤´µM»Ýn¹ï§ó¦h±wªÌªº°l踪¬ã¨s¡C ¦]¦¹³o¤@«½Æ·P¬V¯f¨Ò¡A¨Ã¤£¯à»¡©ú·s«a¬Ì]±a¨Óªº§K¬Ì«OÅ@¯à¤O¤]±N·|¦P¼Ëµu¼È¡C¥Ø«e¦b¬ã·s«a¬Ì]ªº«OÅ@¯à¤O¡AÁÙ»Ýn®É¶¡©M¤j³W¼ÒÁ{§É¸ÕÅç¨ÓÅçÃÒ¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/24 ¤U¤È 12:26:49²Ä 996 ½g¦^À³
|
¥«³õ¤£½àÁy , ¦hŪ®Ñ©Î¤~¯à¦h¤F¸Ñ¤ß®®ªº¼ç¤O? ¹ù¥S¤S¤À¨É¦³ÃöSNG-12 ( Synapsinae ) ªº¤j¤å liawbf.pixnet.net/blog/post/49490293 ÁÂÁ¹ù¥S ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/23 ¤W¤È 08:10:31²Ä 995 ½g¦^À³
|
¹ù¥S¤À¨ÉŪ®Ñ·|ªºÂ²³øÀÉ ¤ß®®±M§Q§Þ³N·§½× liawbf.pixnet.net/blog/post/49489719?utm_source=PIXNET&utm_medium=Blog_login# ÁÂÁ¹ù¥S ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/21 ¤W¤È 10:43:04²Ä 994 ½g¦^À³
|
Antibody therapies could be a bridge to a coronavirus vaccine ¡X but will the world benefit? §ÜÅéÀøªk¥i¥H¦¨¬°«aª¬¯f¬r¬Ì]ªº¾ô¼Ù-¦ý¥@¬É±N±q¤¤¨ü¯q¶Ü¡H Monoclonal antibodies are complex and expensive to produce, meaning poor countries might be priced out. ³æ§J¶©§ÜÅé¥Í²£½ÆÂø¥B©ù¶Q¡A³o·N¨ýµÛ³h½a°ê®a¥i¯à·|³Q²^¨O¡C www.nature.com/articles/d41586-020-02360-y |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/20 ¤W¤È 07:19:36²Ä 993 ½g¦^À³
|
¼~Æ{¯g2030¦~¦¨¥þ²y²Ä¤@¤j¯e¯f ¹w¨¾¡B¶q¤Æ«ÈÆ[¶EÂ_¡B³Ð·sªvÀø¬°ÃöÁä 2020.08.19 Àô²y¥Í§ÞÂø»x°OªÌ/´^±ê²[¡B§õªLÀõ www.gbimonthly.com/2020/08/77711/ wide Depression Pipeline Guide, H1 2020: Therapeutics, Developments, Products, Drugs, Players www.globenewswire.com/news-release/2020/04/28/2023068/0/en/Worldwide-Depression-Pipeline-Guide-H1-2020-Therapeutics-Developments-Products-Drugs-Players.html Dementia - Pipeline Review, H2 2019 - ResearchAndMarkets.com www.businesswire.com/news/home/20191206005158/en/Dementia---Pipeline-Review-H2-2019-- ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/18 ¤W¤È 09:01:42²Ä 992 ½g¦^À³
|
SCHIZOPHRENIA MARKET ANALYSIS, LEADING COMPANIES, EMERGING DRUGS AND EPIDEMIOLOGY FORECAST ºë¯«¤Àµõ¯g¥«³õ¤ÀªR¡A»â¥ý¤½¥q¡A·s¿³ÃĪ«©M¬y¦æ¯f¾Ç¹w´ú Posted On: August 17, 2020 Posted By: Sthakur primefeed.in/news/4496616/schizophrenia-market-size-and-share-analysis/ ¥Ñ©ó¶EÂ_¤èªkªº§ïµ½¡A¹ï¯e¯fªº»{ÃÑ´£°ª¡A¥þ¥@¬ÉÂåÀø«O°·¤ä¥Xªº¼W¥[¥H¤Î¹wp¦b2020¦~¹w´ú´Á¶¡±N¥X²{ªº·s¿³Àøªk¡A¹wpºë¯«¤Àµõ¯g¥«³õªº°ÊºA±N¦b¥¼¨Ó´X¦~µo¥ÍÅܤơC ¡V2030¦~¡Cºë¯«¤Àµõ¯g¥«³õªº´ë¹D«D±`±j¤j¡A¯A¤Î¥¿¦b¶i¦æªº¤@¨Ç¬ã¨s¸ÕÅç¡Cºë¯«¤Àµõ¯g¥«³õ¤¤ªº¤@¨Ç¥Dn¤½¥q¥]¬A¡G GW»sÃÄ Avanir»sÃÄ Minerva Neurosciences Sunovion Concert»sÃÄ SyneuRx°ê»Ú Karuna Therapeutics µ¥¡C ²[»\ªºÃĪ« GWP42002 / GWP42003 AVP-786 Roluperidone KarXT SEP-363856 CTP-692 NaBen µ¥¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/17 ¤U¤È 06:01:06²Ä 991 ½g¦^À³
|
¹ù¥S¬°§Ú̸ѪR [ ¦ó¥H¤ß®®¬O¦bNMDAR¤è±¥þ²y»â¥ýªºCNS·sÃĤ½¥q ? ] liawbf.pixnet.net/blog/post/49478975 ÁÂÁ¹ù¥Sªº¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/16 ¤W¤È 10:22:32²Ä 990 ½g¦^À³
|
Protective effect of gallic acid in experimental model of ketamine-induced psychosis: possible behaviour, biochemical, neurochemical and cellular alterations ¨S¹¤l»Ä¹ï´âÓià¬Pºë¯«¯f¹êÅç¼Ò«¬ªº«OÅ@§@¥Î¡G¥i¯àªº¦æ¬°¡A¥Í¤Æ¡A¯«¸g¤Æ¾Ç©M²ÓM§ïÅÜ pubmed.ncbi.nlm.nih.gov/28577133/ ¥»¬ã¨s¥H¬ã¨s¨S¹¤l»Ä¦b´âÓi଻¤µoªº¤p¹«ºë¯«¯f¹êÅç¼Ò«¬¤¤ªº«OÅ@§@¥Î¡C ¨S¹¤l»Ä³sÄò15¤ÑªººC©ÊªvÀøÅãµÛ´î»´¤F¤p¹«ªº©w«¬¦æ¬°¯gª¬¡C¥Í¤Æ¦ôpªí©ú¡A¨S¹¤l»Ä¥i´î¤Ö¯×½è¹L®ñ¤Æ¨Ã«ì´_Á`¸£³J¥Õ¡C¦¹¥~¡A¨S¹¤l»ÄÅãµÛ°§C¤F¤p¹«¤¤ªº¦h¤ÚÓi¤ô¥¡AAChE¬¡©Ê©Mª¢©Ê¿E¼W¡]¦å²MTNF-£\¡^¡A¨Ã¼W¥[¤FGABAªº¤ô¥©M¼W¥[½\¯Ö¥Ì肽¡C¬ã¨sªí©ú¡A¨S¹¤l»Ä¥i¥H§ïµ½¤p¹«ªººë¯«¯f¯gª¬©M¥Í¤ÆÅܤơAªí©ú¹ïºë¯«¯e¯f¨ã¦³«OÅ@§@¥Î¡C [[[ ªþµù : ºë¯«¤Àµõ¯gªº·s½u¯Á neurosciencenews.com/gaba-schizophrenia-6244/ ºë¯«¤Àµõ¯gªº¾÷¨î«Ü¤jµ{«×¤W¥¼ª¾¡A³oªýê¤F·sÃĪº¶}µo¡C¥Ø«e¥i¥ÎªºÃĪ«¦®¦b´î»´¯gª¬¡A¦ý¶È³¡¤À¦¨¥\¡A¦]¬°¥u¦³20¢Hªº±wªÌµL¯gª¬¡C ¸Ó¶µ¥Øªº³Ìªìµ²ªG²{¦bµoªí¦b¡m¤À¤lºë¯«¯f¾Ç¡nÂø»x¤Wªº¨â¶µ¬ã¨s¤¤¡C¤@¶µ¬ã¨sªí©ú¡A·s¥X²{ªººë¯«¤Àµõ¯g±wªÌªº¸£¯á²G¤¤¯«¸g»¼½èGABAªº¤ô¥§C©ó°·±d¤H¡A¨Ã¥BGABAªº¿@«×¶V§C¡A¨ä¯gª¬´N¶VÄY«¡C GABA°Ñ»P¤j¦h¼Æ¸£¥\¯à¡A¨Ã»P½\®ò»Ä¤@°_¦û©Ò¦³«H¸¹¶Ç»¼ªºªñ90¢H¡C¨¦®ò»Ä¨ë¿E¤j¸£¬¡°Ê¡A¦ÓGABA§í¨î¤j¸£¬¡°Ê¡A¨Ã¥B¨âºØ¯«¸g»¼½è©¼¦¹¬Û¤¬§@¥Î¡C ¥t¥~ , ¦b¦´Áºë¯«¤Àµõ¯g¤¤Æ[¹î¨ìªºTSPOµ²¦X´î¤Ö , ªí©ú¤j¸£¤¤§K¬Ì²ÓM¼Æ¶q´î¤Ö©Î¥\¯à§ïÅÜ¡C Reduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatry www.ncbi.nlm.nih.gov/pmc/articles/PMC5611744/ ½\¯Ö¥Ì肽¡]GSH¡^¬O¤@ºØ«D酶©Ê§Ü®ñ¤Æ¾¯¡A¥i®ø°£¦Û¥Ñ°ò¡A¨Ã³Q»{¬°¦bSZ¤¤°_§@¥Î¡C §Ú̹ï48Ó°·±d¹ï·Ó¡]CON¡^¶i¦æ¤F¾îÂ_±¬ã¨s¡A52¦WSZ±wªÌ©M62¦WBP±wªÌ³q¹L¥Í¤Æ酶¤ÀªR¤ñ¸û¥~©PGSH¤ô¥¡C§ÚÌÅã¥Ü¡A»PCON¬Û¤ñ¡ASZ©MBP±wªÌªº¦å¼ßGSH©úÅã°§C¡C A decrease in GSH level correlated with Positive and Negative Syndrome Scale (PANSS) total and positive scores for SZ and correlated with the PANSS general for BP. Taken together, we provide evidence that SZ and BP display a common molecular signature in the reduction of peripheral GSH in the psychosis dimension ]]] ¬Ý°_¨Ó ( ½Ð°Ñì¤å¹Ïªí---¨S¹¤l»Ä¿@«×¶V°ª , Àø®Ä¶V¦n ) , ¨S¹¤l»Ä¦³¼W¶iºë¯«¤Àµõ¯gÀø®Äªº¥\¯à , ¥t¤@¤è± , ©Î¤]¥i¥H´î§C¦bSND13¥[¦¨ªvÀø¤¤ªº§Üºë¯«ÃĪ«ªº¾¯¶q , ¬Æ©Î¥i¥H¸Õ¸ÕSND13³æÃĪvÀøªº¦¨®Ä , ¨Ó´î»´©Î§K°£§Üºë¯«ÃĪ«ªº°Æ§@¥Î µM¦Ó , ´Á¤¤¤ÀªR¤w¸g§i¶D§ÚÌ , SND13¨S¦³¦w¥þ©Êªº°ÝÃD , ¥iªø´Á¨Ï¥Î , ¤]¨S¦³À@Åé¥~¯gÔ¸s©M¥NÁ¯gÔªº°ÝÃD ¥u¤£¹L¤º¦b°ò¥»»ùȪº´£¤É , «o¤]´£¤£°_ªÑ»ù¬Û¹ïªº¤ÏÀ³ ¤j®a©e¹ê¨¯W¤F ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/14 ¤W¤È 08:42:37²Ä 989 ½g¦^À³
|
¹ù¥S±À¤¶ °]¹Îªk¤HÂåÃÄ«~¬dÅ礤¤ßºô¯¸CDE liawbf.pixnet.net/blog/post/49475894 ¤º¤å¤¤ ÁÙ¦³ÂÅÂå®v¹ïSB ¦ÙÓi»Ä¤HÅé¸ÕÅçµ²ªG¤¶²Ðªº³sµ² ½Ð¦³¿³½ìªº¤j¤jÌ«e©¹¤F¸Ñ ÁÂÁ¹ù¥Sªº¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2020/8/12 ¤W¤È 07:40:34²Ä 988 ½g¦^À³
|
2020/7/27 2020¦~ªü´þ®üÀq¯g¨ó·|°ê»Ú·|ijªºnÂI (www.crossingstv.com/2020-alzheimers-international-conferece-overview-chinese/) 2020/8/3 ¬y·P¡BªÍª¢¬Ì]¤£¥u¯à¨¾·P¬V¡I°ê»Ú¬ã¨s¡GÁٯధC¥¢´¼·ÀI (heho.com.tw/archives/128647) ì¤å:FLU, PNEUMONIA VACCINATIONS TIED TO LOWER RISK OF ALZHEIMER¡¦S DEMENTIA (www.alz.org/aaic/downloads2020/AAIC2020-Vaccines.pdf) |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/8 ¤U¤È 06:48:36²Ä 987 ½g¦^À³
|
¹ù¥S¬°·P©ÀÆ[¥@µµÐÂıo¹D¤é , ¯S¶}©ñ¦n¤Í¤å³¹ 3 ¤Ñ , ¦Ü 8/10 ½Ð¤j®a§â´¤¨}¾÷ , ¦n¦n®®Åª¹ù¥Sªº¤j§@ ÁÂÁ¹ù¥S ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/7 ¤U¤È 08:45:39²Ä 986 ½g¦^À³
|
¤S¬OAxsome FDA±Â¤©±j®Ä¥h¥ÒµÇ¤W¸¢¯À¦AÄá¨ú§í¨î¾¯AXS-12¬ð¯}©ÊÃĪ«¸ê®æ ¨Ó·½¡G¥Íª«¨¦ med.sina.cn/article_detail_100_1_86937.html |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/7 ¤U¤È 08:22:39²Ä 985 ½g¦^À³
|
ªü¤Ñ¤j K»Ä¬OKojic acid , ¥Ø«e¥Î¨Ó¥Ö½§¬ü¥Õ ½²±Ð±Â§â¥¦®³¨Ó¥t¥Î¡A¨ì USPTO©xºô¥i±o¸Ô±¡ ÁÂÁ±z¡I ¥t¥~¦³«h·s»D Lundbeck«äı¥¢½ÕÃĤS¥¢±Ñ¡I¥¼¹F¥Dn²×ÂI ²×¤î¤G´Á¸ÕÅç 2020.08.07 Àô²y¥Í§ÞÂø»x / °OªÌ ¼BºÝ¶® ½sĶ www.gbimonthly.com/2020/08/76357/ |
|
|
·|û¡Gªü¤Ñ10149120 µoªí®É¶¡:2020/8/7 ¤U¤È 05:04:17²Ä 984 ½g¦^À³
|
½Ð°Ý²q·Q¤j¡Ak»Ä«üªº¬O¬Æ»ò¡A¬OþÓ²£«~©O??·PÁ¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/7 ¤W¤È 09:59:42²Ä 983 ½g¦^À³
|
10»õ¬ü¤¸§U¤O©¬ª÷´Ë¯fÀøªk¶}µo´ñ°·©MDenali¹F¦¨¦X§@ ¨Ó·½¡GÃÄ©ú±d¼w¡@2020-08-07 med.sina.com/article_detail_100_2_86877.html ¤µ¤é¡A´ñ°·¤½¥q¡]Biogen¡^©MDenali Therapeutics«Å¥¬¡AÂù¤è¤w¸g¹F¦¨¤@¶µ¨óij¡A¦@¦P¶}µo©M±À¼sDenaliªºLRRK2¤p¤À¤l§í»s¾¯DNL151¡A¥Î©óªvÀø©¬ª÷´Ë¯f¡C ´ñ°·±N¦VDenali¤ä¥I5.6»õ¬ü¤¸ªº«e´Á¥I´Ú¡A¨Ã¹ïDenali¶i¦æ4.65»õ¬ü¤¸ªºªÑÅv§ë¸ê¡CDenaliÁÙ¦³¸ê®æÀò±o°ª¹F11.25»õ¬ü¤¸ªº¼ç¦b¨½µ{¸O¥I´Ú¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/6 ¤U¤È 01:57:47²Ä 982 ½g¦^À³
|
¤ß®®¤S¥Ó½Ð±M§Q K»Äªº¦@´¹»s³Æ¤Î¥Î³~ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/6 ¤W¤È 10:17:16²Ä 981 ½g¦^À³
|
ÁÂÁ¹ù¥SÀ°§Ṳ́¶²Ð SND13 ©Ò±Ä¥Îªº SPCD liawbf.pixnet.net/blog/post/49467449 ¥t¥~ ·s®öºô³ø¾É COVID-19ªvÀøÃĪ«Á{§É¸ÕÅç²×ÂIÀ³¸Ó¥]¬Aþ¨Ç¨ãÅ餺®e¡H ¨Ó·½¡GÃÄ©ú±d¼w¡@2020-08-06 med.sina.com/article_detail_103_2_86810.html ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/5 ¤W¤È 10:59:32²Ä 980 ½g¦^À³
|
SNB1 §Ü SARS-CoV-2 PENTARLANDIR °Ó¼Ð¥Ó½Ð »´ä www.ipd.gov.hk/hkipjournal/29052020/PUBLICATION_TYPE_ACCEPTANCE_FOR_REGISTRATION_SUMMARY.pdf Áú°ê markinfo.co.kr/front/mobile/c1200_r.php?act=search&vm=d&act=search&mark_upclass_cd=24&mark_subclass_cd=441&trademark_name=PENTARLANDIR®_privilege_name=&applicant_name=&asign_product=&application_date1=&application_date2= ¼Ú·ù www.trademarkia.com/ctm/ctm-company-syneurx-international-taiwan-912419-page-1-2 ¬ü°ê uspto.report/TM/90067787 ¤é¥» www.j-platpat.inpit.go.jp/t0201 ^°ê trademarks.ipo.gov.uk/ipo-tmcase/page/Results/1/UK00003483911 ¦L¥§ www.dgip.go.id/images/humas/Berita_Resmi_Merek/2020/BRM2026A.pdf ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/4 ¤W¤È 10:36:04²Ä 979 ½g¦^À³
|
§ïµ½§íÆ{¯gª¬·¨´Ë³Ð·sÀøªkÀò§åªvÀø¦³¦Û±þ¶É¦V§íÆ{¯g±wªÌ ¨Ó·½¡GÃÄ©ú±d¼w¡@2020-08-04 med.sina.com/article_detail_100_2_86694.html ±j¥Í¡]Johnson & Johnson¡^ºX¤U·¨´Ë¡]Janssen¡^¤½¥q¤µ¤Ñ«Å¥¬¡A¬ü°êFDA¤w§åãSpravato¡]esketamine¡^CIII»ó¼QÃú¾¯ªº¸É¥R·sÃĥӽС]sNDA¡^¡A»P¤fªA§Ü§íÆ{ÃÄÁp¥Î¡AªvÀø¦ñ¦³«æ©Ê¦Û±þ©ÀÀY©Î¦æ¬°ªº§íÆ{¯g¡]MDD¡^¦¨¤H±wªÌªº§íÆ{¯gª¬¡C ³\¦h±w¦³§íÆ{¯gªº¤H³£«D±`²M·¡µ´±æªº·Pı¡A¡§¬ü°êºë¯«½Ã¥Í¤¤¤ß¡]Mental Health America¡^ªºº®u¶µ¥Ø©xTheresa Nguyenn¤k¤h»¡¡G¡§¦pªG««×§íÆ{¯gµo®i¦¨¤F¿n·¥ªº¦Û±þ©ÀÀY¡A¨º±N¬O·´·À©Êªº... |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/3 ¤U¤È 04:49:05²Ä 978 ½g¦^À³
|
¹ù¥SÁ|¿ì§äâí°e¦n¤Í¬¡°Ê , §ä½Öªº ? ·íµM¬OSND-13ªº liawbf.pixnet.net/blog/post/49439786 ¥t¥~ ¹ù¥S¤]¦A¦¸¼x¨D¶}¿ì©n©f³¡¸¨®æªº¦@¦PºÞ²zªÌ liawbf.pixnet.net/blog/post/49458509 ÁÙ¦³ÁܽФj®a°Ñ¥[½u¤WŪ®Ñ·| liawbf.pixnet.net/blog/post/49431308 ÁÂÁ¹ù¥S ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/2 ¤W¤È 08:29:12²Ä 977 ½g¦^À³
|
·ç¼w¦è³¥i±æ¤j½æ ¦N§Q¼w½Õ°ª¥þ¦~°]´ú 04:102020/08/01 ¤u°Ó®É³ø ¾G³Ó±o ¡Bºî¦X¥~¹q www.chinatimes.com/newspapers/20200801000127-260203?chdtv ¬ü°ê¥Íª«»sÃĤj¼t¦N§Q¼w¬ì¾Ç¡]Gilead Sciences¡^30¤é¤½¥¬²Ä¤G©u°]³ø¤£¦p¥«³õ¹w´Á¡A¦ý¸Ó¤½¥q½Õ°ª¤µ¦~¥þ¦~°]´ú¡A²z¥Ñ¦b©ó¥L̵û¦ôºX¤U·s«aªÍª¢ÃĪ«·ç¼w¦è³¡]remdesivir¡^¥i±æ±a¨Ó¼Æ¤Q»õ¬ü¤¸À禬¡C ´I·ç¤ÀªR®v©ö³Á¥i¡]Michael Yee¡^ªí¥Ü¡G¡u±q³Ì·s°]´ú¥iª¾¡A¦N§Q¼wµû¦ô¥«±¤W°ß¤@ªº·s«aÃĪ«·ç¼w¦è³¤µ¦~(³Æµù:¤U¥b¦~)±N±a¨Ó10»õ¡ã30»õ¬ü¤¸¦¬¤J¡A³o¬O¥L̦~ªì¥¼³]·Q¨ìªº¡C¡v ·ç¤h«H¶U¶°¹Î¤ÀªR®v¦è®æ°Ò¡]Evan Seigerman¡^«ü¥X¡AY±N¦N§Q¼w¨ä¥LÃĪ«¥i¯à·l¥¢10¡ã25»õ¬ü¤¸¦Ò¶q¦b¤º¡A·ç¼w¦è³¾P°âÃB¥i±æ¹F¨ì30»õ¡ã45»õ¬ü¤¸¡C ·ç¼w¦è³5¤ë®ÉÀò±o¬ü°êFDAºò«æ±ÂÅv¨Ï¥Î¡A¦N§Q¼w©ó7¤ë°_¥¿¦¡¦¬¶O¡A¹wp¤U¥b¦~±N¾P°â100¸U¡ã150¸UÓÀøµ{¡C¬ü°ê¨C¦ì¯f±wªvÀø¶O¥Î¬ù3,120¬ü¤¸¡A¼Ú¬w»P¨ä¥L¥ý¶i°ê®a¨C¦ì¯f±w«hn»ù2,340¬ü¤¸¡C SNB1 ¥[ªo! »°§Ö¤W½uÁ{§É ! ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/8/1 ¤W¤È 08:24:04²Ä 976 ½g¦^À³
|
¹ù¥Sµoªí I got the power ¤§SND13¨ì©³¦³¦h power ? liawbf.pixnet.net/blog/post/49460798 ÁÂÁ¹ù¥S¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡G´M³V10132258 µoªí®É¶¡:2020/7/31 ¤U¤È 12:15:38²Ä 975 ½g¦^À³
|
·PÁÂCliff ¤jªº¤À¨É¡I ³oªi¥Í§Þ¦æ±¡¯àÅý¥xÆWªº¥Í§ÞªÑ¥[±jÄw¸êªºÅé½è! ¦¤é§@¥X³yºÖ¥@¤HªºÃĪ«! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/7/31 ¤W¤È 07:06:07²Ä 974 ½g¦^À³
|
Á¾¨RµL¬O³B¡A§O¦³¤j°®©[ Cliff ¤j®¦¼w¦Û¤]¬O¤@¤è·¶³¤Hª«¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2020/7/31 ¤W¤È 12:53:48²Ä 973 ½g¦^À³
|
ÁÙ¦³ ±q¤µ¦~ªÑªF·|«eªº¦~³ø¼¶¼g»P²{¦b©xºô¤W¹ï´Á¤¤¤ÀªRªº¸ÑªR³ø§i»Pµo¥¬¨Ó¬Ý¡AÓ¤H¬Û«H¡A¦Ñ¥v¤j¤j¨Ã¥¼§Ñ°O¥Lªºªì°J¡F¨Ó¦Û¥Á¶¡¡A·íª¾§ë¸ê¶m¥Á̪º¯eW¡C³oI«á¥²µM¬O¸g¹L¤@µf¬Û·íªº§V¤O»P©Ô¿÷¡A©Ôªñ¤½¥q»P§ë¸ê¤H¤§¶¡ªº¶ZÂ÷¡AÅý¤½¥q¬ãµoªº¶i«×°T®§¤£¬O¶È¶È¦ì©ó°ª°ªªºÄƽz¶³Ãú¶¡¦Ó¤w¡F¤½¥q¸gÀç¥i¥H±a¦³¶W¹Ðµ´«Uªº¥P®ð¡A¦ý¤£nÅýWW¤ä«ùªº§ë¸ê¤HÌ·P¨ì¦B§N¦Ó»»¤£¥i¤Î¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2020/7/31 ¤W¤È 12:45:31²Ä 972 ½g¦^À³
|
³o¬O¤@½g¤£Àç¾iªº¤å¦r¡A¨S¦³¿EÀyªÑ»ùªº§@¥Î¡A¨S¦³¸Ñµª³o¦¸´Á¤¤¤ÀªRµ²ªG¨ì©³¬O¦n¨ÆÁÙ¬OÃa¨Æ¡H§ó§O»¡ÁÙn¤£n¦h¦¬®×¡HÁÙn¦h¤[¥i¥H¸Ñª¼¡H¡K¡K ©Ò¥H¦³©Ò¨Dªº§ë¸ê¤H«Øij¸õ¹L¡A¤£nŪ«á¤Sµo¨cÄÌ¡K¡K §ë¸ê¤ß®®¥H¨Ó¡A¤½¥q«O¦u¤f·»P³h½C¸ê°T©Ò±a¨Óªº¥¢±æ¡A¹ï·Ó©ó¥¼¨ÓNMDA±µ¨ü¾¹ªvÀø¾Ç·s»â°ì¨ì¨Óªº¥R¤À´Á«Ý¡A¤@ª½Åý¤H¦³¤@ºØª¼¤H½à¨d¤¦¡A¤ß¤¤´I¶Q¡A¦ý¹ê´f¤£¦Üªº·Pı¡C ¤µ¦~ªÑªF·|¤W½²¸³¶V¬vÁn°T´£¨ì¡A¤£ºÞSND13´Á¤¤¤ÀªRµ²ªG¦p¦ó¡AÁ{§É¸ÕÅç³£·|Ä~Äò¶i¦æ¤U¥h¡F¦Ó¥B¤£¤î¤@¦¸´£¨ì§ë¸ê¤Hn¦³¦Û¤vªº§PÂ_¡A¤£n³£¬Û«H¥L©Ò»¡ªº¡C³o¨Ç¹ï©ó¤w¸g¬Ý¤£¨ì½²¸³¼v¹³ªº§ë¸ê¤H¦Ó¨¥µLºÃ¥u¬O¼W²K¤ß¤¤ªººÃ¼{»P¤£¸Ñ¡A§ó¤£n»¡«á¨Ó¤SÅ¥¨ì½²¸³´£¨ìªº¤T¦ì·í¤µ·¶³¤Hª«ªº¨º¤@¬q¡K¡K·í¤Uı±o¦Û¤v³s°×¤Ú³£¤£¦p¡C¡]°×¤ÚŪ¥ª¶Ç¡Aº¡¸¡¬K¬î¡F§Ú½úÅ¥½²¸³Án°T¡Aº¡¸£ª°ºÃ¡C¡^ ¦^®a«á·Q¤F´X¤Ñ²×©ó¤F¸Ñ¬°¤°»ò½²¸³n§è¤W¨º¤T¦ì·¶³¤Hª«¡C ½²¸³±q¹L¥h¤Ê¦~¾lªº§ë¤J·P¨ü¨ìNMDA receptor½Õ±±ªººë§®¡A³o§âÆ_°Í¦³«Ü¤jªº¾÷·|¥i¥H¶}±Òºë¯«»â°ì¤@ª½¹L¤£¥hªº¨º¤@¹Dªù¡AÅý¯«¸gºë¯«ªvÀø¦A©¹«e¸ó¤@¤j¨B¡F¦b¥Ø«eGABA receptor¬°¥DªºªvÀøÃĪ«¤¤¶}±Ò¥t¤@®°§Æ±æ¤§µ¡¡A¦Ó¥B¨Ï¥Îªº¬O²³æªºÃĪ«¡C Bill Gates©ó2015¦~ªº¤@³õTEDºtÁ¿¤¤¡A´£¥X¦Û¤vªº¹w´ú¡G¥¼¨Ó´X¤Q¦~¸Ì¡A¥þ²y¤HÃþ³Ì¤jªº¨aÃø¡A¦pªG»¡¦³¤°»òªF¦è¥i¥H±þ¦º¤W¤d¸U¤H¡A¨º«Ü¥i¯à¬OӨ㦳°ª«×¶Ç¬V©Êªº¯f¬r¡I½²¸³ªº¦Ñ®vJoseph T. Coyle¥D±iÓi°ò»Ä¬O¤@ºØ¯«¸g¶Ç¾Éª«½è¡A±a»â½²¸³µ¥¾Ç¥Í¤@¦P¬ã¨s¶}±Ò¤F¤µ¤éNMDAªvÀø¾Çªº§Ç¹õ¡CBill Gates»PJoseph T. Coyle³£¬O¥ýª¾¡A¥ýª¾¥²©w¸g¾ú±I¹æ¡C ½²¸³¥Ñ¾Ç¬É¸ó¤J·~¬É»P¤½¥q¬ãµo¤Hû¤W½aºÑ¸¨§ä·sÃÄ¡A³s¥»¯óºõ¥Ø¤]¤£©ñ¹L¡Fµo²{¤F¤£¤Ö²{¦sªºª«½è¥i¥H¦bºë¯«¬ì»â°ì¤W¦³¤£¦Pªº¾AÀ³¯g¡A¦³«Ü¤j¾÷·|¯àµo´§§ó¦nªºÀø®Ä¡A¦p³Q·í§@¹ª«¨¾»G¾¯ªºf¥Ò»Ä¶u¡B³Q¥Î©óÂý»s¥Ö²ªº³æ¹ç»Ä¡A¥H¤Î¤@ª½¨S³Q¦n¦n§Q¥ÎªºN-¥Ò°ò¥ÌÓi»Ä(Sarcosine)µ¥¡C±¹ï¤£Â_ªº·s¬D¾Ô¤£Â_¦a§ä´M·sªº¥i¯à¸Ñ¨M¤è®×¡A³o»P¹ï©¤¯f¬rÅv«ÂÁé«n¤sªº³B¹Ò«Ü¹³¡C·U¾Ô·U«i¡A¥u¯àµL¤¤³Ð¦³¡A¥¢±Ñ¤F¦A¾Ô¡A¤£¯à´N¦¹©ñ±óªº§V¤O¹Lµ{¬O¥L̦@¦P¸g¾úªº¤ß¹Ò¡C µM¦Ó¹ï©ó¤£¸Ñºç¤¤ì©eªº¥~¬É¡A¨Ò¦p¥u¨D³t®Ä¸Ñ¨Mªº¤t´¶¡ADr.Fauci¤´¤@¥»Âå¾Ç±M·~¸Ó¦³ªº°í«ù¡A¥Î¥L¨º¨F°×ªº¶Úµ»Pºò½Kªº¬ÜÀY¡A¤@¦¸¤S¤@¦¸¦a©IÆ~¤H̤£¥i±¼¥H»´¤ß¡C³o¤d¤s¿W¨B§Ú¤@¤Hªº©t²D¸ò½²¸³±¹ï¶Ò¸êªº§xÃø¡B¥~¬É¹ïºë¯«ªvÀø»â°ìªº¯¥Í»PªÑªFֱ̧֧ÂÅvªº¶Ê«P¡A¨ä³B¹J¹êµL¤GP¡C©Ò¥H½²¸³ªº¤ß±¡¤£¸g·N¦a¦b¤µ¦~ªÑªF·|¤W¬y¬ª¡A±¹ïÁ¿¨s§Ö³t¡B§Q¼íªº§ë¸ê¤H¡AÃø§K·P¹Äª¾¤ß´X¦ó¡H¤£¬O¤½¥q¤£§V¤O¡A¦Ó¬O®ÉÔ¥¼¨ì¡H¡I±I¹æ¡B¾Ä¾Ô¡B§ÜÀ£¬O½²¸³ªº¤ßÁn¡C ©Ò¥H¨S¦³¾¨¶q¾aªñ¥Lªº°ª«×¡A´NÃø¥H²q·Q¥L¬Ý¨ì¤F¬Æ»ò¡C ¨S¦³¾¨¶q±µªñ¤½¥qªº«äºû¡A´N«ÜÃø©ê±o¦í¡C ¯¸¦b¥¨¤HªºªÓ»H¤W¥i¥H¬Ý±o§ó»·¡C SND13¬O¦b¬J¦³ªººë¯«¤Àµõ±wªÌªº¥ÎÃĤW¥[¤W¦pªê²KÁlªº®ÄªG¡F¤£¬OnÁ{§ÉÂå®v§â±wªÌ¥Ø«e¥ÎÃÄ´À´«±¼¡A¦Ó¬O¦A¥[¤Wf¥Ò»Ä¶u§@¥[¦¨ªvÀø¡]add-on therapy¡^´N¬O¤@ºØÃþ¦üªº«äºû¡C»P²{¦³±`¥Î¦Ó½l³y¾P°â¨ÎÁZªºÃĪ«¨Ã¦æ¸µ¾¡C©xºô¤W´Á¤¤¤ÀªR³ø§i¸ÑªRªºÂ²³ø²Ä10¶¡u²Ä¤G¥NÃĪ«Á{§É®ÄªG¶q¤§²Î¦X¤ÀªR¡vù¦C¤F¤»ºØ²{¦æ¾P°â¨ÎÁZªºÃĪ«¡A°£¤F§i¶D§ÚÌY¨ã³Æ¨º¼ËªºES¥i¯à³y´N¤£¤Zªº¾P°â·~ÁZ¤§¥~¡AÁÙ¦³¤@Ó©¶¥~¤§µ¡A´N¬OSND13¥i¥H¼µÛ³o¨ÇÃĪ«³Q¼sªx¨Ï¥Îªº¯Í»H¡A¸òµÛ§Ö³tÃk¤W°ª®p¡C¹ï·Ó2013¦~SND13ªºIIa¸ÕÅç³ø§i¨Ó¬Ý¡A¨º´XӳФU¾P°â¨ÎÁZªºÃĪ«¤]¥¿¬O¨ü¸ÕªÌ°Ñ¥[¦¬®×®É¥¿¦bªA¥ÎªºÃĪ«¡A¨Ò¦pQuetiapine¡]¦~¾P°â°ª®p62»õ¬ü¤¸¡^¡BRisperidone¡]55»õ¬ü¤¸¡^¡BZiprasidone¡]13»õ¬ü¤¸¡^¡K¡K¤£¹L½Ð¤Å»~»{¬°SND13»PQuetiapine¦@¦PªA¥Î®É¡A·|³y¦¨SND13¦~¾P°âª÷ÃB62»õ¬ü¤¸ªº¦¨ÁZ¡C¡]cdn.jamanetwork.com/ama/content_public/journal/psych/929317/yoi130025t1.png?Expires=2147483647&Signature=Q0fleqUI8MaMlPyz1VvvazGdUHCbSHAYAQC9w0rI26jnbhjL~dTsRvFbOwp8jUFmu9bhDQFHrnAd~7Ul1lVx0h2dBavoEZ-zewPVKW-FivUITzFAVW6VjNBaRocvuJu812uGGJXj-J2SJ6zZyj-Jglv~9--OY0zg9YbiDBY0zKGRatLdAVE6YSadnR5amIv0eLJw-lG5YZb7mhK3PryUmvqSwfR0oAjCp1z3OuDqiLLyM8OJlV0NV14WqHWE2sJKg4NeKsGN9D~Vw67FajMlnhusBuBZSe~2GPismBnO5YJUYQ5sHG1y9HiAx2sFzpORuoMGvCulYSA3SmzzFzQdgA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA¡^ ÁÙ¦³³o¦¸ªÑªF·|¤~ª¾¹Dªº±m³J¡Aì¨ÓSND13ªº¦¨¤À¤w¤º§tTannic acid¡A³o¼Ëªºµ¦²¤À³¸Ó·|ÅýÀø®Ä§ó¦n¡F¤£¹L¦h¤¤¤ßªº¸ÕÅç³]p¤£¹³IIa¬O¦P¤@¦ì¸ÕÅç¥D«ù¤H¡A©Ò¥H¥i¯à·|§é·l¤@ÂIÂIES¡A±À´ú¦pªG¥i¥H¹F¨ìES¡G0.5À³¦³¾÷·|¹F¼Ð¡C ¡u·sÃĶ}µo ¬D¾ÔÁ{§É¤TÃö¥d¡v¡G¡]www.cpmda.org.tw/news_show_n1.php?news_id=6138¡^ ¡u¦]¬°´Á¤¤¤ÀªRªº¼Ë¥»¼Æ¤£¨¬¡A¸ÕÅçµ²ªG¨S¦³¹F¨ì²ÎpÀË©w¼Ð·Ç¤]¤£¯à½T©wÃĪ«®ÕªG¤£¦n¡A¦³¨Ç®ÉÔÃĪ«©ú©ú¦bÁ{§É¤W¬O¦³©úÅã®ÄªG¡A¦ý¬O¦b´Á¤¤¤ÀªRªºµ²ªG¤¤¡A¦]Á{§É¸ÕÅç²Îp¤ÀªR¤W¼Ë¥»¼Æ¥Ø¤£¨¬¡AµLªk±o¨ì²Îp¤WªºÅãµÛ·N¸q¡A¦]¦¹´Á¤¤¤ÀªRªºµ²ªG¡A¥u¯à°µ¬°ÃĪ«¬O§_¨ã¦³Àø®Äªº°Ñ¦Ò¸ê®Æ¡A¤@ÓÃĪ«¶}µoªº¦¨±ÑÀ³¸Ó§óÃö¤ß§¹¥þ¸Ñª¼¤§«áªº´Á¥½¤ÀªRµ²ªG¡C¡v Ãö©óDSMC«Øij¥i§â¦¬®×²Ä¤@¶¥¬qªº¤À°t¤ñ¨Ò§ï¬°¹êÅç²Õ¡G¹ï·Ó²Õ¡×1¡G2.5©Ò³y¦¨ªº¼vÅT¡Aª©¤W½Ñ½å¤w°Q½×¹L¡A·Pı¤W¬O´ÂµÛ¦nªº¤è¦Vµo®i¡C«áÄò¦¬®×³t«×¤]§Æ±æ¦]¬°¼Ú¬w¦aÂIªº¶}³]¦Ó¼W§Ö³t«×¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/7/30 ¤U¤È 08:43:59²Ä 971 ½g¦^À³
|
¹ù¥S±N¶}¿ì©n©f³¡¸¨®æ ¼x¨D¦@¦PºÞ²zªÌ liawbf.pixnet.net/blog/post/49458509 ¹ù¥SÀ°§Ṳ́¶²Ð FDA 2019/12 ¤½§Gªº½Õ¾ã¦¡³]pªº·~¬É«ü«n liawbf.pixnet.net/blog/post/49460570 ÁÂÁ¹ù¥Sªº¤À¨É ÁÂÁ¤j®a! ¥t¦³¤@«h AD ±ÂÅvªº·s»D ¥¸¸ê20»õ¬ü¤¸¦A¾ÔAD¡Iù¤óÀò±oUCB¦b¬ã§ÜTau§ÜÅé¿W®a¥þ²y³\¥i ¨Ó·½¡G·s®öÂåÃÄ·s»D¡@2020-07-30 ½sĶ丨¬_¬_ ÀHµÛ§Ü¾ý¯»¼Ë³J¥ÕÀøªk¥Î©ó¯«¸g°h¦æ©Ê¯e¯fªvÀø¡Aù¤ó¥¿¦b¼W¥[tau¹v¦VªvÀø¤è®×ªº¬ãµo§ë¸ê¡C7¤ë29¤é¡AÀu®É¤ñ¡]UCB¡^«Å¥¬»Pù¤ó¤Î¨äºX¤U°ò¦]®õ§J¤w´N¦b¬ã³Ð·s§Ü£n§ÜÅéÀøªkUCB0107¦bªüº¸¯ý®üÀq¯f¡]AD¡^¤¤ªº¥þ²y¶}µo©M°Ó·~¤Æ¡Añq¤F¤@¶µ¥þ²y½d³ò¤ºªº¿W®a³\¥i¨óij¡C ®Ú¾Ú¨óij¡AUCB±N¦Vù¤ó©M°ò¦]®õ§J´£¨ÑUCB0107ªº¿W®a¥þ²y³\¥i¡A§@¬°¦^³ø¡AUCB±NÀò±o1.2»õ¬ü¤¸ªºº´Á¹w¥I´Ú¡CUCB±N¸ê§U¨Ã°õ¦æADªº·§©ÀÅçÃÒ¬ã¨s¡A¤@¥¹¬ã¨sµ²ªG¥i¥Î¡A°ò¦]®õ§J¦³ÅvÄ~Äò¶}µo©Î±N¥þ³¡Åv§QªðÁÙµ¹UCB¡C¦b°ò¦]®õ§J¨M©wÄ~Äò¶i¤@¨BªºÁ{§É¶}µo«á¡AUCB±N¦³¸ê®æÀò±o¶i¤@¨Bªº¼ç¦b¦¨¥»¸ÉÀv¡B¶}µo©M¾P°â¨½µ{¸O¥I´Ú¥H¤Î¯S³\Åv¨Ï¥Î¶O¡A¦b¦¬¨ì¬Y¨ÇºÊºÞ§åã¨Ãº¡¨¬¬Y¨ÇÁ{§É©M¾P°â¨½µ{¸O«á¡A UCB±N¥i¯àÀò±oªñ20»õ¬ü¤¸Á`¥I´Ú¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/7/30 ¤U¤È 08:36:40²Ä 970 ½g¦^À³
|
ÁÂÁÂFaFaFa¤jªº¼W¶iª¾ÃÑ ¤]ÁÂÁ Cliff¤j®¦¼w ªº½×¤å¸É¥R Brain-derived neurotrophic factor/TrkB signaling in memory processes °O¾Ð¹Lµ{¤¤¸£·½©Ê¯«¸gÀç¾i¦]¤l/ TrkB«H¸¹¶Ç¾É pubmed.ncbi.nlm.nih.gov/12719654/ ³Ìªñªºµo²{ªí©úBDNF / TrkB«H¸¹©MNMDA¨üÅ餧¶¡ªº¬Û¤¬§@¥Î¹ï©óªÅ¶¡°O¾Ðªº«n©Ê¡C f¥Ò»Ä¯Ç¤]¥i¤W½Õ BDNF Up-regulation of neurotrophic factors by cinnamon and its metabolite sodium benzoate: Therapeutic implications for neurodegenerative disorders ¦×®Û¤Î¨ä¥NÁ²£ª«f¥Ò»Ä¶u¹ï¯«¸gÀç¾i¦]¤lªº¤W½Õ¡G¹ï¯«¸g°h¦æ©Ê¯e¯fªºªvÀø·N¸q www.ncbi.nlm.nih.gov/pmc/articles/PMC3663914/ Utilization of in situ ELISA method for examining Trk receptor phosphorylation in cultured cells helda.helsinki.fi//bitstream/handle/10138/157612/Antila_H_et_al_in_situ_ELISA.pdf?sequence=1 Interestingly, depending on dose, 5 compounds (tannic acid, fenbendazole, theaflavin, plumbagin, gossypetin) produced either inhibition or facilitation of BDNF-induced TrkB activation (Figure 2g). Gallic acid activates hippocampal BDNF-Akt-mTOR signaling in chronic mild stress ¨S¹¤l»Ä¿E¬¡ºC©Ê»´«×À³¿E®É®ü°¨BDNF-Akt-mTOR«H¸¹¶Ç¾É pubmed.ncbi.nlm.nih.gov/30280285/ ¨S¹¤l»Ä¥i«P¶iCMS»¤¾Éªº®ü°¨¤¤BDNF©Mp-TrkBªº¤ô¥¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2020/7/29 ¤W¤È 08:44:20²Ä 969 ½g¦^À³
|
¾|¥Õ¡]Bai Lu¡^ TrkB agonistic antibody AS86 2020/5:¡uwww.thno.org/v10p6854.htm¡v |
|
|
·|û¡GFaFaFa10140966 µoªí®É¶¡:2020/7/29 ¤W¤È 06:14:23²Ä 968 ½g¦^À³
|
www.bilibili.com/video/BV1Z54y1U744 »ñ°Ä½Ãµø 纪¤j讲°ó 20200718 对§Üªv疗ªüûد÷®üÀq¯gªº·s«ä¸ô 鲁¥Õ 1990¦~获¬ü国±d©`ûؤj学医学°|³Õ¤h学¦ì¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/7/28 ¤W¤È 10:08:47²Ä 967 ½g¦^À³
|
¹ù¥SªºSND13´Á¤¤³ø§ipart 2 ( 8/2 §ï¬°±K½X¤å³¹ ) ¹ù¥SªºSND13´Á¤¤³ø§ipart 1 ( 8/1 §ï¬°±K½X¤å³¹ ) liawbf.pixnet.net/blog/post/49458803?utm_source=PIXNET&utm_medium=Blog_navbar_login#_=_ ·PÁ¹ù¥Sªº¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/7/27 ¤U¤È 04:09:02²Ä 966 ½g¦^À³
|
¾\Ū¤½¥qSND13´Á¤¤¤ÀªR³ø§i¤§§Ú¨£ 1. ²Ä¤@¶¥¬qªvÀø²Õ»P¦w¼¢¾¯²Õ¤§ÀH¾÷¤À°t¤ñ¨Ò¥Ñì³]p¤§1:3½Õ¾ã¬°1:2.5 ¬O§_·t¥ÜµÛ°Ñ¥[²Ä¤G¦¸ÀH¾÷¤À°tªº¼Ë¥»¼Æ¤w¨¬ ? ¦]¬°´Á¤¤¤ÀªR®Éªº¼Ë¥»¼Æ¤w¹F 91 ¤H 2. ¥t¤T¤Q¤H§¹¦¨¸ÕÅ礧«á¦A¶i¦æ½Õ¾ã¤H¼Æ¤ÀªR , ¥Nªí±N©óÁ{§É¶i¦æ¬ù¤T¤À¤§¤G®É¦A¶i¦æ¼Ë¥»¼Æ½Õ¾ã¤ÀªR§ó·Ç½T §Ú̥Ѳ³æªºpºâ , À³¥i±À¥X¤½¥q¶É¦V¦¬®×348¤H¦A¸Ñª¼ , ¦p¦P¦¤W©Ò°Q½× , YES = 0.5 ¤Î £\= 0.05 ¤£ÅÜ , «h POWER ±N´£¤É¦Ü 91.26 % ³oÓ²³æpºâ¦p¤U : ( 174 + 60 )/ 348 = 0.672 ¬ù¬° 2/3 ; ( 91 + 30 )/ 146 = 0.828 ( Â÷ 2/3 ¬Æ»· ) 3. ¹w´ÁÃĪ«¥i¥HÅý¯f¤Hªø´Á¨Ï¥Î¡A¨S¦³À@Åé¥~¯gÔ¸s©Î¥NÁ¯gÔ¸sªº°ÝÃD¡A·¥¨ã¥¿±·N¸q ¥H«e §ÚÌ´£¨ì [[[ ¤é¥»¾ÇªÌªº¬ã¨s: Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyramidal Motor Disorders by Activating the Nigrostriatal Dopaminergic Pathway. www.ncbi.nlm.nih.gov/pubmed/28671605 ¥»¬ã¨sµ²ªGº¦¸ÃÒ©ú¡A³q¹L¿E¬¡¶Â¯¾ª¬Åé¦h¤ÚÓi¯à³~®|¡A¨ë¿ENMDA¨üÅ骺¥Ì®ò»Äµ²¦X¦ìÂI¥i´î»´§Üºë¯«¯fÃÄ»¤¾ÉªºEPS(´ÕÅé¥~®|¯gÔ)¡A³oªí©ú¥Ì®ò»Äµ²¦X¦ìÂI¿³¾Ä¾¯¤£¶È¦³¯q©óÀø®Ä¡A¦Ó¥BÁÙ¦³¯q©ó°Æ§@¥ÎºÞ²z¡C ]]] ¤µ¤é , ¤½¥qÃÒ¹ê¤F³oÓ¹«Å骺¹êÅçÀ³¥Î¦b¤HÅé§ó´Î ( ¨S¦³À@Åé¥~¯gÔ¸s ) ¤S NaBen ªº½á§Î¾¯³æ¹ç»Ä , ¥¦ªº¾¯¶q¯uªº¨¬¥Hµo´§½w¸Ñ¥NÁ¯gÔ¸s ( ¨S¦³¥NÁ¯gÔ¸sªº°ÝÃD ) ¨º§ÚÌn°Ý ³oÓ½á§Î¾¯³æ¹ç»Äªº¾¯¶q , ¬JµM¥i¥H¤j¨ì½w¸Ñ¥NÁ¯gÔ¸s ¨º¬O§_¤]·|µo´§¬Û·í©ó¼W¥[f¥Ò»Ä¶u¾¯¶qªº¥\¯à , ´N¦p¦P¦b¹«Åé¸ÕÅ窺Àø®Ä , §Ú«Ü¦n©_Àø®Ä·|¦n¨ìþ¸Ì ? °Ú«¢! SND13 ¥[¦¨ªvÀø , ²{¦b±ÀºV°_¨Ó , ¬J¥i¼W¥[Àø®Ä , ¤S¥i®ø«Ú²{¦sÃĪ«ªº°Æ§@¥Î ³onþ¸Ì§ä ?! §ÚÌ·PÁ¤½¥q¹Î¶¤ªº±M·~©M§V¤O §Æ±æ»°§Ö¦¨¥\ , ¨Ó³yºÖ±wªÌ , ¨Ã¼W¥[ªÑªFÅv¯q ¶È¨Ñ°Ñ¦Ò , ¤Á¤Å§@¬°±z§ë¸ê¨Ì¾Ú ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/7/27 ¤U¤È 02:24:40²Ä 965 ½g¦^À³
|
¹ù¥S¤SÁ|¿ìSND13´Á¤¤¤ÀªRªº²qÁ¼¼W¦n¤Í¬¡°Ê liawbf.pixnet.net/blog/post/49457897 ½Ð¤j®a¦@Á¸²±Á| ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/7/27 ¤W¤È 10:07:31²Ä 964 ½g¦^À³
|
¹ù¥SªºSND13´Á¤¤³ø§ipart 1 liawbf.pixnet.net/blog/post/49457759?utm_source=PIXNET&utm_medium=Blog_login# ÁÂÁ¹ù¥Sªº¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/7/27 ¤W¤È 06:55:17²Ä 963 ½g¦^À³
|
°w¹ï¥»ª©²Ä962½gªº¶K¤å ¤pªº¦b¦¹n¦A´£¿ô¤j®a DSMC ©|¥¼¨M©w¬O§_¼W¥[¤H¼Æ ¥HDSMC ªº«Øij , n¦A¼W¥[Æ[¹î¼Ë¥»30¤H , ¦A¨M©w¬O§_¼W¥[¤H¼Æ 146 ¡V 91 ¡V 30 = 25 ¤H , Å㨣DSMCªº«O¦uÂÔ·V ³o¬O¯ù¾l¶º«áªº¯À§÷ , µ´¤£¯à§@¬°±z§ë¸êªº¨Mµ¦°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/7/27 ¤W¤È 06:27:49²Ä 962 ½g¦^À³
|
174*3/4 = 130 ¤H , ¥»¦¸´Á¤¤¤ÀªR°Ñ»PÀH¾÷¤À°t¸ÕÅ窺¤H¼Æ¬O 91 ¤H ©Ò¥H91/130=0.7 (¥¼¹F¤ÏÀ³¼Ð·Çªº¤ñ¨Ò , ¤]´N¬O°Ñ»PÀH¾÷¤À°t¸ÕÅ窺¤ñ¨Ò) , ¤½¥q·íªì³W¹ºªº , ¥HES=0.5 , power=85% ©Òºâ±oªº¼Ë¥»¼Æ¬O 146 ¤H , ¤]´N¬O¥Î³oÓ 146 ¤H¥h±Àºâ¦¬®×¼Æn 348 ¤H ¤µ¤Ñ DSMC «Øij±N¤À°t¤ñ¨Ò ¥Ñ 1:3 §ï¬° 1:2.5 , ´N¦p«i©¹ª½«e¤j©Ò´£¥Ü , ³o·|´î·l°Ñ¥[ÀH¾÷¤À°t¸ÕÅ窺¤H¼Æ §Ų́Ópºâ¤@¤U 1 : 2.5 = 2 : 5 , 174*5/7 = 124.3 , 124.3* ( 91/130 ) = 87 ¤H ( ¥u¤ñ91¤H¤Ö¤F4¤H , µM¬°¦ó DSMC n³o¼Ë«Øij ? ¬O¤@Óhint¶Ü ? ¬JµMÁÙ¨S¨M©w¦¬®×¼Æn¤£n¼W¥[ , ¦ó¨Ó§ó§ï¤À°t¤ñ¨Ò¤§Ä³ , ¬O°Ñ¥[¸ÕÅ窺¼Ë¥»¼Æ¸g¦ôp¤w¸g¶W¹L³W¹º¼Æ¤F¶Ü ? ) ´Á¤¤¤ÀªR«e°Ñ¥[ÀH¾÷¤À°t¸ÕÅ窺¤H¼Æ¬O 91 ¤H , ´Á¤¤¤ÀªR«á¸g¦ôºâ¬O 87 ¤H ,¥[°_¨ÓÁ`¦@ 178 ¤H , ³o¤wµM¶W¹L·íªì³W¹ºªº 146 ¤H ²{¦b°ÝÃD¨Ó¤F °²¦p¦b¤£¼W´î¦¬®×¼Æ ( §Y³W¹ºªº 348 ¤H ) ªº«e´£¤U °Ñ¥[ÀH¾÷¤À°t¸ÕÅ窺¤H¼Æ±N¹F 178 ¤H , YES = 0.5 ¤Î £\= 0.05 ¤£ÅÜ , «h POWER ±N´£¤É¦Ü 91.26 % °²¦p¦b¤£¼W¥[¼Ë¥»¼Æ(°Ñ¥[ÀH¾÷¤À°t¸ÕÅ窺¤H¼Æ)ªº«e´£¤U , ¤]´N¬O¥Î·íªì³W¹º°Ñ¥[ÀH¾÷¤À°t¸ÕÅ窺¤H¼Æ 146 ¤H 178 ¡V 146 = 32 ¤H , 32/0.7/(5/7) = 64 ¤H , ³o 64¤H´N¬O¥i¥H´î¤Öªº¦¬®×¼Æ ©Ò¥H´Á¤¤¤ÀªR«áÀ³¦A©Û¦¬ªº¦¬®×¼Æ¬° 174 ¡V 64 = 110 ¤H ´N¬Ý¤½¥qªº³W¹º¤F , ¹ê»ÚªºES¬O¤jÃöÁä ¤pªº¤]¥u¯à²q¨ì³o¸Ì¤F ³o¸Ì©Î³\¦h©Ò»~¸Ñ DSMC ©Ò´£ªº«Øij ¦b»~¸Ñªº±¡ªp©Ò§@ªº²q´ú , ·íµM´N¥u¬O¤@°ï©U§£¦Ó¤w ²q´úµ´¤£¯à§@¬°±z§ë¸ê¨Mµ¦ªº°Ñ¦Ò , §ó¦óªp¬O¤@°ï©U§£ ÁÂÁ¤j®a! |
|
|
·|û¡G¨Dª¾Y´÷10148579 µoªí®É¶¡:2020/7/27 ¤W¤È 12:20:01²Ä 961 ½g¦^À³
|
¦U¦ì¥ý¶i¦n¡A¤@¬q®É¶¡¨S¦³¨Óª©¤W¤F¡A ¥»¦¸´Á¤¤¤½§i«Øij¤£»Ýn¤Ó¦hªº²q´ú¡A¥B¸ÕÅ礣·|´£«e²×¤î¤Î¸Ñª¼¡F (¦p¥H¤p§Ì¥H«e¯d¨¥¥i¨£¡A¤p§Ì¬O³Ì§Æ±æ¥i¥H´£«e¸Ñª¼ªº¡A¥i±¤¥H¸ÕÅç³]p¤è¦V¤£·|¦³) ³o¦¸¤½¥q¤½§iªºÂ²³ø¡A¤ñ¸û¤£¦Pªº¬O¦³¹ï´Á¤¤½Õ¾ãªº¬Ýªk¡A ¦³¾ú¨Ó2¥Nºë¯«¯fÃĦ~¾P¸ê°T¡A¤Î¥L¤½¥q¤G´Á¸ÕÅ稽µ{ª÷µ¥¸ê°T¡A ¦Ó·sÃĤ½¥q´N¬O§@¹Úªº¡AÃÄ¥¼¤W¥«´N¬O½æ¹Úªº¡A ¦]¦¹¡A¥H¤W©Ò»¡ªº¸ê°T¡A¤w¥i¥H¹w´Á©ú¤éªÑ»ùªº¤è¦V¤F¡A¦U¦ì±ß¦w¡C |
|
|
·|û¡G«i©¹ª½«e10141841 µoªí®É¶¡:2020/7/26 ¤U¤È 09:23:01²Ä 960 ½g¦^À³
|
Ãö©ó¤µ¤Ñªº´Á¤¤¤ÀªR³ø§i, ¦b¤U¤ß±o¦p¤U: 1. Kinmen3015¤j»¡ªº¨S¿ù, @¨ü©Ê¨Î, µL¦w¥þ©Ê°ÝÃD, ³oÂI·íµM«Ü«n, ¥i¬O¤j®a¦b·Nªº¬O¦³¨S¦³®ÄªG? ¨p¤ß±À´ú®ÄªGÀ³¸Ó¬Û·í¤£¿ù! ®Ú¾ÚWikipedia Ãö©óDSMC(DSMB) ªº©w¸q»P¥\¯à¥i¥H±À´ú, DSMC¬O¤@¸s¿W¥ß±M·~¤H¤h²Õ¦¨, °£¤F¦w¥þ©ÊºÊ´ú, ÁÙ¦P®ÉºÊ´ú¹êÅ窺®ÄªG ¦bFutility ¤@¬q¤¤¥i¨£, DSMC °ò©ó¤H¹D¦Ò¶qµ¥¦]¯À, ¦pªGtrial°µ¤F¤@¥b, ¹êÅç²Õ»P¹ï·Ó²Õ¨S¦³©úÅã®t²§®É, ¬Æ¦Ü´£¥X°±¤î¹êÅç, ¤@¨Ó¤½¥q¤è¥i¥H¬Ù¿ú, ¤G¨Ó¤w°Ñ»P¹êÅ窺¯f±w, ¥i¥H´M¨D¨ä¥LªºªvÀø¤è¦¡ ¸Ô¨£¥H¤U³sµ²: en.wikipedia.org/wiki/Data_monitoring_committee °ò©óDSMCªº¨¤¦â©w¦ì, ¦pªG¨S¦³ significant ªº®ÄªG, DSMC·|°µ¥X¬Æ»ò¼Ëªº«Øij»P¦w±Æ©O? 2. ¡¦´Á¤¤¤ÀªRDSMC«Øij1:3½Õ¾ã¬°1:2.5¡A¥Nªí¤£¦C¤JÀø®Äµû¦ôªºªvÀø²Õ¯f¤H¼W¥[ ©Ó¤W, ÁöµM¤£¦C¤JÀø®Äµû¦ôªºªvÀø²Õ¯f¤H¤p´T¼W¥[, ¦pªG¨S¦³efficacy, DSMC ·|«ç»ò°µ©O? §O§Ñ¤F~ÁöµM¬O¹êÅç, DSMC ÁÙ¦³ÝÅU¤H¹D¥D¸q¤Î¯f¤HÅv¯qªº¦Ò¶q 3. °w¹ï¤T¤Q¤H§¹¦¨¸ÕÅ礧«á¦A¶i¦æ½Õ¾ã¤H¼Æ¤ÀªR ¦]¬°¤w¸g«Øij1:3 ½Õ¾ã¬°1:2.5, ¦ý¬O¨Ã¨S¦³¦P¦¹®É¨è«Å¥¬n½Õ°ª¤H¼Æ, §O§Ñ¤F~³oÓ¤ñ¨Ò·|Åý²Ä¤@¶¥¬q¶i¤J¦w¼¢¾¯²Õªº¤H¼Æ°§C, ¤]´N¬O¹ê»Ú¤W¤½¥q¸Ñª¼®É¥i¥H±Ä¥Îªº¯f±w¼Æ¶q¤U°, ¦]¦¹³oӰʧ@»¡©ú¤F¬Æ»ò? ©Î³\¦U¦ì¥i¥H·Q·Q! «ä¦Ò³o¤@¬qªº®ÉÔ, ¥i¥H°Ñ¦Ò¤½¥q´Á¤¤¤ÀªR³ø§i¤¤Ãö©óSND-13 Phase 2b/3 ªº¹êÅç³]p¨º¤@¶ ¦Ó°w¹ï¤T¤Q¤H§¹¦¨¸ÕÅ礧«á¦A¶i¦æ½Õ¾ã¤H¼Æ¤ÀªR³o¼Ëªºn¨D, «Ü©úÅã¬O°ò©ó²Îp¾Çªº¨¤«×¨Ó«ä¦Ò, §Æ±æ½T«O¤½¥q SND-13 ¸Ñª¼ªº®ÉÔ, ¤£·|¦]¬°²ÎpÀË©w¤O¤£¨¬ªºÃö«Y (¦]¬°½Õ¾ã¤ñ¨Ò«á, ¸Ñª¼ªº¯f±w¤H¼Æ¤U°) , ¦Ó³y¦¨¥ô¦ó¿ò¯]¤§¾Ñ! ¦]¦¹¦b¤U±À´ú DSMC ªº½T§Æ±æ³oÓ¹êÅç¶i¦æ, ¦Ó¥B¥H³Ì¦³®Ä²vªº¤è¦¡¶i¦æ, ¦P®É¤£¸¨¤J²Îp¾Ç¤WÀË©w¤O¤£¨¬±¡ªp, ¤~µ¹¥X¦A°µ30Ó¤H¦A¨Ó¶i¦æ¬O§_½Õ¾ã¤H¼Æªº¤ÀªR ©Ò¥H, JY¤j©MKinmen3015 ¤jªº·Qªk©M¦b¤U¦p¥X¤@Âá ºî¤W©Òz, ¦U¦ì¥i¥H·Q·Q, ¦pªG±z¬ODSMC ªº¦¨û, ·|°ò©ó¬Æ»ò¼Ëªº¦]¯À¨Ó°µ¥X³o¼Ëªº¨M©w? |
|
|
·|û¡Gº©¹CªÌ10144096 µoªí®É¶¡:2020/7/26 ¤U¤È 08:13:43²Ä 959 ½g¦^À³
|
DSMC¯u¬O12¥Í¨vÄÝÀtªº¡A§Ú¥ý¨Ó·í¤@¤U²q·Q¡C ¦pªG´Á¤¤ES=0.5¡BCP=80%¡A«ö¤½¥qÀɮסA¤£¥Î¥[¦¬¯f¤H¡C ¦ý¦pªG«á¥b¬qªºES¬O0.45¡A«á¥b¬qCP´N¥i¯à¥u¦³75%¡A¥§¡°_¨Ó¡AES=0.475¡B¦³Àø®Ä¡A¥i¥H¥Ó½ÐÃÄÃÒ¡]¤½¥qÀÉ®×P11¡^¡A¦ý«o¦]power=77.5%¨S¹F¨ì80%¡A¥¢±Ñ¡B¥X§½¡I¤j¤HÞªP°Ú¡I => DSMCÀ³¸Ó¤£·|·Q¬Ý¨ì³oºØ´d¼@§a¡C ¦Aµ¥30¤H¦Aµ¹«Øij¡ADSMC·Q¦b¤ßµLÄa©À¤U¤~µ¹Ó»¡ªk¡H |
|
|
·|û¡Gkinmen301510141987 µoªí®É¶¡:2020/7/26 ¤U¤È 06:43:45²Ä 958 ½g¦^À³
|
º¥ýµ¹¤½¥q«öÓÆg!!! ³o¦¸´Á¤¤¤ÀªR, ì¥H¬°¥u¦³¤½§i, ¨S·Q¨ìÁÙ¦³¤ÀªR³ø§i!!! ³ø§i¤ß±o¦p¤U 1. @¨ü©Ê¨Î, µL¦w¥þ©Ê°ÝÃD ¬Y»sÃĤ½¥qªº¼s§i¥xµü, ¥ý¬ã¨s¤£¶Ë¨Åé, ¦AÁ¿¨sÀø®Ä SND13¤w¸g¥ß©óéT¤§°ò 2. DSMC¦³¤T¤Q¤H¦A¦æ½Õ¾ã¤H¼Æ¤§´£Ä³ ¤½¥q«o§Æ±æ°µ¨ì2/3ªº¤H¼Æ³W¼Ò, ¨¬¨£¤½¥q¤§ÂÔ·V Ó¤H¤ß¸Ì²q·Q, Ãø¹D¬ODSMC¬Ý§¹¸ê®Æı±o¦A°µ30¤H, §Y¥i¼fµøn¤£n´£¦µ²®×, ¦ý¬O¤½¥qı±o«OÀI°_¨£, °µº¡ 2/3¦A»¡? ¯ÂºéÓ¤H¦kij 3. ¦¹³ø§iÁôÂä@Ó±m³J, SNB02, ¥O¤H¿E°Ê§r!!! |
|
|
·|û¡GJY10150115 µoªí®É¶¡:2020/7/26 ¤U¤È 06:20:45²Ä 957 ½g¦^À³
|
²×©óµ¥¨ì«°T¤F ¤£¹L¤½¥qÁÙ¬O¤@¼Ë±¤¦r¦pª÷ ¦ý¤p§Ìı±o³o¦¸ªº¤º®e ¦³ÂI@¤H´M¨ý °w¹ï²Ä2ÂI ¦pªGNaBen²Õ¸òPlacebo¨S¦³©Ô¶} ¤£¬OÀ³¸Ó·Óì©wpµe¡@ª½±µ¼W¥[¦¬®×¤H¼Æ´N¦n¤F¶Ü ·|¤£·|¬ODSMC¬Ý¨ì¤F¤°»ò¼Ëªºdata ©Ò¥H»Ýn¦A¬Ý30Ó¤H§¹¦¨²Ä¤G¦¸ÀH¾÷¤À°tªº8¶gªvÀø n½T«O¬Ý¨ìªº¼Æ¾Ú¬O¹ïªº¥B·|«ùÄòµo¥Í¡H °w¹ï²Ä1ÂI §ó¬O©_©Ç ³ºµM½Õ¾ã²Ä¤@¶¥¬qªvÀø²Õ©M»P¦w¼¢¾¯²Õªº¤ñ¨Ò ¦Ó¥B¬O§â¤H¼Æ©¹ªvÀø²Õ¼W¥[ Ãø¹DDSMC¯uªº¬Ý¨ì¤F¤°»ò¼Ëªºdata¤F¶Ü ½Ðª©¤Wªº¤j¤jÀ°¦£¸Ñ´b ·PÁ |
|
|
·|û¡Gseniorbbs10144999 µoªí®É¶¡:2020/7/26 ¤U¤È 05:46:59²Ä 956 ½g¦^À³
|
Ãø±o¤½¥q²Ä¤@®É¶¡µo¥¬´Á¤¤ªº®ø®§¦b¤½¥q©xºô....½Ð¦U¦ì°ª¤âÀ°¦£¸ÑŪ¡AÁÂÁ¡C www.syneurx.com/2020/07/26/snd13/ |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2020/7/26 ¤U¤È 03:51:09²Ä 955 ½g¦^À³
|
§Ç¸¹ 1 µo¨¥¤é´Á 109/07/26 µo¨¥®É¶¡ 14:58:25 µo¨¥¤H «¸§Ó¿« µo¨¥¤H¾ºÙ °ÆÁ`¸g²z µo¨¥¤H¹q¸Ü 02-77422699 ¥D¦® ¥»¤½¥q¦¨¤Hºë¯«¤Àµõ¯g¥[¦¨ªvÀøNaBen(SND13)¤G(b)/¤T´Á ¤HÅéÁ{§É¸ÕÅç±µÀò¦w¥þºÊ´ú©eû·|(DSMC)¤§«Øij ²Å¦X±ø´Ú ²Ä 43 ´Ú ¨Æ¹êµo¥Í¤é 109/07/26 »¡©ú 1.¨Æ¹êµo¥Í¤é:109/07/26 2.¤½¥q¦WºÙ:¤ß®®¥ÍÂåªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¥»¤½¥q¬ãµo¤¤¦¨¤Hºë¯«¤Àµõ¯g¥[¦¨ªvÀø·sÃÄNaBen(SND13)¡A±µÀò¦w¥þºÊ´ú©eû·| (Data Safety Monitoring Committee, DSMC)«Øij¡C (1)Á{§É¸ÕÅç³]p¡G A.¸ÕÅçpµe¦WºÙ¡G¦¨¤Hºë¯«¤Àµõ¯g¤§¥[¦¨ªvÀø(SND13)¡C B.¸ÕÅç¥Øªº¡Gµû¦ôNaBen§ïµ½¦¨¤Hºë¯«¤Àµõ¯gªº¦³®Ä©Ê©M¦w¥þ©Ê¡C C.¸ÕÅ綥¬q¡G¦h°ê¦h¤¤¤ß¤§¤G(b)/¤T´Á¤HÅéÁ{§É¸ÕÅç¡C D.ÃÄ«~¦WºÙ¤Î¾AÀ³¯g¡GNaBen¡B¦¨¤Hºë¯«¤Àµõ¯g¡C E.µû¦ô«ü¼Ð¡G±ø¥óÀË©w¤O(Conditional Power)¡A°ßDSMC¤£·|§iª¾¥»¤½¥q¥H«OÅ@Á{§É ¸ê®ÆÂùª¼¡A¤ÎÁ{§É¸ÕÅ礧§¹¾ã¥i¾a©Ê¡C F.¸ÕÅçpµe¨ü¸ÕªÌ¤H¼Æ¡G¹wp¦¬®×348¤H¡A´Á¤¤¤ÀªR±Ò°Ê±ø¥ó¬O²Ä91¦ì¶i¤J²Ä¤G¦¸ ÀH¾÷¤À°tªº¨ü¸ÕªÌ§¹¦¨8¶gªvÀø©Î´£«eµ²§ôªvÀø¡C (2)¦w¥þºÊ´ú©eû·|«Øij¡G¤@¡B²Ä¤@¶¥¬qªvÀø²Õ(Á{§É³]p¤W¡A¥»²Õ©Ò¦³¨ü¸ÕªÌ¬Ò¤£¦C¤J ÃĪ«Àø®Äµû¦ô)»P¦w¼¢¾¯²Õ¤§ÀH¾÷¤À°t¤ñ¨Ò¥Ñì³]p¤§1:3½Õ¾ã¬°1:2.5¡C¤G¡B¬°·V« °_¨£¡A±N©ó¥t¤T¤Q¤H§¹¦¨¸ÕÅ礧«á(§Y¶i¤J²Ä¤G¦¸ÀH¾÷¤À°tªº¨ü¸ÕªÌ§¹¦¨8¶gªvÀø©Î ´£«eµ²§ôªvÀø)¦A¶i¦æ½Õ¾ã¤H¼Æ¤ÀªR¡C¤T¡BNaBen@¨ü©Ê¨Î¡AµL¦w¥þ©Ê°ÝÃD¡C (3)¥»¦¸¤ÀªR¨ÃµL¸Ñª¼¡A¬G¥»¤½¥q¹ï©óDSMC«ØijµLªk¦h§@¸àÄÀ¡C 6.¦]À³±¹¬I:µL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)¬ãµo·sÃĦWºÙ©Î¥N¸¹¡G¦¨¤Hºë¯«¤Àµõ¯g¥[¦¨ªvÀø·sÃÄNaBen (SND13)¡C (2)¥Î³~¡GªvÀøºë¯«¤Àµõ¯g¡C (3)¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¦h°ê¦h¤¤¤ß¤G(b)/¤T´Á¤HÅéÁ{§É¸ÕÅç¡C (4)¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G A.´£¥X¥Ó½Ð/³q¹L®Öã/¤£³q¹L®Öã¡G±µÀòDSMC´Á¤¤¤ÀªR«Øij¡C B.¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò±Á{¤§·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î¡C C.¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G±N©ó¥_¬ü¤Î¼Ú¬w«ùÄò¼W¥[Á{§É ¸ÕÅ礤¤ß¡A¥[³t¦¬®×¡A¶i¦æÁ{§É²Ä¤G(b)/¤T´Á¸ÕÅç¡C D.¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G¬°ÁקK¼vÅT°ê»Ú±ÂÅv½Í§P¡A«O»Ù¤½¥q¤Î§ë¸ê¤HÅv¯q¡A ¤£¤©¤½¶}´¦ÅS¡C (5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G A.¹wp§¹¦¨®É¶¡:¹wp110-111¦~§¹¦¨¦¬®×¡A±©¹ê»Ú®Éµ{±N¨Ì°õ¦æ¶i«×¨M©w¬O§_½Õ¾ã¡C B.¹wpÀ³t¾á¤§¸q°È¡GµL¡C (6)¥«³õ²{ªp¡G ºë¯«¤Àµõ¯g¬OÄY«¥¼ÀòÂåÀøº¡¨¬ªº¯e¯f¡A¦¨¤H±w¯f²v±µªñ1%¡A²{¦³ÃĪ«¹ï©óªø´Á §xÂZ¯f±wªºt©Ê¯gª¬¡B»{ª¾¥\¯à´î·l¤´µL¨}µ¦¡CSND13§í¨î¥k±ÛÓi°ò»Ä®ñ¤Æ»Ã¯À (D-amino acid oxidase)¡A¥H´£°ª¥k±Ûµ·Ói»Ä(D-serine)¿@«×¡A¬¡¤Æ¤j¸£NMDA¨t²Î¡A ¦´Á¤HÅéÁ{§É¸ÕÅçµo²{¥i¥H¦³®Ä§ïµ½¥¿©Ê¯gª¬¡Bt©Ê¯gª¬¡B»{ª¾¥\¯à´î·l¡A¦]¦¹Àò±o ¬ü°êFDA¬ð¯}©ÊªvÀø»{©w¡C (7)¤¤¼Ï¯«¸g·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{ ·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/7/26 ¤W¤È 08:44:09²Ä 954 ½g¦^À³
|
¹ù¥S¤S¥X¨â½gºë±m·s¤å CASE³ø¬ì¾Çºô¯¸¤§[ºë¯«Âå¾Ç] §ä´Mºë¯«¤Àµõ¯gªºÃĪ«Ãø§½ liawbf.pixnet.net/blog/post/49456673 ClozaBen , SND12ªvÀø¤Wªº±m³J liawbf.pixnet.net/blog/post/49456718 ÁÂÁ¹ù¥Sªº¤À¨É ÁÂÁ¤j®a! |
|
|
·|û¡Gseniorbbs10144999 µoªí®É¶¡:2020/7/25 ¤U¤È 07:43:16²Ä 953 ½g¦^À³
|
§Ú¤]¬O¦b¼ÆÄCÀY¤¤,¦pªG7¤ë©³¤£¥X¨Ó,³o®a¤½¥q¦³¦ó¸Û«H¥i¨¥,¤@¦~ªá2E¡B3E³£¤£ª¾¹D§â¿úªá¦bþ?³£¨S¦³¬Ý¨ì¹ê½è¤Wªº¶i«×....ü... |
|
|
·|û¡G¤p·10148067 µoªí®É¶¡:2020/7/25 ¤U¤È 06:00:26²Ä 952 ½g¦^À³
|
§Ú²{¦b¥u§Æ±æ½²±Ð±Â§O¦A®ÌÂI¤j®a¤F¡ASND-13´Á¤¤¤ÀªRµ²ªG¶ZÂ÷¤@Ӥ뤺ªº´Á³Ñ¨S´X¤Ñ¤F¡I ¦A¤@¦¸µLÁnµL®§¤S¨S¸ÑÄÀªº¸Ü¡A©È¬OªÑ»ù¦A¤@¦¸ªº¼@¯Pªi°Ê¡A¦p¬O³o¼Ë¡I¯uªº¬O·íªì´N§O»¡ÁÙ¤ñ¸û¦n¤@¨Ç°Ú¡I ¬°¦ó¨S§â´¤ÁÙn¶}¤ä²¼¡A¯uªºÅý§Ú«Ü§x´b°Ú⋯ ¼ÆÄCÀY¤¤¡ã |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/7/25 ¤U¤È 05:07:03²Ä 951 ½g¦^À³
|
¤j®a§Ö¨Ó¬Ý , «õ¨ìÄ_¤F¶Ü ? ´¦¨¤Ñù¦aºô ? ¬ÝSARS-CoV-2¥i¥H©¹þ¸Ì¶] ? º¥ý §Ų́Ӭݤ@½g³æ¹ç»Ä¥NÁ²£ª«ªº½×¤å Method for Analysis of Tannic Acid and Its Metabolites in Biological Samples: Application to Tannic Acid Metabolism in the Rat 10.1021/jf020847+ Metabolism of TA has been investigated in sheep (9-11, 18), rat (7), mice (10), and chicken (19). Several studies (19-21) have reported that GA, 4-O-methylgallic acid (4-OMGA), pyrogallol (PY), resorcinol (RE), and ellagic acid (EA) are the metabolites of TA. TAªº¥NÁ²£ª« ¦³GA ¡Bpyrogallol (PY) ¡Bellagic acid (EA) ¡K 1. ³æ¹ç»Ä¦Û¨¦³§í¨î3CL proªº¥\¯à------§í¨î½Æ»s Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3¡¦-digallate (TF3) www.hindawi.com/journals/ecam/2005/607278/ ¦b³o¶µ¬ã¨s¤¤¡A§ÚÌ¿z¿ï¤F¥Ñ720ºØ¤Æ¦Xª«²Õ¦¨ªº¤ÑµM²£ª«®w¡A¸Ó®w¨ã¦³°w¹ï3CLProªº§í¨î¬¡©Ê¡C®w¤¤µo²{¦³¨âºØ¤Æ¦Xª«¨ã¦³§í¨î§@¥Î¡G³æ¹ç»Ä¡]IC50 = 3 µM¡^©M3-²§theflaflavin-3-gallate¡]TF2B¡^¡]IC50 = 7 µM¡^¡C 2. GA ªº¥\¯à ( 1 ) §í¨î¯f¬r¶i¤J²ÓM Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor link.springer.com/article/10.1007/s13337-020-00598-8 §Ú̪º¬ã¨sÅã¥ÜÁ¤¶À¯À¡A¹ç»«ÆP¡A¬\¯ó±ìµß¯ÀA¡AJ´ÔÆP¡A¨~ªG苷¡A¸¦¤Ú¦]¡A¤pberÆP¡A¬ï¤ß½¬¤ºà©M¬ï¤ß½¬¤ºà¹ïSARS-CoV-2©MACE2¨üÅ骺¬ðIJ¿}³J¥Õ¨ã¦³ÅãµÛªºµ²¦X¿Ë©M¤O¡A¨Ã¥B¥i¥Î§@¨î¯f¬rªþµÛ©ó±J¥D²ÓMªºªvÀø¾¯©M/©Î¹w¨¾¾¯¡C ¦Ó¥ÕòÔĪ¾J¡AåÚ¥Ö¯À¡A¤ìµR¯ó¯À¡A¬c¥Ö¯À¡AÁ¤ªo²m©M¨S¹¤l»Ä¶È¨ã¦³¹ïACE2¨üÅ骺ÅãµÛµ²¦X¿Ë©M¤O¡A¦]¦¹¥i¥Î©óACE2¤¶¾ÉªºSARS-CoV-2§í¨î¡C Consequently, resveratrol, quercetin, luteolin, naringenin, zingiberene, and gallic acid could be a useful starting material for the development of potent antiviral agents for the prevention and treatment of SARS-CoV-2 and other coronaviruses if tested further. ( 2 ) §í¨î¯f¬r½Æ»s©Î¶i¤J²ÓM (( 1 )) Inhibition of COVID-19 RNA-Dependent RNA Polymerase by Natural Bioactive Compounds: Molecular Docking Analysis www.researchsquare.com/article/rs-25850/v1 ¥»¬ã¨s¦®¦b³q¹L¤À¤l¹ï±µ¨Óµû¦ô¦h×ôÃþ¤Æ¦Xª«¡]¨S¹¤l»Ä¡AåÚ¥Ö¯À¡A©@°Ø¦]¡A¥ÕòÔĪ¾J¡A¬c¥Ö¯À¡Af¥Ò»Ä¡A¾ñÆVW苷©MÂýªá»Ä¡^§@¬°COVID-19 RNA¨Ì¿à©ÊRNA»E¦X酶¡]PDB ID 6M71¡^ªº§í¨î¾¯¡C ¨S¹¤l»Ä©MåÚ¥Ö¯À¹ï§Q¤Ú³ªL¹ïCOVID-19»E¦X酶ªí²{¥X¤ñ§Q¤Ú³ªL§ó°ªªºµ²¦X¿Ë©M¤O¡A¨Ãªí²{¥X¨}¦nªºÃĪ«¬Û¦ü©Ê©MÃÄ¥N°Ê¤O¾Ç¯S©Ê¡C¦]¦¹¡A¨S¹¤l»Ä©MåÚ¥Ö¯À¥i¯à¥NªíCOVID-19ªº¼ç¦bªvÀø¿ï¾Ü¡C (( 2 )) Natural compounds from Djiboutian Medicinal plants as inhibitors of COVID-19 by In silico investigations For this we carried out a docking with nine biomolecules, £]-Sitosterol , Quercetin, Catechin, Lupeol, Rutin, Kaempferol, Gallic acid, Piperitone and Limonene on three target sites which are SARS-CoV-2 main protease (Mp), SARS-CoV-2 receptor binding domain (RBD) and human furin protease. These targets are chosen because of their role in the process of penetration of the virus into human cells and its multiplication. The phenolic compounds have a very good afinity on these three target sites with binding energies of up to -9.098 kcal/mol for rutin on SARS-CoV-2 Mp, much better than the two reference drugs hydroxychloroquine ( ßm´â喹 ) (-5.816 kcal / mol) and remdesivir ( ¦N§Q¼wªº·ç¼w¦è³ )(-7.194 kcal/mol). These natural compounds do not present toxicities and can be used pending In vitro and In vivo evaluations. SARS-CoV-2 main protease : rutin > Catechin > kaempferol > remdesivir > quercetin > hydroxychloroquine > piperitone > gallic acid > limonene> £]-Sitosterol > lupeol ; SARS-CoV-2 receptor binding domain : remdesivir > rutin> Kaempferol > Catechin > Quercetin > piperitone > gallic acid > hydroxychloroquine > limonene> lupeol > £]Sitosterol ; human furin protease : quercetin> catechin> rutin >gallic acid> kaempferol> remdesivir > hydroxychloroquine > piperitone> £]-sitosterol> lupeol> limonene. ( the spike protein of SARS-CoV-2 ) 3. ¦Ó PYªº¥\¯à©O ? ------¬r±þ¯f¬r Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2 Interestingly, a pyrogallol-enriched fraction (Fr 1C) inactivated all viruses more rapidly and effectively than did any of the component compounds used alone. We found that 25 µg/mL of Fr 1C inactivated >99.6% of SARS-CoV-2 within 10 s (reduction of ≥2.33 log10 TCID50/mL). Fr 1C resulted in the disruption of viral genomes and proteins as determined by gel electrophoresis, electron microscopy, and reverse transcription¡VPCR. Taken together, our results reveal the potential of Fr 1C for development as a novel antiviral disinfectant. Our studies suggest that the pyrogallol B-ring contributed to the virucidal activity observed here to a greater extent than did the catechol B-ring. The results overall point to the contributions of galloyl groups and of the pyrogallol moieties as key virucidal elements. Of particular note, Fr 1C, which is enriched with pyrogallol compounds, promoted the profound disruption of virus genomes and proteins. We anticipate that these findings will generate interest into the potent virucidal activities of Fr 1C, which may contribute to the prevention of virus transmission under our current worldwide pandemic crisis. 4. EA ´N¬O¶W±jªºCK2§í¨î¾¯ , ¬O¥ÍµØ¬ì°õ¦æªø¤f¤¤ªºCOVID-19ªºP©R®zÂI Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application pubmed.ncbi.nlm.nih.gov/16610779/ Using a virtual screening approach, we have identified the ellagic acid, a naturally occurring tannic acid derivative, as a novel potent CK2 inhibitor. At present, ellagic acid represents the most potent known CK2 inhibitor (K(i) = 20 nM). ±q¬r±þ¯f¬r , ¨ì§í¨î¯f¬r¶i¤J , ¦A¨ì§í¨î¯f¬r½Æ»s , ¤]³\ÁÙ¥i¨ì¹w¨¾©ÎªvÀø«¯g ¾ãÓÂåÀø¹Lµ{¥u»Ý³æ¹ç»Ä¤Î¨ä¥NÁª«´N¥þ¥]¤F¶Ü ? ·íµMÁٻݤHÅéÅçÃÒ µM¦Ó SNB1¬O¬Æ»ò ? §Ú̯u±o«Ü¦n©_ §Æ±æSNB1»°§ÖÁ{§É , ¨Ó¬Ý¬Ý·|¤£·|¦³¥Û¯}¤ÑÅ媺Àø®Ä ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10148412 µoªí®É¶¡:2020/7/25 ¤W¤È 09:40:24²Ä 950 ½g¦^À³
|
¤½¥q¨p¶Ò¸êª÷¹B¥Î²Îp 108Q3 : 36,736,468 108Q4 : 44,368,144 109Q1 : 44,706,776 109Q2 : 52,923,875 ( 46,022,451 + 6,901,424 ) ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
|